---
document_datetime: 2023-09-21 19:24:48
document_pages: 171
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/braftovi-epar-public-assessment-report_en.pdf
document_name: braftovi-epar-public-assessment-report_en.pdf
version: success
processing_time: 188.8202147
conversion_datetime: 2025-12-27 21:45:49.10034
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

26 July 2018 EMA/CHMP/554696/2018 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Braftovi

International non-proprietary name: encorafenib

Procedure No. EMEA/H/C/004580/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                | 7                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier .....................................................................................7   |                                                                                                       |
| 1.2. Steps taken for the assessment of the product                                                                      | ........................................................8                                             |
| 2. Scientific discussion................................................................................                | 9                                                                                                     |
| 2.1. Problem statement...............................................................................................9  |                                                                                                       |
| 2.1.1. Disease or condition                                                                                             | ..........................................................................................9           |
| 2.1.1. Biologic features                                                                                                | ...............................................................................................9      |
| 2.1.2. Clinical presentation, diagnosis and stage/prognosis..............................................9              |                                                                                                       |
| 2.1.3. Management...................................................................................................    | 10                                                                                                    |
| 2.2. Quality aspects                                                                                                    | .................................................................................................. 13 |
| 2.2.1. Introduction.................................................................................................... | 13                                                                                                    |
| 2.2.2. Active Substance.............................................................................................    | 13                                                                                                    |
| 2.2.3. Finished Medicinal Product................................................................................       | 16                                                                                                    |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................                      | 18                                                                                                    |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                               | ...................... 18                                                                             |
| 2.2.6. Recommendations for future quality development                                                                   | ............................................... 18                                                    |
| 2.3. Non-clinical aspects............................................................................................   | 19                                                                                                    |
| 2.3.1. Introduction.................................................................................................... | 19                                                                                                    |
| 2.3.2. Pharmacology.................................................................................................    | 19                                                                                                    |
| 2.3.3. Pharmacokinetics                                                                                                 | ............................................................................................ 26       |
| 2.3.4. Toxicology...................................................................................................... | 31                                                                                                    |
| 2.3.5. Ecotoxicity/environmental risk assessment.........................................................               | 37                                                                                                    |
| 2.3.6. Discussion on non-clinical aspects .....................................................................         | 39                                                                                                    |
| 2.3.7. Conclusion on the non-clinical aspects                                                                           | ............................................................... 40                                    |
| 2.4. Clinical aspects                                                                                                   | .................................................................................................. 40 |
| 2.4.1. Introduction.................................................................................................... | 40                                                                                                    |
| 2.4.2. Pharmacokinetics                                                                                                 | ............................................................................................ 45       |
| 2.4.3. Pharmacodynamics..........................................................................................       | 52                                                                                                    |
| 2.4.4. Discussion on clinical pharmacology...................................................................           | 56                                                                                                    |
| 2.4.5. Conclusions on clinical pharmacology.................................................................            | 59                                                                                                    |
| 2.5. Clinical efficacy                                                                                                  | .................................................................................................. 60 |
| 2.5.1. Dose response study(ies) .................................................................................       | 60                                                                                                    |
| 2.5.2. Main study(ies)                                                                                                  | ............................................................................................... 61    |
| 2.5.1. Discussion on clinical efficacy..........................................................................        | 111                                                                                                   |
| 2.5.2. Conclusions on the clinical efficacy ..................................................................          | 115                                                                                                   |
| 2.6. Clinical safety .................................................................................................. | 115                                                                                                   |
| 2.6.1. Discussion on clinical safety............................................................................        | 152                                                                                                   |
| 2.6.2. Conclusions on the clinical safety                                                                               | .................................................................... 157                              |

<div style=\"page-break-after: always\"></div>

| 2.7. Risk Management Plan......................................................................................        |   157 |
|------------------------------------------------------------------------------------------------------------------------|-------|
| 2.8. Pharmacovigilance ...........................................................................................     |   160 |
| 2.9. New Active Substance ......................................................................................       |   161 |
| 2.10. Product information ........................................................................................     |   161 |
| 2.10.1. User consultation.........................................................................................     |   161 |
| 2.10.2. Additional monitoring...................................................................................       |   161 |
| 3. Benefit-Risk Balance...........................................................................                     |   161 |
| 3.1. Therapeutic Context .........................................................................................     |   161 |
| 3.1.1. Disease or condition ......................................................................................     |   161 |
| 3.1.2. Available therapies and unmet medical need.....................................................                 |   161 |
| 3.1.3. Main clinical studies.......................................................................................    |   162 |
| 3.2. Favourable effects............................................................................................    |   162 |
| 3.3. Uncertainties and limitations about favourable effects...........................................                 |   163 |
| 3.4. Unfavourable effects.........................................................................................     |   164 |
| 3.5. Uncertainties and limitations about unfavourable effects .......................................                  |   166 |
| 3.6. Effects Table.................................................................................................... |   166 |
| 3.7. Benefit-risk assessment and discussion...............................................................             |   168 |
| 3.7.1. Importance of favourable and unfavourable effects............................................                   |   168 |
| 3.7.2. Balance of benefits and risks ..........................................................................        |   168 |
| 3.7.3. Additional considerations on the benefit-risk balance .........................................                 |   169 |
| 3.8. Conclusions.....................................................................................................  |   169 |
| 4. Recommendations...............................................................................                      |   170 |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADME

Absorption/Distribution/Metabolism/Excretion

ADR

Adverse Drug Reaction

AE

Adverse Event

AESI

Adverse Event of Special Interest

AJCC

American Joint Committee on Cancer

ALT

Alanine Transaminase

AUC

Area Under the Concentration Time Curve

BA

Bioavailability

BCRP

Breast Cancer Resistance Protein

BCS

Biopharmaceutics Classification System

BID

Twice Daily

BIRC

Blinded Independent Review Committee

BRAF

B-Raf Proto-Oncogene, Serine/Threonine Kinase

CDK

Cyclin Dependent Kinase

CEP

Certificate of Suitability of the EP

CFU

Colony Forming Units

CHMP

Committee for Medicinal Products for Human Use

CI

Confidence Interval

CL/F

Total Clearance

Cmax

Maximum Observed Plasma Concentration

cMET

MET Proto-Oncogene, Receptor Tyrosine Kinase

CNS

Central Nervous System

Combo 300

Encorafenib 300 mg QD in combination with binimetinib 45 mg BID

Combo 450

Encorafenib 450 mg QD in combination with binimetinib 45 mg BID

CQA

Critical Quality Attribute

CR

Complete Response

CSR

Clinical Study Report

CT

Computed Tomography

cuSCC

Cutaneous Squamous Cell Carcinoma

DCR

Disease Control Rate

DDI

Drug-Drug Interaction

DLT(s)

Dose Limiting Toxicity(ies)

DMC

Data Monitoring Committee

DOR

Duration of Response

DSC

Differential Scanning Calorimetry

EC

European Commission

ECHO

Echocardiogram

ECOG

Eastern Cooperative Oncology Group

eCRF

Electronic Case Report Form

Enco 300

Encorafenib 300 mg

EORTC

European Organization for Research and Treatment of Cancer Quality of Life

EOT

End of Treatment

EQ-5D-5L

EuroQoL-5D-5 Level

ERK

Extracellular Signal-Regulated Kinase

ESMO

European Society for Medical Oncology

FACIT

Functional Assessment of Chronic Illness

FACT-G

Functional Assessment of Cancer Therapy-General

FACT-M

Functional Assessment of Cancer Therapy-Melanoma

FAS

Full Analysis Set

FDA

Food and Drug Administration

FGFR

Fibroblast Growth Factor Receptor

GCP

Good Clinical Practice

HPLC

High performance liquid chromatography

HR

Hazard Ratio

ICH

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for

Human Use

IR

Infrared

ITT

Intent to Treat

IVRS

Interactive Voice Response System

KM

Kaplan-Meier

LDH

Lactate Dehydrogenase

LME

Linear Mixed-Effects

LVEF

Left Ventricular Ejection Fraction

MAA

Marketing Authorisation Application

MEB

Medicines Evaluation Board

MEK

Mitogen-Activated Protein Kinase

MPA

Medical Products Agency

MRI

Magnetic Resonance Imaging

MS

Mass Spectrometry

MTD

Maximum Tolerated Dose

NCCN

National Comprehensive Cancer Network

NE

Not Estimable

NMR

Nuclear Magnetic Resonance

## NRAS

Neuroblastoma RAS Viral Oncogene Homolog

NS

Not Specified

ORR

Objective Response Rate

OS

Overall Survival

PAR

Proven Acceptable Range

PD

Progressive Disease

PD-1

Programmed Cell Death Protein 1

PDL-1

Programmed Death (Receptor) Ligand 1

PE

Polyethylene

PFS

Progression-Free Survival

P-gp

P-glycoprotein

Ph. Eur.

European Pharmacopoeia

PK(s)

Pharmacokinetic(s)

PopPK

Population PK

PPE

Palmar Plantar Erythrodysaesthesia

PPS

Per-Protocol Set

PR

Partial Response

PRO

Patient-Reported Outcome

PS

Performance Status

PVC

Polyvinyl chloride

QbD

Quality by design

QD

Once Daily

QLQ-C30

Questionnaire Core 30

QoL

Quality of Life

QTPP

Quality target product profile

RAF

Serine/Threonine-Protein Kinase

RAS

Rat Sarcoma Viral Oncogene Homologue

RECIST

Response Evaluation Criteria in Solid Tumours

RH

Relative Humidity

RP2D

Recommended Phase 2 Dose

rpm

revolutions per minute

RVO

Retinal Vein Occlusion

SAE

Serious Adverse Event

SD

Standard Deviation

SmPC

Summary of Product Characteristics

TAMC

Total Aerobic Microbial Count

Tmax

Time to Maximum Observed Plasma Concentration

TSE

Transmissible Spongiform Encephalopathy

TTR

Time to Response

TYMC

Total Combined Yeasts/Moulds Count

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

UHPLC ultra-high performance liquid chromatography ULN Upper Limit of Normal US United States (of America) USP-NF United States Pharmacopoeia-National Formulary UV Ultraviolet vs. versus Vz/F Volume of Distribution XRPD X-Ray Powder Diffraction

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Pierre Fabre Medicament submitted on 28 July 2017 an application for marketing authorisation to the European Medicines Agency (EMA) for Braftovi, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 21 July 2016.

The applicant applied for the following indication: Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see Section 4.4).

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0054/2016 on the agreement of a paediatric investigation plan (PIP) and an EMA Decision CW/1/2011 on the granting of a class waiver.

At the time of submission of the application, the PIP P/0054/2016 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Applicant's request(s) for consideration

## New active Substance status

The applicant requested the active substance encorafenib contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

## Scientific advice

The applicant did not seek scientific advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Nithyanandan Nagercoil Co-Rapporteur:  Harald Enzmann

| The application was received by the EMA on                                                                                                                                               | 28 July 2017     |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The procedure started on                                                                                                                                                                 | 17 August 2017   |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                                           | 2 November 2017  |
| The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                                        | 3 November 2017  |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                                                                                      | 17 November 2017 |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                  | 14 December 2017 |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                      | 28 March 2018    |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on                                                                  | 4 April 2018     |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                 | 17 May 2018      |
| The CHMP agreed on a list of outstanding issues in writing or in an oral explanation to be sent to the applicant on                                                                      | 31 May 2018      |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                          | 25 June 2018     |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                         | 11 July 2018     |
| The Rapporteurs circulated the updated Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                 | 20 July 2018     |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Braftovi on | 26 July 2018     |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Cutaneous  melanoma,  which  arises  from  the  oncogenic  transformation  of  melanocytes  that  reside  in  the epidermal layer of the skin, is the most lethal form of skin cancer, due to its propensity to metastasise to vital  organs,  including  the  brain,  lungs,  liver  and  other  visceral  organs 1 .  Malignant  melanoma  is  the  19th most common cancer worldwide, with around 232,000 new cases (2% of the total) diagnosed in 2012 2 , 3 . Malignant melanoma is the ninth most common cancer in Europe, with 123,135 new cases (3% of the total) diagnosed  in  2012.  The  European  incidence  of  malignant  melanoma  varies  from  3  to  5/100  000/year  in Mediterranean countries to 12-25 (and rising) in Nordic countries. The most common phenotypic risk factor for developing cutaneous melanoma is having fair skin that tends to burn in the sun. Genetic risk factors also include inheriting melanocortin-1 receptor variant as well as the presence of high numbers of common naevi and those with large congenital naevi, multiple and/or atypical naevi (dysplastic naevi) are at a greater risk to  developing  cutaneous  melanoma.  The  most important  external  risk  factor  is  prolonged  exposure  to  UV irradiation, particularly intermittent sun exposure.

## 2.1.1. Biologic features

There are four main subtypes of cutaneous melanomas: superficial spreading melanoma, nodular melanoma, lentigo  maligna  melanoma,  acral  lentiginous  melanoma.  These  can  be  clinically  and  histologically  defined based  on  overall  appearance,  location  and  histologic  features  of  the  melanocytes.  Approximately  50%  of patients with metastatic melanoma have mutations in BRAF , and over 95% of these are in BRAF exon 15 at V600. The most common V600 mutations are V600E and V600K accounting for 66-91% and 7-30% of all BRAF V600  mutations,  respectively 4 , 5 , 6 , 7 , 8 .  These  mutations  constitutively  activate  BRAF  protein  and downstream signal transduction in the RAF/MEK/ERK pathway (MAPK pathway), which signals for cancer cell proliferation and survival.

## 2.1.2. Clinical presentation, diagnosis and stage/prognosis

Over 90% of melanomas are diagnosed as primary tumours without any evidence of metastasis. The tumourspecific  10-year  survival  for  such  tumours  is  75%-85%,  with  10-20%  of  cases  becoming  metastatic  and eventually fatal 9 , . However, the survival rate of unresectable or metastatic melanoma decreases sharply; the

1 Garbe C., Peris K., Hauschild A. et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. Eur J Cancer. 2016 Aug; 63: 201-17

2 Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J. et al Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374-403.

3 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM,  Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and  major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86

4 Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54.

5 Cheng S, Chu P, Hinshaw M et al. Frequency of mutations associated with targeted therapy in malignant melanoma patient. J Clin Oncol 2011; 29(suppl; abstr 8597)

6 Colombino M., Capone M., Lissia A. et al BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol., 2012; 30(20): 2522-9

7 Jakob J.A., Bassett R.L. Jr., Ng CS et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012;118(16):4014-23

8 Greaves WO, Verma S, Patel KP et al. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn 2013;15(2): 220-6

9 Zbytek B, Carlson J.A., Granese J, Ross J, et al. Current concepts of metastasis in melanoma Expert review of dermatology. 2008;3(5):569-85

<div style=\"page-break-after: always\"></div>

5-year survival rate is 17% and, if left untreated, the median survival is 6-9 months. The clinical presentation of cutaneous melanoma varies depending on the subtype but the typical features relate to asymmetry of the lesion,  irregular  borders,  colour  and  diameter  of  the  lesions.  The  most  important  prognostic  factors  in metastatic melanoma are the site(s) of metastases (presence of visceral metastases) and the presence of elevated serum lactate dehydrogenase (LDH). Prognosis is particularly poor in patients with American Joint Committee on Cancer (AJCC) stage IV M1c melanoma, defined as disease that has metastasised to visceral organs (other than the lungs) and LDH is normal or with elevated LDH and any distant metastases, with an estimated 1-year survival rate of 33% 10 .

Table 1: AJCC staging of melanoma (7th edition)

<!-- image -->

| ANATOMICSTAGE/PROGNOSTICGROUPS   | ANATOMICSTAGE/PROGNOSTICGROUPS   | ANATOMICSTAGE/PROGNOSTICGROUPS   | ANATOMICSTAGE/PROGNOSTICGROUPS   | ANATOMICSTAGE/PROGNOSTICGROUPS   | ANATOMICSTAGE/PROGNOSTICGROUPS   | ANATOMICSTAGE/PROGNOSTICGROUPS   | ANATOMICSTAGE/PROGNOSTICGROUPS   |
|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Clinical Staging'                | Clinical Staging'                | Clinical Staging'                | Clinical Staging'                | PathologicStaging                | PathologicStaging                | PathologicStaging                | PathologicStaging                |
| Stageo                           | Tis                              | NO                               | MO                               | 0                                | Tis                              | NO                               | MO                               |
| StageIA                          | Tla                              | NO                               | MO                               | IA                               | T1a                              | NO                               | MO                               |
| StageIB                          | T1b                              | NO                               | MO                               | IB                               | T1b                              | NO                               | MO                               |
|                                  | T2a                              | NO                               | MO                               |                                  | T2a                              | NO                               | MO                               |
| StagelIA                         | T2b                              | NO                               | MO                               | IIA                              | T2b                              | NO                               | MO                               |
|                                  | T3a                              | NO                               | MO                               |                                  | T3a                              | NO                               | MO                               |
| StageIIB                         | T3b                              | NO                               | MO                               | IIB                              | T3b                              | NO                               | MO                               |
|                                  | T4a                              | NO                               | MO                               |                                  | T4a                              | NO                               | MO                               |
| StageIIC                         | T4b                              | NO                               | MO                               | IC                               | T4b                              | NO                               | MO                               |
| Stagel                           | AnyT                             | ≥N1                              | MO                               | IIIA                             | T1-4a                            | Nla                              | MO                               |
|                                  |                                  |                                  |                                  |                                  | T1-4a                            | N2a                              | MO                               |
|                                  |                                  |                                  |                                  | IIIB                             | T1-4b                            | Nla                              | MO                               |
|                                  |                                  |                                  |                                  |                                  | T1-4b                            | N2a                              | MO                               |
|                                  |                                  |                                  |                                  |                                  | T1-4a                            | N1b                              | MO                               |
|                                  |                                  |                                  |                                  |                                  | T1-4a                            | N2b                              | MO                               |
|                                  |                                  |                                  |                                  |                                  | T1-4a                            | N2C                              | MO                               |
|                                  |                                  |                                  |                                  | IIIC                             | T1-4b                            | N1b                              | MO                               |
|                                  |                                  |                                  |                                  |                                  | T1-4b                            | N2b                              | MO                               |
|                                  |                                  |                                  |                                  |                                  | T1-4b                            | N2c                              | MO                               |
|                                  |                                  |                                  |                                  |                                  | AnyT                             | NB                               | MO                               |
| StageIV                          | AnyT                             | AnyN                             | M1                               | IV                               | AnyT                             | AnyN                             | M1                               |

## Notes

Micrometastasesarediagnosed aftersentinel lymphnodebiopsyand completion lymphadenectomy(ifperformed).

Macrometastasesaredefnedasclinicallydetectablenodalmetastasesconfrmedbytherapeuticymphadenectomyorwhennodalmetastasisexhibitsgrossextracapsularextenson.

3Clinicalstagingincludesmicrostagingof theprimarymelanomaandclinicalradiologicevaluationformetastases.Byconvention,itshould beusedafter completeexcisionof theprimarymelanoma with clinicalassessment forregionalanddistantmetastases.

Pathologicstagingincludesmicrostagingoftheprimarymelanomaandpathologicinformationabouttheregional lymphnodesafterpartialorcomplete lymphadenectomy.PathologicStageOorStagelA patientsarethe exception;they donotrequire pathologicevaluation oftheir lymphnodes.

## 2.1.3. Management

The  current  treatment  options  for  metastatic  melanoma  include  2  classes  of  agents,  immune  checkpoint inhibitors and kinase inhibitors targeting the MAPK pathway in patients with BRAF mutations. BRAF and its downstream target, MEK, are kinases in the MAPK pathway, and play an important role in cell proliferation 11 .

10  Dickson PV and Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 2011 Jan;20 (1):1-17

11  Peyssonnaux C, Eychène A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93(1-2):53-62

<div style=\"page-break-after: always\"></div>

These new therapies have been shown to prolong survival in recent Phase 3 clinical trials 12 , 13 , 14 , 15 , 16 , 17 , with the BRAF/MEK combinations vemurafenib/cobimetinib and dabrafenib/trametinib increasing the median progression-free survival (PFS) to approximately 12 months and the median overall survival (OS) to 22-26 months in metastatic melanoma with a BRAF mutation,.

Vemurafenib single-agent was the first BRAF inhibitor to be approved for patients with advanced unresectable or metastatic BRAF -mutant melanoma, followed by dabrafenib single-agent. In the pivotal Phase 3 studies, the median PFS was 5.3 months with vemurafenib and 1.6 months with dacarbazine 18   while median PFS was 5.1 months for dabrafenib and 2.7 months for dacarbazine 19 . The duration of response (DOR) for single agent BRAF inhibition is often short lived, with resistance developing within approximately 6 months, 20 , . To delay resistance to BRAF inhibition, the combination of BRAF- and a MEK1/2-inhibitors showed prolonged durationof the response in patients with advanced BRAF -mutant melanoma 21 ,  22 , . In addition, the combination of a MEK inhibitor  and  a  BRAF  inhibitor  appears  to  result  in  improved  tolerability  compared  with  either  agent alone, , , , . Based on these data, the BRAF/MEK inhibitors have been the standard of care for patients with previously untreated unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma. Recent European  consensus-based  interdisciplinary  guidelines  recommend  the  use  of  the  BRAF/MEK  inhibitor combinations dabrafenib/trametinib or vemurafenib/cobimetinib for the treatment of BRAFmutated unresectable or metastatic melanoma patients, where targeted therapy is indicated and the combination has overtaken BRAF monotherapies (e.g. vemurafenib monotherapy) as the current standard of care.

## About the product

Encorafenib is a potent and highly selective ATP-competitive small molecule RAF kinase inhibitor. The half maximal inhibitory concentration (IC50) of encorafenib against BRAF V600E , BRAF and CRAF enzymes was determined to be 0.35, 0.47 and 0.30 nM, respectively. The encorafenib dissociation half-life was &gt;30 hours and resulted in prolonged pERK inhibition. Encorafenib suppresses the RAF/MEK/ERK pathway in tumour cells expressing several mutated forms of BRAF kinase (V600E, D and K). Specifically, encorafenib inhibits in vitro and in vivo BRAF V600E, D and K  mutant melanoma cell growth. Encorafenib does not inhibit RAF/MEK/ERK signalling in cells expressing wild-type BRAF.

## Combination with binimetinib

12 Chapman P.B., Hauschild A., Robert C. et al Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med., 2011; 364(26): 2507-16

13 Hodi F.S. O'Day S.J. McDermott D.F. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711-23

14 Larkin J., Ascierto P.A., Dréno B. et al Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med., 2014; 371(20): 1867-76

15 Robert C., Karaszewska B, Schachter J et al Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N. Engl. J. Med., 2015a; 372: 30-9

16 Robert C., Long G.V., Brady B. et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as firstline therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Eur J Cancer 2015b 51 sup3: S-663

17  Ascierto P.A., McArthur G.A., Dréno B. et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016 ;17(9):1248-60

18 Chapman P.B., Hauschild A., Robert C. et al Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med., 2011; 364(26): 2507-16

19 Hauschild A., Grob J.J., Demidov L.V. et al Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2012(9839); 380: 358-65

20  McArthur GA, Chapman PB, Robert C et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutationpositive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15(3):323-32 21 Flaherty K.T., Robert C., Hersey P. et al Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med.,

2012; 367(2):107-14

22

Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371(20):1877-88

<div style=\"page-break-after: always\"></div>

Encorafenib and binimetinib (a MEK inhibitor, see section 5.1 of binimetinib SmPC) both inhibit the MAPK pathway, resulting in higher anti-tumour activity.

Additionally, the combination of encorafenib and binimetinib prevented the emergence of resistance in BRAF V600E  mutant human melanoma xenografts in vivo .

Pharmacotherapeutic group: antineoplastic agent, protein kinase inhibitor, ATC code: not yet assigned

The applicant applied for the following indication:

- -Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see Section 4.4).

The agreed indication was as follows:

- -Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).

Braftovi is supplied as a hard capsule (capsule).

## Braftovi 50 mg hard capsules

Each hard capsule contains 50 mg of encorafenib.

Orange opaque cap and flesh opaque body, printed with a stylised 'A' on the cap and 'LGX 50mg' on the body. The length of the capsule is approximately 22 mm.

## Braftovi 75 mg hard capsules

Each hard capsule contains 75 mg of encorafenib.

Flesh coloured opaque cap and white opaque body, printed with a stylised 'A' on the cap and 'LGX 75mg' on the body. The length of the capsule is approximately 23 mm.

## Method of administration

Braftovi is for oral use. The capsules are to be swallowed whole with water. They may be taken with or without food. The concomitant administration of encorafenib with grapefruit juice should be avoided (see sections 4.4 and 4.5)

Encorafenib treatment in combination with binimetinib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products.

## Posology

The recommended dose of encorafenib is 450 mg (six 75 mg capsules) once daily, when used in combination with binimetinib.

## Dose modification

The management of adverse reactions may require dose reduction, temporary interruption or treatment discontinuation (see Tables 1 and 2).

Dose reduction recommendations for encorafenib are presented in Table 1 of the SmPC.

## Vomiting

<div style=\"page-break-after: always\"></div>

In case of vomiting after administration of encorafenib, the patient should not take an additional dose and should take the next scheduled dose.

## Duration of treatment

Treatment should continue until the patient no longer derives benefit or the development of unacceptable toxicity.

## Missed doses

If a dose of encorafenib is missed, the patient should only take the missed dose if it is more than 12 hours until the next scheduled dose.

## Type of Application and aspects on development

The development programme for encorafenib in combination with binimetinib in unresectable or metastatic BRAF mutant melanoma comprises data from 10 clinical trials: 4 clinical pharmacology studies in healthy volunteers, 1 study in patients with hepatic impairment, 2 clinical pharmacology/ initial tolerability studies in patients with BRAF positive tumours and 4 clinical efficacy and safety studies.

No formal scientific advice was provided by the EMA. In 2013 and 2014, scientific advice was given by 2 national EU Agencies (MPA, Sweden and MEB, Netherlands) on the design of the pivotal Phase 3 study CMEK162B2301, the choice of PFS as primary endpoint for the study as well as the proposed central response assessment.

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is presented as hard capsules containing 50 mg or 75 mg of encorafenib as active substance.

Other ingredients of the capsule content are: copovidone (E1208), poloxamer 188, cellulose microcrystalline (E460i), succinic acid (E363), crospovidone (E1202), silica colloidal anhydrous (E551) and magnesium stearate (E470b). Ingredients of the capsule shell are: gelatin (E441), titanium dioxide (E171), iron oxide red (E172), iron oxide yellow (E172) and iron oxide black (E172). Ingredients of the printing ink are: shellac (E904), iron oxide black (E172) and propylene glycol (E1520).

The product is available in polyamide/aluminium/PVC/aluminium blister as described in section 6.5 of the SmPC.

## 2.2.2. Active Substance

## General information

The chemical name of encorafenib is methyl N-{(2 S )-1-[(4-{3-[5-chloro-2-fluoro-3(methanesulfonamido)phenyl]-1-(propan-2-yl)-1 H -pyrazol-4-yl}pyrimidin-2-yl)amino]propan-2yl}carbamate corresponding to the molecular formula C22H27ClFN7O4S. It has a relative molecular mass of 540.0 and the following structure:

<div style=\"page-break-after: always\"></div>

Figure 1: encorafenib active substance structure

<!-- image -->

The chemical structure of encorafenib was elucidated by a combination of infrared (IR) spectroscopy, proton and carbon nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), elemental analysis, optical rotation, single crystal X-ray, differential scanning calorimetry (DSC) and dynamic vapour sorption. The crystal structure of encorafenib was determined by X-Ray Powder Diffraction (XRPD)

Experimental polymorphism studies demonstrated that encorafenib is present in a single polymorphic form: \"Modification A\". Based on the polymorphism study, the absence of routine test for polymorphism in the active substance specification is considered acceptable. It was also shown that the polymorphic form does not change throughout the shelf life as observed in three batches of the active substance placed on stability studies under long-term and accelerated conditions.

The active substance is a white to almost white non-hygroscopic powder. Although the solubility of encorafenib is high at normal gastric pH, it is not sufficiently high across the full range of physiologically relevant pH values of the gastrointestinal tract for encorafenib to be characterized as a highly soluble compound in the BCS classification system. Because encorafenib demonstrates high apparent permeability, its solubility in media with higher pH results in encorafenib being designated as a BCS Class II drug.

Encorafenib exhibits stereoisomerism due to the presence of a single chiral centre. Enantiomeric purity is controlled routinely by chiral HPLC/UV. The stereoisomerism of the active substance originates from the starting material.

## Manufacture, characterisation and process controls

The active substance is synthesized using a convergent synthesis process bringing together three synthetic lines in chemical transformation steps.

None of the process steps is considered critical; however a number of critical process parameters are defined.

Encorafenib is proposed for the treatment of an advanced cancer. According to the ICH S9 note for guidance and the ICH M7 guideline, active substances and finished products which are indicated for advanced cancer are exempt from the requirements of ICH M7; impurities may be controlled in line with the ICH Q3 guideline. While genotoxic impurities are not targeted for control to limits specified in the ICH M7 guideline, work conducted during pharmaceutical development did confirm that potential genotoxic impurities are not likely to

<div style=\"page-break-after: always\"></div>

be present in the final active substance above the calculated concentration limit based on the threshold of toxicological concern (TTC), which is 22 ppm [(10 µg/day for 1 - 10 years exposure)/(0.45 g encorafenib/day)].

Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances.

Potential and actual impurities were well discussed with regards to their origin and characterised.

The commercial manufacturing process for the active substance was developed in parallel with the clinical development program. Changes introduced have been presented in sufficient detail and have been justified.

The quality of the active substance used in the various phases of the development is considered to be comparable with that produced by the proposed commercial process.

The manufacturing process has been developed using elements of Quality by Design (QbD) such as risk assessment; however no design space is claimed.

## Specification

The active substance specification includes tests for: appearance (visual), identity (IR), related substances (chiral HPLC, UHPLC/UV), residual solvents (GC), water content (KF), particle size (laser diffraction) and assay (UHPLC/UV).

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis data on 11 commercial scale batches of the active substance manufactured using the proposed commercial manufacturing process are provided. Supportive data on 19 additional batches used during development were also provided. The results are within the specifications and consistent from batch to batch.

## Stability

Stability data from 3 batches of the active substance manufactured at scale which is approximately 70% of the commercial scale, by the proposed manufacturer and stored in the intended commercial package for up to 24 months under long term conditions (30 ºC / 75% RH) and for up to 6 months under accelerated conditions (40 ºC / 75% RH) according to the ICH guidelines were provided. The batches were representative of those manufactured using the proposed commercial process.

The following parameters were tested: appearance, assay, related substances (including the undesired R -enantiomer), water content, and polymorphic form. The analytical methods used were the same as for release and were stability indicating.

Photostability testing following the ICH guideline Q1B was performed on a single batch. The results demonstrate that the active substance is not sensitive to light.

Results on stress conditions: acid hydrolysis, base hydrolysis, oxidation, photodegradation, and degradation from heat and heat and humidity were also provided on a single batch. However, the degradation products resulting from these stress conditions have not been observed in the active substance during pharmaceutical

<div style=\"page-break-after: always\"></div>

development and, therefore, no specific manufacturing process controls have been implemented to address these potential degradation pathways.

The stability results indicate that the active substance manufactured by the proposed supplier is sufficiently stable. The stability results justify the proposed retest period.

## 2.2.3. Finished Medicinal Product

## Description of the product and Pharmaceutical development

The finished product is an immediate release hard gelatin capsule for oral administration. Capsules are available in two dosage strengths of 50 mg and 75 mg. The 50 mg capsule is size 0 with a Swedish orange opaque cap and flesh opaque body, printed with a stylized 'A' on the cap and 'LGX 50 mg' on the body. The length of the capsule is approximately 22 mm. The 75 mg capsule is size 00 with a flesh coloured opaque cap and white opaque body, printed with a stylized 'A' on the cap and 'LGX 75 mg' on the body. The length of the capsule is approximately 23 mm. Two presentations differ in terms of size, colouring and imprints.

The critical quality attributes identified are: appearance, aspect (absence of visual capsule defects), size, identification, assay, uniformity of dosage units, degradation products, dissolution, crystallisation of active substance, water content and microbial limits.

As mentioned earlier in the report the active substance is a BCS Class II substance.

All excipients are well known pharmaceutical ingredients and their quality are compliant with Ph. Eur. standards, except for succininc acid for which there is no Ph. Eur. monograph. This excipient is controlled according to an in-house monograph based on the USP-NF monograph.  There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.1.1 of this report.

The compatibility of active substance with excipients described was evaluated to determine the potential of excipients to cause significant active substance instability.

The manufacturing site that was used for the production of pivotal clinical batches and primary stability batches is the proposed commercial manufacturing site. Early development batches and some pivotal batches were manufactured at the development site using the initial manufacturing process. The initial manufacturing process was optimised prior to being transferred to the commercial site. The same equipment class was used for each unit operation at each manufacturing site. A comparison of the capsule manufacturing process parameters used at both sites has been provided and considered acceptable. The changes in process parameters have been supported by conducting optimisation studies. Following the manufacturing process development, the critical process parameters were  identified and the proven acceptable ranges have been established, however no design space is claimed.

The first in human formulation was based on a microemulsion, which was replaced by a capsule formulation in Phase 1 clinical development. The capsule formulation was used throughout clinical development, including the pivotal clinical study, and is the same as the proposed commercial capsule formulation. The finished product formulation, using a common blend for capsules of different strengths, has remained consistent throughout development.

The 50 mg and 75 mg capsule strengths were developed for easier administration compared to the 100 mg capsules used in clinical trials. The 75 mg presentation represents a balance between capsule size and capsule burden (the number of capsules to be taken daily). The 100 mg strength finished product used in

<div style=\"page-break-after: always\"></div>

clinical trials was encapsulated in a size 00EL capsule (length: ~25.5 mm). The size of the 100 mg capsules was considered large and patients may find it difficult in administering the capsules. Although the number of the 75 mg capsules to be taken all at once (six capsules) is considered relatively high, considering the indication of Braftovi is for the treatment of an advanced cancer, and to allow easier administration, the proposed strengths of 50 mg and 75 mg are considered appropriate.

The discriminatory power of the dissolution method has been demonstrated.

The primary packaging is polyamide/aluminium/PVC/aluminium blister. The material complies with Ph. Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product and process controls

The finished product is manufactured using a non-standard manufacturing process. There are no critical steps or intermediates in the manufacture of finished product.

Major steps of the manufacturing process have been validated by a number of studies on three batches of each  of  the  capsule  strength.  It  has  been  demonstrated  that  the  manufacturing  process  is  capable  of producing  the  finished  product  of  intended  quality  in  a  reproducible  manner.  The  in-process  controls  are adequate for this type of manufacturing process and pharmaceutical form.

The available development data, the proposed control strategy and batch analysis data from commercial scale batches fully support the proposed PARs (Proven Acceptable Ranges).

## Product specification

The finished product release specifications include appropriate tests for this kind of dosage form: appearance of  capsule  (visual),  appearance  of  contents  (visual),  identification  (UV,  UHPLC/UV),  assay  (UHPLC/UV), degradation products (UHPLC/UV), crystalline finished product content (XRPD), uniformity of dosage units by content  uniformity  (Ph.  Eur.),  dissolution  (Ph.  Eur.  -  HPLC/UV),  water  content  (Ph.  Eur.  -  KF),  and microbiological enumeration and specified micro-organisms (Ph. Eur).

The undesired R -enantiomer is controlled in the active substance specification but not in the finished product release specification. The R -enantiomer is analysed on the finished product during stability studies. No changes in its level have been observed. Therefore, it is considered acceptable not to control R -enantiomer in the finished product specification.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis results are provided for six batches of each of the capsule strengths at commercial scale and 38 development batches of the finished product confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

The finished product is released on the market based on the above release specifications, through traditional final product release testing.

<div style=\"page-break-after: always\"></div>

## Stability of the product

Stability  data  from  six  batches  of  each  of  the  capsule  strengths  at  commercial  scale  batches  of  finished product stored for up to 24 months under long term conditions (25 ºC / 60% RH), for up to 24 months under intermediate conditions (30 ºC / 75% RH) and for up to six months under accelerated conditions (40 ºC / 75% RH) according to the ICH guidelines were provided. The batches of medicinal product are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing.

Samples were tested for appearance, assay and degradation products, dissolution, water content, undesired R -enantiomer content (HPLC), crystalline active substance content by XRPD, and microbial content. The same analytical methods were used as for the release of the product, apart from the enantiomer analysis that is only performed during the stability study. The analytical procedures used are stability indicating.

The proposed shelf life of 27 months is considered acceptable based on the ICH Q1E guideline.

In  addition,  a  single  batch  of  each  of  the  capsule  strength  was  exposed  to  light  as  defined  in  the  ICH Guideline  on  Photostability  Testing  of  New  Drug  Substances  and  Products.  Good  chemical  and  physical stability was shown upon direct exposure to light.  It is concluded that special labelling or packaging is not needed to mitigate exposure to light. A statement 'Store in the original package in order to protect from moisture' has been included in the product information.

Based on available stability data, the proposed shelf-life of 27 months when stored in the original package in order to protect from moisture as stated in the SmPC (section 6.3) are acceptable.

## Adventitious agents

Gelatine obtained from bovine sources is used in the product. Valid TSE CEP from the suppliers of the gelatine used in the manufacture is provided.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

The applicant has applied QbD principles in the development of the finished product and its manufacturing process. However, no design spaces were claimed for the manufacturing process of the active substance, nor for the finished product.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

## 2.2.6. Recommendations for future quality development

Not applicable.

<div style=\"page-break-after: always\"></div>

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

The non-clinical pharmacology and toxicology studies were performed in several in vitro in and in vivo models. Non-GLP pharmacology, functional, molecular (mechanism of action) and anti-cancer efficacy studies were performed to evaluate the level of activity of encorafenib alone and in combination with binimetinib in both in vitro (isolated enzyme and cell culture) and in vivo (mouse xenograft) model systems. No PK, ADME or toxicology studies have been performed with the combination. The safety pharmacology studies and the pivotal toxicology studies were conducted in compliance with GLP.

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

## In vitro

Encorafenib and the major circulating metabolite, LHY746 (AR00492720-01) were tested for the potency to inhibit wild type BRAF, V600E mutant BRAF, and CRAF using a radiometric assay format.

The IC50 of the metabolite LHY746 against BRAF V600E , BRAF and CRAF enzymes was determined to be 9.27, 15.54 and 9.1 nM, respectively. The IC50 of encorafenib against BRAFV600E, BRAF and CRAF enzymes was 0.8, 1.1 and 0.6 nM.

The selectivity of encorafenib (LGX818) was profiled by evaluating inhibitory activity against 442 kinases at 10  μM  (KinomeScan;  Ambit).  There  were  40  hits  (&lt;25%  percent  of  control)  which  were  followed  up  in  a dose-response study. The dose-response study confirmed activity on BRAF, BRAF V600E  and CRAF. The only other kinases inhibited with an IC50 of similar magnitude (less than 10 nM) was STK36 (~ 5 nM).

## Viability and p-ERK Inhibition by Encorafenib in BRAF-Mutant Humans Melanoma Cell Lines (RD2011-50435, RD-2011-50039, 818-CBiology-0117)

Encorafenib was evaluated in a panel of 512 genetically annotated human cancer cell lines for effects on cell viability and/or proliferation (Cell Titer Glo™ assay).

The majority of cell lines that were sensitive to encorafenib contained the BRAF V600E allele. In contrast, cell lines  lacking  this  allele  were  predominantly  insensitive  to  encorafenib.  In  a  follow-up  assay,  6  colorectal derived lines and 26 melanoma-derived cell lines, all of which harbored V600 alterations (E, D or K), were examined for sensitivity to encorafenib. Results showed that 4/6 (67%) of the colorectal, and 19/26 (73%) of the melanoma cell lines were responsive to encorafenib.

Table 2: Grouping of BRAFV600E/D/K or BRAFV600 WT by encorafenib

| CP=crossing point  BRAFV600  Percentagewith  Fisher'sExactTest  Compound  Status  CP &lt; 1uM  p-value  LGX818  V600E/D/K  74% (28/38)  2.7 x 10-32  LGX818  Wild Type  1.0% (5/455)   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

Encorafenib was titrated in the A375 BRAF mutant melanoma cell line for viability (Cell Titer Glo™ assay) and for phosphorylation of extracellular signal-regulated kinase (p-ERK; in-cell Western blot) (RD-2011-50039). Both assays detect the modulation of phosphor-ERK or phosphor-MEK. The EC50 was calculated to be 0.004 µM for the in-cell Western blot and 0.003 µM for the proliferation assay.

<!-- image -->

Cell Titer GloTM assay was performed, the data was plotted and the absolute ICso values were calculated using the Excel Fit program. Five separate data sets were averaged and the ECgo was calculated to be 0.0044 +/- 0.0011 pM.

## Figure 2:

Cell proliferation assay in A375 melanoma cells treated with encorafenib

The  studies  showed  that  encorafenib  is  approximately  2-fold  more  potent  than  the  metabolite  LHY746  at inhibiting phospho-ERK (33nM vs 76 nM) and approximately 30 fold more potent than LHY746 at inhibiting Malme-3M proliferation (3.7 nM vs 120 nM).

Table 3: Summary of IC50 values

| CellAssay:    | LGX818 1C±SD (nM)   | LHY746 1C±SD(nM)   |   Folddifference inActivity |
|---------------|---------------------|--------------------|-----------------------------|
| phospho-ERK   | 33 ± 2.1            | 76 ± 4.2           |                         2.3 |
| Proliferation | 3.7±0.3             | 119 ±9.2           |                        32   |

## In vivo

## Nude Mouse, A375 (BRAFV600E Mutant) Melanoma Xenografts

The efficacy and tolerability of LGX818 in the A375 (BRAFV600E) human melanoma mouse tumour xenograft model in nude mice were evaluated. A wide dose-range (0.6 to 300 mg/kg, PO, BID) was tested in this two week study. Mean tumour growth data over time are presented in Figure 3.

<div style=\"page-break-after: always\"></div>

Figure 3: Effects of LGX818 on Tumour Growth in the A375 Human BRAF-Mutant

<!-- image -->

N = 5 mice per treatment group Data are mean ± SEM

* p &lt; 0.05 for 6 mg/kg and 300 mg/kg LGX818 versus Vehicle by Kruskal-Wallis ANOVA on ranks followed by pairwise comparisons using Tukey test.

This study was designed to determine the dose-dependent effects of encorafenib alone and in combination with a fixed dose of binimetinib on A375 BRAFV600E mutant-melanoma tumour growth in nude mice. There were 8 treatment groups: vehicle (1% CMC/0.5 % Tween 80 in water), binimetinib (MEK162, 3.5 mg/kg, PO, BID), encorafenib (LGX818, 6, 20 or 60 mg/kg, PO, QD) and 3 combination treatment groups with binimetinib (MEK162, 3.5 mg/kg, PO, BID) plus encorafenib (LGX818, 6, 20 or 60 mg/kg, PO, QD).

Mean tumour growth data (± SEM) over time are presented in Figure 4.

<div style=\"page-break-after: always\"></div>

Figure 4: Effects of Encorafenib and Binimetinib as Single Agents, and in Combination, on Tumour Growth in A375 Human BRAF-Mutant Melanoma Xenografts in Nude Mice

<!-- image -->

N = 7 mice per treatment group at study start

## Binimetinib and Encorafenib as Single Agents and in Combination in the HMEX1906 (BRAFV600E) PDX Model

Mean tumour growth data over time are presented in Figure 5.

<div style=\"page-break-after: always\"></div>

Figure 5: Effects of LGX818 on Tumour Growth in the HMEX1906 BRAF-Mutant

<!-- image -->

Data are Mean ± SEM

N = 10 mice per treatment group

* p&lt;0.05 for 5 mg/kg and 20 mg/kg LGX818 versus Vehicle by Kruskal-Wallis ANOVA on ranks followed by pairwise comparisons using Tukey test.

<div style=\"page-break-after: always\"></div>

Figure 6: Individual Animal Efficacy of Binimetinib and Encorafenib as Single Agents and in Combination in the HMEX1906 (BRAFV600E) PDX Model

<!-- image -->

## Nude Mouse, MEL13B4 (BRAFV600E) Mutant Human Melanoma Primary Xenograft

This study was designed to determine the dose-dependent effects of encorafenib alone and in combination with a fixed dose of binimetinib on MEL13B4 BRAFV600E mutant-melanoma PDX tumour growth in nude mice. There were 8 treatment groups: vehicle (1% CMC/0.5 % Tween 80 in water), binimetinib (binimetinib, 3.5 mg/kg, PO, BID), encorafenib (encorafenib, 6, 20 or 60 mg/kg, PO, QD) and 3 combination treatment groups with binimetinib (binimetinib, 3.5 mg/kg, PO, BID) plus encorafenib (encorafenib, 6, 20 or 60 mg/kg, PO, QD)(Figure 7).

<div style=\"page-break-after: always\"></div>

Figure 7: Efficacy of Binimetinib and Encorafenib as Single Agents and in Combination in the MEL13B4 (BRAFV600E) Melanoma PDX Model

<!-- image -->

N = 8 mice per treatment group at study start except n=6 for the vehicle-treated arm

## Secondary pharmacodynamic studies

## Off target activity of encorafenib (NVP-LGX818)

Encorafenib (NVP-LGX818) was assessed for its off-target activity on 143 GPCRs, transporters, ion channels, nuclear receptors and enzymes. Activities of &gt; 50% inhibition or activation at 10 μM were consistently found only in the PDE4D enzymatic assay (IC50 = 4.4 μM, n=3).

Encorafenib was tested on 7 targets which have been identified as being potentially involved in suicidality. The compound had no activity up to the highest concentrations tested.

## Off-target activity of NVP-LHY746 (A Primary Metabolite of LGX818)

NVP-LHY746 (a primary metabolite of LGX818) was assessed for its off-target activity on 56 GPCRs, transporters, ion channels, nuclear receptors and enzymes. Activities of &gt;50% inhibition at 10 μM were found on KDR kinase (IC50 = 1.8 μM, n=1) and phosphodiesterase PDE4D (IC50 = 4.2 μM, n=2). It was also found to be an agonist of the pregnane X receptor (PXR) (EC50 = 3.8 μM, n=1).

<div style=\"page-break-after: always\"></div>

## Safety pharmacology programme

Table 4: Overview of the results of the safety pharmacology studies

| Organ Systeims Evaluated                 | Species/Strain       | Method of Admin.   | Doses a (mg/kg)   | Gender and No. per Group               | Noteworthy Findings                                                                                                                                                                                                                                          |
|------------------------------------------|----------------------|--------------------|-------------------|----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| hERG Channel                             | HEK293 cells         | In vitro           | Up to 100 μM      | NA                                     | hERG channel inhibition ICso = 73.4 μM                                                                                                                                                                                                                       |
| Neurobehavioral and Respiratory Function | Rat, Sprague- Dawley | PO                 | 0 or 100          | 10M for behavioral; 5M for respiratory | No significant effects at 100 mg/kg NOAEL = 100 mg/kg                                                                                                                                                                                                        |
| Cardiovascular Function                  | Monkey, Cynomolgus   | PO                 | 50, 100,200       | 6M                                     | No significant effects on systemic blood pressures (systolic, diastolic, mean arterial and pulse pressure), electrocardiographic intervals (PR, QT, QTe, QRS), body temperature or ECG waveforms Higher heart rates at all dose levels with no diurnal shift |

a Single dose unless specified otherwise b All studies were conducted using LGX818 and all dose levels refer to active compound. All doses are in units of mg/kg unless otherwise specified.

NA = Not Applicable

## Pharmacodynamic drug interactions

The applicant did not submit pharmacodynamic drug interaction studies (see non-clinical discussion).

## 2.3.3. Pharmacokinetics

PK  data  were  obtained  from  studies  conducted  in  mice,  rats,  dogs  and  monkeys  with  encorafenib administered either orally or/and intravenously.

## Single Dose :

Table 5: Tabulated PK data for single dose encorafenib

| Study ID        | Type of Study               | Species N/Gender   | Route, Dose                    | Results                                                                                                                                                                                                                                            |
|-----------------|-----------------------------|--------------------|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| RD- 2011- 50077 | Single dose PK of free base | Mice Balb/c 3 M    | Oral 10 mg/kg BW IV 2 mg/kg BW | Low clearance (4.3 mL/min/kg) and very low volume of distribution (0.1 L/kg), with a short mean residence time (MRT) of 0.4 h and elimination half-life of 0.9 h. Following oral administration high oral exposure with a mean Cmax and AUC(0- ∞ ) |

<div style=\"page-break-after: always\"></div>

| Study ID        | Type of Study                       | Species N/Gender                                    | Route, Dose                                        | Results                                                                                                                                                                                                                                                                                                                                                  |
|-----------------|-------------------------------------|-----------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| RD- 2011- 50078 | Single dose PK of free base         | Rats Wistar 3 M                                     | Oral 10 mg/kg BW IV 3 mg/kg BW                     | Low clearance (1.06 mL/min/kg) and very low volume of distribution (0.13 L/kg), with a short mean residence time (MRT) of 2.1 h and elimination half-life of 2.3 h. Following oral administration high oral exposure with a mean Cmax and AUC(0- ∞ ) of 48.4 μ M and 144 h* μ M, respectively. Oral bioavailability was 49%.                             |
| DMPK R 1000227  | Single dose PK of [ 14 C] free base | Rats Han Wistar Intact and bile duct- cannulate 3 M | Oral Suspension 50 mg/kg BW IV Solution 5 mg/kg BW | Free base of encorafenib was the main radioactive compound in plasma extracts, accounted for 85% of the total plasma AUC0-24h after either iv. or oral dosing. Elimination primarily through extensive oxidative metabolism and, to a much smaller extent, through parent drug excretion (~10% of the recovered dose in the 0-72h excreta) following iv. |
| RD- 2011- 50053 | Single dose PK of free base         | Dogs Beagle 3 M                                     | Oral 0,3 mg/kg BW IV 0,1 mg/kg BW                  | Moderate total clearance (21 mL/min/kg), a moderate volume of distribution (2.6 L/kg) and a terminal half-life of 5.2 hr. Following an oral administration of free base in solution, the mean maximal plasma concentration (Cmax) of 0.12 _M was achieved on average at 0.3 hour post dose. The oral bioavailability was good at 42%.                    |
| DMPK P 1000065  | Single dose PK of free base         | Monkey Cynomolg us 5 M fasted                       | Oral 10 mg/kg BW IV 0,5 mg/kg BW                   | The absolute mean bioavailability after oral solution was 8.7 ± 0.1 %(Formulation: 2 mg/mL solution of LGX818-NX in 20% PEG300 + 3% VitE-TPGS).                                                                                                                                                                                                          |
| DMPK R 1300268  | Single dose PK of [ 14 C]           | Monkey Cynomolg                                     | Oral 20 mg/kg                                      | Systemic plasma clearance was moderate (20 mL/min/kg), The volume of distribution at steady state was moderate at                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Study ID   | Type of Study   | Species N/Gender   | Route, Dose      | Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|------------|-----------------|--------------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|            | free base       | us 5 M             | BW IV 3 mg/kg BW | approximately 1.00 L/kg and the mean terminal t1/2 was 1.1 hours. After IV administration, the terminal t1/2 was similar at 0.64 hours. Following an oral dose, the Tmax was 2 hours. The overall oral absorption of [14C]encorafenib, estimated from dose-normalized AUCs for radioactivity after IV and oral doses, was estimated to be approximately 60-80% based on blood and plasma, respectively. The bioavailability in this study was calculated to be approximately 22%. Metabolic evaluation see section 3.4. |

## Tissue distribution/Melanin Binding

Tissue distribution studies were performed for drug-derived carbon-14 material using quantitative whole body autoradiography (DMPK R1100588) in Long Evans Hooded (pigmented) rats at 0.25, 1, 2, 4, 7, 24, 72 and 168 hours following a single oral (50 mg/kg) dose of [14C]encorafenib, and at 0.05 and 2 h following a single intravenous (5 mg/kg) dose. Additionally, one HanWistar (albino) rat was sacrificed at 168 hours post 50 mg/kg oral dose for comparison. [14C]encorafenib-derived radioactivity was absorbed and widely distributed to tissues in rats following a single oral (PO) dose with most tissue radioactivity concentrations reaching Cmax between 0.25 to 2 h post-dose.  The tissue:blood ratio based on AUCinf of radioactivity was &gt;1 for the bile, colon wall, liver, and kidney pelvis, cortex, and medulla. The elimination of drug-related radioactivity was moderate in most tissues (t1/2 &lt; ~10 h), except for the liver (t1/2 = 47.2 h). At 72 h post dose, radioactivity in most tissues was not measurable, except for the kidney medulla and liver. Overall, the tissue distribution pattern after an IV dose was similar to that after an oral dose. Drug-related [14C]encorafenib radioactivity showed little or no distribution to the central nervous system (brain and spinal cord) and no retention in the melanin-rich tissues (skin and uveal tract). No radioactivity was detected in either pigmented or non-pigmented rats at 168 hour.

## Plasma protein Binding and Blood Plasma Ratio

Plasma protein binding, which appeared to be independent of encorafenib concentration, ranged from 74.6 to 98.6% across species, with high binding in rodents and moderate binding in other species (DMPK R1100210). In humans, the mean plasma protein binding of encorafenib was moderate, approximately 86.1%, when evaluated by the ultracentrifugation method over the concentration range evaluated (50 to 50,000 ng/mL). The blood-to-plasma concentration ratios, which also appeared to be independent of encorafenib concentration, ranged from 0.61 to 0.81 across species (0.75 in humans). In humans, the blood-to-plasma ratio was approximately 0.75 over the concentration range evaluated (50 to 50000 ng/mL).

<div style=\"page-break-after: always\"></div>

## In vivo Metabolism in Sprague-Dawley Rat

Encorafenib was the major circulating drug-related component in the plasma after either IV or oral dosing, contributing 85% to the total radioactivity by AUC0-24h regardless of administration route. All circulating metabolites were &lt;5% of total radioactivity in plasma of rats for IV and PO administration. The major metabolic pathways of encorafenib in the rat involved oxidative N-dealkylation which included loss of the isopropyl moiety (M32.7), loss of the isopropyl-carbamic acid methyl ester side chain (M42.5A), and loss of both the isopropyl moiety and the isopropylcarbamic acid methyl ester side chain (M23.8). Together, these three metabolites accounted for ~62% of the dose eliminated in rat excreta after intravenous dosing.

The majority of the dose recovered in rat excreta was found in the faeces with a smaller amount in the urine following both routes of administration. In urine, metabolite M23.8 (a double N-dealkylated metabolite derived from the loss of both the isopropyl moiety and the isopropyl carbamic acid methyl ester side chain) was the predominant component, with minimal unchanged encorafenib. In faeces, ~9.96% (intravenous) and ~45.7% (oral) of the dose was associated with unchanged encorafenib, while metabolite M32.7 (Ndesisopropyl encorafenib) was the most abundant metabolite.

The most abundant component in faeces of bile duct-cannulated rats was unchanged encorafenib, accounting for 5.50% and 57.8% of the administered dose for the intravenous and oral groups, respectively.

## Drug Metabolizing Enzymes

The effect of selective chemical inhibitors of CYP enzymes on the rate of total oxidative [14C]encorafenib metabolism in human liver microsomes was also determined. The maximal percent inhibition achieved by CYP3A inhibitors (ketoconazole and azamulin) was 76.3%. The inhibitor quinidine (CYP2D6) inhibited total [14C]encorafenib oxidative metabolism by 36.5%. After accounting for enzyme abundance in the liver, CYP3A4 was predicted to be the major enzyme contributing to total oxidative clearance of encorafenib in human liver microsomes (~83.3%), followed by CYP2C19 and CYP2D6 (~16.0% and 0.71%, respectively). Strong CYP3A4 inhibitor posaconazole when co-administered with encorafenib resulted in ~2.7-fold increase in encorafenib AUC0-24h; co-administration of moderate CYP3A4 inhibitor diltiazem resulted in ~1.8-fold increase in encorafenib AUC0-24h.

## In vivo Metabolism in Monkey

In monkey plasma, [14C]encorafenib accounted for 40% and 10% of the total radioactivity AUClast, after IV and PO administration, respectively. The most prominent plasma metabolites were M22.5A (formed through carbamate hydrolysis followed by oxidative deamination, N-dealkylation, and hydroxylation, accounting for 23% of total radioactivity after IV dosing and 42% after PO dosing) and M23.8 (N-dealkylated metabolite derived from loss of both the isopropyl moiety and the isopropyl-carbamic acid methyl ester side chain, accounting for 7.8% of total radioactivity after IV dosing and 12% after PO dosing). Overall [14C]encorafenib was extensively metabolized to multiple metabolites, where only 2.51% or 6.19% of intact encorafenib remained in excreta after either an intravenous or an oral dose, respectively.

## Enzyme Induction and Inhibition

## CYP Inhibition

Encorafenib was assessed as a potential inhibitor of cytochrome P450s in vitro in human liver microsomes with appropriate probe substrates. Encorafenib showed inhibitory potency for CYP2B6, CYP2C9 and CYP3A4/5 with IC50 values of ~1, ~5 and ~8-15 μM, respectively. Encorafenib showed inhibitory potency for CYP1A2,

<div style=\"page-break-after: always\"></div>

CYP2C8, CYP2C19 and CYP2D6 with IC50 values of ~22, ~20-30, ~50 and ~25 μM, respectively. Very little or no inhibition of CYP2A6 and CYP2E1 was observed at encorafenib concentrations of up to 100 μM.

Encorafenib was also assessed as a potential time-dependent inhibitor of cytochrome P450s in human liver microsomes. Encorafenib showed no apparent time-dependent inhibition of CYP1A2, CYP2C9 or CYP2D6 at encorafenib concentrations of up to 50 μM and weak time-dependent inhibition of CYP3A4/5.

## UGT Inhibition

Encorafenib was assessed as a potential inhibitor of UGT1A1 in vitro using pooled human liver microsomes and recombinant UGT1A1. In vitro experiments indicate that encorafenib is a relatively potent inhibitor of UGT1A1. In pooled microsomes, with estradiol as the probe substrate the IC50 was ~7 μM and with binimetinib (MEK162) as the probe substrate the IC50 was ~1-4 μM. In an assay using recombinant UGT1A1, with estradiol as the probe substrate the IC50 was ~4 μM and with binimetinib as the probe substrate the IC50 was ~3.5 μM.

## CYP Induction

The potential for encorafenib to activate the human pregnane X-receptor (PXR) was assessed in a cell-based reporter gene assay. Assay results indicated a moderate risk of CYP3A4 induction in vitro by encorafenib (≥ 10-50 μM), as the PXR activation ranged between 25-40% of the positive control RIF response at these concentrations.

Encorafenib was investigated as an in vitro inducer of cytochrome P450 enzymes in cryopreserved human hepatocytes in 2 studies based on mRNA as well as activity. Encorafenib was found to be an in vitro inducer of CYP1A2, CYP2B6, CYP2C9 and CYP3A4 based on mRNA and activities (levels &gt; 2-fold) in at least one of the three donor hepatocytes. Maximal CYP1A2 induction by encorafenib (1-100 μM) was 13.0- to 39.2-fold based on mRNA and 2.12- to 3.76-fold based on activity. Maximal CYP2B6 induction donors. Maximal CYP2C9 induction was 2.8- to 5.41-fold based on mRNA but only exceeded 2- fold based on activity in 2 of 3 donors. Maximal CYP3A4 induction was 24.9- to 167-fold based on mRNA and 2.21- to 4.97-fold based on activity. It can be concluded that encorafenib is an inducer of CYP1A2, CYP2B6, CYP2C9 and CYP3A4 mRNA and activity when evaluated in vitro .

## Routes and Extent of Excretion

A mass balance excretion study were performed in intact and bile duct-cannulated rats dosed with [14C]encorafenib. Following IV dosing of [14C]encorafenib at 5 mg/kg in intact rats, urinary and faecal excretion accounted for approximately 24.3% and 74.1% of total radioactivity, respectively. Within 48 hours after a single dose (IV or oral) approximately 86.9-95.9% of the dose was excreted into urine and faeces. By 7 days following [14C]encorafenib administration, by either the IV or oral routes, total recovery of radioactivity in the excreta was approximately 99% or 97.4%, respectively.

A mass balance excretion study was also performed in cynomolgus monkeys dosed with [14C]encorafenib. Following IV dosing of [14C]encorafenib at 3 mg/kg, more radioactivity was excreted in the faeces (68.2%) than urine (14.4%) over a 7 day period (0-168 h). Approximately 0.08% of the encorafenib dose was excreted unchanged in urine and 2.43% in faeces after an IV dose in the monkey. Following PO dosing of [14C]encorafenib at 20 mg/kg, again more radioactivity was excreted in the faeces (59.7%) than urine (17.4%) over a 7 day period. The total recovery of [14C]encorafenib-derived radioactivity in excreta (including cage washes) after an IV and PO dose was approximately 95.0% and 90.6% over a 7 day period, respectively. Approximately 0.16% of encorafenib was excreted unchanged in urine and 6.03% in faeces after a PO dose in the monkey.

<div style=\"page-break-after: always\"></div>

## 2.3.4. Toxicology

## Single dose toxicity

No single dose toxicology studies were submitted (see non-clinical discussion).

## Repeat dose toxicity

## Repeat-dose toxicity studies in rats

A 28 day and 13-week repeat-dose toxicity study were performed in rats.

Table 6: 28 day oral gavage repeat-dose toxicity and toxicokinetic study with encorafenib in rats

| Study Type (Study ID) GLP                                         | Species; Number/Dose Group                                                  | Dose (mg/kg/day) p.o.                                                                                   | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------------------------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 28 day repeat dose toxicity + 4 week recovery (Pcs-r 1070180) GLP | Wistar-Han rat; 10/sex/dose + toxicokinetics recovery: 6/sex/control and HD | 0 (vehicle) 20 100 400* * ♀ HD and HD recovery only dosed D1-9 vehicle: 0.5% CMC/0.5% Tween 80 in water | mortality: 2 ♀ HD by D10 sacrificed moribund: 1 ♂ HD, 8 ♀ HD by D10, 1 ♀ HD recovery on D2 of recovery period body weight: ↓♀ LD-HD, ♂ MD, HD food consumption: ↓↓♀ HD, ↓ ♂HD clinical signs: behavior, appearance, motor abilities, ptosis ( ♀ HD irrev.) skin/fur: flaky and reddened skin, footpad swelling, sore tail ( ♂♀ LD-HD, irrev. ♂♀ ) hematology: ↓ hemoglobin ( ♂ HD) ↓ mean red cell volume ( ♂ HD, ♀ MD) ↑ reticulocytes ( ♀ MD, ♂ HD irrev.) ↓ red blood cell count ( ♀ HD irrev.) ↓ mean RBC corpus - hemoglobin ( ♂ HD, ♀ MD), ↑ neutrophils ( ♂ MD-HD) ↑ lymphocytes ( ♂ MD) ↑ eosinophils ( ♂ MD-HD, ↑♀ MD) serum chemistry: ↓ AST ( ♂ HD), ↓ globulin ( ♂ HD), ↑ A/G ratio ( ♂ HD), ↓ serum triglyceride ( ♂ HD, ♀ MD) ↓ creatinine ( ♂ HD), ↓ phosphorus ( ♂ HD, ♀ MD) sacrificed ♀ HD : ↓ platelets, ↓ reticulocytes, ↑ prothrombin time, ↓ fibrinogen, ↓ protein, ↓ albumin, ↓ globulins, ↓ serum triglyceride 1 ♀ HD severe vacuolar hepatopathy, renal tubular epithelial vacuolation organ weights: |

<div style=\"page-break-after: always\"></div>

|         | ↓ mean epididymides weights ( ♂ LD- HD), ↓ mean prostate weights ( ♂ HD) macroscopic findings: plantar skin: scaly/thickened area irrev. ( ♂ MD,HD, ♀ LD,MD) microscopic findings: testes: tubular degeneration and vacuolation epididymides: irrev. oligospermia, cellular debris ( ♂ LD-HD irrev.), stomach: hyperkeratosis, squamous epithelial hyperplasia ( ♂♀ MD,HD), skin/feet: hyperkeratosis, squamous cell hyperplasia, inflammatory cell infiltration ( ♂ MD,HD, ♀ LD,MD)   |         |         |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|---------|
| NOAEL=Ø | NOAEL=Ø                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | NOAEL=Ø | NOAEL=Ø |

A/G: albumin/globulins, AST: aspartate amino transferase, D: day, HD: high dose, irrev.: irreversible, LD: low dose, MD: mid dose, RBC: red blood cell count

Table 7: 13-week oral gavage repeat-dose toxicity and toxicokinetic study with encorafenib in rats

| Study Type (Study ID) GLP                                          | Species; Number/Dose Group                                                  | Dose (mg/kg/day) p.o.                                        | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|--------------------------------------------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 13 week repeat dose toxicity + 4 week recovery (Pcs-r 1270356) GLP | Wistar-Han rat; 10/sex/dose + toxicokinetics recovery: 6/sex/control and HD | 0 (vehicle) 6 20 60 vehicle: 0.5% CMC/0.5% Tween 80 in water | preterminally euthanised: 1 ♂ HD (recovery) on D82 (gavage error) body weight + body weight gain: ↓♂♀ LD-HD food consumption: ↓♂MD, HD skin: scabbed, dry, flaky, red and/or white, and/or on hind/fore paws, tail ( ♂♀ LD-HD, irrev.) hematology: ↑ neutrophils ( ♂♀ HD), ↑ eosinophils ( ♂MD,HD,♀ MD,HD irrev. ↑ WBC count ( ♀MD, ♀♂HD irrev. in ♀HD.) , ↑ reticulocytes ( ♀ MD,HD) serum chemistry: ↑urea ( ♂MD, HD), ↑glucose ( ♀MD,HD,♂ HD), ↑ cholesterol ( ♂LD- HD), ↓ serum triglyceride( ♂ HD), ↑ serum triglyceride ( ♀ MD,HD) organ weights: ↓ mean abs./rel. epididymides weights ( ♂ MD-HD), ↓ mean abs./rel. prostate weights ( ♂MD- HD) macroscopic findings: skin: hind paws: yellow and thick footpad ( ♂ HD), testis: abnormal consistency, small |

<div style=\"page-break-after: always\"></div>

| ( ♂MD, HD), epididymides: abnormal consistency, small ( ♂MD, HD), microscopic findings: testes: tubular degeneration epididymides: oligo/aspermia, cellular debris ( ♂ LD- HD; irrev.), stomach: epithelial hyperplasia, non-glandular, hyperkeratosis ( ↑MD,HD, ♀HD, irrev.), skin (hind paws): hyperkeratosis, epithelial hyperplasia ( ♂♀ LD-HD irrev.)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

NOAEL= 20 mg/kg/day ( ♂rats Cmax=42.1 µ g/mL; AUC=178 µ g.h/mL; ♀rats Cmax=54.5 µ g/mL, AUC= 414 µ g.h/mL)

abs.: absolute, D: day, HD: high dose, irrev.: irreversible, LD: low dose, MD: mid dose, rel.: relative, WBC: white blood cell

Table 8: 28-day repeat-dose toxicity and toxicokinetic study in Cynomolgous monkeys with oral (gavage) administration of encorafenib

| Study Type (Study ID) GLP                                                                        | Species; Number/Dose Group                                                                       | Dose (mg/kg/day) p.o.                                                                            | Major findings                                                                                                                               |
|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| 28-day repeat dose toxicity + 4 week recovery (Pcs- 1070179) GLP                                 | Cynomolgous monkey; 3/sex/dose + toxicokinetics recovery: 2/sex/control and HD                   | 0 (vehicle) 5 20 100 vehicle: 56:29:15% w:w:w PEG400: Cremophor EL: Oleic acid                   | ↓ body weight ( ♂♀ HD) ↓ food consumption: ( ↓♂♀ HD) clinical signs: fecal findings, diarrhea ( ♂♀ HD); emesis with feed +/-compound ( ♀ HD) |
| NOAEL= 100 mg/kg (mean AUC 0-24h (ng.h/mL) for ♂ / ♀ : 63900/61100; 28500/12000 on Days 1 and 29 | NOAEL= 100 mg/kg (mean AUC 0-24h (ng.h/mL) for ♂ / ♀ : 63900/61100; 28500/12000 on Days 1 and 29 | NOAEL= 100 mg/kg (mean AUC 0-24h (ng.h/mL) for ♂ / ♀ : 63900/61100; 28500/12000 on Days 1 and 29 | NOAEL= 100 mg/kg (mean AUC 0-24h (ng.h/mL) for ♂ / ♀ : 63900/61100; 28500/12000 on Days 1 and 29                                             |

HD: high dose

Table 9: 13-week repeat-dose toxicity study in Cynomolgous monkey with oral (gavage) administration of encorafenib

| Study Type (Study ID) GLP                      | Species; Number/Dose Group    | Dose (mg/kg/day) p.o.   | Major findings                       |
|------------------------------------------------|-------------------------------|-------------------------|--------------------------------------|
| 13-week repeat dose toxicity + 4 week recovery | Cynomolgus monkey; 4/sex/dose | 0 (vehicle) 6* 20* 60*  | slightly ↓ body weight gain ( ♂♀ HD) |

<div style=\"page-break-after: always\"></div>

| 1270357)                                                                                                | recovery: 2/sex/control and HD                                                                          | *encorafenib as blend containing15% active ingredient                                                   | GLP                                                                                                     |
|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| NOAEL=60 mg/kg/day (mean AUC 0-24h (ng.h/mL) for ♂/♀ : 2490/1260, 5330/3550, 1190/794 on Days 1, 28, 84 | NOAEL=60 mg/kg/day (mean AUC 0-24h (ng.h/mL) for ♂/♀ : 2490/1260, 5330/3550, 1190/794 on Days 1, 28, 84 | NOAEL=60 mg/kg/day (mean AUC 0-24h (ng.h/mL) for ♂/♀ : 2490/1260, 5330/3550, 1190/794 on Days 1, 28, 84 | NOAEL=60 mg/kg/day (mean AUC 0-24h (ng.h/mL) for ♂/♀ : 2490/1260, 5330/3550, 1190/794 on Days 1, 28, 84 |

HD: high dose

Table 10: 13-week repeat-dose study in Cynomolgous monkeys with oral (gavage) administration of encorafenib

| Study Type (Study ID) GLP                                                                                    | Species; Number/Dose Group                                                                                   | Dose (mg/kg/day) p.o.                                                                                        | Major findings                                                                                                                                                                                                                                                                                                                                                              |
|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 13 week repeat dose toxicity + 10 week recovery (Pcs- 1370471) GLP                                           | Cynomolgous monkey; 4/sex/dose + toxicokinetics recovery: +2/sex/control + HD                                | 0 (vehicle) 20* 60* vehicle: purified water *encorafenib as 15% solid dispersion                             | ↓ body weight ( ♀ LD, HD) clinical signs: emesis + emesis with apparent compound ( ♀ LD, ♂♀ HD), salivation ( ♀ HD) ophthalmic findings: blister-like lesions and yellow substance in fovea; histopathology: separation/detachment in the retina between the outer rods and cones layer and the retinal pigmented epithelium at the central macula fovea ( ♂ HD1/6, ♀HD1/6) |
| NOAEL= 20 mg/kg/day (mean AUC 0-24h (ng.h/mL) for ♂ / ♀ : 5830/11100, 2730/4940, 3120/4280 on Days 1, 23, 86 | NOAEL= 20 mg/kg/day (mean AUC 0-24h (ng.h/mL) for ♂ / ♀ : 5830/11100, 2730/4940, 3120/4280 on Days 1, 23, 86 | NOAEL= 20 mg/kg/day (mean AUC 0-24h (ng.h/mL) for ♂ / ♀ : 5830/11100, 2730/4940, 3120/4280 on Days 1, 23, 86 | NOAEL= 20 mg/kg/day (mean AUC 0-24h (ng.h/mL) for ♂ / ♀ : 5830/11100, 2730/4940, 3120/4280 on Days 1, 23, 86                                                                                                                                                                                                                                                                |

HD: high dose; LD: low dose

## Genotoxicity

Table 11: Overview of genotoxicity studies performed with encorafenib

| Type of test/study ID/GLP                                      | Test system                                          | Concentrations/ Concentration range/ Metabolising system                                                                                                 | Results Positive/negative/equivocal                                                                                                                        |
|----------------------------------------------------------------|------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Gene mutations in bacteria / Pcs- r1070208 / Yes               | Salmonella strains TA1535, TA97a, TA98, TA100, TA102 | 0 - 5000 µg/ +/- S9                                                                                                                                      | Negative for relevant increase in reverse mutations                                                                                                        |
| Chromosome aberrations in mammalian cells / Pcs-r1070206 / Yes | Human peripheral blood lymphocytes                   | Experiment 1: -S9: 25 to 600 μg/mL; +S9: 25 to 700 μg/mL (3+17h) Experiment 2: -S9: 5 to 150 μg/mL; +S9: 25 to 600 μg/mL (20+0h and 3+17h respectively ) | No relevant metaphases with chromosome aberrations Mitotic inhibition >50% at ≥ 400 µg/mL with 3+17 h exposure; and at ≥ 50 µg/mL with 20 h exposure (-S9) |
| Chromosomal aberrations in vivo                                | Male Hanover Wistar rats, 6/dose,                    | 0, 200, 1000, 2000 mg/kg, oral gavage                                                                                                                    | No increase in micronucleated PCEs.                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| / Pcs-r1270199/ Yes   | micronuclei in bone marrow (polychromatic erythrocytes, PCEs)   | separated by 24h, harvest point 24h post treatment   | No significant decrease in PCE/NCE ratio, exposure not determined, no clinical signs.   |
|-----------------------|-----------------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------------------------------------------|

## Carcinogenicity

The applicant did not submit studies in carcinogenicity (see non-clinical discussion).

## Reproduction Toxicity

The applicant did not submit studies in reproduction toxicity (see non-clinical discussion).

Table 12: Embryofetal development (EFD) studies in pregnant rats and rabbits, respectively

| Study type/ Study ID                              | Species; Number Female/ group                         | Route & daily dose (mg/kg)   | Dosing period   | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | NOAEL (mg/kg) AUC                                                                                                             |
|---------------------------------------------------|-------------------------------------------------------|------------------------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| EFD Study No.: 9000201 Novartis Ref. No.: 1370077 | Rats, Wistar Hannover Crl:WI (Han) 24 + additional TK | Oral / gavage 0 0.5 5 20     | gd 6 - 17       | F 0 : Mortality : 1 HD TK found dead on gd 16 after blood sampling; prior to death  activity, sustained convulsions, pallor skin + laboured breathing, no macroscopic findings Body weight gain: HD ↓↓ gd 6 - gd 9 (only transitory) F 1 : Fetal weights : HD males ↓↓ External malformations (not considered treatment related): Abnormal flexure of hindlimb unilateral: 1 Co, 1 MD, 2 HD out of 1 litter Omphalocele : 2 MD out of 1 litter Multiple anomalies (anasarca, small upper + lower jaw + small eye bulge + abnormal flexure of left hindlimb): 1 HD Visceral anomalies: Small left lens : 1 LD; dark discoloration of right vitreous body : 1 LD; bilateral small lens + dark discoloration of left vitreous body : 1 HD Skeletal variations (likely due to ↓↓ fetal weights in HD): Parietal and interparietal bone incomplete ossification: HD ↑↑ Thoracic centrum unossified / incomplete / semi-bipartite / bipartite: HD ↑↑ | 0-24 F 0 : 20 mg/kg/d AUC 0-24 : 370 µg*h/ml Safety margin*: 20 X F 1 : 5 mg/kg/d AUC 0-24 : 90.2 µg*h/ml Safety margin*: 7 X |
| DRF EFD Study No.:                                | Rabbits (Hra[NZW] SPF)                                | 0 50                         | gd 7 - 20       | F 0 : Mortality : 200: 2/3 found dead and 1/3 euthanized on                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| 9000202 Novartis Ref. No.: 1370123                | 3 - 6                                     | 75 100 200              |           | gd 13. Prior to death all does no food consumption +  /liquid fecal output 100: 1/3 euthanized on gd 17 due to extreme bw loss, thinness,  fecal size Clinical signs: ↓ fecal output Food consumption : ≥ 50 ↓ Body weight : 100 ↓ F 1 : Malformations : 50: 1 fetus with exencephaly                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                     |
|---------------------------------------------------|-------------------------------------------|-------------------------|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| EFD Study No.: 9000203 Novartis Ref. No.: 1370141 | Rabbits (Hra[NZW] SPF) 20 + additional TK | Oral / gavage 0 5 25 75 | gd 7 - 20 | F 0 : Mortality : 4 HD; signs prior to death:  food consumption,  feces/liquid feces; partly closed eyes (1 HD), prominent backbones (2 HD), thinness (1 HD) Body weight gain : HD ↓↓ Food consumption : HD ↓↓ (gd 15 - 23) F 1 : Fetal weights: HD ↓ (but within historical control range, likely due to ↓↓ maternal food intake) Total malformations (no. of foetuses / no. of litters): Control: 2/1 (1 with microcaudia ; 1 with cleft skin at ventral sacral region ) - LD:0/0 - MD: 2/2 (1 with microphtalmia ; 1 with gastroschisis ) - HD: 4/4 (1 with diaphragm hernia + small lung lobe ; 1 with absent spleen ; 2/2 with multiple heart malformations ) Visceral anomalies : Heart malformations in HD group: misshapen heart, dilation of ascending aorta, stenosis of pulmonary trunk, absent interventricular septum, dilatated aortic arch Skeletal variations : ↑↑ in no. of fetuses and litters with semi bipartite thoracic centra in MD + HD | F 0 + F 1 : 25 mg/kg/d AUC 0-24 : 1010 µg*h/ml Safety margin*: 79 X |

HD = high dose: MD = mid dose; LD = low dose; gd = gestation day; bw = body weight; ↑↑ = significant increase(d); ↓↓ = significant decrease(d); * = based on comparison to exposure in patients at 450 mg (AUC0-24 = 12.9 μg.hr/ml)

## Toxicokinetic data

Table 13: Animal to human exposure multiples at the NOAEL of the different pivotal toxicity studies performed for encorafenib in rats, monkeys and rabbits

| Study                               | NOAEL (mg/kg/day)   | AUC 0-24h ( µ g.h/mL)   | Animal to human exposure multiples   |
|-------------------------------------|---------------------|-------------------------|--------------------------------------|
| 4-week study in rats (Pcs-r1070180) | N.D.                |                         |                                      |
| 13-week study in rats on Day 90     | ♂ ♀ 20              | ♂ : 178                 | 14                                   |

<div style=\"page-break-after: always\"></div>

| (Pcs-r1270356)                                   |          | ♀ : 414   | 32   |
|--------------------------------------------------|----------|-----------|------|
| 4-week study in monkeys on Day 29                | ♂ ♀ 100  | ♂ : 28.5  | 2.2  |
| (Pcs-1070179)                                    |          | ♀ : 12    | 0.9  |
| 13-week study in monkeys on Day 86 (Pcs-1370471) | ♂ ♀ 20   | ♂ : 3.12  | 0.24 |
| 13-week study in monkeys on Day 86 (Pcs-1370471) |          | ♀ : 4.28  | 0.33 |
| Embryo-fetal development in rats                 |          |           |      |
|                                                  | F 0 : 20 | 370       | 30   |
|                                                  | F 1 : 5  | 90.2      | 7    |
| Embryo-fetal development in rabbits              | F 0 : 25 | 1010      | 79   |
| Embryo-fetal development in rabbits              | F 1 : 25 | 1010      | 79   |

ND: not determined

## Local Tolerance

Three male New Zealand White rabbits were exposed to 500 mg of encorafenib, moistened with 0.4 mL water by application onto clipped skin for 4 hours using a semi-occlusive dressing. Skin reactions were assessed 1, 24, 48 and 72 hours post exposure. No skin irritation, corrosion or discoloration was caused by 4 hours exposure to encorafenib.

## Other toxicity studies

## In vitro phototoxicity study (vh 090801 - non-GLP)

Encorafenib was assayed for phototoxicity to BALB/c 3T3 fibroblast cells using the Neutral Red Uptake assay.

Cells  were  treated  with  a  range  of  encorafenib  concentrations  up  to  185.18 µ M  or  the  positive  control (chlorpromazine). With encorafenib treatment, in the absence of UV-vis light, there was a minimal decrease in  cell  survival.  In  the  presence  of  UV-vis  light,  cytotoxicity  was  observed  at  the  highest  5  concentrations analysed (1.86 to 185.15 µ M). The Photo-Irritation-Factor (PIF) was estimated to be &gt;82. The PIF for the positive control was 33.

## 2.3.5. Ecotoxicity/environmental risk assessment

Table 14: Summary of main study results

| Substance (INN/Invented Name):      | Substance (INN/Invented Name):                 | Substance (INN/Invented Name):                                    | Substance (INN/Invented Name):                 |
|-------------------------------------|------------------------------------------------|-------------------------------------------------------------------|------------------------------------------------|
| CAS-number (if available):          | CAS-number (if available):                     | CAS-number (if available):                                        | CAS-number (if available):                     |
| PBT screening                       |                                                | Result                                                            | Conclusion                                     |
| Bioaccumulation potential- log K ow | OECD107                                        | log Pow at pH 4 = 2.5 log Pow at pH 7 = 2.6 log Pow at pH 9 = 1.0 | Potential PBT N                                |
| PBT-assessment                      | PBT-assessment                                 | PBT-assessment                                                    | PBT-assessment                                 |
| PBT-statement :                     | The compound is not considered as PBT nor vPvB | The compound is not considered as PBT nor vPvB                    | The compound is not considered as PBT nor vPvB |
| Phase I                             | Phase I                                        | Phase I                                                           | Phase I                                        |
| Calculation                         | Value                                          | Unit                                                              | Conclusion                                     |
| PEC surfacewater , default or       |                                                | 0.016 µ g/L                                                       | > 0.01 threshold                               |

<div style=\"page-break-after: always\"></div>

| refined (e.g. prevalence, literature)                            |                                                |                                                                                                                                   |                                                                                                                                   |                                                                                                                                   | (Y)                                                  |
|------------------------------------------------------------------|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|
| Other concerns (e.g. chemical class)                             |                                                |                                                                                                                                   |                                                                                                                                   |                                                                                                                                   | (N)                                                  |
| Phase II Physical-chemical properties and fate                   | Phase II Physical-chemical properties and fate | Phase II Physical-chemical properties and fate                                                                                    | Phase II Physical-chemical properties and fate                                                                                    | Phase II Physical-chemical properties and fate                                                                                    | Phase II Physical-chemical properties and fate       |
| Study type                                                       | Test protocol                                  | Results                                                                                                                           | Results                                                                                                                           | Results                                                                                                                           | Remarks                                              |
| Adsorption-Desorption                                            | OECD 106 or …                                  | Sludge Koc = 287.1 - 341.0 mL.g -1 Soil Koc = 845.5 - 2 397.2 mL.g                                                                | Sludge Koc = 287.1 - 341.0 mL.g -1 Soil Koc = 845.5 - 2 397.2 mL.g                                                                | Sludge Koc = 287.1 - 341.0 mL.g -1 Soil Koc = 845.5 - 2 397.2 mL.g                                                                | Adsorption to sludge and soil low                    |
| Ready Biodegradability Test                                      | OECD 301                                       | 0-2 %, not readily biodegradable                                                                                                  | 0-2 %, not readily biodegradable                                                                                                  | 0-2 %, not readily biodegradable                                                                                                  |                                                      |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems | OECD 308                                       | DT50 (total system) = 203.7-468.6 days DT50 (water) = 19.3-44.4 days DT90 (total system) = 676.8-1 000 days DT90 (water) = 147.5- | DT50 (total system) = 203.7-468.6 days DT50 (water) = 19.3-44.4 days DT90 (total system) = 676.8-1 000 days DT90 (water) = 147.5- | DT50 (total system) = 203.7-468.6 days DT50 (water) = 19.3-44.4 days DT90 (total system) = 676.8-1 000 days DT90 (water) = 147.5- | Not required if readily biodegradable                |
| Phase IIa Effect studies                                         | Phase IIa Effect studies                       | Phase IIa Effect studies                                                                                                          | Phase IIa Effect studies                                                                                                          | Phase IIa Effect studies                                                                                                          | Phase IIa Effect studies                             |
| Study type                                                       | Test protocol                                  | Endpoint                                                                                                                          | value                                                                                                                             | Unit                                                                                                                              | Remarks                                              |
| Algae, Growth Inhibition Test/ Species                           | OECD 201                                       | 72h- NOEC = 0.75 mg.L -                                                                                                           |                                                                                                                                   | µg/L                                                                                                                              | Pseudokirchneriella subcapitata , strain: NIVA CHL 1 |
| Daphnia sp . Reproduction Test                                   | OECD 211                                       | 21d- NOEC = 0.21 mg.L -                                                                                                           |                                                                                                                                   | µg/L                                                                                                                              | Daphnia magna                                        |
| Fish, Early Life Stage Toxicity Test/ Species                    | OECD 210                                       | 30d- NOEC ≥ 10 mg.L -1                                                                                                            |                                                                                                                                   | µg/L                                                                                                                              | Zebra fish                                           |
| Activated Sludge, Respiration Inhibition Test                    | OECD 209                                       | 3h-NOEC = 1000 mg.L -1                                                                                                            |                                                                                                                                   | µg/L                                                                                                                              | Micro-organisms in activated sludge.                 |
| Phase IIb Studies                                                | Phase IIb Studies                              | Phase IIb Studies                                                                                                                 | Phase IIb Studies                                                                                                                 | Phase IIb Studies                                                                                                                 | Phase IIb Studies                                    |
| Bioaccumulation                                                  | OECD 305                                       | BCF                                                                                                                               |                                                                                                                                   | L/kg                                                                                                                              | %lipids:                                             |
| Aerobic and anaerobic transformation in soil                     | OECD 307                                       | DT50 %CO                                                                                                                          |                                                                                                                                   |                                                                                                                                   | for all 4 soils                                      |
| Soil Micro organisms: Nitrogen Transformation Test               | OECD 216                                       | 2 %effect                                                                                                                         |                                                                                                                                   | mg/ kg                                                                                                                            |                                                      |
| Terrestrial Plants, Growth Test/ Species                         | OECD 208                                       | NOEC                                                                                                                              |                                                                                                                                   | mg/ kg                                                                                                                            |                                                      |
| Earthworm, Acute Toxicity Tests                                  | OECD 207                                       | NOEC                                                                                                                              |                                                                                                                                   | mg/ kg                                                                                                                            |                                                      |
| Collembola, Reproduction Test                                    | ISO 11267                                      | NOEC                                                                                                                              |                                                                                                                                   | mg/ kg                                                                                                                            |                                                      |
| Sediment dwelling organism                                       |                                                | NOEC                                                                                                                              |                                                                                                                                   | mg/ kg                                                                                                                            | species                                              |

<div style=\"page-break-after: always\"></div>

## 2.3.6. Discussion on non-clinical aspects

In vitro, encorafenib was shown to be a selective ATP-competitive small molecule RAF kinase inhibitor which suppresses the RAF/MEK/ERK pathway in tumour cells expressing BRAFV600E and other muttions (K/D/R) at position V600. The treatment with encorafenib showed that phosphorylated MEK (pMEK) and phosphorylated ERK (pERK) in A375 human melanoma cells was suppressed as well as inhibition of cell proliferation. Encorafenib had no anti-proliferative activity in tumour cell lines that express wild-type BRAF. The primary metabolite, LHY746, was evaluated in in vitro activity studies and was inactive in the  inhibition of melanoma cell proliferation. Consequently, in the efficacy and safety studies LHY746 exposure was not assessed.

Tumour regression has been demonstrated in various models at doses as low as 0.6 mg/kg with reproducible and robust effects, including at dose levels of &gt; 3 mg/kg (the absolute exposure (AUC) at the of 5 mg/kg/d is 6.5 μg.h/mL. However, the effect was transient with encorafenib as a single agent and the majority of tumours developed resistance over the course of 4 months of treatment. The combination of encorafenib and binimetinib prevented the emergence of resistant tumours over the 4 month duration of the study resulting in enhanced survival. These data support the hypothesis that combining encorafenib and binimetinib will be efficacious in treating human melanoma.

Safety pharmacology studies were conducted in male rats and monkeys to assess the effects of encorafenib on the cardiovascular, respiratory, and neurobehavioral systems. There were no significant in vivo safety findings at doses up to 100 mg/kg in rats.

No preclinical pharmacokinetic studies were performed with encorafenib and binimetinib in combination, this is acceptable as data in clinical studies are deemed more informative.

Secondary pharmacodynamic evaluations showed that encorafenib demonstrated high selectivity for BRAF versus over 143 GPCRs, transporters, ion channels, nuclear receptors and enzymes. Therefore, off-target kinase activity at relevant free-therapeutic concentrations in vivo is not anticipated.

The lack of distribution to the CNS is likely due to encorafenib being a P-gp substrate, as P-gp is an important component of the endothelial cell blood-to-brain barrier.

The lack of studies on pharmacodynamics drug interactions, single dose toxicity, carcinogencity and reproduction toxicity are acceptable as per the ICH S9 guideline.

In the 4 week and 13 week rat toxicity studies, clinical signs, reduced body weight reduced epididymides and prostate weights and microscopic findings in testes, epididymides, stomach and skin were noted. Partial reversibility of these findings was noted after a 4 week recovery period. There are no data on the effects of encorafenib on fertility in humans. Based on findings in animals, the use of encorafenib may impact fertility in males of reproductive potential (see section 5.3). As the clinical relevance of this is unknown, male patients should be informed of the potential risk for impaired spermatogenesis. Additionally, in the 13 week rat toxicity study, reversible clinical pathology changes were noted at doses ≥ 100 mg/kg/d. No NOAEL could be established for the 4 week study. The NOAEL for the 13 week study was at 14  to 32 times human therapeutic exposures.

In the 4 week and 13 week monkey toxicity study, isolated/sporadic episodes of emesis and diarrhoea as well as ophthalmic lesions were observed at slightly above human therapeutic exposures. Ophthalmic lesions were partially reversible and consisted of a separation or detachment in the retina between the outer rods and cones layer and retinal pigmented epithelium at the central macula at the fovea. This observation was similar to that described in humans as central serous like chorioretinopathy or central serous retinopathy.

<div style=\"page-break-after: always\"></div>

Encorafenib was not genotoxic.

Fertility studies were not conducted with encorafenib. In the sub-acute 28 day and sub chronic 13 week rat toxicology studies, encorafenib treatment at 20 mg/kg/d (dose level approximately 8 times the human exposure at the recommended dose) resulted in decreased testes and epididymis weights with tubular degeneration and oligospermia. In the 13 week study, partial reversibility was noted at the highest dose level (60 mg/kg/d). The embryo-foetal development study in rats indicated that encorafenib induced foetal toxicity with lower foetal weights and delays in skeletal development. A warning on the risk for pregnant women and to the foetus has been included in section 4.6 of the SmPC. Women of childbearing potential must use effective contraception during treatment with encorafenib and for at least 1 month following the last dose. Encorafenib may decrease the efficacy of hormonal contraceptives (see section 4.5). Therefore, female patients using hormonal contraception are advised to use an additional or alternative method such as a barrier method (e.g. condom) during treatment with encorafenib and for at least 1 month following the last dose.

The embryo-foetal development study in rabbits indicated that encorafenib induced foetal toxicity with lower foetal weights and transitory changes in skeletal development. Dilatation of the aortic arc was observed in some foetuses.

It is unknown whether encorafenib or its metabolites are excreted in human. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue encorafenib therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the mother.

Encorafenib was phototoxic in an in vitro 3T3 Neutral Red Uptake Test. Encorafenib was not a sensitiser in the in vivo mouse sensitization assay. Collectively, these data indicate that encorafenib has a risk of phototoxic potential and minimal risk for sensitization at therapeutic doses in patients.

Encorafenib is not expected to bioaccumulate, or to show any significant transfer to sludge and soil. Therefore, encorafenib is not expected to pose a significant risk to the environment. As for all non-readily biodegradable human medicines, patients should be advised not to dispose of unused encorafenib drug product via wastewater. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## 2.3.7. Conclusion on the non-clinical aspects

The non-clinical studies (pharmacology, pharmacokinetics and toxicology), submitted for the marketing authorisation application for encorafenib were considered adequate and acceptable for the assessment of non-clinical aspects. The risks to fertility and embryo-foetal development observed in the non-clinical studies have been included in the SmPC. Encorafenib is not expected to pose a significant risk to the environment.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant

<div style=\"page-break-after: always\"></div>

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

Table 15: Clinical Pharmacology

| Study                                        | Objectives                                                                                                                                                                      | Design                                                                    | Test Product; Regimen; Route                                                                                                                                                                                                                                                               | Number of Subjects                                                              | Treatment Duration   |
|----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------------|
| Encorafenib                                  | Encorafenib                                                                                                                                                                     | Encorafenib                                                               | Encorafenib                                                                                                                                                                                                                                                                                | Encorafenib                                                                     | Encorafenib          |
| ARRAY- 818-102 Complete; Full                | Determine effect of high fat meal on single oral dose PK                                                                                                                        | Open-label, randomised, single dose, 2-way crossover                      | Encorafenib capsules (100mg strength); single dose; 2 fed/fasted treatment periods; oral                                                                                                                                                                                                   | 40 healthy adult subjects                                                       | Single dose          |
| ARRAY- 162-105 /CMEK162 A2106 Complete; Full | Investigate influence of a PPI (rabeprazole) on binimetinib or encorafenib PK                                                                                                   | Fixed sequence, single-centre, open-label, 2- or 3-period crossover study | Binimetinib tablets 3 x 15 mg (45 mg) or encorafenib tablet 1 x 300 mg single dose on Day 1, rabeprazole (20 mg) QD days 4-8; Binimetinib tablets 3 x 15 mg (45 mg) or encorafenib tablet 1 x 100 mg single dose Day 8; Encorafenib tablet 1 x 100 mg single dose on Period 3, Day 1; Oral | 15 (Binimetinib) 15 (Encorafenib) Healthy subjects                              | ~6 weeks             |
| CLGX818 A2101 Complete; full                 | Determine rates and routes of excretion of encorafenib related radioactivity -Determine PK of total radioactivity in blood and in plasma -Characterise plasma PK of encorafenib | Phase 1, single-centre, open-label                                        | [14C]-encorafenib Single 100 mg dose as a micro-emulsion; Oral                                                                                                                                                                                                                             | 4 Healthy male subjects                                                         | Single dose          |
| ARRAY- 818-101 Ongoing                       | Evaluate the PK, safety and tolerability of encorafenib following a single 50-mg oral dose of encorafenib in subjects with impaired and normal hepatic function                 | Phase 1, open- label, multicentre,                                        | Encorafenib single dose 50 mg capsule; Oral                                                                                                                                                                                                                                                | 6 subjects with mild hepatic impairment (Child-Pugh Class A) 6 healthy subjects | Single dose          |

<div style=\"page-break-after: always\"></div>

| ARRAY- 818-105 Complete; Full   | Part 1: To determine the effect of multiple oral doses of posaconazole on the single oral dose PK of encorafenib in healthy adult subjects Part 2: To determine the effect of multiple oral doses of diltiazem on the single oral dose PK of encorafenib in healthy adult subjects   | Open-label, 2- period, fixed- sequence, 2-part study   | Part 1: Encorafenib (50 mg capsules) Posaconazole (40 mg/mL oral suspension); Encorafenib 50 mg QD on Day 1 followed by 400 mg posaconazole BID for 9 days with 50 mg encorafenib QD on Day 7; Oral Part 2: Encorafenib (50 mg capsules) Diltiazem (240 mg capsules); Encorafenib 50 mg QD on Day 1 followed by 240 mg diltiazem QD for 4 days with 50 mg encorafenib QD on Day 2                                                                                                                                           | Part 1: 16 subjects Part 2: 16 subjects Healthy, nontobacco using, adult subjects                                          | Part 1: 9 days Part 2: 4 days   |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| ARRAY- 818-103 Ongoing          | Evaluate the effects of encorafenib in combination with binimetinib on the PK of losartan, midazolam, caffeine, omeprazole, and dextromethorphan administered in a cocktail approach and on the PK of rosuvastatin in patients with BRAF V600- mutant tumours                        | Sequential 2- arm, open-label Phase 1 study            | Encorafenib (50 mg capsules); Binimetinib (15 mg tablets); CYP probe cocktail (losartan 50mg tablet, midazolam 2 mg/mL oral syrup, caffeine 20 mg/mL oral liquid, omeprazole 20 mg capsule, and dextromethorphan 15 mg capsule) Rosuvastatin 10 mg tablet Arms 1 and 2: Encorafenib 450 mg QD plus binimetinib 45 mg BID on Day 1 Arm 1: CYP probe cocktail (losartan 50 mg, midazolam 2mg, caffeine 100mg, omeprazole 20mg and dextromethorphan 30 mg) on Days -7, 1, and 14 Arm 2: Rosuvastatin 10mg on Days -7, 1 and 14 | 30 Arm 1: 20 Arm 2: 10 Patients with BRAF V600- mutant unresectable or metastatic melanoma or other advanced solid tumours | 14 days                         |

Table 16: Efficacy and Safety

| Study Identifier Status Report     | Objective(s)                       | Design                             | Test Product(s); Dosage Regimen; Route   | Number of Subjects                 | Diagnosis                          | Treatment Duration                 |
|------------------------------------|------------------------------------|------------------------------------|------------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| Encorafenib - Initial tolerability | Encorafenib - Initial tolerability | Encorafenib - Initial tolerability | Encorafenib - Initial tolerability       | Encorafenib - Initial tolerability | Encorafenib - Initial tolerability | Encorafenib - Initial tolerability |

<div style=\"page-break-after: always\"></div>

| CLGX818 X2101 Complete Full report                      | Determine the MTD and/or RP2D of oral encorafenib in adult BRAF V600 mutant patients with locally advanced or metastatic melanoma                               | Phase 1 multicentre, open-label, dose escalation study of encorafenib in adult patients with locally advanced or metastatic BRAF-mutant melanoma or mCRC   | Dose escalation phase: Encorafenib (30 mg/mL micro- emulsion) - 50 and 100 mg QD; Encorafenib (10, 25, 50 & 100 mg capsules) - 50, 100, 150, 200, 300, 450, 550 and 700 mg QD; 75, 100 and 150                   | 107 Dose escalation: 54 melanoma patients Dose expansion: 35 melanoma, 18 mCRC patients                                                                                              | Adult patients with locally advanced or metastatic BRAF-mutant melanoma or mCRC                                                                                                                                                                         | Until progressive disease, unacceptable toxicity or withdrawal of informed consent                                                                                                                           |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Encorafenib and binimetinib - Initial tolerability      | Encorafenib and binimetinib - Initial tolerability                                                                                                              | Encorafenib and binimetinib - Initial tolerability                                                                                                         | Encorafenib and binimetinib - Initial tolerability                                                                                                                                                               | Encorafenib and binimetinib - Initial tolerability                                                                                                                                   | Encorafenib and binimetinib - Initial tolerability                                                                                                                                                                                                      | Encorafenib and binimetinib - Initial tolerability                                                                                                                                                           |
| CMEK162 X2110 Complete Full report                      | Phase 1b: MTD and/or RP2D finding study of encorafenib/ binimetinib & encorafenib/ binimetinib/ ribociclib Phase 2: Efficacy of the dual and triple combination | Multicentre, open-label, dose-finding, Phase 1b dose escalation followed by a Phase 2 efficacy part                                                        | Phase 1b: Encorafenib (10, 25, 50 & 100 mg capsules) - 50, 100, 200, 400, 450, 600 or 800mg QD & binimetinib (15mg film- coated tablets) 45mg BID Phase 2: Encorafenib 450 or 600mg QD & binimetinib 45mg BID po | Phase 1b: 47 6: 50 mg 5: 100 mg 4: 200 mg 5: 400 mg 13: 450 mg 8: 600 mg 6: 800 mg (all QD) Phase 2: 79 11 mCRC, 26 prior BRAF inhibitor melanoma, 42 BRAF inhibitor- naïve melanoma | Phase 1b: Patients with BRAF V600 dependent advanced solid tumours Phase 2: Arm 1 - BRAF 600 mutant mCRC Arm 2- metastatic V600 mutant melanoma progressed after prior BRAFi treatment Arm 3 - metastatic V600 mutant melanoma naive to BRAFi treatment | Dual combination until PD, unacceptable toxicity and/ or treatment discontinued at Investigator's discretion or patient refusal                                                                              |
| Encorafenib and binimetinib - controlled clinical study | Encorafenib and binimetinib - controlled clinical study                                                                                                         | Encorafenib and binimetinib - controlled clinical study                                                                                                    | Encorafenib and binimetinib - controlled clinical study                                                                                                                                                          | Encorafenib and binimetinib - controlled clinical study                                                                                                                              | Encorafenib and binimetinib - controlled clinical study                                                                                                                                                                                                 | Encorafenib and binimetinib - controlled clinical study                                                                                                                                                      |
| CMEK162 B2301 Part 1: completed (CSR) Part 2: ongoing   | Efficacy/ safety of Combo 450 in BRAF V 600 mutant locally advanced unresectable or metastatic melanoma                                                         | Multicentre, randomised, open label, 2 part, phase 3 study comparing efficacy & safety of Combo 450 to vemurafenib and encorafenib monotherapy             | Combo 450 arm: encorafenib 450mg QD 7 binimetinib 45mg BID (continuous) Vemurafenib arm: 960mg BID (continuous) Encorafenib arm: 300mg QD (continuous)                                                           | Randomised 577 pts: 192 in Combo 450, 194 in encorafenib, 191 in vemurafenib arm                                                                                                     | Adult patients (aged ≥18 years) with locally advanced unresectable or metastatic BRAF V600E /V600K- mutant melanoma or unknown primary melanoma (stage IIIB,                                                                                            | Until locally assessed PD confirmed by the BIRC, unacceptable toxicity, death, physician decision, study termination or discontinuation for any other reason (e.g. withdrawal of consent, lost to follow-up) |

<div style=\"page-break-after: always\"></div>

|                                                                          |                                                                                                                                                                                                                           |                                                                                                                                                                                                                                      |                                                                                                             |                                                                                              | IIIC or IV per AJCC)                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                      |
|--------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Encorafenib/ Encorafenib and binimetinib - uncontrolled clinical studies | Encorafenib/ Encorafenib and binimetinib - uncontrolled clinical studies                                                                                                                                                  | Encorafenib/ Encorafenib and binimetinib - uncontrolled clinical studies                                                                                                                                                             | Encorafenib/ Encorafenib and binimetinib - uncontrolled clinical studies                                    | Encorafenib/ Encorafenib and binimetinib - uncontrolled clinical studies                     | Encorafenib/ Encorafenib and binimetinib - uncontrolled clinical studies                                                                                                                                                                                                                                                                            | Encorafenib/ Encorafenib and binimetinib - uncontrolled clinical studies                                                                                                                                                                                             |
| CLGX818 X2102 Completed, Full report                                     | Assess anti- tumour activity of encorafenib combined with targeted agents after progression on encorafenib single agent therapy                                                                                           | Phase 2, open label, multicentre, 2- part study                                                                                                                                                                                      | Encorafenib 50 & 100mg capsule strength Part 1 300mg QD Part 2: Encorafenib 450mg OQ + binimetinib 45mg BID | Part 1: 15 patients Part 2: 100 patients (planned) 1 patient                                 | BRAF V600 mutant locally advanced unresectable or metastatic melanoma                                                                                                                                                                                                                                                                               | Until disease progression, unacceptable toxicity, discontinuation by Investigator or withdrawal of informed consent                                                                                                                                                  |
| CLGX818 X2109 Ongoing Interim CSR on Part 1                              | Assess the anti-tumour activity, MTD and safety of encorafenib +binimetinib + 3 rd targeted agent after progression on encorafenib + binimetinib in BRAF V600 mutant locally advanced unresectable or metastatic melanoma | Multicentre, nonrandomised, open-label, 2- part, Phase 2 study of sequential encorafenib + binimetinib until progression, then rational encorafenib + binimetinib + 3 rd targeted agent (based on genetic analysis of tumour biopsy) | Part 1: encorafenib 450mg QD + binimetinib 45mg BID (continuous)                                            | FAS and safety set: 140 (planned), 158 (actual); 75 treatment naïve, 83 non- treatment naïve | Adults with ECOG PS≤2, unresectable stage III or metastatic BRAF V600 mutant melanoma. Part 1: Group A : BRAF and MEK inhibitor naïve. Group B : progressed post single- agent BRAF or MEK inhibitor or combination (excluding encorafenib, binimetinib), or did not tolerate prior BRAF and/or MEK inhibitor (including encorafenib, binimetinib). | Part 1: Patients treated with encorafenib + binimetinib until progression, unacceptable toxicity, or treatment discontinuation at the Investigator's discretion or by withdrawal of consent. Non-naïve patients treated with encorafenib + binimetinib for ≥ 3 weeks |
| CLGX818 AUS03 Complete Full report                                       | To assess clinical benefit associated with encorafenib treatment based on local investigator assessment                                                                                                                   | Phase 2, open- label                                                                                                                                                                                                                 | Encorafenib 300mg (3 x100mg) QD, continuous dosing with 28 day cycle                                        | 12 patients                                                                                  | Solid tumours/ haematological malignancies, pre-identified to have BRAF V600 mutation and disease progression on/ after standard treatment                                                                                                                                                                                                          | Until disease progression, unacceptable toxicity, death and/or treatment discontinuation due to any other reasons                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

## 2.4.2. Pharmacokinetics

The PK of encorafenib was assessed in 1 clinical study conducted in healthy subjects administered singleagent encorafenib (Study CLGX818A2101), 1 clinical study conducted in advanced cancer patients administered single-agent encorafenib (Study CLGX818X2101) and 3 clinical studies conducted in advanced cancer patients administered encorafenib in combination with binimetinib (Studies CMEK162X2110, CGLX818X2109 and CMEK162B2301).

## Absorption

Because encorafenib demonstratesd high apparent permeability and its solubility in media with higher pH, encorafenib was designated as a BCS Class II drug.

In the clinical ADME study CLGX818A2101, 4 healthy subjects received a single oral dose of 100 mg [14C]encorafenib. The extent of oral absorption was estimated to be at least ~86% based on a mean of 47.2% of the radioactivity dose eliminated in the urine and 39% of the radioactivity dose recovered in the faeces as metabolites.

After oral administration, encorafenib is rapidly absorbed with a median Tmax of 1.5 to 2 hours.

Table 17: Summary statistics of plasma PK parameters for encorafenib (PAS) - Study CLGX818A2101

| Statistics    | AUCinf (ng*hr/mL)   | AUClast (ng*hr/mL)      | AUC0-24 (ng*hr/mL)   | Cmax (ng/mL)   | Tmax (hr)     | T1/2 (hr)    | CL/F (L/hr)   | Vz/F (L)   |
|---------------|---------------------|-------------------------|----------------------|----------------|---------------|--------------|---------------|------------|
| n             | 4                   | 4                       | 4                    | 4              | 4             | 4            | 4             | 4          |
| Mean (SD)     |                     | 3940 (1430)3910 (1450)  | 3850 (1370)          | 1050 (171)     | N/A           | 6.11 (1.84)  | 27.9 (9.15)   | 235 (73.7) |
| CV% mean      | 36.4                | 37.0                    | 35.6                 | 16.3           | N/A           | 30.0         | 32.8          | 31.4       |
| Geo-mean      | 3750                | 3720                    | 3680                 | 1040           | N/A           | 5.88         | 26.6          | 226        |
| CV% geo- mean | 36.3                | 37.1                    | 35.7                 | 17.3           | N/A           | 34.0         | 36.3          | 32.7       |
| Median        | 3610                | 3600                    | 3570                 | 1080           | 0.767         | 6.32         | 28.4          | 228        |
| [Min-Max]     |                     | [2660-5860] [2600-5840] | [2600-5670]          | [820; 1230]    | [0.500; 1.00] | [3.74; 8.09] | [17.1; 37.6]  | [168; 316] |

## Influence of food

The effect of food on encorafenib PK was evaluated in Study ARRAY-818-102.

The administration of a single oral 100 mg dose of encorafenib with food resulted in no significant change in total exposure (i.e., AUC) following a High Fat Meal (HFM); however, the rate of absorption for encorafenib was slower in the fed state, as evidenced by an approximate 2.3-hour delay in the time to maximum observed plasma concentration (i.e., Tmax) and a lower peak concentration (i.e., 340.5 ng/mL lower Cmax) in the fed state.

<div style=\"page-break-after: always\"></div>

The AUCinf decreased by approximately 4% after administration of a HFM (GMR=95.91%); however, the treatment groups were bioequivalent in terms of the AUCinf as indicated by the 90% CI of the GMR (91.62, 100.39).

Peak exposure (i.e., Cmax) decreased by approximately 36% (GMR=63.97%) and this change was found to be statistically significant as indicated by the 90% CI of the GMR for Cmax (57.73, 70.90). The nonparametric median differences in Tmax (2.253 [90% CI 2.002, 2.516]) were also found to be statistically significant (p &lt; 0.0001) between the 2 treatments.

Figure 8: Mean plasma concentration-time profiles of encorafenib following administration of a single oral dose of 100 mg encorafenib under fasted and fed conditions

<!-- image -->

Table 18: Plasma Encorafenib Pharmacokinetic Parameters Following Administration of a Single Oral Dose of 100 mg Encorafenib Under Fasted and Fed Conditions

| Treatmenta        | Statisticb   | AUCo-inf (ng.h/mL)   | max (ng/mL)   | (h)   |
|-------------------|--------------|----------------------|---------------|-------|
| Encorafenib       | n            | 30                   | 31            | 31    |
| (Fasted)          | Geo-mean     | 3121                 | 961.5         |       |
| (100 mg)          | Geo-CV (%)   | 42.3                 | 32.9          |       |
|                   | Median       |                      |               | 1.495 |
|                   | Min          |                      |               | 0.997 |
|                   | Max          |                      |               | 3.49  |
| Encorafenib (Fed) | n            | 31                   | 31            | 31    |
| (100 mg)          | Geo-mean     | 3034                 | 621.0         |       |
|                   | Geo-CV (%)   | 38.4                 | 45.2          |       |
|                   | Median       |                      |               | 3.499 |
|                   | Min          |                      |               | 2.00  |
|                   | Max          |                      |               | 5.00  |

<div style=\"page-break-after: always\"></div>

## Distribution

In the human ADME study, the mean blood-to-plasma concentration ratio for total radioactivity was 0.58.

The in vitro mean plasma protein binding of encorafenib was approximately 86.1% over the concentration range of 50 to 50,000 ng/mL. The in vitro mean protein binding for AR00492720 (encorafenib metabolite) was 95.8, 89.6 and 88.6 in rat, monkey and human plasma, respectively.

The geometric mean (% CV) Vz/F for encorafenib was 226 L (32.7%).

Based on the population PK analysis, the typical initial distribution half-life into the second compartment of the population PK model was 0.34 hours and the total volume of the central compartment (V/F) was 27 L.

## Elimination

In the ADME study, 4 healthy subjects received a single oral dose of 100 mg [14C]-encorafenib. The plasma encorafenib concentrations exhibited a biphasic elimination. The extent of oral absorption was estimated to be at least ~86% based on a mean of 47.2% of the radioactivity dose eliminated in the urine and 39% of the radioactivity dose recovered in the faeces as metabolites.

The percentage of the dose eliminated in the urine as unchanged encorafenib was approximately 1.8% of the apparent total clearance after oral administration (CL/F). The estimated mean encorafenib renal clearance (CLr) was 0.5 L/h and was 7% of the glomerular filtration rate (7.5 L/h), suggesting minimal involvement of renal transporters in its elimination process. The percentage of the dose eliminated in the faeces as unchanged encorafenib was also minor with a mean of 5.0%.

Therefore, metabolism was found to be the major clearance pathway (~88% of the recovered radioactive dose) for encorafenib in humans.

In the same study, the median (range) t1/2 for encorafenib was 6.32 hours (3.74 to 8.09 hours). The geometric mean (% CV) CL/F and apparent volume of distribution following oral administration (Vz/F) were 26.6 L (36.3%) and approximately 226 L (32.7%), respectively.

Based on the population PK analysis, the population estimate of CL/F for encorafenib was 27.9 L/h. The elimination t1/2 derived with the model was 12.1 h.

In the ADME study in human, metabolism was found to be the major clearance pathway (~88% of the recovered radioactive dose) for encorafenib in humans, leading to an estimated level of oral absorption of at least ~86%.

## Dose proportionality and time dependencies

The dose proportionality for encorafenib was assessed for AUCτ,ss and Cmax,ss  over pooled dose ranges of 50 to 800 mg and 50 to 600 mg.

Encorafenib was rapidly absorbed with a median Tmax that ranged from 0.50 to 2.50 hours across doses. Plasma AUCs and Cmax of encorafenib increased in a slightly less than dose-proportional manner as the encorafenib dose increased from 50 to 800 mg on Day 15. Encorafenib concentrations rapidly declined and the geometric mean t1/2 was similar across doses (ranging from 2.88 to 4.63 hours).

Accumulation of encorafenib was also assessed with an ANOVA performed on log-transformed AUCtau,ss and Cmax,ss using an LME model with day (Day 15 versus Day 1) as a fixed effect and subject as a random

<div style=\"page-break-after: always\"></div>

effect. The estimated ratios for Cmax (RCmax) and for AUC (RAUC) were 0.63 and 0.45, respectively, which is consistent with the effect of auto-induction of CYP3A4. The intra-subject variability was approximately 37.36% and 36.40%, respectively.

The typical CL/F of encorafenib was estimated to be 34% faster after Cycle 1 Day 1. An Emax function was used to describe time-dependent behaviour for the CL/F of encorafenib during the treatment, with 50% of the maximum CL/F (T50) achieved at 18.33 hours after the 1st administration.

Table 19: Encorafenib pharmacokinetic parameters on Cycle 1 Day 1 Study CLGX818X2101

| Dose and Regimen (2)   | Pharmacokinetic Parameter on Day 1?   | Pharmacokinetic Parameter on Day 1?   | Pharmacokinetic Parameter on Day 1?   | Pharmacokinetic Parameter on Day 1?   | Pharmacokinetic Parameter on Day 1?   | Pharmacokinetic Parameter on Day 1?   |
|------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| Parameter Unit         | Cmax b (ng/mL)                        | Tmax C (b)                            | AUCtaud b (ng.h/mL)                   | T1/2 (b)                              | CL/Fb (L/h)                           | V/Fb (L)                              |
| 50 mg QD (1)           | 970 (NC)                              | 2 (2,2)                               | 5360 (NC)                             | 4.38 (4.38, 4.38)                     | 9.14 (NC)                             | 57.8 (NC)                             |
| 100 mg QD (5)          | 1630 (42.4)                           | 2 (0.5, 2)                            | 7610 (83)                             | 3.47 (3.38, 3.88)                     | 13 (83.4)                             | 67 (79.4)                             |
| 150 mg QD (6)          | 1570 (28.8)                           | 2 (0.52, 4.0)                         | 9400 (20.1)                           | 3.66 (3.09, 4.5)                      | 15.8 (20.1)                           | 84.5 (28.2)                           |
| 200 mg QD (4)          | 1850 (28.1)                           | 2 (2,2)                               | 9860 (26.5)                           | 3.3 (2.56, 3.58)                      | 20.2 (26.2)                           | 91.9 (39.6)                           |
| 300 mg QD (5)          | 3310 (42.5)                           | 2 (2,8)                               | 20300 (29.1)                          | 3.42 (2.84, 4.77)                     | 15 (33.4)                             | 76.5 (33.7)                           |
| 450 mg QD (6)          | 5970 (56.4)                           | 2 (2, 2.3)                            | 32800 (69.1)                          | 2.92 (2.32, 4.98)                     | 13.6 (70.3)                           | 60.5 (53.3)                           |
| 550 mg QD (5)          | 5360 (36.9)                           | 2 (2, 2.07)                           | 31700 (45.3)                          | 3.32 (3.28, 3.61)                     | 17.2 (45.5)                           | 84.8 (42.0)                           |

<div style=\"page-break-after: always\"></div>

Table 20: Encorafenib pharmacokinetic parameters on Cycle 1 Day 15

| Study Code, Dose and Regimen (n)            | Cmax,ss (ng/mL)                             | Tmax (h)                                    | AUCtau,ss (ng.h/mL)                         | RAUC                                        | CL/F (L/h)                                  | V/F (L)                                     |
|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Study CLGX818X2101 Encorafenib Single Agent | Study CLGX818X2101 Encorafenib Single Agent | Study CLGX818X2101 Encorafenib Single Agent | Study CLGX818X2101 Encorafenib Single Agent | Study CLGX818X2101 Encorafenib Single Agent | Study CLGX818X2101 Encorafenib Single Agent | Study CLGX818X2101 Encorafenib Single Agent |
| 50 mg Encorafenib QD (N=1)                  | 465 (NC)                                    | 2 (2,2)                                     | 2660 (NC)                                   | 0.496 (NC)                                  | 18.8 (NC)                                   | 112 (NC)                                    |
| 100mgEncorafenib QD (N=5)                   | 959 (25.19)                                 | 2.99 (2, 4)                                 | 5330 (36.58)                                | 0.535 (21.08)                               | 18.8 (36.58)                                | 103 (36.42)                                 |
| 150 mg Encorafenib QD (N=6)                 | 1300 (29.08)                                | 2 (0.5, 2.03)                               | 4750 (12.25)                                | 0.476 (20.79)                               | 31.5 (12.25)                                | 188 (43.23)                                 |
| 200 mg Encorafenib QD (N=4)                 | 1300 (31.12)                                | 2 (2, 2.17)                                 | 5060 (35.79)                                | 0.468 (19.72)                               | 39.5 (35.79)                                | 177 (31)                                    |
| 300 mg Encorafenib QD (N=5)                 | 2920 (34.41)                                | 2 (2,2.02)                                  | 10100 (53.35)                               | 0.541 (73.21)                               | 29.6 (53.35)                                | 128 (12.49)                                 |
| 450mgEncorafenib (N=6)                      | 3950 (49.12)                                | 2 (0.5,2)                                   | 13100 (34.85)                               | 0.401 (51.64)                               | 34.3 (34.85)                                | 157 (38.55)                                 |
| 550mgEncorafenib QD (N=5)                   | 4170 (48.94)                                | 2 (2,2)                                     | 15300 (36.38)                               | 0.468 (59.74)                               | 36 (36.38)                                  | 221 (75.92)                                 |

## Population PK

The final population PK model of encorafenib consisted of a 2-compartment model with time varying clearance. The absorption of encorafenib was described with a first-order rate of absorption.

The population estimates of CL/F and V/F for encorafenib were 27.9 L/h and 14.1 L, respectively. The t1/2 derived with the model was 12.1 h. Total volume of distribution was 27.3 L.

Table 21: Final Population PK Model of Encorafenib (Enco 06) - Typical Value

|                                       | Fixed Effects   | Fixed Effects        | Random effects   | Random effects   | Random effects   |
|---------------------------------------|-----------------|----------------------|------------------|------------------|------------------|
| Parameters                            | Estimate        |                      | Variance         | IIV%             | Shrinkage        |
| Ka                                    | 0.357           | hr                   | 0.008            | 8.93%            | 38.33%           |
| V/F                                   | 14.106          | L                    | 1.646            | 128.29%          | 20.91%           |
| V2/F                                  | 13.197          | L                    | 0.187            | 43.26%           | 73.97%           |
|                                       | 27.863          | L/h                  | 0.103            | 32.13%           | 29.27%           |
| CL2/F                                 | 0.779           | L/h                  | 0.204            | 45.16%           | 77.69%           |
| Tlag                                  | 0.446           | h                    |                  |                  |                  |
| T50 (h)                               | 18.33 (fixed)   | h                    |                  |                  |                  |
| Emax                                  | -0.340          | hrl                  | 1.034            | 101.67%          | 72.81%           |
| Stdevo(additiveerroronIn-transformed) | 0.986           |                      |                  |                  |                  |
|                                       |                 | Multiplicativefactor |                  |                  |                  |
| WT effect on CL/F - (WT/75)*          | 0.270           |                      |                  |                  |                  |
| WT effect on V/F - (WT/75)8           | 0.850           |                      |                  |                  |                  |
| Disease effect on CL/F -exp(0)        | -0.121          | x0.886               |                  |                  |                  |
| Age on V/F -(Age/53)8                 | -0.125          |                      |                  |                  |                  |
| Totalproteins on CL/F -(TPROT/70)     | 0.058           |                      |                  |                  |                  |
| Bilirubin on CL/F - (BIL/0.4678)8     | -0.137          |                      |                  |                  |                  |
| Moderate Inhibitor on CL/F-exp(0)     | -0.205          | x0.815               |                  |                  |                  |
| Strong Inhibitor on CL/F - exp(0)     | -0.170          | x0.844               |                  |                  |                  |
| LDH on CL/F - (LDH/327)               | -0.030          |                      |                  |                  |                  |
| ECOG on CL/F -exp(0 *(ECOG=1))        | -0.100          | x0.905               |                  |                  |                  |
| ECOG on CL/F -exp(0 *(ECOG=2))        | -0.165          | x0.848               |                  |                  |                  |
| eGFR on CL/F -(eGFR/111.6)            | 0.064           |                      |                  |                  |                  |

Note : Time effect on CL/F was implemented using the following equation : 1-Emax*t(T50+t)

BIL=Bilirubin (mg/dL); CL/F=Apparent clearance;CL2/F=Apparent inter-compartmental clearance;ECOG=Eastem Cooperative Oncology Group status;eGFR=Estimatedglomerular filtration rate (mL/min/1.73m); Emax= Maximum effect; IV%= Inter-individual variability, LDH = Lactate dehydrogenase (U/L); Stdev0= Standard deviation of log-additive error, t= Time (h); T50= Time to reach WT=Body weight(kg)

<div style=\"page-break-after: always\"></div>

## Special populations

## Renal impairment

The applicant did not submit studies in renal impaired patients. However, the effect of the mild and moderate renal impairment on the PK of encorafenib was evaluated using a population PK approach. In a population pharmacokinetic analysis, no clear trend in encorafenib CL/F was observed in patients with mild (eGFR 60 to 90 mL/min/1.73 m2) or moderate (eGFR 30 to 59 mL/min/1.73 m2) renal impairment compared with subjects with normal renal function (eGFR ≥ 90 mL/min/1.73 m2). A small decrease in CL/F ( ≤ 5%) was predicted for patients with mild and moderate renal impairment, which is unlikely to be clinically relevant.

## Hepatic impairment

The pharmacokinetics of 50 mg encorafenib was investigated in mild hepatic impairment subjects versus healthy subjects. Healthy subjects were enrolled based on matched age, gender and body weight to a hepatic impaired subject and could have matched more than one subject in a different impairment group. The lowest possible dose of 50 mg encorafenib was administered in this study. After review of the safety and PK data, a total of 6 subjects with mild hepatic impairment and 6 matching healthy subjects were dosed. Results from this cohort indicated an approximate 25% increase in overall encorafenib exposure (AUCinf) in subjects with mild hepatic impairment compared with matching healthy subjects. Considering the unbound encorafenib fraction, Cmax was increased by 21%, AUC increased by 55% and Cl/F reduced by 36%.

Table 22: Geometric mean (geometric coefficient of variation) plasma pharmacokinetic parameters for encorafenib and unbound encorafenib

| Parameter          | Encorafenib       | Encorafenib       | UnboundEncorafenib   | UnboundEncorafenib   |
|--------------------|-------------------|-------------------|----------------------|----------------------|
|                    | Healthy           | Child-Pugh A      | Healthy              | Child-Pugh A         |
| Cmax (ng/mL)       | 494 (31.4)        | 484 (26.6)        | 33.5 (32.8)          | 40.7 (24.9)          |
| Tmax (h)a          | 1.50 (1.00, 3.00) | 1.50 (1.00- 2.00) | NA                   | NA                   |
| AUCO-inf (h.ng/mL) | 1990 (29.5)       | 2490 (47.1)       | 135 (26.8)           | 209 (48.5)           |
| CI/F (L/h)         | 25.2 (29.5)       | 20.1 (47.1)       | 371 (26.8)           | 239 (48.5)           |
| Fu (%)             | 6.77 (9.1)        | 8.40 (4.9)        | NA                   | NA                   |

FU: fraction of encorafenib unbound.

In the population PK analysis, the covariate of hepatic impairment indicated no significant impact on the encorafenib CL/F or V/F when comparing healthy subjects with mild hepatic impairment subjects. Information on unbound encorafenib fraction (6.77%) from the healthy volunteers obtained in the HI study ARRAY-818101 was included to predict AUC and Cmax and was also compared with predicted values based on previous in vitro FU values (13.9%).

The model predicted an unbound encorafenib fraction for subjects with Child-Pugh A of 8.17% (ex vivo value measured in the clinical HI study was 8.4%.

## Gender

Based on the results of the population PK modelling, gender was not retained as a covariate in the final model for encorafenib.

<div style=\"page-break-after: always\"></div>

## Race

Based on the results of the population PK modelling, no apparent trend for V/F and race or ethnic origin was observed in the exploratory plots.

## Weight

Based on the results of the population PK modelling, for an individual in the 95th percentile of weight (i.e. 112 kg), the population PK analysis indicated a 11.4% increase in CL/F compared to the typical individual of 78 kg. For an individual in the 5th percentile of weight (i.e. 54 kg), the population PK analysis indicated an 8.5% decrease in CL/F compared to the typical individual of 75 kg. The exponent for weight on clearance in the POPPK model was 0.27.

## Elderly

Age as a covariate was not retained in the final model on the CL/F term.

|             |              | CL/F (L/h)    | CL/F (L/h)    | CL/F (L/h)   | CL/F (L/h)   | V/F (L)       | V/F (L)       | V/F (L)   | V/F (L)   |
|-------------|--------------|---------------|---------------|--------------|--------------|---------------|---------------|-----------|-----------|
| Study       | Age category | 65 - 74 years | 75 - 84 years | 85+ years    | Adults       | 65 - 74 years | 75 - 84 years | 85+ years | Adults    |
| All studies | NObs         | 201           | 70            | 7            | 749          | 201           | 70            | 7         | 749       |
| All studies | Mean         | 23.4          | 23.7          | 24.1         | 26.5         | 22.7          | 25            | 58        | 31.2      |
| All studies | CV%          | 24            | 22.5          | 41.6         | 25.5         | 180           | 164           | 203       | 164       |
| All studies | Min          | 7.42          | 9.41          | 14.8         | 7.49         | 0.662         | 1.55          | 2.44      | 0.626     |
| All studies | Median       | 22.7          | 23.6          | 22.8         | 25.9         | 10.7          | 13.3          | 14.7      | 13.7      |
| All studies | Max          | 49.9          | 43.9          | 45.2         | 51.5         | 428           | 213           | 323       | 682       |

Nobs: number of values na : not applicable ; CL/F : Apparent Clearance ; V/F : Apparent central volume of distribution ;

## Pharmacokinetic interaction studies

The available data suggest that CYP3A4 is the primary enzyme likely to cause a clinical DDI. CYP3A4 is the major enzyme contributing to total oxidative clearance of encorafenib in human liver microsomes (~83.3%), followed by CYP2C19 and CYP2D6 (~16.0% and 0.71%, respectively), with CYP2C19 being the major contributor (70.1%) to the oxidative metabolism of AR0049272.

Given that encorafenib is a substrate of both CYP3A4 and P-glycoprotein (P-gp), the effect of both CYP3A4 and P-gp transporter inhibitors on encorafenib exposure was evaluated. Based on the results of the PBPK analysis, encorafenib can be classified as low-to-moderate passive permeability compound when P-gp is not saturated/inhibited and as high passive permeability compound in presence of P-gp inhibitor or at encorafenib concentrations higher than 164 μM.  Encorafenib exhibited potential inhibition of P-gp transportation in vitro at concentrations up to 1000 µM, with a calculated Ki ~75µM. This is much lower than the calculated gut concentrations and the PBPK model predicted local concentrations of 5 mM.

The predicted DDI effect for ketoconazole and itraconazole were approximately 5-fold and could be classified as moderate-to-strong.

Co-administration of posaconazole (a strong CYP3A4 inhibitor) increased the overall encorafenib exposure (i.e., AUC) by approximately 3-fold when a multiple dose of posaconazole was co-administered with a single dose of encorafenib 50 mg in healthy subjects. Based on the predicted DDI using higher dose of posaconazole at the steady state, a similar effect of posaconazole on the PK of encorafenib was observed.

<div style=\"page-break-after: always\"></div>

Similarly, co-administration of diltiazem (a moderate CYP3A4 inhibitor and P-gp transporter inhibitor) increased the overall encorafenib exposure by approximately 2-fold. The Tmax values were similar.

Encorafenib appears to inhibit hepatic uptake transporters OCT1, OATP1B1 and OATP1B3, renal uptake OAT1, OAT3 and OCT2 and BCRP transporter involved in efflux in the gut, liver and kidney.

The DDI module in GastroPlus™ v. 9.0 was used to run dynamic simulations to predict the extent of DDIs between ketoconazole (KET) or itraconazole (ITZ) and CYP3A4 substrates midazolam (MID), triazolam (TRZ), and quinidine (QND) using PBPK models. The full itraconazole model overpredicted the DDI effect in four studies (ratio of predicted/observed RAUC values ranging from 1.06 to 1.51) and underpredicted the DDI effect in the eight remaining studies (ratio of predicted/observed RAUC values ranging from 0.42 to 0.88). In clinical studies the observed effect of itraconazole on midazolam PK ranged from 3 to 11-fold increase in AUC and the model predicted a range of 2 to 8-fold. For triazolam, the observed effects of itraconazole ranged from 2 to 5-fold increases in AUC and the model predicts a slightly lower range of 1.2 to 4-fold. For quinidine the observed 2-fold increase in AUC, when co-administered with itraconazole was well predicted by the model (1.7 fold).

The ketoconazole model was evaluated by predicting the DDI effect with MID and TRZ from two different studies. The ratio of predicted/observed RAUC was 0.96 and 0.79, respectively. Predictions of inhibition effect of posaconazole, ketoconazole, and itraconazole on encorafenib PK in patients on day 1 and day 7 after coadministration of encorafenib and inhibitor for 7 days were performed and are shown in Table 23.

Table 23: Predicted effect of CYP3A4 inhibitors on encorafenib exposures in cancer patients

α The encorafenib model was for a 59.3 year-old male cancer patient that weighed 79.8 kg. The R values presented here are a comparison of encorafenib exposure with a CYP3A4 inhibitor compared to encorafenib exposure without a CYP3A4 inhibitor both on Day 1 and

| Encorafenib dose   |                           | Category   | Day 1   | Day 1   | Steady state   | Steady state   |
|--------------------|---------------------------|------------|---------|---------|----------------|----------------|
|                    | CYP3A4inhibitor (dose)    |            | RCmax   | RAUcb   | RCmax          | RAUC           |
| 300 mg QD          | Posaconazole (400 mgBID)  | Strong     | 2.33    | 2.49    | 2.90           | 3.12           |
|                    | Ketoconazole (400 mg QD)  | Strong     | 3.05    | 4.58    | 4.01           | 5.83           |
|                    | ITZ-full (200 mg QD)c     | Strong     | 2.69    | 3.27    | 3.61           | 4.98           |
| 450 mg QD          | Posaconazole (400 mg BID) | Strong     | 2.14    | 2.30    | 2.66           | 2.89           |
|                    | Ketoconazole (400 mg QD)  | Strong     | 2.79    | 4.23    | 3.68           | 5.42           |
|                    | ITZ-full (200 mg QD)      | Strong     | 2.47    | 3.02    | 3.31           | 4.63           |

## Pharmacokinetics using human biomaterials

See section on metabolism.

## 2.4.3. Pharmacodynamics

## Mechanism of action

See non-clinical section.

<div style=\"page-break-after: always\"></div>

## Primary and Secondary pharmacology

## Cardiac safety

A post hoc analysis of Phase 1 Study CLGX818X2101 was conducted to evaluate the potential for therapeutic concentrations of encorafenib to cause QT prolongation (Report CP17-005 ). An increase in ΔQTcF from Baseline of &gt;30ms was observed in 47 out of 105 evaluable patients (44.8%) and an increase in QTcF &gt;60ms was observed in 5 patients (4.8%). A new QTcF &gt;480ms occurred in 2 patients (1.9%); no new QTcF &gt;500ms were observed.

The datasets included 77 subjects and 1002 time-matched ECG-concentration pairs for encorafenib and were analysed with a linear mixed effects (LME) model. In the central tendency analysis for the 450mg dose group, the mean ΔQTcF (upper bound two-sided 90% CI) at 2 hours post-dose (Tmax) was 12.7ms (16.2ms) on Day 1 and 19.9ms (26.5ms) on Day 15. For the 300mg dose group, the mean ΔQTcF (upper bound twosided 90% CI) at 2 hours post-dose (Tmax) was 5.2ms (9.2ms) on Day 1 and 12.9ms (19.0ms) on Day 15. In the escalation phase, the mean maximum postbaseline ΔQTcF across patients at the 300mg dose was 26.2msec (90% CI = 7.8 to 44.6) and 24.9msec (90% CI = 20.2 to 29.7 msec) at the 450mg dose. In the expansion phase, the mean maximum postbaseline ΔQTcF across patients at the 300mg dose was 30.9msec (90% CI = 24.8 to 37.0 msec) and 33.4msec (90% CI = 28.0 to 38.8 msec) at the 450mg dose.

## Exposure-safety relationship

Exposure safety (E-S) analysis was conducted based on 4 clinical studies using logistic regression to model predicted AUCss and the expected incidence of selected adverse events, specifically all-grade ALT, and ≥ grade 2 PPE, pyrexia and diarrhoea. In general, the predicted exposure-safety relationships for both substances were similar in combination due to mutual confounding effects.

However, when the encorafenib dose was fixed, higher AUCss of binimetinib resulted in a higher probability of ALT increase relative to encorafenib monotherapy, although not statistically significant.

The probability of PPED was up to 44% for encorafenib monotherapy and the encorafenib effect was attenuated by binimetinib co-administration. Higher binimetinib exposure as indicated by AUCss, Cmaxss and Cminss was associated with lower probability of PPED.

The applicant conducted additional exposure-safety analyses using the updated popPK model; these were skin rash (grade ≥ 2), skin infections (grade ≥ 2), skin neoplasms (grade ≥ 2), retinal events (grade ≥ 2), high levels of AST (all grades), high levels of GGT (all grades), CK elevations (all grades) and arthralgia (grade ≥ 2). Increasing encorafenib exposure in mono-and combination treatment was associated with an increased probability of elevated CK (all grades) and a reduced probability of skin infection.

## Exposure-efficacy relationship

Kaplan-Meier plots of PFS (time-to-event) were derived by high/low exposure (relative to the median) and by quartiles of AUCss, Cmax,ss, and Cmin,ss for encorafenib and binimetinib based on the randomised dose.

Encorafenib monotherapy showed a similar median PFS between patients with higher and lower encorafenib exposure (PFS of 9.56 and 9.33 months respectively). PFS was higher in the Combo 450 arm but patients with high encorafenib exposure showed lower PFS compared to patients with lower encorafenib exposure (11.0 and 18.0 months, respectively). On review, patients with higher encorafenib exposure in the Combo 450 arm had poorer prognostic factors, particularly an increased proportion with LDH above the median. The

<div style=\"page-break-after: always\"></div>

median PFS time in patients with baseline LDH below and above the median were 21.9 and 9.0 months, respectively.

The logistic regression models for ORR and Cox hazard models for PFS were updated and results for Combo and encorafenib monotherapy treatments were presented for Part 1 and Part 2 and both parts combined, although only limited analyses involving encorafenib monotherapy from Part 2 alone were presented. The median PFS with encorafenib monotherapy was shorter in Part 2 (7.36 months) than Part 1 (9.56 months).

Figure 9: PFS Stratified by Encorafenib AUCss Above and Below the Median in Combo 450 (Part 1)

<!-- image -->

Figure 10: PFS Stratified by Encorafenib AUCss Above and Below the Median in Combo 300 (Part 2)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 11: Part1 - Combo450 - stratification of PFS by encorafenib AUC and LDH Left:   For patients with high LDH (&gt;173 U/L) median AUC is calculated with 15.3 µg*h/ml Right: For patients with low LDH median AUC is calculated with 14.1 µg*h/ml

<!-- image -->

Figure 12: Part 2 - Combo300 - stratification of PFS by encorafenib AUC and LDH Left:   For patients with high LDH (&gt;202 U/L) median AUC is calculated with 6.7 µg*h/ml Right: For patients with low LDH median AUC is calculated with 8.15 µg*h/ml

<!-- image -->

The applicant re-evaluated the Cox proportional hazard models for Part 2 and Part 1 and 2 combined utilising 'corrected' median AUC values. A significant positive treatment effect as a function of encorafenib exposure (AUCss) was not established.

Graphs of the probability of PFS according to encorafenib exposure (AUCss) were provided for Combo 450, Combo 300, Enco 300 Part 1 and Enco 300 Part 2 in the D180 responses. Also, graphs of probability of ORR and PFS by encorafenib Cmin were provided for these different populations. There was no clear relationship between Cminss of encorafenib and PFS or ORR in Part 1 or Part 2 of the COLOMBUS study for single agent encorafenib or in combination with binimetinib. It was not possible to establish a target Cmin,ss or Ctrough for encorafenib in order to guide dosing. No consistent relationship was observed between AUCss and PFS. The only trend (although not statistically significant) was a decrease in PFS with increased encorafenib AUCss with Combo450 in Part 1, as noted previously. This could have arisen by chance, due to higher baseline LDH levels or be the result of interaction with an unidentified covariate/ confounding factor. Patients with higher baseline LDH levels still had a positive treatment effect with Combo450 compared to vemurafenib in terms of PFS; however, this was not statistically significant with the confidence interval crossing 1 [PFS Combo 450 vs. vemurafenib: high LDH HR 0.73 (95% CI 0.47, 1.14); low LDH HR 0.47 (95% CI 0.33, 0.67)].

<div style=\"page-break-after: always\"></div>

## 2.4.4. Discussion on clinical pharmacology

The pharmacokinetics of encorafenib were studied in healthy subjects and patients with solid tumours, including advanced and unresectable or metastatic cutaneous melanoma harbouring a BRAF V600E or K mutation. The pharmacokinetics of encorafenib have been shown to be approximatively dose linear after single and multiples doses. After repeat once-daily dosing, steady state conditions were reached within 15 days. The accumulation ratio of approximately 0.5 is likely due to auto induction of CYP3A4. The inter subject variability (CV%) of AUC is ranged from 12.3% to 68.9%.

Encorafenib is moderately (86.1%) bound to human plasma proteins in vitro . Following a single oral dose of 100 mg [ 14 C] encorafenib in healthy subjects, the mean (SD) blood-to-plasma concentration ratio is 0.58 (0.02) and the mean (CV%) apparent volume of distribution (Vz/F) of encorafenib is 226 L (32.7%).

After oral administration, encorafenib is rapidly absorbed with a median Tmax of 1.5 to 2 hours. Following a single oral dose of 100 mg [14C] encorafenib in healthy subjects, at least 86% of the encorafenib dose was absorbed. Administration of a single 100 mg dose of encorafenib with a high-fat, high-calorie meal decreased the Cmax by 36%, while the AUC was unchanged. A drug interaction study in healthy subjects indicated the extent of encorafenib exposure was not altered in the presence of a gastric pH-altering agent (rabeprazole).

Following a single oral dose of 100 mg [ 14 C] encorafenib in healthy subjects, metabolism was found to be the major clearance pathway for encorafenib (approximately 88% of the recovered radioactive dose). The predominant biotransformation reaction of encorafenib was N-dealkylation. Other major metabolic pathways involved hydroxylation, carbamate hydrolysis, indirect glucuronidation and glucose conjugate formation.

Following a single oral dose of 100 mg [ 14 C] encorafenib in healthy subjects, radioactivity was eliminated equally in both the faeces and urine (mean of 47.2%). In urine, 1.8% of the radioactivity was excreted as encorafenib. The mean (CV%) apparent clearance (CL/F) of encorafenib was 27.9 L/h (9.15%). The median (range) encorafenib terminal half-life (T1/2) was 6.32 h (3.74 to 8.09 h).

For dose modifications see Table 1 of the SmPC. Administration of encorafenib at a dose of 450 mg once daily as a single agent is not recommended. If binimetinib is temporarily interrupted, encorafenib should be reduced at 300 mg once daily during the time of binimetinib dose interruption (see section 4.2 of binimetinib Summary of Product Characteristics [SmPC]) as encorafenib is not well-tolerated at the dose of 450 mg as a single agent. If binimetinib is permanently discontinued, encorafenib should be discontinued.

If encorafenib is temporarily interrupted (see Table 2), binimetinib should be interrupted. If encorafenib is permanently discontinued, then binimetinib should be discontinued.

## Effect of CYP enzymes on encorafenib

Encorafenib is metabolised by CYP3A4, CYP2C19 and CYP2D6. In vitro , CYP3A4 was predicted to be the major enzyme contributing to total oxidative clearance of encorafenib in human liver microsomes (~83.3%), followed by CYP2C19 and CYP2D6 (~16.0% and 0.71%, respectively).

Encorafenib is primarily metabolised by CYP3A4. Stronger CYP3A4 inhibitors (e.g. posaconazole, ketoconazole, itraconazole) are expected to have moderate to strong effects on encorafenib exposure. Moderate CYP3A4 inhibitor and P-gp transporter inhibitor (e.g diltiazem) are expected to moderately increase the overall encorafenib exposure (approximately 2-fold). Concomitant treatment of encorafenib with strong

<div style=\"page-break-after: always\"></div>

CYP3A4 inhibitors should be avoided and co-administration with moderate inhibitors should be considered with caution. See section 4.5 of the SmPC for information on effect of CYP3A4 inhibitors and inducers on encorafenib exposure.

## Effect of encorafenib on CYP substrates

In vitro experiments indicate encorafenib is a relatively potent reversible inhibitor of UGT1A1, CYP2B6, CYP2C9 and CYP3A4/5, as well as a time-dependent inhibitor of CYP3A4. Encorafenib induced CYP1A2, CYP2B6, CYP2C9 and CYP3A4 in human primary hepatocytes. Simulations of 450 mg encorafenib coadministered with probe substrates for CYP2B6, CYP1A2, CYP2C9, CYP2C19 and CYP2D6 on Day 1 and Day 15 all indicated no clinically relevant interactions are expected. For co-administration with CYP3A4 and UGT1A1 substrates that undergo gut extraction, a minor to moderate interaction is expected. While binimetinib is a UGT1A1 substrate, it does not undergo gut extraction and therefore no DDI with encorafenib is expected. Additionally, no differences in exposure have been observed clinically when binimetinib is coadministered with encorafenib.

Encorafenib is both an inhibitor and inducer of CYP3A4. Concomitant use with agents that are substrates of CYP3A4 (e.g., hormonal contraceptives) may result in increased toxicity or loss of efficacy of these agents. Women of childbearing potential must use effective contraception during treatment with encorafenib and for at least 1 month following the last dose. Encorafenib may decrease the efficacy of hormonal contraceptives (see SmPC section 4.5). Therefore, female patients using hormonal contraception are advised to use an additional or alternative method such as a barrier method (e.g. condom) during treatment with encorafenib and for at least 1 month following the last dose.

Concurrent use of strong CYP3A inhibitors during treatment with encorafenib should be avoided. If concomitant use with a strong CYP3A inhibitor is necessary, patients should be carefully monitored for safety (see section 4.5). Caution should be exercised if a moderate CYP3A inhibitor is co-administered with encorafenib.

Agents that are CYP3A4 substrates should be co-administered with caution.

Encorafenib is an inhibitor of UGT1A1. Concomitant agents that are substrates of UGT1A1 (e.g. raltegravir, atorvastatin, dolutegravir) may have increased exposure and should be therefore administered with caution.

## Effect of transporters on encorafenib

Encorafenib was found to be a substrate of the P-glycoprotein (P-gp) transporters. Inhibition of P-gp is unlikely to result in a clinically important increase in encorafenib concentrations as encorafenib exhibits high intrinsic permeability. The involvement of several uptake transporter families (OCT1, OATP1B1, OATP1B3 and OATPB1) was investigated in vitro using relevant transporter inhibitors. The data suggest that hepatic uptake transporters are not involved in encorafenib distribution into primary human hepatocytes.

## Effect of encorafenib on transporters

In vitro , encorafenib inhibited the hepatic transporter OCT1, but is unlikely to be an effective inhibitor clinically. Based on in vitro studies, there is potential for encorafenib to inhibit renal transporters OCT2, OAT1, OAT3 and hepatic transporters OATP1B1 and OATP1B3 at clinical concentrations. In addition, encorafenib may inhibit P-gp in the gut and BCRP at the expected clinical concentrations.

Encorafenib should be therefore co-administered with caution.  (SmPC section 4.6)

<div style=\"page-break-after: always\"></div>

For special populations, in contrast to gender, age and body weight were found to be signifcant covariates for volume distribution. However it is unlikely they have a clinically relevant effect and no dose adjustments are needed. (SmPC section 4.2 and 5.3). There are insufficient data to evaluate potential differences in the exposure of encorafenib by race or ethnicity.

While encorafenib is a relatively potent reversible inhibitor of UGT1A1, no differences in binimetinib exposure have been observed clinically when binimetinib was co-administered with encorafenib.

Encorafenib undergoes minimal renal elimination. No formal clinical study has been conducted to evaluate the effect of renal impairment on the pharmacokinetics of encorafenib. The covariate analysis showed no clear trend evaluating the effect of renal impairment on the encorafenib CL/F in subjects with mild and moderate renal impairment compared with subjects with normal renal function. No relationship between renal function and V/F was found in the population PK analysis. A small decrease in CL/F ( ≤ 5%) was predicted for patients with mild and moderate renal impairment, which is unlikely to be clinically relevant. The pharmacokinetics of encorafenib have not been studied in patients with severe renal impairment. A warning has been included in section 4.4 of the SmPC if administering to severe renal impaired patients. No dose adjustment is required for patients with mild or moderate renal impairment based on a population pharmacokinetics (PK) analysis. There are no clinical data with encorafenib in patients with severe renal impairment. Therefore, the potential need for dose adjustment cannot be determined. Encorafenib should be used with caution in patients with severe renal impairment (see SmPC sections 4.2, 4.4 and 5.2).

Results from a dedicated clinical study indicate a 25% higher total encorafenib exposures in patients with mild hepatic impairment (Child-Pugh Class A) compared with subjects with normal liver function. This translates into a 55% increase of the unbound encorafenib exposure. Therefore, a reduced dose of encorafenib 300 mg once daily in patients with mild hepatic impairment (Child Pugh Class A) is recommended in that population (SmPC section 4.2 and 4.4). The pharmacokinetics of encorafenib has not been evaluated clinically in patients with moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment. As encorafenib is primarily metabolised and eliminated via the liver, based on PBPK modelling, patients with moderate to severe hepatic impairment may have greater increases in exposure than patients with mild hepatic impairment. No dosing recommendation can be made in patients with moderate (Child Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment (see sections 4.2 and 4.4). A warning has been included in section 4.4 of the SmPC for patients with hepatic impairment, where no dosing recommendation can be made in patients with moderate (Child Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment and therefore,.encorafenib is not recommended in patients with moderate or severe hepatic impairment. Closer monitoring of encorafenib related toxicities in patients with mild hepatic impairment is recommended, including clinical examination and liver function tests, with assessment of ECGs as clinically appropriate during treatment.

Encorafenib and binimetinib combination administration can increase QTc interval at the doses used clinically. QT Prolongation has been observed in patients treated with BRAF-inhibitors. A thorough QT study to evaluate the QT prolongation potential of encorafenib has not been conducted.

Overall, results suggest that single agent encorafenib has the potential to cause mild increases in heart rate. Across pooled combination studies of encorafenib and binimetinib at the recommended doses and a singleagent encorafenib study, results suggest that encorafenib has the potential to result in small increases in QTc interval (see section 5.1).

There are insufficient data to exclude a clinically significant exposure dependent QT prolongation.

<div style=\"page-break-after: always\"></div>

Due to the potential risk for QT prolongation, it is recommended that serum electrolytes abnormalities, including magnesium and potassium, are corrected and risk factors for QT prolongation controlled (e.g. congestive heart failure, bradyarrhythmias) before treatment initiation and during treatment.

It is recommended that an electrocardiogram (ECG) is assessed before initiation of encorafenib, one month after initiation, and then at approximately 3-month intervals or more frequently as clinically indicated, while on treatment. The occurrence of QTc prolongation can be managed with dose reduction, interruption or discontinuation with correction of abnormal electrolytes and control of risk factors (see section 4.2).

PFS was shorter in patients with higher encorafenib exposure in the Combo 450 arm only. As a confounding factor, baseline LDH was higher in patients with AUCss above the median and PFS was shorter in patients with higher LDH. In the high LDH group in Part 1 of the study only patients with high encorafenib exposure in Combo 450 did worse. There was no such finding with Combo 300 in Part 2. The following is concluded from the updated exposure-response analyses. Nevertheless, addition of binimetinib has a positive effect on the efficacy of encorafenib so combination treatment.

Graphs of the probability of PFS according to encorafenib exposure (AUCss) and ORR and PFS by encorafenib Cmin were provided for Combo 450, Combo 300, Enco 300 Part 1 and Enco 300 Part 2. There was no clear relationship between Cminss of encorafenib and PFS or ORR in Part 1 or Part 2 of the COLOMBUS study for single agent encorafenib or in combination with binimetinib. It was not possible to establish a target Cmin,ss or Ctrough for encorafenib in order to guide dosing. No consistent relationship was observed between AUCss and PFS. The only trend (although not statistically significant) was a decrease in PFS with increased encorafenib AUCss with Combo450 in Part 1. This could have arisen by chance, due to higher baseline LDH levels or be the result of interaction with an unidentified covariate/ confounding factor. Patients with higher baseline LDH levels still had a positive treatment effect with Combo450 compared to vemurafenib in terms of PFS; however, this was not statistically significant with the confidence interval crossing 1 [PFS Combo 450 vs. vemurafenib: high LDH HR 0.73 (95% CI 0.47, 1.14); low LDH HR 0.47 (95% CI 0.33, 0.67)].

## 2.4.5. Conclusions on clinical pharmacology

The data submitted by the applicant are considered sufficient to adequatey characterise the pharmacokinetic and pharmacodynamic aspects of encorafenib. However, drug interaction will be investigated in a DDI cocktail study aimed to evaluate the DDI of encorafenib and binimetinib as perpetrator on relevant metabolic pathways and transporters. A reduced dose of encorafenib is recommended in patients with mild hepatic impairment while the administration is not recommended in patients with moderate and severe hepatic impairment. This information has been adequately reflected in the SmPC in section 4.2, 4.4 and 5.2. Furthermore, biomarker and genomic analyses would be helpful in supporting pharmacodynamic aspects of the combination therapy.

The CHMP requests the following measures to address the issues related to pharmacology:

- -DDI cocktail study: OATP and BCRP will be explored in the ongoing DDI study with rosuvastatin (study ARRAY-818-103)
- -Overall survival results stratified by LDH level for Combo 300 and Enco 300 (Part 2).
- -To collect PK samples from BRAF melanoma patients with moderate and severe hepatic impairment after repeated dosing of encorafenib in combination with binimetinib to determine the plasma concentrations in relation to administered dose and AEs observed to guide dosing recommendations in these patient populations.

<div style=\"page-break-after: always\"></div>

The CHMP expects the applicant to submit the following measures to address the issues related to pharmacology:

- -The applicant should commit to submit the results of the planned biomarker analyses for Study B2301 (from all 3 treatment arms) for evaluation as soon as available, to support the synergistic pharmacodynamic activity of encorafenib in combination with binimetinib. Genomic analysis of baseline samples remaining after centralized BRAF testing. As indicated in the protocol, genomic alterations in BRAF, HRAS, KRAS, NRAS, PTEN, cKIT, PIK3CA, MAP2K1, MAP2K2, ARAF, c-MET, CRAF, EGFR and CCND1 may be explored to find a potential association between baseline mutations and efficacy outcomes.
- -The relationship between baseline mutations and efficacy outcomes should be performed, and a date provided to submit the results.

## 2.5. Clinical efficacy

## 2.5.1. Dose response study(ies)

There were 2 early phase studies in patients with V600 mutant tumours (melanoma and colorectal cancer) to provide information on encorafenib dosing.

Phase 1 Study CLGX818X2101 assessed single agent encorafenib at doses up to 700mg QD. The MTD was determined to be 450mg QD but, due to the number of patients who required dose reduction without experiencing a dose limiting toxicity, encorafenib 300mg QD was declared to be the RP2D. BID dosing was explored briefly but stopped due to poor tolerability.

Table 24: Summary of best overall response by patient and treatment group (FAS, dose escalation phase)

|                                      | 50mg pb (N=4) n (%)   | 100mg pb (N=10) n (%)   | 150mg pb (N=6) n (%)   | 75mg bid (N=3) n (%)   | 200mg pb (N=4) n (%)   | 100mg bid (N=5) n (%)   | 300 mg pb (N=5) n (%)   | 150mg 450mg bid (N=4) n (%)   | pb (N=6) n (%)   | 550mg pb (N=5) n (%)   | 700mgqd (N=2) n (%)   | AllMel Nai (N=25) n (%)   | All Mel Pre (N=29) n (%)   | Encor- afenib All patients (N=54) n (%)   |
|--------------------------------------|-----------------------|-------------------------|------------------------|------------------------|------------------------|-------------------------|-------------------------|-------------------------------|------------------|------------------------|-----------------------|---------------------------|----------------------------|-------------------------------------------|
| Bestoverallresponse                  |                       |                         |                        |                        |                        |                         |                         |                               |                  |                        |                       |                           |                            |                                           |
| CompleteResponse(CR)                 | 1 (25.0)              | 0                       | 0                      | 0                      | 1 (25.0)               | 0                       | 0                       | 1 (25.0)                      | 0                | 0                      | 0                     | 2 (8.0)                   | 1 (3.4)                    | 3 (5.6)                                   |
| Partial Response (PR)                | 2 (50.0)              | 1 (10.0)                | 3 (50.0)               | 1 (33.3)               | 1 (25.0)               | 2 (40.0)                | 0                       | 2 (50.0) 2 (33.3)             |                  | 1 (20.0)               | 0                     | 13 (52.0)                 | 2 (6.9)                    | 15 (27.8)                                 |
| Unconfirmed CR                       | 0                     | 0                       | 0                      | 0                      | 0                      | 0                       | 0                       | 0                             | 0                | 0                      | 0                     | 0                         | 0                          | 0                                         |
| StableDisease                        | 0                     | 5 (50.0)                | 1 (16.7)               | 2 (66.7)               | 0                      | 1 (20.0)                | 2 (40.0)                | 0                             |                  | 1(16.7) 2 (40.0)       | 1 (50.0)              | 5 (20.0)                  | 10 (34.5)                  | 15 (27.8)                                 |
| Unconfirmed CR/PR                    | 0                     | 0                       | 0                      | 1 (33.3)               | 0                      | 0                       | 0                       | 0                             | 0                | 0                      | 0                     | 1 (4.0)                   | 0                          | 1 (1.9)                                   |
| Progressive Disease                  | 1 (25.0)              | 2 (20.0)                | 2 (33.3)               | 0                      | 2 (50.0)               | 1 (20.0)                | 2 (40.0)                | 1 (25.0) 2 (33.3)             |                  | 1 (20.0)               | 0                     | 0                         | 14 (48.3)                  | 14 (25.9)                                 |
| Unconfirmed CR/PR                    | 0                     | 0                       | 0                      | 0                      | 0                      | 0                       | 0                       | 0                             | 0                | 0                      | 0                     | 0                         | 0                          | 0                                         |
| Unknown                              | 0                     | 2 (20.0)                | 0                      | 0                      | 0                      | 1 (20.0)                | 1 (20.0)                | 0                             | 1 (16.7)         | 1 (20.0)               | 1 (50.0)              | 5 (20.0)                  | 2 (6.9)                    | 7 (13.0)                                  |
| Unconfirmed CR/PR                    | 0                     | 1 (10.0)                | 0                      | 0                      | 0                      | 0                       | 0                       | 0                             | 0                | 0                      | 0                     | 1 (4.0)                   | 0                          | 1(1.9)                                    |
| Overallresponserate (ORR)(CRor PR)   | 3 (75.0)              | 1 (10.0)                | 3 (50.0)               | 1 (33.3)               | 2 (50.0)               | 2 (40.0)                | 0                       | 3 (75.0) 2 (33.3)             |                  | 1 (20.0)               | 0                     | 15 (60.0)                 | 3 (10.3)                   | 18 (33.3)                                 |
| 95%Confidenceinterval                | (19.4, 99.4)          | (0.3, 44.5)             | (11.8, 88.2)           | (0.8, 90.6)            | (6.8, 93.2)            | (5.3, 85.3)             | (0.0, 52.2)             | (19.4, 99.4)                  | (4.3, 77.7)      | (0.5, 71.6)            | (0.0, 84.2)           | (38.7, 78.9)              | (2.2, 27.4)                | (21.1, 47.5)                              |
| Diseasecontrolrate (DCR)(CRorPRorSD) | 3 (75.0)              | 6 (60.0)                | 4 (66.7)               | 3 (100)                | 2 (50.0)               | 3 (60.0)                | 2 (40.0)                | 3 (75.0) 3 (50.0)             |                  | 3 (60.0)               |                       |                           | 1(50.0)20 (80.0)13 (44.8)  | 33 (61.1)                                 |
| 95%Confidenceinterval                | (19.4, 99.4)          | (26.2, 87.8)            | (22.3, 95.7)           | (29.2, 100.0)          | (6.8, 93.2)            | (14.7, 94.7)            | (5.3, 85.3)             | (19.4, 99.4)                  | (11.8, 88.2)     | (14.7, 94.7)           | (1.3, 98.7)           | (59.3, 93.2)              | (26.4, 64.3)               | (46.9, 74.1)                              |

BestoverallresponseisbasedonInvestigator'sassessmentofdiseasestatususingRECiST1.0.

The95%ConfidenceInterval(Cl)iscalculated usingtheexactmethod.

CRandPRareconfirmedbyrepeatassessmentsperformed notlessthan4weeks afterthecriteriaforresponseisfirst met.

Source:Table14.2-1.1.1.

Encorafenib monotherapy showed clinical activity at the lowest dose of 50mg QD with wide 95% Cis [ORR= 75% (95%-CI: 19.4; 99.4)].

<div style=\"page-break-after: always\"></div>

Phase 1b/ 2 Study CMEK162X2110 tested encorafenib at doses up to 800mg QD with binimetinib 45mg BID (the RP2D). The MTD was not reached and 2 RP2Ds of encorafenib were declared (450mg &amp; 600mg QD). Patients on 600mg encorafenib plus binimetinib experienced increased serum creatinine so all patients were started on or switched to encorafenib 450mg QD.

The Phase 3 doses were based on maximum tolerability with the hypothesis that higher doses might prevent the emergence of resistance or prolong the duration of tumour response.

## 2.5.2. Main study(ies)

COLUMBUS: A 2-part phase III randomized, open label, multicenter study of LGX818 plus MEK162 versus vemurafenib and LGX818 monotherapy in patients with unresectable or metastatic BRAF V600 mutant melanoma

## Methods

Figure1:StudyCMEK162B2301RandomisationScheme

<!-- image -->

BID:twicedaily;Combo300:encorafenib300mgQDincombinationwithbinimetinib45mgBID;Combo450:binimetinib 45mgBIDincombinationwithencorafenib450mgQD;LGX818:encorafenib300mgmonotherapy:QD:oncedaily;Rando: randomised.

## PART 1

## Study Participants

## Inclusion Criteria

1. Signed written informed consent;
2. Male or female patient, age &gt; 18 years;
3. Histologically confirmed diagnosis of locally advanced, unresectable or metastatic cutaneous melanoma or unknown primary melanoma AJCC Stage IIIB, IIIC or IV;
4. Presence of BRAF V600E and/or V600K mutation in tumor tissue prior to enrollment, as determined by a Sponsor designated central laboratory(ies);
5. Naive untreated patients or patients who have progressed on or after prior first-line immunotherapy for unresectable locally advanced or metastatic melanoma;

<div style=\"page-break-after: always\"></div>

Note : Prior adjuvant therapy is permitted (e.g. IFN, IL-2 therapy, any other immunotherapy, radiotherapy or chemotherapy), except the administration of BRAF or MEK inhibitors.

6. Evidence of at least one measurable lesion as detected by radiological or photographic methods according to guidelines based on RECIST version 1.1 (Appendix 2);

Note : A previously irradiated lesion is eligible to be considered as a measurable lesion provided that there is objective evidence of progression of the lesion since discontinuation of therapy and prior to starting study drug.

7. ECOG performance status of 0 or 1;
8. Adequate bone marrow, organ function and laboratory parameters:
- Absolute neutrophil count (ANC) &gt; 1.5 x 10 9 /L,
- Hemoglobin (Hgb) &gt; 9 g/dL without transfusions,
- Platelets (PLT) &gt; 100 x 109/L without transfusions,
- AST and/or ALT &lt; 2.5 × upper limit of normal (ULN); patient with liver metastases &lt; 5 ×ULN,
- Total bilirubin &lt; 2 × ULN,
- Creatinine &lt; 1.5 mg/dL, or calculated creatinine clearance (determined as per CockcroftGault) &gt; 50mL/min;
9. Adequate cardiac function:
- left ventricular ejection fraction (LVEF) &gt; 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram,
- triplicate average baseline QTc interval &lt; 480 ms;
10. Able to take oral medications;
11. Patient is deemed by the Investigator to have the initiative and means to be compliant with the protocol (treatment and follow-up);
12. Negative serum β-HCG test (female patient of childbearing potential only) performed within 72 hours prior to first dose.

## Exclusion criteria

1. Any untreated central nervous system (CNS) lesion. However, patients are eligible if: a) all known CNS lesions have been treated with radiotherapy or surgery and b) patient remained without evidence of CNS disease progression &gt; 4 weeks and c) patients must be off corticosteroid therapy for &gt; 3 weeks.
2. Uveal and mucosal melanoma;
3. History of leptomeningeal metastases;
4. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes);

<div style=\"page-break-after: always\"></div>

5. History of allogeneic bone marrow transplantation or organ transplantation;
6. History of Gilbert ' s syndrome;
7. Previous or concurrent malignancy with the following exceptions:
- adequately treated basal cell or squamous cell carcinoma of the skin (adequate wound healing is required prior to study entry),
- in situ carcinoma of the cervix, treated curatively and without evidence of recurrence for at least 3 years prior to the study,
- or other solid tumor treated curatively, and without evidence of recurrence for at least 3 years prior to study entry; (note: based on mechanism of action, BRAF inhibitors may cause progression of cancers associated with RAS mutations. Thus, benefits and risks should be carefully considered before administering a BRAF inhibitor to patients with a prior cancer associated with RAS mutation).
8. Prior therapy with a BRAF inhibitor (including but not limited to vemurafenib, dabrafenib, LGX818, and XL281/BMS-908662) and/or a MEK inhibitor (including but not limited to trametinib, AZD6244, MEK162, GDC-0973 and RDEA119);
9. Any previous systemic chemotherapy treatment, extensive radiotherapy or investigational agent other than immunotherapy, or patients who have received more than one line of immunotherapy for locally advanced unresectable or metastatic melanoma; Note: Ipilimumab or other immunotherapy treatment must have ended at least 6 weeks prior to randomization. Chemotherapy given as part of isolated limb perfusion, regional or intralesional treatment will not be considered systemic treatment.
10. Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following:
- History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) &lt;6 months prior to screening,
- Symptomatic chronic heart failure, history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality &lt;6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia;
11. Uncontrolled arterial hypertension despite medical treatment;
12. Known positive serology for HIV(Human immunodeficiency virus), active hepatitis B, and/or active hepatitis C infection;
13. Patients who have neuromuscular disorders that are associated with elevated CK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy);
14. Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment.
15. Impairment of gastrointestinal function (e.g., active ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome);
16. Any other condition that would, in the Investigator ' s judgment, contraindicate the patient ' s participation in the clinical study due to safety concerns or compliance with clinical study procedures,

<div style=\"page-break-after: always\"></div>

e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc.;

17. Patients who have undergone major surgery or radiotherapy &lt; 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure;
18. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test;
19. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study and for 8 weeks (6 months for women of child-bearing potential randomized to vemurafenib) after study drug discontinuation.
20. Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study.
21. Patients taking non-topical medication known to be a strong inhibitor of CYP3A4.

## Treatments

Encorafenib was supplied as 50mg and 100mg capsules (the MAA is for 50mg and 75mg capsules). Patients were not to have eaten anything for 2 hours before and 1 hour after the morning dose of study drug.

Patients received study treatment until progressive disease (PD) per RECIST v1.1 as determined by the blinded independent review committee (BIRC), unacceptable toxicity, withdrawal of consent, death, physician decision or early termination of the study.

The permitted dose reduction levels for encorafenib were 300 mg, 200 mg, 100 mg and 50 mg QD with specific recommendations regarding eye disorders, CK elevation, decreased LVEF, QTc prolongation, skin, gastrointestinal and liver-related AEs. Dose re-escalation was permitted if toxicity improved to ≤ Grade 1, except for QT prolongation (QTcF &gt;500msec). A patient in the Combo 450 arm who permanently discontinued binimetinib could continue encorafenib monotherapy but, if encorafenib was permanently discontinued, then binimetinib had to be discontinued due to its limited efficacy in monotherapy.  Patients requiring treatment interruption &gt;28 days were to be permanently discontinued.

## Objectives

The  primary  objective  was  to  determine  whether  treatment  with  Combo  450  prolongs  progression-free survival (PFS) compared with vemurafenib in patients with BRAF V600 mutant locally advanced unresectable or metastatic melanoma. This was addressed by Part 1 of the study.

The  key  secondary  objectives  were  to  determine  the  contribution  of  binimetinib  to  the  combination  by comparing  the  PFS  of  Combo  450  vs.  encorafenib  (Part  1)  and  to  further  quantify  the  contribution  of binimetinib to the combination by comparing the PFS of Combo 300 vs. encorafenib (Part 2).

Other secondary objectives included:

Part 1 only - to compare the treatment effect of Combo 450 vs. vemurafenib in terms of overall survival (OS); to estimate the treatment effect of combo 450 vs. encorafenib in terms of OS; to determine the safety and tolerability of Combo 450 and encorafenib in this patient population

<div style=\"page-break-after: always\"></div>

Part 2 only- to estimate the safety and tolerability of combo 300 vs. encorafenib in this patient population; to estimate the safety and tolerability of Combo 300 vs. Combo 450 in this patient population; to estimate the treatment effect of Combo 300 vs. encorafenib in terms of OS; to estimate the treatment effect of Combo 300 vs. vemurafenib in terms of PFS and OS; to estimate the treatment effect of Combo 300 vs. Combo 450 in terms of PFS and OS.

Parts  1  &amp;  2-  to  estimate  the  treatment  effect  of  encorafenib  vs.  vemurafenib  in  terms  of  PFS  and  OS;  to assess  objective  response  rate  (ORR)  by  treatment  arms;  to  describe  time  to  response  (TTR);  to  assess disease  control  rate  (DCR);  to  evaluate  duration  of  response  (DOR);  to  compare  the  patient-reported outcomes (PROs) and the ECOG PS between the treatment arms and to characterise the PK of encorafenib and binimetinib in this patient population.

Exploratory objectives included:

Part  1-  to  assess  whether  the BRAF mutation  status  in  circulating  tumour  DNA  correlates  with  the BRAF mutation status in tumour tissue

Parts 1 &amp; 2- to explore baseline molecular status of genes relevant to RAF/MEK/ERK and PI3K/AKT signalling in  tumour  tissue  and  their  potential  correlation  to  efficacy  outcomes  and  to  explore  potential  markers  of acquired resistance to encorafenib and encorafenib plus binimetinib

## Outcomes/endpoints

The primary efficacy endpoint of the study was PFS, defined as the time from the date of randomisation to the date of the first documented progression based on tumour assessment read centrally by a BICR according to RECIST v1.1 criteria, or death due to any cause, whichever occurred first. If a patient did not have an event at the time of the analysis cut-off or at the start of any new antineoplastic therapy, PFS was censored at  the  date  of  the  last  adequate  tumour  assessment.  If  a  patient  discontinued  treatment  for  'disease progression',  without  documented  evidence  of  progression  based  on  RECIST  v1.1,  it  was  not  to  be considered as a PFS event.

The key secondary for Part 1 was PFS per BIRC on Combo 450 vs. Enco 300.

## Other secondary endpoints

Other secondary efficacy endpoints included:

- OS (time from the date of randomization to date of death due to any cause);
- ORR (proportion of patients with a best overall response of CR or PR, calculated for confirmed and unconfirmed responses separately);
- TTR (time from date of randomization until first documented CR or PR);
- DCR (proportion of patients with a best overall response of CR, PR or stable disease);
- DOR (time from the date of first documented CR or PR to the first documented progression or death due to underlying cancer) and
- the  PROs  i.e.  Functional  Assessment  of  Cancer  Therapy  Melanoma  [FACT-M]  v  4,  European Organization  for  Research  and  Treatment  of  Cancer  Quality  of  Life  Questionnaire  Core  30  [EORTC QLQ-C30] v 3.0 and EuroQoL-5D-5 Level (EQ-5D-5L] v 4.0. The main PRO endpoints were time to definitive 10% deterioration in the FACT-M melanoma subscale and global health status score of the

<div style=\"page-break-after: always\"></div>

EORTC QLQ-C30; change from baseline  in  the  FACT-M  melanoma  subscale,  EQ-5D-5L,  and  global health  status  score  of  the  EORTC  QLQ-C30;  change  from  baseline  in  the  other  EORTC  QLQ-C30 subscales.

Efficacy and PROs were assessed every 8 weeks until week 105 and every 12 weeks thereafter until progression or end of treatment. Patients were then followed every 12 weeks for survival and use of subsequent anticancer therapy. Safety was assessed every 4 weeks. Patients in the combination arms had an ophthalmic exam at the start of each treatment cycle and pre- and post-dose PK samples.

## Sample size

For the vemurafenib arm, a median PFS of 7 months was assumed based on results from studies in previously untreated patients and patients who progressed after at least one prior systemic treatment were studied, respectively, where the median PFS values were 6.9 and 6.8 months, respectively.

Based on the dose-escalation results and the dose-expansion results of the Clinical Study CLGX818X2101, the observed median for patients treated with encorafenib was 7.1 months (95% CI 3.7, 14.7) and 7.4 months (95% CI 7.4, not estimable [NE]), respectively. In this less advanced patient population, the median PFS was therefore expected to be around 8 months.

Based on results from Clinical Study CMEK162X2110, Combo 450 was expected to result in a 42% reduction in hazard rate compared to vemurafenib (corresponding to an increase in median from 7 months to 12 months).

The observed benefit with Combo 300 was expected to be lower than with Combo 450. The median PFS was therefore anticipated to be around 11 months.

In study Part 1, patients were randomized in a 1:1:1 ratio to receive Combo 450, encorafenib or vemurafenib. The sample size driver for study Part 1 was the Combo 450 vs. encorafenib comparison. For the comparison of Combo 450 vs. encorafenib, 191 PFS events were required to detect a HR of 0.667 with an 80% power using a log-rank test at a one-sided 2.5% level of significance. For the Part 1 primary comparison, Combo 450 vs. vemurafenib, 145 PFS events were required to detect a HR of 0.58 with a 90% power using a log-rank test at a one-sided 2.5% level of significance.

A total of 576 patients (192 patients in each arm) were planned to be recruited in Part 1 over around 15 months, accounting for 15% loss to follow-up. The primary analysis was to be performed when a sufficient number of PFS events for both the primary and key secondary comparisons were available, which was expected to occur around 22 months after first treatment of the first patient.

In Part 2, the new Combo 300 arm was added. The data already collected in Part 1 for the encorafenib arm represented a considerable amount of information; therefore, the randomization ratio for Combo 300 to encorafenib in Part 2 was 3:1.

Considering a 3:1 randomization ratio in the second part of the study and aiming for a similar number of patients in the Combo 300 and the encorafenib arm (combining Part 1 and 2), 320 additional patients were to be randomized (80 in the encorafenib arm and 240 in the Combo 300 arm).

The Part 2 PFS Analysis was to be performed when approximately 340 PFS events had occurred in total in the encorafenib (both parts) and Combo 300 arms. Based on the differential follow-up and expected median PFS

<div style=\"page-break-after: always\"></div>

times, it was expected that approximately 330 of these events would contribute to the HR estimate and logrank test, and would result in approximately 80% power to detect a HR of 0.727 (8/11) at a one-sided 2.5% level of significance. This was anticipated to occur approximatively 37 months after first treatment of the first patient.

## Randomisation

In Part 1, approximately 576 patients were to be randomised in a 1:1:1 ratio to one of the 3 treatment arms.

Randomisation was stratified by AJCC stage (IIIB + IIIC + IVM1a + IVM1b vs. IVM1c); ECOG PS (0 vs. 1), BRAF mutation status (V600E vs. V600K) and prior first-line immunotherapy for unresectable or metastatic disease (yes vs. no).

Prior first line immunotherapy (yes vs. no) added with Protocol Amendment 2 (post enrolment of 2 patients), when inclusion of this patient group was allowed.

BRAF mutation status (V600E vs. V600K) was removed as a stratification factor with Protocol Amendment 2, as the V600K stratum was expected to be very small.

## Blinding (masking)

The study was open label. However, blinded tumour assessment data read centrally by a BIRC were used in the primary efficacy analysis.

## Statistical methods

The following analysis populations were defined:

The Full Analysis Set (FAS) was defined according to the Intention-to-Treat (ITT) principle, and consisted of all randomized patients. Following the ITT principle, patients were analyzed according to the treatment and stratification factors they were assigned to at randomization.

The Per-protocol Set (PPS) consisted of all patients from the FAS without any major protocol deviations and who received at least one dose of study medication.

The Safety Set included all patients who received at least one dose of the study medication and had at least one valid post-baseline safety evaluation. Patients were analyzed according to the study treatment they actually received.

The Pharmacokinetic Analysis Set (PAS) consisted of all patients who received at least one dose of encorafenib or binimetinib and had at least one evaluable post-baseline encorafenib or binimetinib concentration measurement. The same definition applied to the Japanese subgroup.

All efficacy analyses were performed using the FAS, unless otherwise specified.

The primary and key secondary efficacy comparisons were based on PFS, defined as the time from the date of randomization to the date of the first documented progression, or death due to any cause, whichever occurred first. Censoring rules to be applied to the PFS endpoint are described in the following table.

<div style=\"page-break-after: always\"></div>

Table 25: Censoring rules to be applied to the progression-free survival analysis

|    | Situation                                                                                                                                     | Erent Date                                                                                                                            | Outcome             |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| A  | No baseline assessment                                                                                                                        | Date of randomization                                                                                                                 | Censored            |
| B  | Progression or death at or before next scheduled assessment                                                                                   | Date of progression (or death)                                                                                                        | Progressed          |
| 10 | Progression or death after exaetly one missing assessment                                                                                     | Date of progression (or death)                                                                                                        | Progressed          |
| C2 | Progression or death after two or more missing assessments                                                                                    | Date of last adequate tumor assessment*                                                                                               | Censored            |
| D  | No progression                                                                                                                                | Date of last adequate tumor assessment*                                                                                               | Censored            |
| E  | Treatment discontinuation due to \"Disease progression\" without documented progression, i.e., clinical progression based on investigator claim | N/A (not considered as an event, patient without documented PD should be followed for progression after discontinuation of treatment) | Information ignored |
| F  | New anticancer therapy given                                                                                                                  | Date of last adequate tumor assessment*                                                                                               | Censored            |

protocol in which case a PFS event at the date of death is coumted

The rare exception to this is if the patient dies no later than the time of the second scheduled assessment as defined in the

* tumor assessment with non-missing and non-umknown overall lesion response

Blinded tumor assessment data read centrally by a BIRC were used in the primary efficacy analysis. The local Investigator's assessments were used in a supportive analysis of PFS.

The primary analysis was the comparison of the distribution of PFS between Combo 450 and vemurafenib using a stratified log-rank test at a one-sided 2.5% cumulative level of significance.

The null and the alternative hypothesis were defined as follows:

where Svem(t) is the survival distribution function of PFS in the control arm (i.e. vemurafenib) and SC450(t) is the survival distribution function of PFS in the experimental arm (i.e. Combo 450). Ho: Sc45o(t) ≤ Svem(t) vs HA: Sc45o(t) &gt; Svem(t), t≥ 0

Progression-free survival was analyzed based on the data from the FAS according to the treatment arm and 2 of the stratification factors (cancer stage and ECOG PS) patients were randomized to. Due to the relatively low expected prevalence of patients with prior immunotherapy (around 15%), the 2 prior immunotherapy strata (yes and no) were combined at the time of the analysis to avoid small or empty strata. The same principle applied to all stratified tests and models in this study.

The distribution of PFS was described in tabular and graphical format by treatment arm using Kaplan-Meier methods, reporting estimated median (in months) with 95% confidence interval (CI), 25th and 75th percentiles and Kaplan-Meier estimated probabilities with corresponding 95% CIs at several time points (including at least 2, 4, 6, 8, 10, 12 and 14 months).

A Cox regression model stratified by randomization stratification factors was used to estimate the HR of PFS, along with 95% CI based on the Wald test.

To control type I error, a hierarchical testing procedure was used and the secondary endpoint of OS Combo 450  vs  vemurafenib  was  to  be  tested  only  if  the  primary  and  key  secondary  PFS  comparisons  were statistically significant.

<div style=\"page-break-after: always\"></div>

Data cut-off for Part 1 was to take place once the planned number of patients had been randomised to Part 1 (i.e. 576 patients) and sufficient PFS events were available for the final primary and Part 1 key secondary comparison  (i.e.145  PFS  events  for  Combo  450  vs.  vemurafenib  and  191  PFS  events  for  Combo  450  vs. encorafenib). The analysis was performed at 204 PFS events for Combo 450 vs. vemurafenib and 223 PFS events for Combo 450 vs. Enco 300.

Figure 13: Timing of Testing of Primary and Key Secondary Endpoints (hierarchical testing sequence)

<!-- image -->

C450= Combo 450; C300= Combo 300; L=LGX818 (encorafenib); V= vemurafenib

Overall  survival  was  defined  as  the  time  from  the  date  of  randomization  to  the  date  of  death  due  to  any cause. If a death was not observed by the date of analysis cutoff, OS was to be censored at the date of last contact. Survival time for patients with no post-baseline survival information was to be censored on the date of  randomization. For analysis of OS, a group sequential design with one interim analysis (at time of PFS analysis (Part 2)) was planned to be used. To maintain the overall type-I error rate for the trial, the type-1 error rate was based on a α-spending function using a Gamma function with parameter 1. At the time of the Primary PFS Analysis (Part 1), no formal testing of OS was performed in order to preserve Sponsor blinding to OS and maintain the integrity of the planned first interim analysis.

Secondary efficacy variables were analyzed in the FAS and were to include ORR, TTR, DCR, DOR and PROs.

The BIRC assessments were used for the main analyses of best overall response (BOR), ORR, TTR, DCR and DOR. ORR and DCR were presented by treatment arm along with exact 95% CI using the Clopper-Pearson method.

Time to response and duration of response were descriptively analyzed using the Kaplan-Meier method.

The change in tumor size was to be depicted using waterfall plots presenting the best percentage change from baseline in the sum of the diameter of all target lesions. These plots were to display the best percentage change from baseline in the sum of the diameter of all target lesions for each patient.

Health-related  QoL  data  were  collected  via  PROs.  The  FACT-M,  EQ-5D-5L  and  EORTC  QLQ-C30  patient questionnaires were used in this study. Health-related QoL data were analyzed using the FAS. The FACT-M melanoma subscale, index score of EQ-5D-5L and the global health status/QoL score of the EORTC QLQ-C30 were  identified  as  the  primary  PRO  variables  of  interest.  Physical  functioning,  emotional  functioning  and social functioning scale scores of the EORTC QLQ-C30 were considered as secondary.

<div style=\"page-break-after: always\"></div>

The  primary  PRO  analysis  was  to  assess  the  difference  in  distribution  of  the  time  to  definitive  10% deterioration  in  the  FACT-M  subscale  among  the  treatment  arms  in  the  full  analysis  set  (FAS).  Only assessments collected while the patient was on treatment and at the EOT visit were included.

## Results

## Participant flow

## Patient Flow Chart for Part 1 of Study CMEK162B2301

BiD: Twice daily; QD: once daily:*Primary reason; + at the time of date cutoff of19 May 2016

<!-- image -->

## Recruitment

Patients were randomised at 162 sites in 28 countries; 20 sites in North America, 124 sites in Europe and 18 sites in selected countries from the rest of the world. A small number were enrolled per site so data from all sites were pooled.

<div style=\"page-break-after: always\"></div>

## Conduct of the study

The proportion of patients with at least one protocol deviation was similar among the 3 treatment arms (62.0% Combo 450, 66.0% encorafenib, 64.4% vemurafenib arm). Most protocol deviations were due to key procedures not performed as per protocol (48.4% Combo 450, 52.6% encorafenib, 54.5% vemurafenib arm). Deviations due to eligibility criteria not met were reported in each treatment arm (8.9% Combo 450 arm, 10.8% encorafenib arm, 4.7% vemurafenib arm).

There were 4 amendments to the original study protocol (dated 13 May 2013).

Version 1, Amendment 1 (3 October 2013) was issued before any patients were randomised and included clarification that patients known to be NRAS mutation positive should not be selected for pre-screening.

Version 2, Amendment 2 (20 December 2013) after 2 patients had been randomised allowed inclusion of patients progressing on or after first line immunotherapy.

Version 3, Amendment 3 (4 November 2014) was issued when 364 patients had been randomised. Part 2 was added. Consequently, allocation to Part 1 was reduced, the primary objective of analysis of PFS of encorafenib monotherapy vs. vemurafenib was changed to a secondary endpoint and the key secondary endpoint of overall survival for Combo 450 vs. vemurafenib was changed to a secondary endpoint to be tested hierarchically after the Part 2 key secondary endpoint.

Version 4, Amendment 4 (13 Jul 2015), documented a change in study sponsorship.

At the time of the primary PFS analysis (data cut-off 19 May 2016), the required number of survival events had not occurred for analysis of overall survival (OS). On 14 October 2016, the DMC reviewed un-blinded data from Part 1 (data cut-off 19 May 2016) and un-blinded survival data, to which the Sponsor (Array) and Pierre Fabre remained blinded. The DMC recommended the following:

- Terminate the planned analyses and inform all patients (in Parts 1 and 2) of the Part 1 results.
- Inform patients in the vemurafenib arm that a combination of commercially available BRAF and MEK inhibitors may be a better alternative regimen.

There were no specific recommendations regarding the encorafenib monotherapy arm. The decision to continue encorafenib monotherapy or change to a BRAF/MEK inhibitor combination was to be based on a discussion between the patient and physician.

To minimise the delay in the timing of the OS interim analysis, the applicant proposed that the protocol be amended to de-couple the Part 1 OS analysis from the primary Part 2 PFS analysis. The timing of the Part 1 OS analysis became event driven; the interim OS data was submitted with the response to the D120 list of questions.

Per Protocol Amendment 5.0, two OS analyses of Combo 450 vs. vemurafenib were planned based on the number of OS events in the Combo 450 and vemurafenib arms combined:

Part 1 OS Interim Analysis: The primary OS analysis was to be performed when approximately 232 OS events were observed

Final OS Update: to be performed when approximately 309 OS events were observed

The data cut-off date for this Part 1 OS interim analysis was 7 November 2017, by which time a total of 232 OS events were observed in the Combo 450 and vemurafenib arms combined in Part 1 of the study.

<div style=\"page-break-after: always\"></div>

Table 26: Reasons Leading to Exclusion of Patients from Per-protocol Set (Full Analysis Set, Part 1)

| Reason                                                                                                                                          | Combo 450 N=192 n (%)   | Encorafenib N=194 n (%)   | Vemurafenib N=191 n (%)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|---------------------------|---------------------------|
| Patients excluded from Per-protocol set                                                                                                         | 4 (2.1)                 | 10 (5.2)                  | 7 (3.7)                   |
| Patient did not receive at least one dose of study medication                                                                                   | 0                       | 2 (1.0)                   | 5 (2.6)                   |
| No histologically confirmed diagnosis of umresectableormetastaticcutaneous melanoma or unknownprimarymelanoma (stage IIIB, IIIC to IV per AJCC) | 1 (0.5)                 | 1 (0.5)                   | 0                         |
| Not positive for BRAF V600 mutation ?                                                                                                           | 0                       | 2 (1.0)                   | 0                         |
| Prior treatment for unresectable or metastatic cutaneous melanoma other than immunotherapy                                                      | 1 (0.5)                 | 0                         | 0                         |
| Prior treatment with a RAF and/or MEK inhibitor a                                                                                               | 0                       | 1 (0.5)                   | 0                         |
| No measurable lesion as detected by local review of radiological or photographic methods based on RECIST version 1.1 d                          | 1 (0.5)                 | 0                         | 1 (0.5)                   |
| New anti-neoplastic therapy administered after start of study treatment and prior to first tumof assessment                                     | 1 (0.5)                 | 4 (2.1)                   | 1 (0.5)                   |

## Baseline data

Table 27: Demographics (Full Analysis Set, Part 1)

a Last non-missing ECOG performance status prior to/at the start of study treatment for patients who took at least one study treatment or prior to/ on Cycle 1 Day 1 for patients who didn't take any study treatment.

| Demographic Variable                                                                                                                                                                                           | Combo 450 N=192                                                                                                                       | Encorafenib N=194                                                                                                                           | Vemurafenib N=191                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Age (years) Mean (SD) Median Min - Max Age category (years), n (%) < 65 ≥ 65 Sex, n (%) Female Male Race, n (%) Caucasian Asian Native American Other Unknown b Missing c ECOG performance status, n (%) a 0 1 | 56.2 (13.62) 57.0 20 - 89 132 (68.8) 60 (31.3) 77 (40.1) 115 (59.9) 181 (94.3) 5 (2.6) 0 3 (1.6) 2 (1.0) 1 (0.5) 136 (70.8) 56 (29.2) | 54.6 (12.63) 54.0 23 - 88 154 (79.4) 40 (20.6) 86 (44.3) 108 (55.7) 174 (89.7) 6 (3.1) 2 (1.0) 2 (1.0) 9 (4.6) 1 (0.5) 140 (72.2) 54 (27.8) | 55.2 (14.18) 56.0 21 - 82 140 (73.3) 51 (26.7) 80 (41.9) 111 (58.1) 166 (86.9) 8 (4.2) 2 (1.0) 2 (1.0) 12 (6.3) 1 (0.5) 140 (73.3) 51 (26.7) |

<div style=\"page-break-after: always\"></div>

b  Unknown denotes 'unknown' was selected on the eCRF.

c Missing denotes the race field on the eCRF was not completed.

Table 28: Patient and Disease Characteristics (Full Analysis Set, Part 1)

| Disease history                                                     | Combo 450 N=192   | Encorafenib N=194   | Vemurafenib N=191   |
|---------------------------------------------------------------------|-------------------|---------------------|---------------------|
| Primary site of cancer, n (%)                                       |                   |                     |                     |
| Skin Melanoma                                                       | 191 (99.5)        | 192 (99.0)          | 190 (99.5)          |
| Unknown                                                             | 1 (0.5)           | 2 (1.0)             | 1 (0.5)             |
| Stage at time of study entry, n (%)                                 |                   |                     |                     |
| Stage IIIB                                                          | 0                 | 2 (1.0)             | 1 (0.5)             |
| Stage IIIC                                                          | 9 (4.7)           | 4 (2.1)             | 10 (5.2)            |
| Stage IV M1A                                                        | 26 (13.5)         | 29 (14.9)           | 24 (12.6)           |
| Stage IV M1B                                                        | 34 (17.7)         | 39 (20.1)           | 31 (16.2)           |
| Stage IV M1C with elevated LDH                                      | 50 (26.0)         | 50 (25.8)           | 36 (18.8)           |
| Stage IV M1C with normal LDH                                        | 73 (38.0)         | 70 (36.1)           | 89 (46.6)           |
| Time from initial diagnosis to onset of metastatic disease (months) |                   |                     |                     |
| n                                                                   | 187               | 191                 | 187                 |
| Mean (SD)                                                           | 37.02 (61.090)    | 36.45 (62.708)      | 38.14 (52.994)      |
| Median                                                              | 15.05             | 13.04               | 14.92               |
| Min - Max                                                           | 0.0- 448.5        | 0.0 - 388.8         | 0.0 - 280.5         |
| Number of organs involved at Baseline a, n (%)                      |                   |                     |                     |
| 1                                                                   | 47 (24.5)         | 56 (28.9)           | 45 (23.6)           |
| 2                                                                   | 58 (30.2)         | 52 (26.8)           | 59 (30.9)           |
| 3                                                                   | 45 (23.4)         | 42 (21.6)           | 42 (22.0)           |
| >3                                                                  | 42 (21.9)         | 44 (22.7)           | 45 (23.6)           |
| LDH at Baseline (U/L)                                               |                   |                     |                     |
| n1                                                                  | 192               | 194                 | 191                 |
| Mean (SD)                                                           | 298.7 (368.93)    | 265.2 (251.21)      | 239.8 (189.27)      |
| Median                                                              | 173.0             | 188.5               | 174.0               |
| Min - Max                                                           | 76 -3590          | 75 -1886            | 57- 1285            |
| LDH at Baseline , n (%)                                             |                   |                     |                     |
| Low                                                                 | 0                 | 0                   | 0                   |
| Normal                                                              | 137 (71.4)        | 147 (75.8)          | 139 (72.8)          |
| High                                                                | 55 (28.6)         | 47 (24.2)           | 52 (27.2)           |
| Missing                                                             | 0                 | 0                   | 0                   |

Note: The time from initial diagnosis to onset of metastatic disease are calculated only for patients with metastatic disease. A patient may have multiple metastatic sites. Metastatic sites and organs involved were derived from Diagnosis and Extent of Cancer eCRF page.

a For patients with stage IIIB and IIIC at study entry, the number of organs involved at baseline is equal to one and presented as skin.

b Low and high categories defined by normal ranges.

<div style=\"page-break-after: always\"></div>

Table 29: Prior Antineoplastic Therapy - Overall (Full Analysis Set, Part 1)

|                                            | Combo 450 N=192 n (%)   | Encorafenib N=194 n (%)   | Vemurafenib N=191 n (%)   |
|--------------------------------------------|-------------------------|---------------------------|---------------------------|
| Any therapy                                | 158 (82.3)              | 161 (83.0)                | 165 (86.4)                |
| Medication                                 | 62 (32.3)               | 63 (32.5)                 | 59 (30.9)                 |
| Surgery                                    | 146 (76.0)              | 149 (76.8)                | 157 (82.2)                |
| Radiotherapy                               | 30 (15.6)               | 42 (21.6)                 | 25 (13.1)                 |
| Medication: setting at last treatment      |                         |                           |                           |
| Adjuvant                                   | 52 (27.1)               | 46 (23.7)                 | 46 (24.1)                 |
| Neoadjuvant                                | 0                       | 1 (0.5)                   | 1 (0.5)                   |
| Therapeutic - Metastatic                   | 10 (5.2)                | 16 (8.2)                  | 12 (6.3)                  |
| Radiotherapy: setting at last radiotherapy |                         |                           |                           |
| Adjuvant                                   | 17 (8.9)                | 20 (10.3)                 | 11 (5.8)                  |
| Neoadjuvant                                | 0                       | 1 (0.5)                   | 0                         |
| Therapeutic - metastatic                   | 6 (3.1)                 | 11 (5.7)                  | 6 (3.1)                   |
| Therapeutic                                | 3 (1.6)                 | 6 (3.1)                   | 4 (2.1)                   |
| Palliative                                 | 2 (1.0)                 | 4 (2.1)                   | 2 (1.0)                   |
| Other                                      | 2 (1.0)                 | 0                         | 0                         |
| Missing                                    | 0                       | 0                         | 2 (1.0)                   |

Table 30: Prior Antineoplastic Therapies - Ipilimumab, anti-PD1/PDL1 or Interferons/Interleukins (Full Analysis Set, Part 1)

|                                     | Combo 450 N=192 n (%)   | Encorafenib N=194 n (%)   | Vemurafenib N=191 n (%)   |
|-------------------------------------|-------------------------|---------------------------|---------------------------|
| Any immunotherapy                   | 57 (29.7)               | 58 (29.9)                 | 57 (29.8)                 |
| Ipilimumab                          | 7 (3.6)                 | 10 (5.2)                  | 7 (3.7)                   |
| Anti-PD1/PDL1                       | 1 (0.5)                 | 2 (1.0)                   | 0                         |
| Interferons/Interleukins            | 51 (26.6)               | 51 (26.3)                 | 52 (27.2)                 |
| Ipilimumab - Setting  ab            | n=7                     | n=10                      | n=7                       |
| Adjuvant                            | 2 (28.6)                | 1 (10.0)                  | 2 (28.6)                  |
| Therapeutic-metastatic              | 5 (71.4)                | 9 (90.0)                  | 5 (71.4)                  |
| Anti-PD1/PDL1 - Setting ab          | n=1                     | n=2                       | n=0                       |
| Therapeutic-metastatic              | 1 (100)                 | 2 (100)                   | 0                         |
| Interferons/Interleukins -- Setting | n=51                    | n=51                      | n=52                      |
| Adjuvant                            | 47 (92.2)               | 46 (90.2)                 | 46 (88.5)                 |
| Neoadjuvant                         | 0                       | 1 (2.0)                   | 1 (1.9)                   |
| Therapeutic-metastatic              | 4 (7.8)                 | 4 (7.8)                   | 5 (9.6)                   |

PD1 = programmed death 1 (receptor); PDL1 = programmed death (receptor) ligand 1

a A patient may have multiple settings.

b A patient may have received ipilimumab or anti-PD1/PDL1 in combination.

A similar percentage of patients (29.7% Combo 450, 29.9% Enco 300, 29.8% vemurafenib arm) received prior immunotherapy (metastatic and adjuvant). This was mainly cytokines (interferon/ interleukin); the proportion who received prior ipilimumab was &lt;5% and anti PD1/ anti PDL1 &lt;1%.

<div style=\"page-break-after: always\"></div>

The median age of patients was 56 years (range 20¬-89), 58% were male, 90% were Caucasian, and 72% of patients had baseline ECOG performance status of 0. Most patients had metastatic disease (95%) and were Stage IVM1c (64%); 27% of patients had elevated baseline serum lactate dehydrogenase (LDH), and 45% of patients had at least 3 organs with tumour involvement at baseline and 3.5% had brain metastases. 27 patients (5%) had received prior checkpoint inhibitors (anti-PD1/PDL1 or ipilimumab) (8 patients in Combo 450 arm (4%); 7 patients in vemurafenib arm (4%); 12 patients in Enco 300 arm (6%) including 22 patients in the metastatic setting (6 patients in Combo 450 arm; 5 patients in vemurafenib arm; 11 patients in Enco 300 arm) and 5 patients in the adjuvant setting (2 patients in Combo 450 arm; 2 patients in vemurafenib arm; 1 patient in Enco 300 arm).

Table 31: Anti-neoplastic Therapy Since Study Drug Discontinuation

| Discontinued treatment/ not treated           | Combo 450 N=124   | Encorafenib N=148   | Vemurafenib N=164   |
|-----------------------------------------------|-------------------|---------------------|---------------------|
| Subsequent antineoplastic therapy, n (n%)     | 65 (52.4%)        | 90 (60.8%)          | 106 (64.6%)         |
| Subsequent monoclonal antibodies, n (n%)      | 48 (38.7%)        | 53 (35.8%)          | 63 (38.4%)          |
| Subsequent BRAF/ BRAF + MEK inhibitor, n (n%) | 17 (13.7%)        | 35 (23.6%)          | 55 (33.5%)          |
| Subsequent encorafenib + binimetinib, n (%)   | 0                 | 4 (2.7%)            | 5 (3.0%)            |

A similar proportion of patients in each treatment arm received subsequent treatment with checkpoint inhibitors, mainly pembrolizumab, nivolumab and ipilimumab (34.4% Combo 450 arm, 36.1% encorafenib arm, 39.8% vemurafenib arm).

## Numbers analysed

Table 32: Analysis Sets (Part 1)

| Analysis Set                   | Combo 450 N=192 n (%)   | Encorafenib N=194 n (%)   | Vemurafenib N=191 n (%)   | Total N=577 n (%)   |
|--------------------------------|-------------------------|---------------------------|---------------------------|---------------------|
| Full Analysis Set a            | 192 (100)               | 194 (100)                 | 191 (100)                 | 577 (100)           |
| Safety Set b                   | 192 (100)               | 192 (99.0)                | 186 (97.4)                | 570 (98.8)          |
| Per-protocol Set c             | 188 (97.9)              | 184 (94.8)                | 184 (96.3)                | 556 (96.4)          |
| Pharmacokinetic Analysis Set d | 192 (100)               | 191 (98.5)f               | 0                         | 383 (66.4)          |

<div style=\"page-break-after: always\"></div>

Twenty-one patients (3.6%) were excluded from the PPS (4 patients [2.1%] Combo 450, 10 patients [5.2%] encorafenib, 7 patients [3.7%] vemurafenib). The most common reasons were that patients did not receive at least one dose of study medication or new anti-neoplastic therapy was administered after the start of study treatment and prior to first tumour assessment.

## Outcomes and estimation

## Primary Endpoint: PFS based on BIRC review in the FAS

PFS for the Combo 450 vs. vemurafenib alone was 14.9 vs. 7.3 months, respectively, with a HR of 0.54 (95% CI 0.41, 0.71, 1 sided stratified log rank p&lt;0.001). No imputations were used for the start or end dates for the primary PFS analysis.

Table 33: Kaplan-Meier Summary of PFS by BIRC - Combo 450 vs. Vemurafenib (FAS, Part 1)

|                                                        | Combo 450 N=192   | Vemurafenib N=191   |
|--------------------------------------------------------|-------------------|---------------------|
| Patients with events/Patients included in analysis (%) | 98/192 (51.0)     | 106/191 (55.5)      |
| Percentiles (95% C1) °                                 |                   |                     |
| 25th                                                   | 7.3 (5.5, 7.5)    | 3.7 (3.6, 4.0)      |
| 50th                                                   | 14.9 (11.0, 18.5) | 7.3 (5.6, 8.2)      |
| 75th                                                   | 25.0 (22.0, NE)   | 18.5 (12.8, NE)     |
| Event-free probability estimates (95% CI) b            |                   |                     |
| 4 months                                               | 86.9 (80.9, 91.1) | 68.9 (61.1, 75.5)   |
| 8 months                                               | 65.6 (57.9, 72.2) | 42.7 (34.6, 50.6)   |
| 12 months                                              | 56.7 (48.8, 63.9) | 33.4 (25.6, 41.4)   |
| 16 months                                              | 48.7 (40.6, 56.2) | 28.3 (20.7,36.4)    |
| 20 months                                              | 38.6 (30.0, 47.1) | 23.9 (16.2,32.3)    |
| 24 months                                              | 32.3 (22.7, 42.2) | 23.9 (16.2,32.3)    |

<div style=\"page-break-after: always\"></div>

Figure 14: Kaplan-Meier Estimate of PFS Based on BIRC - Combo 450 vs. Vemurafenib (FAS, Part1)

<!-- image -->

The median PFS values based on Kaplan-Meier estimates were 14.8 months (95% CI 10.4, 18.4) and 7.3 months (95% CI 5.7, 8.5) for the Combo 450 and vemurafenib arms, respectively (HR of 0.49, 95% CI 0.37, 0.64; nominal p &lt; 0.001).

Median follow-up time for PFS per BIRC was 16.7 months for the Combo 450 arm and 14.4 months for the vemurafenib arm. Just under half of the patients were censored for the primary PFS analyis, most prior to the median PFS in each arm. The most common reason for censoring in the Combo 450 and encorafenib arms was because patients remained on treatment (29.7% and 24.2%, respectively), whilst in the vemurafenib arm it was because patients had started a new cancer therapy (19.9%).

<div style=\"page-break-after: always\"></div>

Table 34: Reasons for Censoring Patients in the PFS by BIRC - Combo 450 Arm, Encorafenib Arm, Vemurafenib Arm (FAS, Part 1) i.e. Primary &amp; Secondary PFS Analyses

a

|                                          | Combo 450 N=192 n (%)   | Encorafenib N=194 n (%)   | Vemurafenib N=191 n (%)   | Total N=577 n (%)   |
|------------------------------------------|-------------------------|---------------------------|---------------------------|---------------------|
| Nunber of patients censored              | 94 (49.0)               | 98 (50.5)                 | 85 (44.5)                 | 277 (48.0)          |
| Reason for censoring                     |                         |                           |                           |                     |
| Ongoinga                                 | 57 (29.7)               | 47 (24.2)                 | 25 (13.1)                 | 129 (22.4)          |
| Lost to follow-up                        | 1 (0.5)                 | 1 (0.5)                   | 0                         | 2 (0.3)             |
| Adequate assessment no longer availablec | 7 (3.6)                 | 2 (1.0)                   | 6 (3.1)                   | 15 (2.6)            |
| Event after 2 or more missed assessments | 4 (2.1)                 | 7 (3.6)                   | 1 (0.5)                   | 12 (2.1)            |
| New anti-neoplastic therapy given        | 18 (9.4)                | 27 (13.9)                 | 38 (19.9)                 | 83 (14.4)           |
| No baseline assessment                   | 2 (1.0)                 | 2 (1.0)                   | 0                         | 4 (0.7)             |
| No post-baseline assessment              | 4 (2.1)                 | 11 (5.7)                  | 11 (5.8)                  | 26 (4.5)            |
| Withdrew consent                         | 1 (0.5)                 | 1 (0.5)                   | 4 (2.1)                   | 6 (1.0)             |

Patients without event and had adequate follow-up as of data cut-off.

b Recorded on the End of treatment eCRF, Study evaluation completion eCRF.

c Patients censored without adequate evaluations for a specified period (missed 2 scheduled tumour assessments) prior to data cut-off.

## Sensitivity analyses

The median PFS by investigator assessment was similar to the BIRC result: 14.8 months (95% CI 10.4, 18.4) vs. 7.3 months (95% CI 5.7, 8.5) for the Combo 450 and vemurafenib arms, respectively, with a HR of 0.49 (95% CI 0.37, 0.64; nominal p &lt; 0.001). In general, there was agreement regarding the type of event (PD/ death) between the Investigator and BIRC. There was discordance regarding the timing of the PD event in about 30% of cases, with no evidence of bias between the arms.

The results in the per protocol set (PPS) by BIRC were reflective of the primary analysis. The median PFS was 15.5 months (95% CI, 11.0, 18.7) in the Combo 450 arm and 7.3 months (95% CI, 5.6, 8.3) in the vemurafenib arm (HR =0.53; 95% CI, 0.40, 0.70; nominal p &lt; 0.001).

Results of additional sensitivity analyses of PFS by BIRC were consistent with the primary PFS analysis, yielding similar HRs (0.53 - 0.56), median PFS values and p values.

These included:

- using unstratified log-rank and Cox regression tests in the FAS
- using stratification factors per the eCRF (per the SAP due to &gt; 5% discordance between randomization strata and eCRF strata)
- 'Actual event' including those after ≥2 missing tumour assessments

<div style=\"page-break-after: always\"></div>

- 'Backdating' events after missing tumour assessments to 8 weeks after the last adequate tumour assessment
- Tumour assessments after initiation of subsequent anticancer therapy

Table 35: Analysis of PFS by BIRC, Sensitivity Analyses (Full Analysis Set, Part 1)

|                                                | Median (95% C1) a   | HR (95% CI)       | P value b   |
|------------------------------------------------|---------------------|-------------------|-------------|
| Primary PFS analysis (FAS)                     |                     |                   |             |
| Combo 450                                      | 14.9 (11.0, 18.5)   |                   |             |
| Vemurafenib                                    | 7.3 (5.6, 8.2)      | 0.54 (0.41, 0.71) | <0.001      |
| PFS by eCRF stratification factors             |                     |                   |             |
| Combo 450                                      | 14.9 (11.0, 18.5)   |                   |             |
| Vemurafenib                                    | 7.3 (5.6, 8.2)      | 0.54 (0.41, 0.72) | <0.001      |
| PFS by “Actual Event\" analysis                 |                     |                   |             |
| Combo 450                                      | 14.5 (10.7, 18.0)   |                   |             |
| Vemurafenib                                    | 7.3 (5.6, 8.2)      | 0.54 (0.41, 0.72) | <0.001      |
| PFS by “Backdating\" analysis                   |                     |                   |             |
| Combo 450                                      | 14.1 (9.4, 18.0)    |                   |             |
| Vemurafenib                                    | 7.3 (5.6, 7.9)      | 0.55 (0.42, 0.72) | <0.001      |
| PFS by “Further Anticancer Treatment\" analysis |                     |                   |             |
| Combo 450                                      | 14.9 (11.0, 18.0)   |                   |             |
| Vemurafenib                                    | 7.3 (5.6, 7.9)      | 0.53 (0.40, 0.70) | <0.001      |

The effect of potential prognostic factors was investigated using a multivariate Cox regression model stratified AJCC stage and ECOG PS.

Table 36: Stratified Multivariate Cox Regression Model of PFS per Central Review with treatment and Other Prognostic Variables as Covariates Encorafenib 450mg + Binimetinib versus Vemurafenib (FAS, Part 1)

| Prognostic Variables                        | Hazard ratio   | 95% CI       | P-value     |
|---------------------------------------------|----------------|--------------|-------------|
| Full Cox regression model [1] Treatment     |                |              |             |
| Combo 450 vs. Vemurafenib [2]               | 0.47           | (0.35, 0.62) | <0.001      |
| V600E vs. V600k                             | 0.83           | (0.52, 1.32) | 0.430       |
| LDH (increase of 125 IU/L)                  | 1.18           | (1.13, 1.24) | <0.001      |
| Male vs. Female                             | 1.02           | (0.76, 1.37) | 0.871       |
| Baseline brain metastases Yes vs. No Region | 1.11           | (0.48, 2.54) | 0.807 0.242 |

<div style=\"page-break-after: always\"></div>

| North America vs. Europe Australia vs. Europe 0.902 Other vs. Europe Age (increase of 10 years)   | 1.67 1.07 1.20 1.01   | (1.01, 2.75) (0.39, 2.89) (0.70, 2.05) (0.91, 1.13)   | 0.047 0.902 0.502 0.851   |
|---------------------------------------------------------------------------------------------------|-----------------------|-------------------------------------------------------|---------------------------|

[1] Cox model stratified by IVRS AJCC stage and ECOG performance status.

- [2] Hazard Ratio Encorafenib 450mg + Binimetinib versus Vemurafenib. Vemurafenib is the reference group.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 15: Forest Plot of PFS by BIRC - Combo 450 vs. Vemurafenib (Full Analysis Set, Part 1)

<!-- image -->

## Key Secondary Efficacy Endpoint

## PFS Combo 450 vs. Encorafenib

In Part 1, the median PFS was 14.9 months (11.0, 18.5) and 9.6 months (7.5, 14.8) for Combo 450 and encorafenib respectively (HR 0.75, 95% CI 0.56, 1.00). The PFS difference was not statistically significant (p = 0.0256) by the one-sided stratified log-rank test according to the threshold of p &lt; 0.025. Approximately half  the  patients  in  each  arm  had  a  PFS  event  (98  patients  [51.0%]  Combo  450;  96  patients  [49.5%] encorafenib). The median follow-up time for PFS per BIRC was 16.7 months for the Combo 450 and 16.6 months for the encorafenib arm.

An updated PFS analysis performed on 07 November 2017 gave a similar result (median PFS: Combo 450 vs encorafenib 14.9 vs 9.6 months, HR: 0.77 (95% CI [0.59-1]), one sided nominal p value=0.0249).

<div style=\"page-break-after: always\"></div>

Figure 16: Kaplan-Meier Estimate of PFS Based on BIRC - Combo 450 vs. Encorafenib (FAS, Part 1)

<!-- image -->

Per Investigator assessment of response, the median PFS estimates were 14.8 months (95% CI 10.4, 18.4) and 9.2 months (95% CI 7.4, 12.9) in the Combo 450 and encorafenib arms, respectively (HR 0.68; 95% CI 0.52, 0.90; nominal p = 0.003). Approximately half the patients in each arm had a PFS event (102 [53.1%] Combo 450; 108 [55.7%] encorafenib).

Sensitivity analyses of PFS by BIRC using data from the FAS were conducted as per the primary efficacy endpoint.

The HR for PFS of Combo 450 vs. encorafenib using unstratified log-rank and Cox regression tests was 0.81 (95% CI 0.61, 1.07; nominal p = 0.0714).

The remaining sensitivity analyses yielded nominal p values &lt;0.025 (see Table below).

Table 37: Analysis of PFS by BIRC, Sensitivity Analyses of Secondary Endpoint (FAS, Part 1)

|                                                | Median (95% C1) a   | HR (95% C1) b     | P value   |
|------------------------------------------------|---------------------|-------------------|-----------|
| Secondary PFS analysis (FAS)                   |                     |                   |           |
| Combo450                                       | 14.9 (11.0, 18.5)   |                   |           |
| Encorafenib                                    | 9.6 (7.5, 14.8)     | 0.75 (0.56, 1.00) | 0.0256    |
| PFS by eCRF stratification factors             |                     |                   |           |
| Combo 450                                      | 14.9 (11.0, 18.5)   |                   |           |
| Encorafenib                                    | 9.6 (7.5, 14.8)     | 0.73 (0.55, 0.98) | 0.0173    |
| PFS by \"Actual Event\" analysis                 |                     |                   |           |
| Combo 450                                      | 14.5 (10.7, 18.0)   |                   |           |
| Encorafenib                                    | 9.6 (7.5, 13.8)     | 0.74 (0.56, 0.98) | 0.0190    |
| PFS by “Backdating\" analysis                   |                     |                   |           |
| Combo 450                                      | 14.1 (9.4, 18.0)    |                   |           |
| Encorafenib                                    | 9.3 (7.4, 12.9)     | 0.74 (0.56, 0.98) | 0.0166    |
| PFS by “Further Anticancer Treatment\" analysis |                     |                   |           |
| Combo 450                                      | 14.9 (11.0, 18.0)   |                   |           |
| Encorafenib                                    | 9.5 (7.5, 13.0)     | 0.72 (0.55, 0.96) | 0.0114    |

<div style=\"page-break-after: always\"></div>

Table 38: Unstratified Cox Regression Model for PFS per Central Review by Subgroup (FAS, Part 1)

|                                 | Event /N (%)             | Median Time (95% CI)         | Cox Model [1]   | Cox Model [1]   |
|---------------------------------|--------------------------|------------------------------|-----------------|-----------------|
|                                 |                          | (months) [2]                 | Hazard Ratio    | 95% CI          |
| All Subjects                    |                          |                              |                 |                 |
| Combo 450                       | 98/192 (51.0)            | 14.9 (11.0, 18.5)            |                 |                 |
| Encorafenib [3]                 | 96/194 (49.5)            | 9.6 (7.5, 14.8)              | 0.81            | (0.61, 1.07)    |
| Vemurafenib [4]                 | 106/191 (55.5)           | 7.3 (5.6, 8.2)               | 0.58            | (0.44, 0.77)    |
| AJCC stage                      |                          |                              |                 |                 |
| IIIB, C, IVM1a, b Combo 450     | 37/ 84 (44.0)            | 17.8 (11.4, NE)              |                 |                 |
| Encorafenib [3]                 | 36/ 84 (42.9)            | 16.6 (9.2, NE)               | 0.97            | (0.61, 1.53)    |
| Vemurafenib [4]                 | 42/ 84 (50.0)            | 11.0 (7.3, 14.7)             | 0.67            | (0.43, 1.04)    |
| IVM1c                           |                          |                              |                 |                 |
| Combo 450                       | 61/108 (56.5)            | 13.0 (7.5, 18.0)             |                 |                 |
| Encorafenib [3]                 | 60/110 (54.5)            | 7.4 (5.5, 12.8)              | 0.68            | (0.47, 0.98)    |
| Vemurafenib [4]                 | 64/107 (59.8)            | 5.6 (3.8, 7.3)               | 0.48            | (0.34, 0.69)    |
| ECOG PS ECOG PS                 |                          |                              |                 |                 |
| =0 Combo 450                    | 63/139 (45.3)            | 17.7 (12.3, 25.9)            |                 |                 |
| Encorafenib [3]                 | 65/143 (45.5)            | 13.0 (9.2, 17.3)             | 0.83            | (0.58, 1.17)    |
| Vemurafenib [4]                 | 73/140 (52.1)            | 7.3 (5.6, 10.1)              | 0.54            | (0.38, 0.76)    |
| ECOG PS =1                      |                          |                              |                 |                 |
| Combo 450                       | 35/ 53 (66.0)            | 11.0 (5.6, 16.6)             |                 |                 |
| Encorafenib [3]                 | 31/ 51 (60.8)            | 5.5 (3.7, 9.1)               | 0.70            | (0.43, 1.15)    |
| Vemurafenib [4]                 | 33/ 51 (64.7)            | 7.3 (3.6, 8.6)               | 0.62            | (0.38, 1.01)    |
| Prior first-line immunotherapy  |                          |                              |                 |                 |
| Yes Combo 450                   | 5/ 8 (62.5)              | 11.4 (3.7, NE)               |                 |                 |
| Encorafenib [3] Vemurafenib [4] | 5/ 11 (45.5) 4/ 7 (57.1) | 5.6 (1.4, NE) 5.6 (3.8, 8.3) | 0.81 0.40       | (0.10, 1.64)    |
| No                              |                          |                              |                 |                 |
| Combo                           | 93/184 (50.5)            | 14.9 (11.0, 18.7)            |                 |                 |
| 450 Encorafenib                 | 91/183 (49.7)            | 11.0 (8.0, 14.8)             | 0.81            | (0.60, 1.08)    |
| [3] Vemurafenib [4]             | 102/184 (55.4)           | 7.3 (5.6, 8.6)               | 0.59            | (0.44, 0.78)    |
| Prior adjuvant immunotherapy    |                          |                              |                 |                 |
| Yes Combo 450                   | 27/ 49 (55.1)            | 15.5 (9.1, 25.0)             |                 |                 |
| Encorafenib [3]                 | 23/ 47 (48.9)            | 12.8 (5.6, NE)               | 0.80            | (0.45, 1.40)    |
| Vemurafenib [4]                 | 25/ 48 (52.1)            | 11.1 (5.5, NE)               | 0.78            | (0.45, 1.35)    |
| No                              |                          |                              |                 |                 |
|                                 | 71/143 (49.7)            | 18.7)                        |                 |                 |
| Encorafenib [3]                 |                          |                              | 0.82            | (0.59, 1.13)    |
| Vemurafenib [4]                 |                          | 7.3 (5.6, 7.7)               |                 | (0.37, 0.71)    |
|                                 | 81/143 (56.6)            |                              |                 |                 |
| Combo 450                       |                          | 14.9 (10.4,                  |                 |                 |
|                                 | 73/147 (49.7)            | 9.6 (7.4, 15.7)              |                 |                 |
|                                 |                          |                              | 0.51            |                 |
| BRAF Mutation Status            |                          |                              |                 |                 |
| V600E Combo 450                 | 90/170 (52.9)            | 14.9 (10.4, 18.5)            |                 |                 |
| Encorafenib [3]                 | 87/173 (50.3)            | 11.0 (8.0, 14.8)             | 0.86            | (0.64, 1.15)    |
| Vemurafenib [4]                 | 91/168 (54.2)            | 7.4 (5.6, 9.2)               | 0.64            | (0.48, 0.85)    |

<div style=\"page-break-after: always\"></div>

| V600K Combo 450   | 8/ 22 (36.4)   | NE (7.5, NE)    |      | (0.20, 1.44)   |
|-------------------|----------------|-----------------|------|----------------|
| Encorafenib [3]   | 8/ 19 (42.1)   | 9.2 (3.7, NE)   | 0.53 |                |
| Vemurafenib [4]   | 15/ 23 (65.2)  | 5.5 (3.7, 12.8) | 0.27 | (0.11, 0.68)   |

Overall 103 out of the 577 (17.9%) patients randomised in the CMEK162B2301 study changed therapy before progression. Of these 103, 44 (42.7%) were followed until progression or death (death as first event, all due to study indication): 9 (37.5%), 14 (42.4%) and 21 (45.7%) in the Combo 450, Enco 300 and vemurafenib arms respectively.

Table 39: Outcomes of patients who received a new anticancer treatment before progression, death [CMEK162B2301, FAS (Part 1)]

| Outcomes after change of therapy a      | Encorafenib 450mg + Binimetinib N=24 n (%)   | Encorafenib N=33 n (%)   | Vemurafenib N=46 n (%)   |
|-----------------------------------------|----------------------------------------------|--------------------------|--------------------------|
| Progression                             | 1 (4.2)                                      | 9 (27.3)                 | 4 (8.7)                  |
| Death                                   | 8 (33.3)                                     | 5 (15.2)                 | 17 (37.0)                |
| Censored                                | 15 (62.5)                                    | 19 (57.6)                | 25 (54.3)                |
| No baseline assessment                  | 2 (8.3)                                      | 0                        | 0                        |
| No post-baseline assessment             | 1 (4.2)                                      | 4 (12.1)                 | 4 (8.7)                  |
| Adequate assessment no longer available | 10 (41.7)                                    | 12 (36.4)                | 16 (34.8)                |
| Withdrew Consent                        | 0                                            | 1 (3.0)                  | 3 (6.5)                  |
| Lost to Follow-up                       | 0                                            | 1 (3.0)                  | 0                        |
| Ongoing                                 | 2 (8.3)                                      | 1 (3.0)                  | 2 (4.3)                  |

To fufil the EMA guidelines definition, three additional sensitivity analyses were performed as requested during the procedure. These supported the results of the initial analysis with regards to Combo 450 vs vemurafenib (primary objective) and Combo 450 vs encorafenib 300mg QD (key secondary objective).

<div style=\"page-break-after: always\"></div>

Table 40: Stratified Cox Regression Model of Progression Free Survival per Central Review - Sensitivity analysis [CMEK162B2301, FAS]

|                                                                               | Event N(%)     | Median (95% CI) (month)   | Survival (%) at 24 months   | P value   | HR (95% CI)        |
|-------------------------------------------------------------------------------|----------------|---------------------------|-----------------------------|-----------|--------------------|
| Primary analysis[1]                                                           |                |                           |                             |           |                    |
| Encorafenib 450mg + Binimetinib                                               | 98/192 (51.0)  | 14.9 (11.0, 18.5)         | 32.3 (22.7, 42.2)           |           |                    |
| Encorafeniba                                                                  | 96/194 (49.5)  | 9.6 (7.5, 14.8)           | 35.5 (27.5, 43.7)           | 0.0513    | 0.75 (0.56 - 1.00) |
| Vemurafenibb                                                                  | 106/191 (55.5) | 7.3 (5.6, 8.2)            | 23.9 (16.2, 32.3)           | <.0001    | 0.54 (0.41 -0.71)  |
| 'Objective event (EMA recommendation) sensitivity analysis[2]                 |                |                           |                             |           |                    |
| Encorafenib 450mg+Binimetinib                                                 | 112/192 (58.3) | 14.1 (10.7, 16.6)         | 27.5 (18.9, 36.9)           |           |                    |
| Encorafeniba                                                                  | 118/194 (60.8) | 9.3 (7.4, 12.3)           | 29.5 (22.4, 36.9)           | 0.0181    | 0.73 (0.56 -0.95)  |
| Vemurafenibb                                                                  | 129/191 (67.5) | 7.3 (5.6, 8.6)            | 17.6 (11.4, 24.9)           | <.0001    | 0.56 (0.43 - 0.72) |
| 'Change of therapy and withdrawal included as events' sensitivity analysis[3] |                |                           |                             |           |                    |
| Encorafenib 450mg+Binimetinib                                                 | 128/192 (66.7) | 10.7 (9.1, 13.0)          | 24.8 (17.0, 33.4)           |           |                    |
| Encorafeniba                                                                  | 144/194 (74.2) | 7.2 (5.6, 9.1)            | 22.2 (15.9, 29.2)           | 0.0018    | 0.68 (0.53 -0.87)  |
| Vemurafenibb                                                                  | 161/191 (84.3) | 5.6 (4.4, 6.1)            | 12.7 (8.1, 18.2)            | <.0001    | 0.48 (0.38 -0.61)  |
| Push back censoring' sensitivity analysis[4]                                  |                |                           |                             |           |                    |
| Encorafenib 450mg+Binimetinib                                                 | 112/192 (58.3) | 16.4 (12.3, 19.2)         | 36.6 (28.4, 44.7)           |           |                    |
| Encorafeniba                                                                  | 118/194 (60.8) | 11.8 (9.1, 14.8)          | 37.9 (30.9, 44.9)           | 0.1317    | 0.82 (0.63 -1.06)  |
| Vemurafenibb                                                                  | 129/191 (67.5) | 8.2 (7.2, 11.0)           | 31.0 (24.3, 37.9)           | 0.0017    | 0.67 (0.52 -0.86)  |

[1] Primary analysis uses censoring of events occurring after 2 or more missing tumour assessments or change of therapy

[2] 'Objective event' analysis includes the event (progressive disease or death) whenever it occurs even after 2 or more missing tumour assessments, withdrawal or new anticancer therapy.

[3] 'Change of therapy and withdrawal included as events' analysis considers as events progression and death as well as change of therapy or withdrawal whichever occurs the first

[4] 'Push back censoring' analysis includes the event (progressive disease or death) whenever it occurs and censored patients at the clinical cut-off date.

## Other Secondary Efficacy Endpoints

## PFS, Encorafenib vs. Vemurafenib

Analysis of the PFS by BIRC of encorafenib vs. vemurafenib treatment showed a difference of approximately 2.3 months (9.6 months vs. 7.3 months; nominal one-sided log-rank p = 0.004; HR = 0.68, 95% CI 0.52, 0.90). Investigator assessment of response gave similar PFS durations (encorafenib 9.2 months, vemurafenib 7.3 months; nominal one-sided log-rank p = 0.004; HR = 0.68, 95% CI 0.52, 0.90). Median PFS values by BIRC were the same in the PPS as in the FAS.

<div style=\"page-break-after: always\"></div>

Figure 17: Kaplan-Meier Estimate of PFS Based on BIRC Assessment -Encorafenib vs. Vemurafenib (FAS, Part 1)

<!-- image -->

## Objective Response Rate and Disease Control Rate

Table 41: Best Overall Response by BIRC (FAS, Part 1)

|                                                    | Combo 450 N=192 n (%)   | Encorafenib N=194 n (%)   | Vemurafenib N=191 n (%)   |
|----------------------------------------------------|-------------------------|---------------------------|---------------------------|
| Patients with measurable disease at baseline?      | 175 (91.1)              | 180 (92.8)                | 183 (95.8)                |
| Patientswithnon-measurablediseaseonly at baselinea | 15 (7.8)                | 12 (6.2)                  | 8 (4.2)                   |
| Confirmed ORR:CR +PR                               | 121 (63.0)              | 98 (50.5)                 | 77 (40.3)                 |
| 95% CI                                             | (55.8, 69.9)            | (43.3, 57.8)              | (33.3, 47.6)              |
| Confirmed BORbc                                    |                         |                           |                           |
| CR                                                 | 15 (7.8)                | 10 (5.2)                  | 11 (5.8)                  |
| PR                                                 | 106 (55.2)              | 88 (45.4)                 | 66 (34.6)                 |
| Stable disease                                     | 46 (24.0)               | 53 (27.3)                 | 73 (38.2)                 |
| Non-CR/Non-PDd                                     | 10 (5.2)                | 12 (6.2)                  | 6(3.1)                    |
| PD                                                 | 2 (1.0)                 | 6 (3.1)                   | 13 (6.8)                  |
| DCR:CR+PR+stable disease+ Non-PD/Non-CR            | 177 (92.2)              | 163 (84.0)                | 156 (81.7)                |
| 95% CIe                                            | (87.4,95.6)             | (78.1 , 88.9)             | (75.4 , 86.9)             |
| Unknownf                                           | 11 (5.7)                | 25 (12.9)                 | 22 (11.5)                 |
| Not Assesseds                                      | 2(1.0)                  | 0                         | 0                         |

<div style=\"page-break-after: always\"></div>

e

The 95% CI for the frequency distribution of each variable were computed using Clopper-Pearson's method. f Unknown response: Not included in BOR assessment but included in denominator for ORR and DCR. Progression has not been documented and one or more lesions have not been assessed or have been assessed using a different method than baseline. See Table 14.2-3.2a for reasons for unknown status.

g Not included in BOR assessment but included in denominator for ORR and DCR. No assessment has occurred by BIRC; not included in patients with measurable or non-measurable disease at baseline.

Median time to objective response (TTR) per BIRC, calculated for responding patients only (confirmation not required), was 1.9 months in the Combo 450 arm (95% CI 1.9, 1.9), 2.0 months in the encorafenib arm (95% CI 1.9, 3.6) and 2.1 months in the vemurafenib arm (95% CI 1.9, 3.7). Median TTR per Investigator assessment was also approximately 2 months for each arm. This timing corresponded with the first postbaseline response assessment at Cycle 3 Day 1.

Kaplan-Meier estimates of median duration of response (DOR) per BIRC, calculated for confirmed responses, were 16.6 months in the Combo 450 arm (95% CI 12.2, 20.4; range 1.64 - 22.11), 14.9 months in the encorafenib arm (95% CI 11.1, NE; range 0.62 - 15.47) and 12.3 months in the vemurafenib arm (95% CI 6.9, 16.9; range 0.92 - 16.89).

Investigator review revealed a similar pattern but a higher ORR in each arm (75.0 % [95% CI 68.3, 81.0]; 57.7% [95% CI 50.4, 64.8]; 49.2 % [95% CI 41.9, 56.5], respectively).

The confirmed CR by Investigator review was higher than by BIRC (16.1%, 8.8% and 7.3% of patients in the Combo 450, encorafenib and vemurafenib arms, respectively) and their median time to CR was 5.5 months, 5.5 months and 3.9 months, respectively.

The DCR per Investigator review was similar to per BIRC.

Median TTR per Investigator assessment was also approximately 2 months for each arm. This timing corresponded with the first post-baseline response assessment at Cycle 3 Day 1.

Kaplan-Meier estimates of median DOR per Investigator, calculated for confirmed responses, were similar to those by BIRC: 16.2 months, 14.8 months and 8.4 months in the Combo 450, encorafenib and vemurafenib arms.

## Overall Survival, Combo 450 vs. Vemurafenib

As of the data cut-off (7 November 2017), 80 patients (13.9%) were ongoing in the treatment period of the study (22.4% Combo 450 arm, 12.4% encorafenib arm, 6.8% vemurafenib arm). The median duration of exposure to study treatment in the Combo 450 arm (11.8 months) was longer than in the encorafenib (7.2 months) and vemurafenib (6.1 months) arms. Within the Combo 450 arm, median durations of exposure to encorafenib and binimetinib were identical (11.8 months).

The most common reason for discontinuation from study treatment, in all arms, was progressive disease and the rate was higher in the vemurafenib arm (57.1%) as compared with the Combo 450 (51.6%) and encorafenib (51.5%) arms. The rates of withdrawal by physician and by patients were higher for vemurafenib (8.9% each) and encorafenib (12.4% and 8.8%) vs Combo 450 (4.7% and 5.7%). The proportion of patients censored for this OS analysis in the Combo 450 arm (45.3%) was higher than that observed in the vemurafenib arm (33.5%). Most censored patients in both groups who were alive and ongoing had a last contact within the 12 weeks prior to data cut-off.

For all randomized patients, the median time between randomisation and OS cut-off dates was 37.45 months [30.98-46.29 months]. When measured as the time from randomisation until event/censoring, the median

<div style=\"page-break-after: always\"></div>

potential follow-up duration using reverse Kaplan Meier for OS was 37.2 months in the Combo 450 arm, 36.3 months in the encorafenib arm and 35.9 months in the vemurafenib arm.

A lower proportion of patients in the Combo 450 arm (41.7%) received antineoplastic therapy after discontinuation of study treatment compared with the encorafenib (55.7%) and vemurafenib (62.3%) arms, partly due to a higher proportion of patients in the Combo 450 arm who continued to receive study treatment as of the data cut-off. A similar proportion of patients in each arm received subsequent treatment with a monoclonal antibody, mainly checkpoint inhibitors (34.4% Combo 450, 36.1% encorafenib, 39.8% vemurafenib arm). A lower proportion of patients in the Combo 450 arm (10.9%) received subsequent treatment with BRAF inhibitors and/or combinations of BRAF and MEK inhibitors after discontinuation of study treatment as compared with either the encorafenib (21.6 %) or the vemurafenib (32.9%) arms.

Figure 18: Kaplan-Meier Plot of Overall Survival, Combo 450 vs. Vemurafenib (Full Analysis Set, Part 1)

<!-- image -->

An estimated 39% reduction in the risk of death was observed for patients treated with Combo 450 compared to those treated with vemurafenib (HR 0.61, 95% CI 0.47, 0.79), with median OS values of 33.6 months (95% CI 24.4, 39.2) and 16.9 months (95% CI 14.0, 24.5), respectively.

Estimates of OS at 12 months and 24 months were 75.5% (95% CI 68.8, 81.0) and 57.6% (95% CI 50.3, 64.3) for Combo 450 compared to 63.1% (95% CI 55.7, 69.6) and 43.2% (95% CI 35.9, 50.2) for vemurafenib.

The results of sensitivity analyses are consistent with those of the interim OS analysis and lead to similar conclusions about treatment effect.

<div style=\"page-break-after: always\"></div>

A  multivariate  Cox  regression  model  stratified  by  the  study  stratification  factors  was  used  to  explore  the robustness  of  the  statistical  significance  of  treatment  effect  on  OS  when  adjusting  for  main  prognostic factors.  The  only  other  prespecified  covariate  that  reached  statistical  significance  was  LDH,  which  was associated with an increase in the relative risk of death which was associated with an increase in the relative risk of death (HR 1.21; 95% CI 1.16, 1.27; p &lt; 0.001, 2-sided) for each 125 IU/L increase in LDH.

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 19: Forest Plot of Hazard Ratio with 95% Confidence Interval for Overall Survival from Subgroup Analysis Encorafenib 450mg+Binimetinib versus Vemurafenib (Full Analysis Set, Part 1)

<!-- image -->

## Overall Survival, Combo 450 vs. Encorafenib

Median OS values for Combo 450 and encorafenib were 33.6 months (24.4, 39.2) and 23.5 months (19.6, 33.6) respectively (HR 0.81, 95% CI 0.61, 1.06, nominal p value =0.0613, 2-sided).

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviations:CI=confidenceinterval

Figure 20: Kaplan-Meier Plot of Overall Survival, Combo 450 vs. Encorafenib (Full Analysis Set, Part 1)

Estimates of OS at 12 months and 24 months were 75.5% (68.8, 81.0) and 57.6% (50.3, 64.3) for Combo 450 compared to 74.6% (67.6, 80.3) and 49.1% (41.5, 56.2) for encorafenib.

A  multivariate  Cox  regression  model  stratified  by  the  study  stratification  factors  was  used  to  explore  the robustness  of  the  statistical  significance  of  treatment  effect  on  OS  when  adjusting  for  main  prognostic factors.  The  only  other  prespecified  covariate  that  reached  statistical  significance  was  LDH,  which  was associated with an increase in the relative risk of death (HR 1.21; 95% CI 1.16, 1.27; p &lt; 0.001, 2-sided) for each 125 IU/L increase in LDH. All unstratified subgroup analyses demonstrated median OS point estimates in  favour  of  the  Combo  450  arm  except  for  Japanese  patients  (6  patients  in  total)  and  Region  Other  (27 patients in total) and &gt; 3 organs involved at baseline (66 patients in total).

## Overall Survival, Encorafenib vs. Vemurafenib

The median OS was 23.5 months (95% CI 19.6, 33.6) and 16.9 months (95% CI 14.0, 24.5), respectively, for  patients  treated  with  encorafenib  compared  with  vemurafenib  with  a  HR  0.76  (95%  CI  0.58,  0.98). Estimates  of  OS  at  12  months  and  24  months  were  74.6%  (67.6,  80.3)  and  49.1%  (41.5,  56.2)  for encorafenib compared to 63.1% (55.7, 69.6) and 43.2% (35.9, 50.2) for vemurafenib.

<div style=\"page-break-after: always\"></div>

Figure 21: Kaplan-Meier Plot of Overall Survival, Encorafenib vs. Vemurafenib (Full Analysis Set, Part 1)

<!-- image -->

The data cut-off date for the OS analysis reviewed by the DMC was 19 May 2016, by which time a total of 157 OS events were observed in the Combo 450 and vemurafenib arms combined in Part 1 of the study.

For patients treated with Combo 450, median OS value was 26.0 months compared to 16.9 months for those treated with vemurafenib (HR 0.58, 95% CI 0.42, 0.80. Confidence intervals were not provided.

For patients treated with Combo 450 compared to those treated with encorafenib (HR 0.77, 95% CI 0.55, 1.08), median OS values were 26.0 months and 23.5 months, respectively.

<div style=\"page-break-after: always\"></div>

Table 42: Study CMEK162B2301, Part 1: Overall survival interim results (cut-off date: 7 November 2017)

|                                                         | Encorafenib + binimetinib N=192 (Combo 450)   | Encorafenib N=194 (Enco 300)   | Vemurafenib N=191 (Vem)   |
|---------------------------------------------------------|-----------------------------------------------|--------------------------------|---------------------------|
| OS                                                      |                                               |                                |                           |
| Number of events (%)                                    | 105 (54.7)                                    | 106 (54.6)                     | 127 (66.5)                |
| Median, months (95% CI)                                 | 33.6 (24.4, 39.2)                             | 23.5 (19.6, 33.6)              | 16.9 (14.0, 24.5)         |
| Survival at 12 months (95% CI)                          | 75.5% (68.8, 81.0)                            | 74.6% (67.6, 80.3)             | 63.1% (55.7, 69.6)        |
| Survival at 24 months (95% CI)                          | 57.6% (50.3, 64.3)                            | 49.1% (41.5, 56.2)             | 43.2% (35.9, 50.2)        |
| HR (95% CI) (vs Vem) p-value (stratified log-rank)      | 0.61 (0.47, 0.79) <0.0001                     |                                |                           |
| HR (95% CI) (vs Enco 300) p-value (stratified log-rank) | 0.81 (0.61,1.06) 0.061                        |                                |                           |

## Health related Quality of Life (HRQoL) Analyses

Patient  compliance  with  the  3  QoL  instruments  (FACT-M,  EORTC-QLQ-C30,  EQ-5D-5L)  was  calculated  for patients still 'at-risk' i.e. receiving treatment or in post-treatment follow-up on the protocol-scheduled PRO assessment date. Compliance with the 3 questionnaires was equivalent among the 3 treatment arms, with approximately 80%-95% of patients still at risk completing the assessment from baseline to Cycle 25.

At baseline, the mean [SD] FACT-M score was similar in the 3 treatment arms: Combo 450 (52.39 [9.05]), Enco  300  (52.84  [8.23])  and  vemurafenib  arm  (52.01  [8.65]).  The  median  time  to  definitive  10% deterioration in the FACT-M global health status score was not reached in the Combo 450 arm (95% CI 22.1, NE) and was 22.1 months (95% CI 15.2, NE) in the vemurafenib arm with a HR for the difference of 0.46 (95% CI 0.29, 0.72) using a stratified Cox regression model. The median time to definitive 10% deterioration in  the  FACT-M  was  20.3  months  (95%  CI  15.0,  NE)  in  the  encorafenib  arm  with  a  HR  for  the  difference between Combo 450 and encorafenib of 0.48 (95% CI 0.31, 0.75) using a stratified Cox regression model.

<!-- image -->

EMA/CHMP/554696/2018

Patients at risk

Figure 22: Kaplan-Meier Plot of Time to Definitive 10% Deterioration in FACT-M Global Health Status - Combo 450 vs. Vemurafenib (FAS, Part 1)

Page 94/171

<div style=\"page-break-after: always\"></div>

Figure 23: Kaplan-Meier Plot of Time to Definitive 10% Deterioration in FACT-M Global Health Status - Combo 450 vs. Enco 300 (FAS, Part1)

<!-- image -->

At baseline, the mean [SD] EORTC QLQ-C30 global health status score  was similar in the 3 treatment arms: Combo 450 (66.72 [21.59]), Enco 300 (66.10 [21.16]) and the vemurafenib arm (64.74 [23.61]). The median time to definitive 10% deterioration in the EORTC QLQ-C30 global health status score was delayed by more than 7 months in the Combo 450 arm compared to the vemurafenib arm: 23.9 months (95% CI 20.4, NE) vs. 16.6 months (95% CI 11.9, NE) with a HR for the difference of 0.55 (95% CI 0.37, 0.80) using a stratified  Cox  regression  model. The  median  time  to  definitive  10%  deterioration  in  the  QLQ-C30  global health status scores was longer in the Combo 450 arm compared with the Enco 300 arm (14.7 months [95% CI 9.2, 18.4]), with a HR for the difference of 0.45 (95% CI 0.31, 0.65) using a stratified Cox regression model .

At baseline, the mean EQ-5D-5L index score was similar for each arm (Combo 450 = 0.74, encorafenib = 0.76, vemurafenib = 0.73) and the median was 0.77 for each of the 3 treatment arms. The Combo 450 arm showed a slight improvement at Cycle 3 Day 1 from baseline and the vemurafenib showed no change. In subsequent visits, the scores decreased over time for both arms. Comparison of the Combo 450 arm vs. the encorafenib arm showed similar results to the comparison of the Combo 450 arm and vemurafenib arm.

## Study CMEK162B2301 PART 2

The main objective of Part 2 (a key secondary objective) was to further quantify the contribution of binimetinib to the combination of encorafenib and binimetinib, by comparing PFS of Combo 300 (encorafenib 300 mg QD and binimetinib 45 mg BID) vs. encorafenib single-agent (encorafenib 300 mg QD).

Approximately 320 patients were planned to be randomised in a 3:1 ratio to Combo 300: Enco 300. The inclusion - exclusion criteria were identical to Part 1.

<div style=\"page-break-after: always\"></div>

## Statistical Methods for Efficacy Analyses in the Part 2 CSR (Combo 300 vs. Enco 300)

An unplanned initial analysis of Part 2 based on 293 events (vs 340 events planned) was performed using a data cut-off date of 09 November 2016 in agreement with the FDA. Analysis of the Part 1 key secondary endpoint (PFS, Combo 450 vs. encorafenib) was not statistically significant; therefore, per protocol-specified testing hierarchy, the data in this PFS part 2 analysis are summarized descriptively without formal testing.

As pre-specified, (SAP version IV), the Part 2 initial CSR reports data from the combined Part 1 and Part 2 encorafenib monotherapy patients (N=280) and Part 2 encorafenib monotherapy patients only (N=86) through to the cut-off date for the Part 2 report.

All efficacy analyses were performed using the full analysis set (FAS).

## Results

Part 2 patients were randomised between 19 March 2015 and 12 November 2015. A total of 344 patients were randomised during Part 2, 258 patients in the Combo 300 arm and 86 in the encorafenib arm.

<!-- image -->

BiD:Twice daily;QD: once daily:*Primary reason; +Atthe time of date cutoff of 09 November 2016

## Figure 24: Patient flow chart for Part 2 of study CMEK162B2301

The two treatment groups (Combo 300 and Enco 300 [Parts 1 + 2]) were reasonably well balanced in terms of baseline and disease characteristics. As would be expected because these were directly randomised groups, the Combo 300 and Enco 300 Part 2 populations were similar at baseline.

<div style=\"page-break-after: always\"></div>

However, there were some differences between the two encorafenib monotherapy arms (Part 1 and Part 2). Patients in the encorafenib Part 2 arm were older (median age 57 years, 30.2% were ≥ 65 years old) than those in the encorafenib Part 1 arm (median age 54 years, 20.6% were ≥ 65 years old). The proportion of patients with Stage IV M1C with elevated LDH was higher in the Enco 300 Part 2 arm compared with Enco 300 Part 1 (37.2% vs. 25.8%). More Enco 300 Part 1 patients had Stage IV M1B (20.1% vs 11.6%), and Stage IV M1C with normal LDH (36.1% vs 30.2% respectively). A difference was seen in the overall duration of disease with a median time from initial diagnosis to randomisation that was nearly 5 months longer in the Enco 300 Part 2 population (28.4 vs 23.6 months). Distribution of disease location was similar between combinations for skin and/or lymph nodes; however more Enco 300 Part 1 patients had lung metastases (19.6% vs 8.1% respectively), while more patients in Enco 300 Part 2 had other organs involved. Baseline LDH levels were higher in Enco 300 Part 2 patients, with a mean of 338 U/L vs 265 UI/L and a median of 217 U/L vs 189 U/L vs respectively.

<div style=\"page-break-after: always\"></div>

Table 43: Patient and Disease Characteristics (Full Analysis Set, Part 2 Initial)

| Disease history                                                     | Combo 300 N=258                                                     | Encorafenib (Part l + Part 2) N=280                                 | Encorafenib (Part 1) N=194                                          | Encorafenib (Part 2) N=86                                           |
|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| Primary site of cancer, n (%)                                       |                                                                     |                                                                     |                                                                     |                                                                     |
| Skin Melanoma                                                       | 239 (92.6)                                                          | 271 (96.8)                                                          | 192 (99.0)                                                          | 79 (91.9)                                                           |
| Unknown                                                             | 19 (7.4)                                                            | 9 (3.2)                                                             | 2 (1.0)                                                             | 7 (8.1)                                                             |
| Stage at time of study entry, n (%)                                 |                                                                     |                                                                     |                                                                     |                                                                     |
| Stage IIIB                                                          | 0                                                                   | 2 (0.7)                                                             | 2 (1.0)                                                             | 0                                                                   |
| Stage IIIC                                                          | 8 (3.1)                                                             | 9 (3.2)                                                             | 4 (2.1)                                                             | 5 (5.8)                                                             |
| Stage IV M1A                                                        | 31 (12.0)                                                           | 42 (15.0)                                                           | 29 (14.9)                                                           | 13 (15.1)                                                           |
| Stage IV M1B                                                        | 47 (18.2)                                                           | 49 (17.5)                                                           | 39 (20.1)                                                           | 10 (11.6)                                                           |
| Stage IV M1C                                                        | 172 (66.7)                                                          | 178 (63.6)                                                          | 120 (61.9)                                                          | 58 (67.4)                                                           |
| Stage IV M1C with elevated LDH c                                    | 73 (28.3)                                                           | 82 (29.3)                                                           | 50 (25.8)                                                           | 32 (37.2)                                                           |
| Stage IV M1C with normal LDH                                        | 99 (38.4)                                                           | 96 (34.3)                                                           | 70 (36.1)                                                           | 26 (30.2)                                                           |
| Time from initial diagnosis to onset of metastatic disease (months) | Time from initial diagnosis to onset of metastatic disease (months) | Time from initial diagnosis to onset of metastatic disease (months) | Time from initial diagnosis to onset of metastatic disease (months) | Time from initial diagnosis to onset of metastatic disease (months) |
|                                                                     | 249                                                                 | 276                                                                 | 191                                                                 | 85                                                                  |
| Mean (SD)                                                           | 28.13 (45.617)                                                      | 36.53 (58.902)                                                      | 36.45 (62.708)                                                      | 36.72 (49.639)                                                      |
| Median                                                              | 10.41                                                               | 14.31                                                               | 13.04                                                               | 15.84                                                               |
| Min - Max                                                           | 0 -306.7                                                            | 0-388.8                                                             | 0-388.8                                                             | 0-262.4                                                             |
| Number of organs involved at Baseline *, n (%)                      | Number of organs involved at Baseline *, n (%)                      | Number of organs involved at Baseline *, n (%)                      | Number of organs involved at Baseline *, n (%)                      | Number of organs involved at Baseline *, n (%)                      |
| 1                                                                   | 78 (30.2)                                                           | 79 (28.2)                                                           | 56 (28.9)                                                           | 23 (26.7)                                                           |
| 2                                                                   | 66 (25.6)                                                           | 74 (26.4)                                                           | 52 (26.8)                                                           | 22 (25.6)                                                           |
| 3                                                                   | 59 (22.9)                                                           | 61 (21.8)                                                           | 42 (21.6)                                                           | 19 (22.1)                                                           |
| >3                                                                  | 55 (21.3)                                                           | 66 (23.6)                                                           | 44 (22.7)                                                           | 22 (25.6)                                                           |
| LDH at Baseline (U/L)                                               | LDH at Baseline (U/L)                                               | LDH at Baseline (U/L)                                               | LDH at Baseline (U/L)                                               | LDH at Baseline (U/L)                                               |
| 1n                                                                  | 258                                                                 | 280                                                                 | 194                                                                 | 86                                                                  |
| Mean (SD)                                                           | 300.8 (319.24)                                                      | 287.7 (293.43)                                                      | 265.2 (251.21)                                                      | 338.4 (368.19)                                                      |
| Median                                                              | 201.5                                                               | 197.0                                                               | 188.5                                                               | 217.0                                                               |
| Min - Max                                                           | 103-3095                                                            | 75-2101                                                             | 75-1886                                                             | 115-2101                                                            |
| LDH at Baseline b, n (%)                                            | LDH at Baseline b, n (%)                                            | LDH at Baseline b, n (%)                                            | LDH at Baseline b, n (%)                                            | LDH at Baseline b, n (%)                                            |
| Low                                                                 | 0                                                                   | 0                                                                   | 0                                                                   | 0                                                                   |
| Normal                                                              | 178 (69.0)                                                          | 201 (71.8)                                                          | 147 (75.8)                                                          | 54 (62.8)                                                           |
| High c                                                              | 80 (31.0)                                                           | 79 (28.2)                                                           | 47 (24.2)                                                           | 32 (37.2)                                                           |

Note: The time from initial diagnosis to onset of metastatic disease are calculated only for patients with metastatic disease.A patient may have multiple metastatic sites.

* For patients with stage IIB and IIIC at study entry, the number of organs involved at baseline is equal to one and presented as skin.

Note: Metastatic sites and organs involved were derived from Diagnosis and Extent of Cancer eCRF page.

b Low and high categories defined by normal ranges.

° Some discrepancies were noted between the numbers of patients with Stage IV M1c LDH elevated and LDH high at baseline. The LDH level assessed for staging (M1c LDH elevated) was determined at screening whereas baseline values were used to report LDH at baseline. Also patients with Stage III disease could have elevated LDH.

Source:Table14.1-3.2.1b;Table14.1-3.3.1b

## Combo 300 vs Enco 300 (Parts 1 and 2)

The median follow-up for PFS per BIRC (Kaplan-Meier) was 13.9 months for the Combo 300 arm and 18.5 months for the encorafenib (Parts 1 + 2) group.

For the primary analysis of Part 2 the PFS in the Combo 300 arm was 3.7 months longer than that of the encorafenib (Parts 1 + 2) group, with median PFS estimates of 12.9 months (95% CI 10.1, 14.0) and 9.2 months (95% CI 7.4, 11.0), respectively (HR=0.77, 95% CI 0.61, 0.97; nominal one-sided p=0.015).

<div style=\"page-break-after: always\"></div>

## [Parts 1 + 2] (FAS, Part 2 Initial)

Figure 25: Kaplan-Meier Estimate of PFS Based on BIRC - Combo 300 vs. Enco 300 (Part 1 and 2)

<!-- image -->

The analysis was supported by the sensitivity analysis of the Investigator assessment (HR=0.72, 95% CI: 0.57, 0.91; nominal p=0.003), which had the same median PFS values as those by BIRC at 12.9 months (95% CI: 10.9, 14.8) and 9.2 months (95% CI: 7.4, 11.1) for the Combo 300 arm and the encorafenib (Parts 1 + 2) group.

Sensitivity analyses of PFS by BIRC were conducted: per protocol, unstratified, actual event, backdating and further anticancer therapy yielded similar HRs (0.75 - 0.78).

Most subgroup analyses of PFS per BIRC demonstrated point estimates in favour of the Combo 300 arm. In the 3 subgroups for which point estimates were in favour of the encorafenib (Parts 1 +2) group ( BRAF V600K mutation status, AJCC stage IIIb-IVM1B and one organ involved at baseline), all had large 95% CIs which overlapped with the other subgroup of the respective category.

The confirmed ORR per BIRC in the Combo 300 arm was 65.9% (95% CI: 59.8, 71.7) compared with 50.4% (95% CI 44.3, 56.4) in the Enco 300 (Parts 1 + 2) group. Responses were of similar duration with a median DOR for confirmed responses per BIRC of one year in each treatment group (Combo 300 arm=12.7 months [95% CI: 9.3, 15.1]; encorafenib (Parts 1 + 2) group=12.9 months [95% CI 8.9, 15.5].

The ORR per Investigator review was higher in both the Combo 300 arm and the encorafenib (Parts 1 + 2) group than by BIRC, with the difference in favour of Combo 300 maintained (72.5% Combo 300 arm, 56.4% Enco 300 [Parts 1 + 2] group). Median DORs per Investigator were approximately 13 months in each treatment group.

## Combo 300 vs. Enco 300 Part 2

<div style=\"page-break-after: always\"></div>

PFS including only the encorafenib monotherapy patients who were concurrently randomised in Part 2 was conducted as a sensitivity analysis as per protocol. The median follow-up for PFS per BIRC (Kaplan-Meier) was 13.9 months for the Combo 300 arm and 14.8 months for the encorafenib Part 2 arm.

In patients randomised concurrently in Part 2 of the study, there was an estimated 43% risk reduction in BIRC-assessed PFS in the Combo 300 arm (N=258) compared to the encorafenib monotherapy arm (N=86); HR=0.57, 95% CI: 0.41, 0.78; nominal stratified one-sided log-rank p&lt;0.001. Median PFS was 12.9 months (95% CI: 10.1, 14.0) and 7.4 months (95% CI: 5.6, 9.2), respectively.

Figure 26: Kaplan-Meier Estimate of PFS Based on BIRC - Combo 300 vs. Enco 300 [Part 2] (FAS, Part 2 Initial)

<!-- image -->

The effect of treatment on PFS was estimated using a non-adjusted regression analysis, stratified by the study randomisation stratification factors (ECOG and disease stage). The crude HR was 0.57 (95% CI: 0.42, 0.79).

The four Propensity Score approaches including stratification (3 and 5 strata), matching, and IPW showed a benefit of Combo 300 over Enco 300 Part 2. HRs ranged from 0.52 to 0.70 (upper 95% cI 0.80 to 1.00).

## PFS by BIRC - Encorafenib 300 Part 1  vs. Encorafenib 300  Part 2

Results of the prespecified sensitivity analysis of PFS by BIRC for the encorafenib arm (Part 1) vs. encorafenib arm (Part 2) showed an estimated 32% risk reduction in the encorafenib (Part 1) arm (HR 0.68; 95% CI: 0.49, 0.95; nominal one-sided p=0.013). The median PFS times of the encorafenib Part 1 arm vs. Part 2 arm were 9.6 months (95% CI: 7.4, 14.8) and 7.4 months (95% CI: 5.6, 9.2), respectively.

<div style=\"page-break-after: always\"></div>

Figure 27: Kaplan-Meier plot of PFS by BIRC - Encorafenib Part 1 vs Encorafenib Part 2 (Full Analysis Set, Part 2 Initial)

<!-- image -->

PFS analyses of Enco 300 Part 1 vs Part 2, adjusted for confounding factors in the context of two independent cohorts, were conducted using the propensity score (PS) test. However, the PS is normally used for the description of populations accrued at a similar time point, whereas Enco 300 populations were recruited sequentially in Parts 1 and 2. The model cannot account for the potential bias introduced by this temporal difference.

Table 44: Comparison of Baseline Covariates for Enco Part 1 vs. Enco Part 2

|                                                                                                                                                                                                                                                                                                                                      | P-value                                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Sex Age Baseline Body Mass Index (kg/m) Race Region ECOG at baseline first dose Time from initial diagnosis to first metastasis Primary site of cancer at study entry Stage BRAF status Number of organs involved at baseline Baseline brain metastases Baseline liver metastases Prior adjuvant immunotherapy LDH at baseline (U/L) | 0.4849 1 0.2453 0.0110 0.7956 1 0.0034 1 0.9901 1 0.4192 0.0043 2 0.3792 1 0.4316 1 0.8712 1 0.7287 2 0.0892 1 0.1372 1 0.0177 |

Tests: Wilcoxon for continuous variables, Chi-square (1) or Fisher (2) for categorical variables.

The effect of treatment on PFS was estimated using a non-adjusted regression analysis, stratified by the stratification factors (ECOG performance status and stage). The crude HR was 0.69 (95% CI: 0.49, 0.96).

<div style=\"page-break-after: always\"></div>

Four PS approaches including stratification (3 and 5 strata), matching, and IPW were then used to estimate the treatment effect on PFS and were adjusted for confounding. The different PS methods (adjusted and nonadjusted) gave HRs ranging from 0.57 to 0.68 and all showed a significant increase in the risk of disease progression or death for Enco 300 in Part 2 over Enco 300 in Part 1.

## Contribution of binimetinib 45 mg BID to the efficacy of Combo 450: Combo 450 vs. Combo 300

A post hoc comparison of data from the Combo 450 arm [Part 1 of CMEK162B2301 (N=192) at the cut-off date for the primary analysis of 19 May 2016] and the Combo 300 arm [Part 2 (N=258) unplanned initial analysis at the cut-off date of 09 November 2016] was conducted. The two data cut-offs were chosen to allow similar duration of follow up, as the populations were not recruited concomitantly. Median potential follow-up for PFS was comparable for the two populations (16.7 months vs 13.9 months) and the median follow-up time was 9.3 months for both combinations. A supportive analysis was performed using the 09 November 2016 for the two arms.

The Combo 450 and Combo 300 populations were similar in terms of age, sex, race and ECOG performance status. A slightly higher proportion of patients was enrolled in Europe, North America and Australia in Combo 450 compared to Combo 300 (9.5% difference). Median time from initial diagnosis to onset of metastatic disease was longer in the Combo 450 than the Combo 300 population (15.0 vs 10.4 months). Distribution of disease location and disease burden were similar between combinations, although a higher proportion of patients had only one disease site in Combo 300 (30.2% vs 24.5% with Combo 450). Median LDH levels at baseline were slightly higher in Combo 300 (202 vs. 173 U/L).

Median PFS (per BIRC) was 2 months longer for Combo 450 (14.9 months) than for Combo 300 (12.9 months), but the difference was not statistically significant (log rank p value 0.0845).

Figure 28: Kaplan-Meier PFS Comparison for Combo 450 (cut-off date: 19 May 2016) vs Combo 300 (Cut-off date: 09 November 2016) - FAS Population

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 45: Direct Comparison of Combo 450 (cut-off date: 19 May 2016) vs Combo 300 (Cut-off date: 09 November 2016) - FAS Population - Stratified Analyses

|                                         | Combo 450 Part 1 (N=192)   | Combo 300 Part2 (N=258)   |
|-----------------------------------------|----------------------------|---------------------------|
| PFS by BIRC                             |                            |                           |
| # events n/N (%)                        | 98/192 (51.0%)             | 133/258 (51.6%)           |
| Median (95% C1) in months               | 14.9 (11.0, 18.5)          | 12.9 (10.1, 14.0)         |
| Log-rank p-value (*)                    | 0.0845                     |                           |
| Generalized Wilcoxon p-value (*)        | 0.3647                     |                           |
| HR (95% CI) (*)                         | 0.79 (0.60, 1.03)          |                           |
| PFS by Investigator                     |                            |                           |
| # events n/N (%)                        | 102/192 (53.1%)            | 136/258 (52.7%)           |
| Median (95% C1) in months               | 14.8 (10.4, 18.4)          | 12.9 (10.9, 14.8)         |
| Log-rank p-value (*)                    | 0.1918                     |                           |
| Generalized Wilcoxon p-value (*)        | 0.4569                     |                           |
| HR (95% CI) (*)                         | 0.84 (0.64, 1.09)          |                           |
| Confirmed Response per BIRC             |                            |                           |
| # responders (%)                        | 121 (63.0%)                | 170 (65.9%)               |
| 95% CI                                  | (55.8, 69.9)               | (59.8, 71.7)              |
| Confirmed DCR per BIRC                  |                            |                           |
| # responders (%)                        | 177 (92.2%)                | 234 (90.7%)               |
| 95% CI                                  | (87.4, 95.6)               | (86.5, 93.9)              |
| Duration of Confirmed Response per BIRC |                            |                           |
| # responders n/N (%)                    | 54/121 (44.6%)             | 81/170 (47.6%)            |
| Median (95% CI)                         | 16.6 (12.2, 20.4)          | 12.7 (9.3, 15.1)          |

Other efficacy parameters by BIRC showed similar results for the two combinations (ORR = 63.0% vs 65.9% and DCR = 92.2% vs 90.7%, respectively).  However, the duration of confirmed responses was longer for Combo 450 vs Combo 300 (16.6 months vs 12.7 months) which is aligned with the difference in PFS.

Similar results were seen when comparing median PFS per Investigator (14.8 vs 12.9 months, respectively). ORRs per Investigator review were also similar, although higher (75.0% vs 72.5%).

The analysis performed using the 09 November 2016 cut-off date for the two arms was supportive.

<div style=\"page-break-after: always\"></div>

Table 46: Direct Comparisons Combo 450 vs Combo 300 (Cut-off date for both: 09 Nov 2016) - FAS Population - Stratified Analyses

|                                     | Combo 450 P1 (N=192) 09Nov2016   | Combo 300 P2 (N=258) 09Nov2016   |
|-------------------------------------|----------------------------------|----------------------------------|
| PFS by BIRC                         |                                  |                                  |
| # events n/N (%)                    | 104/192 (54.2%)                  | 133/258 (51.6%)                  |
| Median (95% C1) in months           | 15.5 (11.0, 20.2)                | 12.9 (10.1, 14.0)                |
| Event-free at 12 months, % (95% CI) | 56.7 (48.8, 63.9)                | 51.9 (45.1, 58.2)                |
| Log-rank p-value (*)                | 0.0573                           |                                  |
| Generalized Wilcoxon p-value (*)    | 0.3205                           |                                  |
| HR (95% CI) (*)                     | 0.77 (0.58, 1.01)                |                                  |
| PFS by Investigator                 |                                  |                                  |
| # events n/N (%)                    | 109/192 (56.8%)                  | 136/258 (52.7%)                  |
| Median (95% C1) in months           | 14.8 (10.4, 18.4)                | 12.9 (10.9, 14.8)                |
| Event-free at 12 months, % (95% CI) | 53.8 (46.0, 60.9)                | 50.5 (43.9, 56.8)                |
| Log-rank p-value (*)                | 0.1664                           |                                  |
| Generalized Wilcoxon p-value (*)    | 0.4314                           |                                  |
| HR (95% CI) (*)                     | 0.83 (0.63, 1.08)                |                                  |

status

The multivariate Cox regression model stratified by the study stratification factors the applicant concluded a benefit of Combo 450 over Combo 300 for PFS when adjusting for the main prognostic factors [HR 0.74 (95% CI 0.56-0.98), nominal p value =0.0387] at the cut-off dates for initial analysis (19 May 2016 and 9 November 2016, respectively).

The propensity score was estimated using a logistic regression model that incorporates 14 variables potentially related to the outcome and/ or treatment decision.

Table 47: Comparison of Baseline Covariates for Combo 450 and Combo 300

|                                                                                                                                                                                                                                                                           | P-value                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Sex Age Baseline BMI (kg/m) Race Region ECOG at baseline a Time from initial diagnosis to first metastasis Stage BRAF status Number of organs involved at baseline Baseline brain metastases Baseline liver metastases Prior adjuvant immunotherapy LDH at baseline (U/L) | 0.7702 1 0.5053 0.2979 0.2601 1 0.0067 1 0.5704 1 0.0453 0.5653 1 0.5846 1 0.3332 1 0.2633 1 0.8398 1 0.0970 1 0.0128 |

Tests: Wilcoxon for continuous variables, Chi-square (1) or Fisher (2) for categorical variables.

<div style=\"page-break-after: always\"></div>

The effect of treatment on PFS was estimated using a non-adjusted regression analysis, stratified by the study stratification factors (ECOG and Stage). Then four PS approaches, including stratification (3 and 5 strata), matching, and inverse probability weighting (IPW), were used to estimate the treatment effect on PFS and adjust for confounding factors. The different PS methods (adjusted and non-adjusted) gave similar results when comparing Combo 450 and Combo 300 for PFS, reaching an HR of 0.75 to 0.79, with an upper 95% CI above 1 (1.01 to 1.09).

## Ancillary analyses

None.

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table EF-03: Summary of efficacy for trial CMEK162B2301 (COLUMBUS, Part 1 only)

Title:  A  2-part  phase  III  randomized,  open  label,  multicentre  study  of  LGX818  plus MEK162 versus vemurafenib and LGX818 monotherapy in patients  with unresectable or metastatic BRAF V600 mutant melanoma

| Study identifier          | B2301                                                                          | B2301                                                                          | B2301                                                                                                    |
|---------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| Design                    | 2-part, multicentre, randomised, 3-arm, open-label                             | 2-part, multicentre, randomised, 3-arm, open-label                             | 2-part, multicentre, randomised, 3-arm, open-label                                                       |
| Design                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase: | Duration of main phase: Duration of Run-in phase: Duration of Extension phase: | Until PD/ unacceptable toxicity/ death Screening up to 21 days Follow-up post study drug discontinuation |
| Hypothesis                | Superiority                                                                    | Superiority                                                                    | Superiority                                                                                              |
| Treatments groups         | Combo 450                                                                      | Combo 450                                                                      | Encorafenib 450mg QD + binimetinib 45mg BID, N= 192                                                      |
| Treatments groups         | Enco 300                                                                       | Enco 300                                                                       | Encorafenib 300mg QD, N= 194                                                                             |
| Treatments groups         | Vemurafenib                                                                    | Vemurafenib                                                                    | Vemurafenib 960mg BID, N=191                                                                             |
| Endpoints and definitions | Primary endpoint                                                               | PFS by BIRC                                                                    | Combo 450 vs. vemurafenib                                                                                |
| Endpoints and definitions | Key secondary endpoint                                                         | PFS by BIRC                                                                    | Combo 450 vs. encorafenib                                                                                |
| Endpoints and definitions | Other secondary endpoints                                                      | ORR                                                                            | Assess ORR by treatment arms                                                                             |
| Database lock             | 19 May 2016                                                                    | 19 May 2016                                                                    | 19 May 2016                                                                                              |

## Results and Analysis

<div style=\"page-break-after: always\"></div>

| Analysis description                            | Primary Analysis                                             | Primary Analysis                                             | Primary Analysis                                             | Primary Analysis                                             | Primary Analysis                                             |
|-------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Analysis population and time point description  | Intent to treat (Full analysis set) read centrally by a BIRC | Intent to treat (Full analysis set) read centrally by a BIRC | Intent to treat (Full analysis set) read centrally by a BIRC | Intent to treat (Full analysis set) read centrally by a BIRC | Intent to treat (Full analysis set) read centrally by a BIRC |
| Descriptive statistics and estimate variability | Treatment group                                              | Combo 450                                                    | Enco 300                                                     | Enco 300                                                     | Vemurafenib                                                  |
| Descriptive statistics and estimate variability | Number of subjects                                           | 192                                                          | 194                                                          | 194                                                          | 191                                                          |
| Descriptive statistics and estimate variability | Median PFS per BIRC (months)                                 | 14.9                                                         | 9.6                                                          | 9.6                                                          | 7.3                                                          |
| Descriptive statistics and estimate variability | 95% CI                                                       | 11.0, 18.5                                                   | 7.5, 14.8                                                    | 7.5, 14.8                                                    | 5.6, 8.2                                                     |
| Descriptive statistics and estimate variability | ORR per BIRC (%)                                             | 63.0                                                         | 50.5                                                         | 50.5                                                         | 40.3                                                         |
| Descriptive statistics and estimate variability | 95% CI                                                       | 55.8, 69.9                                                   | 43.3, 57.8                                                   | 43.3, 57.8                                                   | 33.3, 47.6                                                   |
| Effect estimate per comparison                  | Primary endpoint                                             | Comparison groups                                            | Comparison groups                                            | PFS Combo 450 vs. Vemurafenib                                | PFS Combo 450 vs. Vemurafenib                                |
| Effect estimate per comparison                  | Primary endpoint                                             | HR                                                           | HR                                                           | 0.54                                                         | 0.54                                                         |
| Effect estimate per comparison                  | Primary endpoint                                             | 95% CI                                                       | 95% CI                                                       | 0.41, 0.71                                                   | 0.41, 0.71                                                   |
| Effect estimate per comparison                  | Primary endpoint                                             | 1 sided stratified log rank P-value                          | 1 sided stratified log rank P-value                          | <0.001                                                       | <0.001                                                       |
| Effect estimate per comparison                  | Key secondary endpoint                                       | Comparison groups                                            | Comparison groups                                            | PFS Combo 450 vs Enco                                        | PFS Combo 450 vs Enco                                        |
| Effect estimate per comparison                  | Key secondary endpoint                                       | HR                                                           | HR                                                           | 300 0.75                                                     | 300 0.75                                                     |
| Effect estimate per comparison                  | Key secondary endpoint                                       | 95% CI                                                       | 95% CI                                                       | 0.56, 1.00                                                   | 0.56, 1.00                                                   |
| Effect estimate per comparison                  | Key secondary endpoint                                       | 1 sided P-value                                              | 1 sided P-value                                              | 0.026                                                        | 0.026                                                        |

## Analysis performed across trials (pooled analyses and meta-analysis)

The applicant did not submit analyses across trials.

## Clinical studies in special populations

In study B2301 the following proportions of patients aged ≥65 years were recruited to each treatment arm.

## Table 48: Proportions of patients aged ≥ 65 years were recruited to each treatment arm

|                     | Encorafenib 450mg + Binimetinib N=192   | Encorafenib N=194   | Vemurafenib N=191   | Total N=577   |
|---------------------|-----------------------------------------|---------------------|---------------------|---------------|
| Age ≥65 years, n(%) | 60 (31.3)                               | 40 (20.6)           | 51 (26.7)           | 151 (26.2)    |

<div style=\"page-break-after: always\"></div>

Table 49: Unstratified Cox Regression Model for PFS per Central Review by Subgroup -age ≥ 65 years (FAS, Part 1)

|                          | Event N (%)   | Median Time [2]   | Cox model [1]   | Cox model [1]   |
|--------------------------|---------------|-------------------|-----------------|-----------------|
|                          |               | months (95% CI)   | Hazard ratio    | 95% CI          |
| Age ≥ 65 years Combo 450 | 29/ 60 (48.3) | 11.0 (7.6, NE)    |                 |                 |
| Encorafenib [3]          | 21/ 40 (52.5) | 8.0 (5.4, 15.9)   | 0.71            | (0.40, 1.25)    |
| Vemurafenib [4]          | 26/51 (51.0)  | 7.3 (4,1. 11.0)   | 0.66            | (0.39, 1.12)    |

[4] Analyses comparing Encorafenib 450 + Binimetinib versus Vemurafenib only consider data from patients randomized to those treatment groups. Hazard ratio Encorafenib 450mg + Binimetinib versus Vemurafenib. Vemurafenib is the reference group.

## Supportive study(ies)

## Supportive study: CLGX818X2109- LOGIC 2

Study CLGX818X2109 (LOGIC 2) is an ongoing multicentre, open-label, 2-part Phase 2 study of sequential LGX818/MEK162  (encorafenib/binimetinib)  combination  followed  by  a  rational  combination  with  targeted agents after progression, with the aim of overcoming resistance in adult patients with locally advanced or metastatic BRAF V600 melanoma. There was no control group.

BRAF mutation was assessed from blood samples locally and from tumour samples (archival or fresh), both locally  and  centrally.  Eligibility  was  based  on  local  tumour BRAF mutation  results  and  included  all  V600 mutations (e.g. V600E, K, D, L or R).

Patients  were  to  be  ≥  18  years  of  age  with  AJCC  stage  IIIC  or  IV  melanoma,  measurable  disease  as determined by RECIST v1.1 and an ECOG PS of ≤2. Patients were to have no symptomatic brain metastases or symptomatic/ untreated leptomeningeal disease. No prior treatment was allowed with radiation therapy (&gt; 30% of the bone marrow reserve), chemotherapy, biological therapy within ≤ 4 weeks or small molecule therapeutics or investigational agents within 5-half-lives prior to starting study drug. Patients had to have recovered from the side effects of prior therapy.

In Part 1, patients were treated with the recommended Phase 2 dose (RP2D) of encorafenib 450mg QD in combination with binimetinib 45 mg BID [Combo 450]) until PD (as defined per RECIST v1.1) or no clinical benefit. Three different patient populations were included:

- Group A: Patients naïve to treatment with BRAF inhibitors
- Group B: Patients who progressed after single-agent BRAF or MEK inhibitor or after combination BRAF and MEK inhibitors other than binimetinib/encorafenib or receiving binimetinib and/or encorafenib, who had not progressed yet or, in consultation with the Sponsor, who received any BRAF and/or MEK inhibitor other than binimetinib and/or encorafenib and had not progressed yet.
- Group C: Patients who progressed after binimetinib/encorafenib combination therapy

In Part 2, patients previously treated with binimetinib/encorafenib combination therapy and who relapsed on this therapy received tailored combination treatment with binimetinib/encorafenib and a third agent in one of four arms based on genetic assessment of a tumour biopsy obtained at disease progression. The four agents

<div style=\"page-break-after: always\"></div>

were  BKM120  (PI3K  inhibitor),  BGJ398  (FGFR  inhibitor),  INC280  (cMET  inhibitor)  and  LEE011  (CDK  4/6 inhibitor).

No primary efficacy endpoint was defined for Part 1 as it was designed as a run-in stage for Part 2 to allow patients initially naïve to treatment with BRAF/MEK inhibitors (Group A) to meet the Part 2 eligibility criterion of being resistant to the MEK/BRAF inhibitor combination.

The primary efficacy endpoint for Part 2 of the study was the ORR, defined as the proportion of patients with a best overall response [BOR] of CR or PR as determined by the Investigator using RECIST v1.1. The key secondary endpoint was PFS with other secondary endpoints of DOR, TTR (time to response), DCR (disease control rate) and OS. Evaluations of ORR, PFS, DOR, TTR and DCR were also performed and analysed for Part 1. The CSR for Part 1 presents data for Groups A, B and C but the focus here is on data from Group A i.e. BRAF  and  MEK  inhibitor-naïve  patients.  The  FAS  included  all  patients  who  received  at  least  one  dose  of encorafenib or binimetinib and was used for the analysis of all endpoints unless noted otherwise.

A total of 75 treatment-naïve patients were enrolled into Part 1 (Group A) of the study between 31 July 2014 and 15 January 2016. As of the data cut-off (18 February 2016), 44 patients (58.7%) were ongoing with Combo 450 treatment. The most common reason for discontinuation from Combo 450 study treatment was PD (25.3%). As of the data cut-off, 13 patients (17.3%) had continued to Part 2 of the study.

Table 50: Study CLGX818X2109: Patient Disposition (Treatment-Naïve Patients, Part 1)

| Disposition Reason                                                                                                                                                                                                                                                                                                                                                                                       | Combo 450 (Treatment-Naïve) N =75 n (%)                                                     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Patients treated in Part 1 Treatment ongoing a End of treatment Primary reason for end of Part 1 treatment Adverse event(s) Completed Death Physician decision Progressive disease Withdrawal by parent/guardian Study follow-up after end of Part 1 treatment b Patients entering Part 2 Patients continuing to be followed for study evaluation Patients no longer being followed for study evaluation | 44 (58.7) 31 (41.3) 3 (4.0) 0 5 (6.7) 1 (1.3) 19 (25.3) 3 (4.0) 13 (17.3) 2 (2.7) 16 (23.1) |

a Patients ongoing at the time of the cut-off 18 February 2016.

b Patients in Part 1 who have ended treatment. This summary requires evaluation of data from Part 2 of the study which may be incomplete as the study is ongoing.

Most patients were Caucasian (n=74, 98.7%), and there were more males enrolled (n= 47, 62.7%) than females.  The  median  age  was  56  years  and  nearly  a  quarter  were  aged  ≥65  years  (n=18,  24%).  Most patients  had  an  ECOG  PS  of  0  (n=55,  73.3%)  and  had  AJCC  stage  IV  disease  (93.3%)  at  study  entry. Baseline LDH was high in 18.7% (n=14) of patients; however, 40 patients (53.3%) did not have a baseline LDH value reported as this was not required until Protocol Amendment 2 (November 2014).

The proportion of patients with skin melanoma as the primary site of cancer was lower than in Columbus (82.7%  vs  &gt;99%)  but,  conversely,  the  proportion  of  patients  with  an  unknown  primary  site  was  higher (6.7%).  The most common sites of metastases were lymph nodes (70.7%), lung (57.3%), liver (40.0%) and bone (26.7%). Brain metastases at baseline were reported in 5.3% of patients. Forty-percent of patients had

<div style=\"page-break-after: always\"></div>

received prior-antineoplastic  medication.  More  patients  had  received  prior  immunotherapy  with  ipilimumab (21%)  than  in  study  B2301  (≤5%).  Patients  could  have  had  prior  systemic  chemotherapy  and  2.7%  of treatment-naïve patients in Study CLGX818X2109 had prior treatment with alkylating agents (dacarbazine, dacarbazine citrate).

Table 51: Study CLGX818X2109: Prior Cancer Therapy (Treatment-Naïve Patients, Part 1)

| Disease history                            | Combo 450 (Treatment-Naïve) N =75 n (%)   |
|--------------------------------------------|-------------------------------------------|
| Any therapy                                |                                           |
| Medication                                 | 30 (40.0)                                 |
| Surgery                                    | 74 (98.7)                                 |
| Radiotherapy                               | 18 (24.0)                                 |
| Antineoplastic medication                  |                                           |
| Protein kinase inhibitors                  | 0                                         |
| Monoclonal antibodies                      | 21 (28.0)                                 |
| Ipilimumab                                 | 16 (21.3)                                 |
| Pembrolizumab                              | 3 (4.0)                                   |
| Nivolumab                                  | 5 (6.7)                                   |
| Other                                      | 1 (1.3)                                   |
| Interferons                                | 12 (16.0)                                 |
| Radiotherapy: setting at last radiotherapy |                                           |
| Adjuvant                                   | 12 (16.0)                                 |
| Therapeutic                                | 1 (1.3)                                   |
| Palliative                                 | 5 (6.7)                                   |

Protocol deviations in BRAF/MEK-treatment naïve patients were reported for 28.0% of patients, 4.0% were due to eligibility violations and 21.3% were assessment deviations.

At data cut-off (18 February 2016), the median duration of exposure to study treatment for treatment naïve patients was 31.14 weeks (range, 3.86 to 80.57). The confirmed ORR per investigator was 69.3% (95% CI 57.9,  79.5).  Most  patients  experienced  disease  improvement  or  control,  as  the  DCR  was  90.7%  (95%  CI 81.7, 96.2).

Updated results from the data cut-off point of 30 December 2016 have been provided and are summarised in the table below.

<div style=\"page-break-after: always\"></div>

Table 52: Study CLGX818X2109: Best Overall Response per Investigator Assessment (FAS, Part 1)

|                          | Combo 450 (Treatment-Naive) N =75 n (%)   |
|--------------------------|-------------------------------------------|
| Confirmed BORa, b        |                                           |
| CR                       | 6 (8.0)                                   |
| PR                       | 49 (65.3)                                 |
| SD                       | 15 (20.0)                                 |
| PD                       | 3 (4.0)                                   |
| Unknown                  | 2 (2.7)                                   |
| Confirmed ORR: CR +PR    | 55 (73.3)                                 |
| 95% CId                  | (61.9, 82.9)                              |
| Confirmed DCR: CR+PR+ SD | 70 (93.3)                                 |
| pIO %S6                  | (85.1, 97.8)                              |

BID: twice daily; BOR: best overall response; Combo 450: binimetinib 45 mg BID in combination with encorafenib 450 mg QD; CR: complete response; DCR: disease controlrate; ORR: objective response rate; PD: progressive disease; PR: partial response; QD: once daily; SD: stable disease

Source: Efficacy Appendix Table Q40BT 3.1

* Best overall response is based on local assessment using RECIST v1.1.

* Unknown = Progression has not been documented and one or more lesions have not been assessed or have been assessed using a different method than baseline.

b CR and PR are confirmed by repeat assessments perfomed not less than 4 weeks after the criteria for response is first met.

dThe 95% CI for the frequency distribution of each variable were computed using Clopper-Pearson's method.

Table 53: Study CLGX818X2109: Kaplan-Meier Summary of PFS by Investigator Assessment (FAS, Part 1)

|                                  | Combo 450 (Treatment-Naive) N=75 n (%)   |
|----------------------------------|------------------------------------------|
| Number of PFS events             | 44/75 (58.7)                             |
| Progression                      | 38 (50.7)                                |
| Death without progression        | 6 (8.0)                                  |
| Number censored                  | 31 (41.3)                                |
| Percentiles (95% C1)a (months)   |                                          |
| 25th                             | 6.3 (4.6, 7.1)                           |
| 50th                             | 10.8 (8.1, 15.2)                         |
| 75th                             | 22.8 (15.4, NE)                          |
| Kaplan-Meier estimates (95% C1)b |                                          |
| 6 months                         | 76.2 (64.5, 84.4)                        |
| 12 months                        | 42.1 (30.3, 53.5)                        |
| 18 months                        | 35.2 (23.4, 47.2)                        |
| 24 months                        | 17.6 (1.9, 46.6)                         |

Source: Efficacy Appendix Table Q40BT1.1 and Q40B T1.2

Represents the estimated time (95% Cl), reported in months, at which the specified percentiles occur based on the Kaplan-Meier analysis. Note that the5Othpercentile is the same as the median time to event.Values were calculated using theBrookmeyer and Crowley method inPROC

<div style=\"page-break-after: always\"></div>

Table 54: Study CLGX818X2109: Kaplan-Meier Plot of PFS by Investigator Assessment (FAS, Part 1)

<!-- image -->

Source : Efficacy Appendix Figure Q40 B F.1, cut-off date: 30DEC2016

## 2.5.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The pivotal study CMEK162B2301 (COLUMBUS) was a Phase 3, randomised, open label study comprising 2 parts. The primary endpoint was PFS with Combo 450 vs. vemurafenib. The key secondary endpoint was PFS with  Combo  450  vs.  Enco  300  from  Part  1  (plus  PFS  Combo  300  vs.  Enco  300  from  Part  2).  With  the hierarchical testing procedure, the secondary endpoint of OS Combo 450 vs. vemurafenib was to be tested only if these comparisons were statistically significant. The PFS analyses were conducted after more than the planned number of events had occurred [204 PFS events (planned 145) for Combo 450 vs. vemurafenib and 223 PFS events (planned 191) for Combo 450 vs. Enco 300].

The DMC reviewed the results (and unblinded survival data) to which the applicant remained blinded and recommended that the planned analyses be terminated and all patients be informed of the Part 1 results. Patients in the vemurafenib arm were to be advised that a BRAF-MEK inhibitor combination might be a better alternative.  There were no specific recommendations regarding the encorafenib monotherapy arm. The OS analysis will likely be confounded by patients in the monotherapy arms seeking alternative treatments. This early termination is probably inevitable as Combo 450 was being compared to single agent BRAF inhibitor which  would  not  now  be  considered  standard  of  care  in  this  setting.  Patients  with  V600  mutant  tumours would routinely be treated with a BRAF-MEK inhibitor combination. Still, it is accepted that at the time the trial was designed, the combination of BRAF/MEK inhibitor was not the SoC..

The  study  was  open  label,  given  the  likelihood  of  functional  unblinding  from  the  predicted  treatment toxicities.  Efficacy  assessment  by  blinded  independent  review  was  appropriate  to  prevent  evaluation  bias.

<div style=\"page-break-after: always\"></div>

Progression  free  survival  as  the  primary  endpoint  is  accepted  as  a  meaningful  reduction  in  the  risk  of progression or death represents a clinical benefit in patients with BRAF mutation-positive melanoma. It also allowed for more rapid assessment, mitigating the potentially confounding effects of post-study treatments on OS. Overall, the design of the study is acceptable and the study was well conducted.

Supportive data is provided from Study CLGX818X2109 (LOGIC 2) ,  an  open-label,  single  arm,  Phase  2 trial. Data has been provided from a subsection of patients (n=75) in Part 1 - Group A - no prior treatment with a BRAF inhibitor.  There was no pre-defined efficacy endpoint but ORR, PFS, DOR, TTR and DCR were evaluated and provided supportive evidence of efficacy.

## Efficacy data and additional analyses

The primary endpoint of the pivotal study, CMEK162B2301, was met as Combo 450 significantly improved median PFS versus vemurafenib alone (14.9 vs. 7.3 months) based on BIRC review in the full analysis set (FAS) with a HR of 0.54 (95% CI, 0.41, 0.71) (one-sided stratified log rank p&lt;0.001) which was statistically significant. PFS curves separate early (after approximately 1-2 months) and do not intersect until near the end of follow-up where the number of patients in each arm is ≤ 4. Median follow-up time for PFS per BIRC was 16.7 months for the Combo 450 arm and 14.4 months for the vemurafenib arm. About 50% of patients were censored at the time of the analysis, approximately 30% in the Combo 450 arm due to remaining on treatment  and  20%  in  the  vemurafenib  arm  for  starting  a  new  anti-cancer  therapy.  As  the  DMC recommended termination  of  further  analyses  and  all  patients  in  the  vemurafenib  arm  receive  BRAF-MEK inhibitor combination therapy there will be no further information on this direct comparison.

The sensitivity PFS analyses yielded similar HRs (95% CI) and median PFS values to the primary analysis, reflecting the robustness of the PFS benefit. These included the investigator assessment in the FAS, the per protocol set (PPS) and tumour assessments after initiation of further anti-cancer therapy. The efficacy results based on investigator assessment were consistent with the independent central assessment.

Other than treatment, the only prognostic factor that significantly influenced PFS was LDH increase of 125 IU/L.  The  PFS  benefit  was  consistent  across  the  subgroups  analysed,  apart  from  the  presence  of  brain metastases. Only 12 patients (9 Combo 450 and 3 vemurafenib) had brain metastases at baseline so there were insufficient patients to evaluate efficacy in this subgroup. All patients had BRAF mutant V600 E or K melanoma, which comprise most BRAF mutant patients Across the 3 treatment arms only 24 patients (3.7% of the Combo 450 arm) had received prior ipilimumab in the adjuvant or metastatic setting and 3 patients (0.5% of the Combo arm) had received a prior anti PD1/PDL1 inhibitor in the metastatic setting. The HR favoured Combo 450 in the small group of patients that had received prior immunotherapy (n=15; 8 Combo 450  vs  7  vemurafenib)  although  the  confidence  intervals  were  large.  The  use  of  Combo  450  in  patients previously treated with a BRAF or MEK inhibitor is not supported. The median PFS in non-naïve patients in LOGIC 2 was 3.5 months.

Results for overall survival have been presented from the OS interim analysis with cut-off date 7 th  November 2017, by which time a total of 232 OS events were observed in the Combo 450 and vemurafenib arms combined in Part 1 of the study. The median OS was 33.6 months (24.4, 39.2) and 16.9 months (14.0, 24.5), respectively, for patients treated with Combo 450 compared to those treated with vemurafenib with a HR 0.61 (95% CI 0.47, 0.79, nominal p value &lt;0.0001). The median OS was 33.6 months (24.4, 39.2) and 23.5 months (19.6, 33.6), respectively, for patients treated with Combo 450 compared to those treated with encorafenib with a HR 0.81 (95% CI 0.61, 1.06, nominal p value=0.0613). The observed HR and numerical increase in median OS supports the relevant contribution of binimetinib and demonstrates a statistically

<div style=\"page-break-after: always\"></div>

significant and clinically meaningful improvement in overall survival with the combination treatment of binimetinib and encorafenib compared with vemurafenib.

For Combo 450 vs vemurafenib and Combo450 vs encorafenib, results of the planned sensitivity analyses were  consistent  with  those  from  the  interim  OS  analysis  and  lead  to  similar  conclusions  about  treatment effect.  Most  unstratified  subgroup  analyses also demonstrated median OS point estimates in favour of the Combo 450.

For the key secondary efficacy endpoint, the median PFS estimates by BIRC in the FAS were 14.9 and 9.6 months  for  Combo  450  and  encorafenib,  respectively,  with  a  HR  of  0.75  (95%  CI  0.56,  1.00).  The  PFS difference of 5.3 months just missed statistical significance (p = 0.0256) by the one-sided stratified log-rank test  with  a  threshold  of  p  &lt;  0.025.  Therefore,  by  the  hierarchical  testing  procedure  none  of  the  further endpoints  can  be  considered  statistically  significant  and  nominal  p  values  are  presented  for  descriptive purposed only. Per Investigator assessment of response, the PFS difference between the Combo 450 and the encorafenib arm was consistent with that reported by the BIRC (14.8 months Combo 450 vs. 9.2 months Enco 300) and this difference reached nominal significance at the one-sided 0.025 level (HR 0.68; 95% CI 0.52, 0.90; nominal 1-sided p=0.003). The subgroup analyses, including the unstratified HRs, were generally consistent with the analysis in the full population, allowing for wide confidence intervals in the subgroups with small numbers of patients.  There were some groups with small patient numbers where the HR was greater than 1 (e.g. number of organs involved at baseline 1 or &gt;3) but this is likely due to chance. Unstratified subgroup analyses demonstrated point estimates in favour of Combo 450, including LDH at baseline, ECOG performance status and AJCC stage. This supports benefit for the combination over single agent encorafenib, likely  due  to  the  increased  tolerability  of  encorafenib  with  a  MEK  inhibitor  allowing  a  higher  dose  of encorafenib  to  be  administered  (450mg  vs  300mg)  as  well  as  the  anti-tumour  contribution  of  binimetinib itself.

Part 2 of Study CMEK162B2301 was designed to assess the contribution of binimetinib to the encorafenib and binimetinib combination. Preliminary Part 2 data, at a cut-off date of 9 November 2016, demonstrated the contribution of binimetinib with an improved median PFS estimate of 12.9 months (95% CI: 10.1, 14.0) for Combo 300 compared to 9.2 months (95% CI: 7.4, 11.0) for Enco 300 (Parts 1 and 2) per independent central review (BIRC). The confirmed ORR per BIRC was 65.9% (95% CI: 59.8, 71.7) for Combo 300 and 50.4% (95% CI: 44.3, 56.4) for Enco 300 (Parts 1 and 2). Median DOR for confirmed responses per BIRC was 12.7 months [95% CI: 9.3, 15.1] for Combo 300 and 12.9 months [95% CI: 8.9, 15.5] for Enco 300. The median duration of treatment was longer for Combo 300 vs Enco 300, 52.1 weeks vs 31.5 weeks. The addition of binimetinib 45mg BID to encorafenib 300mg QD increased the median PFS by 3.7 months (stratified HR 0.77, 95% CI 0.61, 0.97; nominal 1-sided p=0.015) and the ORR by 15.5%. The investigator assessment and sensitivity analyses of PFS were similar. When only the patients randomised to Part 2 were assessed the results again supported a binimetinib contribution to efficacy; median PFS values (95% CI) were 12.9 months (10.1, 14.0) and 7.4 months (5.6, 9.2), respectively (HR 0.57, 95% CI: 0.41, 0.78; nominal one-sided p&lt;0.001 per stratified log-rank test). However, it is worth noting that the results for encorafenib monotherapy are better in part 1 than part 2 with a difference of over 2 months in median PFS. It is possible that differences in baseline characteristics (in particular age, stage of disease and elevated LDH) may be responsible for this difference in outcome. Some baseline imbalances can also be seen between Combo300 and Enco300 part 2. In particular, a greater proportion of the Enco 300 patients (Part 2) have Stage IV disease with elevated LDH compared with the Combo 300 patients.

Therefore, for patients that must reduce the dose to 300 mg due to ADRs, the data seems to indicate that patients will continue to have a similar magnitude of treatment effect.  The proposed dose regimen in the

<div style=\"page-break-after: always\"></div>

applied indication is Combo 450 (binimetinib 45mg BID and encorafenib 450mg QD). Combo 450 (part 1, n=192) and Combo 300 (part 2, n=258) were compared post-hoc. Median PFS by BIRC was not statistically significantly longer with Combo 450 vs Combo 300 (14.9 months [95% CI 11.0, 18.5] vs 12.9 months [95% CI 10.1, 14.0]; HR 0.79 [95% CI 0.60, 1.03]; one-sided log-rank p=0.0845) at the cut-off dates for initial analysis (19 May 2016 and 9 November 2016, respectively). Combo 450 did not increase the proportion of confirmed responses (63.0% vs. 65.9%), although the median duration of confirmed response was longer (16.6 vs. 12.7 months, with overlapping confidence intervals).  When Combo 450 and Combo 300 were compared at the same cut-off (9 November 2016) there had been an additional 5 PFS events in the Combo 450 arm; median PFS by BIRC was 15.5 vs. 12.9 months (stratified HR 0.77, 95% CI 0.58, 1.01; 2-sided log rank p value 0.0573). However as noted above, patients enrolled to part 2 of the trial seem to have a worse prognosis than those in part 1.

The  confirmed  response  rate  (CR  +  PR)  was  higher  in  the  Combo  450  group  (63.0%)  compared  with encorafenib (50.5%) and vemurafenib (40.3%). Confirmed ORR in the small subgroup of patients with prior first-line immunotherapy was lower but showed the same pattern as in the overall population; Combo 450 (N=8) 50.0%; encorafenib (N=11) 45.5%; vemurafenib (N=7) 28.6%. These were all partial responses, with no complete responses in this subgroup. The median time to response for responders in all treatment arms was short (1.9 - 2.1 months), which corresponds with the first post-baseline response assessment at Cycle 3 Day 1. The median duration of response (DOR) per BIRC, calculated for confirmed responses, was longer in the  Combo  450  arm  (16.6  months)  in  the  Combo  450  arm  than  the  encorafenib  (14.9  months)  or vemurafenib arms (12.3 months).

The PRO findings appeared supportive. The Functional Assessment of Cancer Therapy-Melanoma (FACT M), the European Organisation for Research and Treatment of Cancer's core quality of life questionnaire (EORTC QLQ  C30)  and  the  EuroQoL  5  Dimension  5  Level  examination  (EQ  5D  5L)  were  used  to  explore  patientreported outcomes (PRO) measures of health-related Quality of Life, functioning, melanoma symptoms, and treatment-related adverse reactions. A definitive 10% deterioration in FACT M and in EORTC QLQ-C30 was significantly delayed in patients treated with Combo 450 relative to other treatments. The median time to definitive  10%  deterioration  in  the  FACT-M  score  was  not  reached  in  the  Combo  450  arm  and  was  22.1 months (95% CI: 15.2, NE) in the vemurafenib arm with a HR for the difference of 0.46 (95% CI: 0.29, 0.72).  An  analysis  of  time  to  definitive  10%  deterioration  in  EORTC  QLQ  C30  score  provided  with  similar results.

Patients receiving Combo 450 reported no change or a slight improvement in the mean change from baseline EQ 5D 5L index score at all visits, whilst patients receiving vemurafenib or encorafenib reported decreases at all visits (with statistical significant differences). An evaluation of change over time in score yielded the same trend for EORTC QLQ C30 and at all visit for FACT M).

The results from the Phase 2 study CLGX818X2109 provided preliminary support regarding the efficacy of Combo 450 in the treatment of BRAF V600 mutant melanoma. The overall response rate (confirmed ORR) of 69.3% was similar but the median PFS was shorter (14.9 months in Study CMEK162B2301 vs. 9.5 months in Study CLGX818X2109). This may be because the PFS data was not fully mature at the time of data cut off; median follow up time was 6.4 months compared to 16.7 months for the Combo 450 arm in the COLUMBUS trial.  Tumour  assessments  were  performed  every  8  weeks  in  COLUMBUS  compared  to  every  4  weeks  in LOGIC 2.

Encorafenib is to be given in combination with binimetinib. For additional information on warnings and precautions associated with binimetinib treatment, see section 4.4 of binimetinib SmPC.

<div style=\"page-break-after: always\"></div>

## BRAF mutation testing

Before taking encorafenib in combination with binimetinib, patients must have BRAF V600 mutation confirmed by a validated test. The efficacy and safety of encorafenib have been established only in patients with tumours expressing BRAF V600E and V600K mutations. Encorafenib should not be used in patients with wild type BRAF malignant melanoma.

Encorafenib in combination with binimetinib in patients who have progressed on a BRAF inhibitor

There are limited data for the use of the combination of encorafenib with binimetinib in patients who have progressed on a prior BRAF inhibitor given for the treatment of unresectable or metastatic melanoma with BRAF V600 mutation. These data show that the efficacy of the combination would be lower in these patients.

Encorafenib in combination with binimetinib in patients with brain metastases

There are limited efficacy data with the combination of encorafenib and binimetinib in patients with a BRAF V600 mutant melanoma which have metastasised to the brain (see section 5.1).

## Paediatric population

The safety and efficacy of encorafenib have not yet been established in children and adolescents. No data are available.

The European Medicines Agency has deferred the obligation to submit the results of studies with encorafenib in one or more subsets of the paediatric population in melanoma (see section 4.2 for information on paediatric use).

## 2.5.4. Conclusions on the clinical efficacy

Overall, Combo 450 demonstrates both a statistically significant and clinically meaningful benefit in PFS over the  comparator  vemurafenib  as  well  as  a  clinically  relevant  benefit  over  encorafenib  monotherapy  at  its maximally  tolerated  monotherapy  dose  of  300  mg  QD.  The  OS  results  of  Part  I  of  the  COLUMBUS  study demonstrate a statistically significant benefit favouring the Combo 450 treatment over vemurafenib.

The  combination  therapy  of  binimetinib  and  encorafenib  showed  an  improved  efficacy  compared  to  BRAF inhibitors given as monotherapies (vemurafenib and encorafenib) which is consistent with clinical data from other  combination  therapies  of  BRAF/MEK  inhibition  of  patients  with  advanced  or  metastatic  melanoma harbouring BRAF V600 mutations.

The CHMP requests the following measures to address issues related to efficacy:

- -OS results for Combo 300 and updated Combo 300 PFS analysis, including more mature data for the Enco300 Part 2 arm.

## 2.6. Clinical safety

## Patient exposure

As of 11 May 2016, a total of 1495 subjects (91 healthy volunteers and 1404 patients with advanced cancer) had been exposed to encorafenib. Safety data from 5 clinical trials in patients with unresectable or metastatic BRAF V600 mutant melanoma were presented in overlapping populations.

For combination treatment:

<div style=\"page-break-after: always\"></div>

'Combo 450': (N=192) treated with 450 mg QD encorafenib plus 45 mg BID binimetinib in Phase 3 study CMEK162B2301 Part 1

'Combo 450 RP': 'restricted' combination, (N=274) treated with Combo 450 in CMEK162B2301 Part 1 (n=192), CLGX818X2109 Part A (n=75) and CMEK162X2110 previously naïve to BRAF inhibitors (n=7)

'Combo 450 BP': 'broad' combination, (N=433) treated with encorafenib 300mg-600mg QD (higher/ lower encorafenib doses outside this range were not pooled) and binimetinib 45mg BID in CMEK162B2301 Part 1 (n=192), CLGX818X2109 (n=158) and CMEK162X2110 (n=87). The number of patients treated with encorafenib doses other than 450mg QD vs those who were not BRAF/ MEK inhibitor naïve was not presented.

## For encorafenib monotherapy treatment:

'Enco 300': (N=192) treated with 300mg QD encorafenib in Study CMEK162B2301 Part 1

'Enco 300 P': (N=217), treated with 300mg QD encorafenib in CMEK162B2301 Part 1 (=192) and BRAF inhibitor naïve patients from CLGX818X2102 and CLGX818X2101 (n=25)

These were compared to the vemurafenib 960mg BID arm of the Phase 3 study (N=186).

In the Combo 450 RP population, the median duration of combination binimetinib and encorafenib exposure was 41.9 weeks, with 121 patients (44.2%) exposed to treatment for ≥48 weeks. The median duration of exposure was shorter in the Enco 300 P population (29.7 weeks) with 77 patients (35.5%) exposed to treatment for ≥48 weeks.

A similar median relative dose intensity (RDI) was reported for each component (binimetinib 99.6%, encorafenib 100%) of the Combo 450 RP population with an RDI of 100% for 44.5% and 50% of patients for binimetinib and encorafenib, respectively. The median RDI of encorafenib was lower in the Enco 300 P monotherapy population (87.5%) and the proportion with an RDI of 100% was only 28.1%. Exposure in most subgroups in the Combo 450 RP population was close to the median. Median exposure was lower in patients with baseline liver metastases (N=97), Asian patients and patients with moderate renal impairment but still &gt;32 -36 weeks and the last 2 groups involved small patient numbers (n=6 and 4, respectively). Duration of treatment in the single patient ≥85 years was only 14 weeks.

A 4-month safety update was provided in response to the Day 120 list of questions, focussing on pooled data from the same studies as presented in the initial MAA. The data cut-off dates and number of patients in each study included in the pooled analyses are presented below. The 4-month safety update provides an additional 750 patient-months of exposure in the Combo 450 RP population and 219 patient-months in the Enco 300 P population.

<div style=\"page-break-after: always\"></div>

Table 55: Clinical Studies Included in Pooled Safety Summaries (Initial MAA and 4Month Safety Update)

|                                    | Initial MAA                        | Initial MAA                        | 4-Month Safety Update              | 4-Month Safety Update              |
|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| Study                              | Cut-off Date                       | Pts Included in PooledSummaries    | Cut-off Date                       | Pts Included in PooledSummaries    |
| Encorafenib+BinimetinibCombination | Encorafenib+BinimetinibCombination | Encorafenib+BinimetinibCombination | Encorafenib+BinimetinibCombination | Encorafenib+BinimetinibCombination |
| CMEK162B2301 Part 1                | 19 May 2016                        | 192                                | 09 Nov 2016                        | 192                                |
| CLGX818X2109                       | 18 Feb 2016                        | 158                                | 30 Dec 2016                        | 158                                |
| CMEK162X2110                       | 31 Aug 2015                        | 87                                 | 31 Dec 2016                        | 87                                 |
| Single-agentEncorafenib            | Single-agentEncorafenib            | Single-agentEncorafenib            | Single-agentEncorafenib            | Single-agentEncorafenib            |
| CMEK162B2301 Part 1                | 19 May 2016                        | 192                                | 09 Nov 2016                        | 192                                |
| CLGX818X2101                       | 18 Aug 2014                        | 10                                 | Same as initial MAAab              | Same as initial MAAab              |
| CLGX818X2102                       | 05 May2015                         | 15                                 | Same as initial MAAab              | Same as initial MAAab              |

Abbreviations: CSR = clinical study report; MAA =: Marketing Authorisation Application; Pts = patients; SAE = serious adverse event

² Same cutoff date as initial MAA due to minimal/no data changes.

b Listing of treatment-emergent SAEs occuring between the cut-off dates for the initial MAA to 31 Dec 2016 is provided for Studies CLGX818X2101 and CMEK162A2301. For Studies CLGX818X2102 and CMEK162X2201, no treatment emergentSAEs occurred during this timeframe (Module 5.3.5.3, SAE Listings).

The median duration of exposure was 11.7 months in patients treated with Combo 450, 7.1 months in patients treated with Enco 300 and 6.2 months in patients treated with vemurafenib. The median duration of exposure to study treatment in the Combo 450 RP population increased by ~9 weeks from 41.9 to 50.6 weeks, with 142 patients (51.8%) exposed to treatment for ≥48 weeks (increase by nearly 8%). In the Enco 300 P population, the median duration of exposure to study treatment (29.7 weeks) and the percentage of patients exposed to treatment for ≥48 weeks (35.5%) were unchanged.

The median relative dose intensity (RDI) for Combo 450 was 100% for encorafenib and 99.6% for binimetinib; the median RDI was 86.2% for Enco 300 and 94.5% for vemurafenib. The median relative dose intensity decreased slightly (&lt; 5.0%) for the Enco 300 P population, (84.98% vs 87.53% in the initial MAA), although the number of patients (n=61, 28.1%) receiving a relative dose intensity of 100% remained unchanged.

In the Combo 450 RP population, the median relative dose intensity of encorafenib and binimetinib was 99.66% and 99.50%, respectively, similar to that reported in the initial MAA. The relative dose intensity in the Combo 450 RP population at the 4-month safety update for encorafenib was 100% in 123 patients (44.9%) and 100% for binimetinib in 109 patients (39.8%).

## Adverse events

For Combo 450 P, the incidence of AEs was 98.9% with Grade 3/4 AEs reported in 57.8% patients (Grade 3, 48.2%; Grade 4, 9.9%); the median time to onset of the first Grade 3/4 AE was 2.5 months.

For Enco 300 P, the incidence of AEs was 99.5% with Grade 3/4 AEs observed in 67.3% patients (Grade 3, 58.1%; Grade 4, 9.2%); the median time to onset of the first Grade 3/4 AE was 0.4 months.

<div style=\"page-break-after: always\"></div>

For vemurafenib, the incidence of AEs was 98.4%, with Grade 3/4 AEs in 63.4% patients (55.4% Grade 3 AEs and 8.1% Grade 4 AEs); the median time to onset of first Grade 3/4 AEs was 1.3 months.

Table 56: Overall Summary of Adverse Events by Treatment

|                                              | Enco 300mg QD N=217 n (%)   | Combo pooled doses N=433 n (%)   | Combo 450mg QD N=274 n (%)   | Combo 450mg QD N=192 n (%)   | Enco 300mg QD N=192 n (%)   | Vemurafenib N=186 n (%)   |
|----------------------------------------------|-----------------------------|----------------------------------|------------------------------|------------------------------|-----------------------------|---------------------------|
| On-treatment deaths [1]                      | 15 (6.5)                    | 44 (10.2)                        | 23 (8.4)                     | 17 (8.9)                     | 14 (7.3)                    | 19 (10.2)                 |
| AE                                           | 216 (99.5)                  | 426 (98.4)                       | 271 (98.9)                   | 189 (98.4)                   | 191 (99.5)                  | 185 (99.5)                |
| Grade 3/4                                    | 146 (67.3)                  | 254 (58.7)                       | 159 (58.0)                   | 111 (57.8)                   | 127 (66.1)                  | 118 (63.4)                |
| SAE                                          | 69 (31.8)                   | 158 (36.5)                       | 98 (35.8)                    | 66 (34.4)                    | 65 (33.9)                   | 69 (37.1)                 |
| Grade 3/4                                    | 58 (26.7)                   | 142 (32.8)                       | 87 (31.8)                    | 57 (29.7)                    | 54 (28.1)                   | 60 (32.3)                 |
| AEleadingtotreatment discontinuation         | 38 (17.5)                   | 45 (10.4)                        | 28 (10.2)                    | 24 (12.5)                    | 27 (14.1)                   | 31 (16.7)                 |
| Grade 3/4                                    | 29 (13.4)                   | 33 (7.6)                         | 24 (8.8)                     | 22 (11.5)                    | 21 (10.9)                   | 18 (9.7)                  |
| AE requiring dose interruption and/or change | 152 (70.0)                  | 208 (48.0)                       | 129 (47.1)                   | 92 (47.9)                    | 135 (70.3)                  | 114 (61.3)                |
| Grade 3/4                                    | 93 (42.9)                   | 142 (32.8)                       | 88 (32.1)                    | 63 (32.8)                    | 85 (44.3)                   | 71 (38.2)                 |
| AE requiring additional therapy              | 189 (87.1)                  | 364 (84.1)                       | 236 (86.1)                   | 165 (85.9)                   | 181 (94.3)                  | 171 (91.9)                |
| Grade 3/4                                    | 107 (49.3)                  | 160 (37.0)                       | 101 (36.9)                   | 67 (34.9)                    | 106 (55.2)                  | 91 (48.9)                 |

[1] Deaths occurring &gt;30 days after end of treatment are not included. [2] Additional therapy includes all non-drug therapy and concomitant medications. A patient is counted once within each category. MedDRA Version 19.0 has been used for the reporting of adverse events

<div style=\"page-break-after: always\"></div>

Table 57: Overall summary of relevant intra-population differences since initial MAA in the Enco 300P and COMBO 450 RP (Restricted Safety Set)

|                                                  |            | Initial MAA               | Initial MAA                | 4-month safety update     | 4-month safety update      |
|--------------------------------------------------|------------|---------------------------|----------------------------|---------------------------|----------------------------|
|                                                  |            | Enco 300mg QD N=217 n (%) | Combo 450mg QD N=274 n (%) | Enco 300mg QD N=217 n (%) | Combo 450mg QD N=274 n (%) |
| On-treatment deaths [1]                          |            | 15 (6.9)                  | 23 (8.4)                   | 16 (7.4)                  | 28 (10.2)                  |
| Adverse events (AEs)                             | All Grades | 216 (99.5)                | 271 (98.9)                 | 216 (99.5)                | 271 (98.9)                 |
|                                                  | Grades 3-4 | 109 (50.2)                | 159 (58.0)                 | 147 (67.7)                | 168 (61.3)                 |
| Serious AEs                                      | All Grades | 69 (31.8)                 | 98 (35.8)                  | 71 (32.7)                 | 110 (40.1)                 |
|                                                  | Grades 3-4 | 58 (26.7)                 | 87 (31.8)                  | 60 (27.6)                 | 94 (34.3)                  |
| AEsleadingtodiscontinuation                      | All Grades | 38 (17.5)                 | 28 (10.2)                  | 39 (18.0)                 | 32 (11.7)                  |
|                                                  | Grades 3-4 | 29 (13.4)                 | 24 (8.8)                   | 28 (12.9)                 | 26 (9.5)                   |
| AEsrequiring dose interruption and/or adjustment | All Grades | 152 (70.0)                | 130 (47.4)                 | 154 (71.0)                | 143 (52.2)                 |
|                                                  | Grades 3-4 | 93 (42.9)                 | 88 (32.1)                  | 96 (44.2)                 | 94 (34.3)                  |
| AEs requiring additional therapy [2]             | All Grades | 205 (94.5)                | 236 (86.1)                 | 206 (94.9)                | 246 (89.8)                 |

QD -- once daily; Bold text denotes the relevant intra-population difference since the initial MAA.

[1] Deaths occurring &gt;30 days after end of treatment are not included.

Source: ISS Table 2.2.1 and ISSPartl u Table 2.2.1-u

[2]Additional therapyincludesallnon-drugtherapyandconcomitantmedications.

The incidence of patients in the Enco 300P population with at least one dose modification of encorafenib was unchanged [155 of 217 (71.4%)].

In the Combo 450 RP population, the incidence of dose modifications had slightly increased; 147 of 274 (53.6%) required at least 1 dose modification of encorafenib, 164 of 274 (59.9%) required at least 1 dose modification of binimetinib. Modification of encorafenib dose due to an AE occurred in 41.2% of patients, including dose reductions (17.5%) and dose interruptions (38.7%). Modification of binimetinib dose due to an AE occurred in 45.6% of patients, including dose reductions (30.7%) and dose interruptions (40.5%).

The proportion of patients requiring at least one dose modification of encorafenib due to an AE (including dose reductions and interruptions) remained lower in the Combo 450 RP compared to the Enco 300 P population:

- 53.6% vs 71.4% of patients with dose modifications for any reason
- 41.2% vs 65.9% of patients with dose modifications due to AEs.

<div style=\"page-break-after: always\"></div>

Table 58: Adverse Events, Regardless of Study Drug Relationship, by System Organ Class by Treatment -Overall and Maximum Grade 3 or 4 ( ≥ 20% in any population)

|                                                                     | Melanoma                  | Melanoma                  | Melanoma                       | Melanoma                  | StudyCMEK162B2301          | StudyCMEK162B2301         | StudyCMEK162B2301       |
|---------------------------------------------------------------------|---------------------------|---------------------------|--------------------------------|---------------------------|----------------------------|---------------------------|-------------------------|
| PrimarySystem Organ Class Preferred Term Grades                     | Bini 45mg BID N=427 n (%) | Enco 300mg QD N=217 n (%) | Combo pooled doses N=433 n (%) | Combo450mg QD N=274 n (%) | Combo 450mg QD N=192 n (%) | Enco 300mg QD N=192 n (%) | Vemurafenib N=186 n (%) |
| Any primary system organ class                                      |                           |                           |                                |                           |                            |                           |                         |
| All grades                                                          | 427 (100)                 | 216 (99.5)                | 426 (98.4)                     | 271 (98.9)                | 189 (98.4)                 | 191 (99.5)                | 185 (99.5)              |
| Grades 3/4                                                          | 283 (66.3)                | 146 (67.3)                | 254 (58.7)                     | 159 (58.0)                | 111 (57.8)                 | 127 (66.1)                | 118 (63.4)              |
| Gastrointestinaldisorders                                           |                           |                           |                                |                           |                            |                           |                         |
| All grades                                                          | 305 (71.4)                | 151 (69.6)                | 320 (73.9)                     | 201 (73.4)                | 138 (71.9)                 | 130 (67.7)                | 127 (68.3)              |
| Grades 3/4                                                          | 39 (9.1)                  | 26 (12.0)                 | 58 (13.4)                      | 35 (12.8)                 | 22 (11.5)                  | 25 (13.0)                 | 19 (10.2)               |
| Skin and subcutaneoustissue disorders                               |                           |                           |                                |                           |                            |                           |                         |
| All grades                                                          | 375 (87.8)                | 207 (95.4)                | 255 (58.9)                     | 174 (63.5)                | 125 (65.1)                 | 184 (95.8)                | 170 (91.4)              |
| Grades 3/4                                                          | 37 (8.7)                  | 49 (22.6)                 | 10 (2.3)                       | 7 (2.6)                   | 6 (3.1)                    | 43 (22.4)                 | 38 (20.4)               |
| General disordersandadministrationsite conditions                   |                           |                           |                                |                           |                            |                           |                         |
| All grades                                                          | 320 (74.9)                | 138 (63.6)                | 266 (61.3)                     | 168 (61.3)                | 122 (63.5)                 | 123 (64.1)                | 130 (69.9)              |
| Grades 3/4                                                          | 45 (10.5)                 | 25 (11.5)                 | 44 (10.2)                      | 28 (10.2)                 | 24 (12.5)                  | 21 (10.9)                 | 24 (12.9)               |
| Eye disorders                                                       |                           |                           |                                |                           |                            |                           |                         |
| All grades                                                          | 237 (55.5)                | 58 (26.7)                 | 252 (57.7)                     | 158 (57.7)                | 104 (54.2)                 | 53 (27.6)                 | 62 (33.3)               |
| Grades 3/4                                                          |                           |                           |                                |                           |                            | 1 (0.5)                   | 1 (0.5)                 |
| Investigations                                                      | 16 (3.7)                  | 1 (0.5)                   | 12 (2.8)                       | 6 (2.2)                   | 5 (2.6)                    |                           |                         |
| All grades                                                          | 268 (62.8)                | 82 (37.8)                 | 244 (56.4)                     | 156 (56.9)                | 103 (53.6)                 | 71 (37.0)                 | 77 (41.4)               |
| Grades 3/4                                                          | 130 (30.4)                | 20 (9.2)                  | 96 (22.2)                      | 61 (22.3)                 | 47 (24.5)                  | 17 (8.9)                  | 14 (7.5)                |
| Musculoskeletaland connective tissue disorders                      |                           |                           |                                |                           |                            |                           |                         |
| All grades                                                          |                           |                           | 237 (54.5)                     | 150 (54.7)                | 102 (53.1)                 | 149 (77.6)                | 125 (67.2)              |
| Grades 3/4                                                          |                           |                           | 17 (3.9)                       | 12 (4.4)                  |                            | 43 (22.4)                 | 19 (10.2)               |
|                                                                     | 157 (36.8) 20 (4.7)       | 172 (79.3) 46 (21.2)      |                                |                           | 5 (2.6)                    |                           |                         |
| All grades                                                          | 175 (41.0)                | 92 (42.4)                 | 192 (44.3)                     |                           | 97 (50.5)                  | 82 (42.7)                 | 92 (49.5)               |
|                                                                     |                           |                           |                                | 137 (50)                  |                            |                           |                         |
| Infections and infestations                                         |                           |                           |                                |                           |                            |                           |                         |
| Grades 3/4                                                          | 32 (7.5)                  |                           | 33 (7.6)                       | 25 (9.1)                  | 19 (9.9)                   | 6 (3.1)                   | 9 (4.8)                 |
| Nervous system disorders                                            |                           | 7 (3.2)                   |                                |                           |                            |                           | 77 (41.4)               |
| All grades                                                          | 133 (31.1)                | 126 (58.1)                | 190 (43.9)                     | 129 (47.1)                | 95 (49.5)                  | 107 (55.7) 18 (9.4)       |                         |
| Grades 3/4                                                          | 17 (4.0)                  | 20 (9.2)                  | 34 (7.9)                       | 26 (9.5)                  | 18 (9.4)                   |                           | 14 (7.5)                |
| All grades Grades 3/4                                               | 119 (27.9) 20 (4.7)       | 57 (26.3) 10 (4.6)        | 16 (3.7)                       | 9 (3.3)                   | 8 (4.2)                    | 10 (5.2)                  | 8 (4.3)                 |
| Respiratory, thoracic and mediastinal disorders                     |                           |                           | 134 (30.9)                     | 76 (27.7)                 | 57 (29.7)                  | 52 (27.1)                 | 50 (26.9)               |
|                                                                     | 62 (14.5)                 | 26 (12.0)                 | 96 (22.2)                      | 63 (23.0)                 | 40 (20.8)                  | 20 (10.4)                 | 30 (16.1)               |
| Blood and lymphatic system disorders                                |                           |                           |                                |                           |                            |                           |                         |
| All grades                                                          | 20 (4.7)                  |                           |                                | 17 (6.2)                  |                            |                           | 9 (4.8)                 |
| Grades 3/4                                                          |                           | 11 (5.1)                  | 30 (6.9)                       |                           | 11 (5.7)                   | 9 (4.7)                   |                         |
| Metabolism and nutrition disorders                                  |                           | 75 (34.6)                 | 124 (28.6)                     | 62 (22.6)                 |                            |                           | 49 (26.3)               |
| All grades                                                          |                           | 83 (38.2)                 |                                |                           | 10 (5.2)                   |                           |                         |
| Grades 3/4                                                          | 87 (20.4) 20 (4.7)        | 18 (8.3)                  | 33 (7.6)                       | 14 (5.1)                  | 44 (22.9)                  | 61 (31.8) 14 (7.3)        | 10 (5.4)                |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                           |                           |                                |                           |                            |                           |                         |
| All grades                                                          |                           |                           | 88 (20.6) 13 (3.0)             |                           |                            |                           |                         |
| Grades 3/4                                                          | 22 (5.2) 5 (1.2)          | 13 (6.0)                  |                                | 60 (21.9) 6 (2.2)         | 44 (22.9) 5 (2.6)          | 72 (37.5) 11 (5.7)        | 82 (44.1) 22 (11.8)     |
| Psychiatric disorders                                               |                           |                           |                                |                           |                            |                           | 0                       |
| All grades                                                          | 45 (10.3)                 | 78 (35.9)                 | 76 (17.6)                      | 53 (19.3)                 | 42 (21.9)                  | 64 (33.3)                 | 31 (16.7)               |
| Grades 3/4                                                          | 3 (0.7)                   | 8 (3.7)                   | 7 (1.6)                        | 5 (1.8)                   | 3 (1.6)                    | 6 (3.1)                   |                         |
| Vascular disorders                                                  |                           |                           |                                |                           |                            |                           |                         |
| All grades                                                          | 98 (23.0)                 | 43 (19.8)                 | 87 (20.1)                      | 52 (19.0)                 | 36 (18.8)                  | 36 (18.8)                 | 36 (19.4)               |
| Grades 3/4                                                          | 44 (10.3)                 | 7 (3.2)                   | 22 (5.1)                       | 17 (6.2)                  | 12 (6.3)                   | 7 (3.6)                   | 6 (3.2)                 |

<div style=\"page-break-after: always\"></div>

Table 59: Relevant intra -population differences since initial MAA in incidences of AEs and Grade 3/4 AEs whatever relationship to study treatment by Primary SOC ( ≥ 20% in any population) (Restricted Safety Set)

| Parameter                                                           | Initial MAA   | 4-monthsafetyupdate   |
|---------------------------------------------------------------------|---------------|-----------------------|
| Intra-population differences in incidences*                         |               |                       |
| By SOCS -all grades (grade 3-4)                                     |               |                       |
| Overal incidence                                                    | 98.9% (58.0%) | 98.9% (61.3%)         |
| Blood and lymphatic system disorders                                | 23.0% (6.2%)  | 25.5% (6.6%)          |
| Eye disorders                                                       | 57.7% (2.2%)  | 61.7% (2.6%)          |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 21.9 % (2.2%) | 24.5 % (4.4%)         |
| Injury poisoning                                                    | 13.1% (1.1%)  | 17.9% (1.5%)          |
| Reproductive system disorder -                                      | 9.9% (0.0)    | 12.4% (0.7%)          |
| Respiratory, thoracic and mediastinal disorders                     | 27.7% (2.6%)  | 31.4% (3.3%)          |
| Nervous system disorders                                            | 26% (9.5%)    | 31% (11.3%)           |
| By PTs - all grades (grade 3-4)                                     |               |                       |
| Arthralgia                                                          | 24.8%         | 27.0%                 |
| Blood CK increased                                                  | 24.8%         | 27.0%                 |
| Asthenia                                                            | 13.9%         | 15.7%                 |
| Muscle spasms                                                       | 11.3%         | 13.5%                 |
| Hyperkeratosis                                                      | 12.4%         | 13.5%                 |
| Dizziness                                                           | 11.3%         | 12.4%                 |
| Back pain                                                           | 8.8%          | 10.9%                 |
| Enco300P; N=217                                                     |               |                       |
| By S0CS - all grades (grade 3-4)                                    |               |                       |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 38.2% (6.6%)  | 40.5% (6.3%)          |
| Eye disorders                                                       | 26.7% (0.5%)  | 30.5% (0.5%)          |
| Metabolism and nutrition disorder                                   | 34.6% (8.3%)  | 31.6% (6.6%)          |
| By PTs                                                              | NA            | NA                    |

<div style=\"page-break-after: always\"></div>

Adjusted for exposure, the rate of AEs was lower in the Combo 450 RP population compared to the Enco 300 P population (142.83 vs 604.83 per 100 patient-months) and compared to vemurafenib (226.32 per 100 patient-months).

When individual AEs were adjusted for duration of exposure, the rate of diarrhoea (4.87 vs 1.46 per 100 ptmnths) and increased CK (2.66 vs 0.1 per 100 pt-mnths) was higher with combination treatment; the rates of alopecia (1.39 vs. 13.14) , PPE (0.55 vs. 10.45), arthralgia (2.71 vs. 8.4), hyperkeratosis (1.23 vs. 7.13) and rash (12.0 vs. 21.7) were higher with single agent encorafenib (Combo 450 RP vs. Enco 300P).

At the 4 month update no new PTs were reported with an exposure-adjusted incidence rate (EAIR) ≥5 per 100 patient-months in the Combo 450 RP or Enco 300 P populations.

Table 60: Adverse Events, Regardless of Study Drug Relationship, Adjusted for Patient-month Exposure, by Preferred Term and Treatment (Exposure Adjusted Incidence Rate - EAIR ≥ 5 in any population)

| Preferred Term        | Bini 45mg BID N=427 n (%)   | Enco 300mg QD N=217 n (%)   | Combo pooled doses N=433 n (%)   | Combo 450mg QD N=274 n (%)   | Combo 450mg QD N=192 n (%)   | Enco 300mg QD N=192 n (%)   | Vemurafenib N=186 n (%)   |
|-----------------------|-----------------------------|-----------------------------|----------------------------------|------------------------------|------------------------------|-----------------------------|---------------------------|
| Any prefered tem      |                             |                             |                                  |                              |                              |                             |                           |
| [1] (%) u             | 427 (100)                   | 216 (99.5)                  | 426 (98.4)                       | 271 (98.9)                   | 189 (98.4)                   | 191 (99.5)                  | 185 (99.5)                |
| Exposure (months) [2] | 108.39                      | 35.71                       | 241.64                           | 189.73                       | 160.39                       | 33.87                       | 81.74                     |
| EAIR[3]               | 393.96                      | 604.83                      | 176.29                           | 142.83                       | 117.83                       | 563.88                      | 226.32                    |
| Nausea                |                             |                             |                                  |                              |                              |                             |                           |
| [1] (%) u             | 128 (30.0)                  | 82 (37.8)                   | 178 (41.1)                       | 108 (39.4)                   | 79 (41.1)                    | 74 (38.5)                   | 63 (33.9)                 |
| Exposure (months) [2] | 1475.09                     | 1396.04                     | 2705.68                          | 2073.2                       | 1569.45                      | 1299.81                     | 1128.94                   |
| EAIR [3]              | 8.68                        | 5.87                        | 6.58                             | 5.21                         | 5.03                         | 5.69                        | 5.58                      |
| Dianhoea              |                             |                             |                                  |                              |                              |                             |                           |
| n(%) [1]              | 182 (42.6)                  | 27 (12.4)                   | 161 (37.2)                       | 99 (36.1)                    | 70 (36.5)                    | 26 (13.5)                   | 63 (33.9)                 |
| Exposure (months) [2] | 1142.64                     | 1854.29                     | 2655.34                          | 2034.17                      | 1579.4                       | 1711.41                     | 1076.93                   |
| EAIR [3]              | 15.93                       | 1.46                        | 6.06                             | 4.87                         | 4.43                         | 1.52                        | 5.85                      |
| Fatigue               |                             |                             |                                  |                              |                              |                             |                           |
| n(%) [1]              | 114 (26.7)                  | 60 (27.6)                   | 135 (31.2)                       | 83 (30.3)                    | 55 (28.6)                    | 48 (25.0)                   | 57 (30.6)                 |
| Exposure (months) [2] | 1439.61                     | 1527.23                     | 3004.88                          | 2308.44                      | 1820.12                      | 1442.86                     | 1130.28                   |
| EAIR [3]              | 7.92                        | 3.93                        | 4.49                             | 3.6                          | 3.02                         | 3.33                        | 5.04                      |
| Vomiting              |                             |                             |                                  |                              |                              |                             |                           |
| n(%) [1]              | 84 (19.7)                   | 58 (26.7)                   | 123 (28.4)                       | 73 (26.6)                    | 57 (29.7)                    | 52 (27.1)                   | 28 (15.1)                 |
| Exposure (months) [2] | 1588.34                     | 1644.32                     | 3307.1                           | 2454.21                      | 1869.93                      | 1524.34                     | 1385.59                   |
| EAIR [3]              | 5.29                        | 3.53                        | 3.72                             | 2.97                         | 3.05                         | 3.41                        | 2.02                      |
| Arthralgia            |                             |                             |                                  |                              |                              |                             |                           |
| [1] (%)u              | 31 (7.3)                    | 93 (42.9)                   | 100 (23.1)                       | 68 (24.8)                    | 49 (25.5)                    | 84 (43.8)                   | 83 (44.6)                 |
| Exposure (months) [2] | 1671.33                     | 1107.22                     | 3347.98                          | 2509.96                      | 1914.78                      | 1011.71                     | 828.98                    |
| EAIR[3]               | 1.85                        | 8.4                         | 2.99                             | 2.71                         | 2.56                         | 8.3                         | 10.01                     |
| Blood CK              |                             |                             |                                  |                              |                              |                             |                           |
| increased             |                             |                             |                                  |                              |                              |                             |                           |
| n(%) [1]              | 191 (44.7)                  | 2 (0.9)                     | 93 (21.5)                        | 68 (24.8)                    | 44 (22.9)                    | 2 (1.0)                     | 4 (2.2)                   |
| Exposure (months) [2] | 1012.9                      | 2017.87                     | 3437.63                          | 2552.25                      | 1996.52                      | 1872.46                     | 1509.45                   |
| EAIR [3]              | 18.86                       | 0.1                         | 2.71                             | 2.66                         | 2.2                          | 0.11                        | 0.26                      |
| Alopecia              |                             |                             |                                  |                              |                              |                             |                           |
| [1] (%) u             | 42 (9.8)                    | 122 (56.2)                  | 50 (11.5)                        | 38 (13.9)                    | 26 (13.5)                    | 107 (55.7)                  | 68 (36.6)                 |
| Exposure (months) [2] | 1668.7                      | 928.3                       | 3746.14                          | 2737.74                      | 2127.64                      | 861.5                       | 1002.15                   |
| EAIR [3]              | 2.52                        | 13.14                       | 1.33                             | 1.39                         | 1.22                         | 12.42                       | 6.79                      |
| Hyperkeratosis        |                             |                             |                                  |                              |                              |                             |                           |
| [1] (%)u              | 9 (2.1)                     | 89 (41.0)                   | 44 (10.2)                        | 34 (12.4)                    | 27 (14.1)                    | 72 (37.5)                   | 54 (29.0)                 |
| Exposure (months) [2] | 1817.4                      | 1247.51                     | 3762.99                          | 2758.77                      | 2118.8                       | 1196.52                     | 1103.15                   |
| EAIR[3]               | 0.5                         | 7.13                        | 1.17                             | 1.23                         | 1.27                         | 6.02                        | 4.9                       |
| Rash                  |                             |                             |                                  |                              |                              |                             |                           |
| [1] (%) u             | 146 (34.2)                  | 47 (21.7)                   | 58 (13.4)                        | 33 (12.0)                    | 27 (14.1)                    | 41 (21.4)                   | 54 (29.0)                 |

<div style=\"page-break-after: always\"></div>

| Exposure(months)[2]                        | 1256.18    | 1608.41    | 3713.35   | 2779.56   | 2121.72   | 1486.19   | 1097.1    |
|--------------------------------------------|------------|------------|-----------|-----------|-----------|-----------|-----------|
| EAIR [3]                                   | 11.62      | 2.92       | 1.56      | 1.19      | 1.27      | 2.76      | 4.92      |
| Oedema peripheral                          |            |            |           |           |           |           |           |
| n (%) [1]                                  | 174 (40.7) | 19 (8.8)   | 54 (12.5) | 33 (12.0) | 20 (10.4) | 15 (7.8)  | 20 (10.8) |
| Exposure(months) [2]                       | 1139.22    | 1823.11    | 3792.76   | 2820.27   | 2206.39   | 1688.34   | 1357.11   |
| EAIR [3]                                   | 15.27      | 1.04       | 1.42      | 1.17      | 0.91      | 0.89      | 1.47      |
| Palmar-plantar erythrodysaesthesiasymdrome |            |            |           |           |           |           |           |
| n (%) [1]                                  | 5 (1.2)    | 112 (51.6) | 19 (4.4)  | 16 (5.8)  | 13 (6.8)  | 98 (51.0) | 26 (14.0) |
| Exposure(months)[2]                        | 1840.72    | 1072.13    | 3968.85   | 2923.33   | 2275.15   | 1003.6    | 1372.55   |
| EAIR [3]                                   | 0.27       | 10.45      | 0.48      | 0.55      | 0.57      | 9.76      | 1.89      |
| Dermatitisacneiform                        |            |            |           |           |           |           |           |
| n(%) [1]                                   | 177 (41.5) | 9 (4.1)    | 13 (3.0)  | 10 (3.6)  | 5 (2.6)   | 8 (4.2)   | 8 (4.3)   |
| Exposure(months)[2]                        | 1157.03    | 1947.96    | 4076.71   | 3014.01   | 2356.96   | 1811.25   | 1494.34   |
| EAIR [3]                                   | 15.3       | 0.46       | 0.32      | 0.33      | 0.21      | 0.44      | 0.54      |
| Any preferred tem                          |            |            |           |           |           |           |           |

## Combo 450 RP

The most common AEs (≥20% of patients) were nausea (39.4%), diarrhoea (36.1%), fatigue (30.3%), vomiting (26.6%), increased blood CK (24.8%), arthralgia (24.8%) and constipation (22.6%).

Grade 3/4 AEs (≥5% of patients) were increased GGT (8%), hypertension (5.8%) and increased blood CK (5.5%).

AEs requiring dose adjustment or study drug interruption (≥5% of patients) were nausea (6.6%), vomiting (5.8%), increased ALT (5.5%) and decreased ejection fraction (5.1%).

AEs requiring additional therapy (≥10% of patients) were nausea (20.8%), diarrhoea (13.5%) and constipation (12.4%).

Of the 196 patients who received Combo 450 for ≥6 months, 113 (57.7%) reported Grade 3/4 AEs.

AEs reported at a higher incidence (≥10% difference) in patients exposed more than 6 months (n=196) compared with patients exposed less than 6 months (n=78) were diarrhoea (39.8% vs 26.9%), abdominal pain (21.4% vs 2.6%), arthralgia (29.6% vs 12.8%), increased CK (27.6% vs 17.9%), pyrexia (18.9% vs 7.7%) and hyperkeratosis (15.3% vs 5.1%). Other AEs that increased after 6 months treatment (&lt;10% difference) included alopecia (16.3% vs. 7.7%), hypertension (13.3% vs. 6.4%) and decreased ejection fraction (7.7% vs. 3.8%).

No Grade 3-4 AE was reported at a higher incidence (≥2% difference) in patients who received ≥ 6 months compared those who received &lt; 6 months of study drug.

AEs reported at a lower incidence (≥10% difference) in patients exposed for more than 6 months were increased AST (6.1% vs 17.9%) and ALT (9.2 vs 21.8%).

Of patients exposed for ≥6 months, 171 had a first or worst occurrence of an AE, with 67 patients (34.2%) having Grade 3/4 events. New AEs were reported in the following proprtions of patients: arthralgia (14.8%), diarrhoea (12%), nausea (11.2%) and headache (10.7%). New Grade 3/4 AEs affected &lt;5% of patients; these included increased blood CK (3.1%), anaemia (2.6%) and hypertension (2%).

## Enco 300 P

The encorafenib single agent (300 mg orally once daily) safety profile is based on data from 217 patients with unresectable or metastatic BRAF V600-mutant melanoma (hereafter referred to as the pooled encorafenib 300 population). The most common adverse drug reactions (ADRs) (&gt;25%) reported with

<div style=\"page-break-after: always\"></div>

encorafenib 300 were hyperkeratosis, alopecia, PPES, fatigue, rash, arthralgia, dry skin, nausea, myalgia, headache, vomiting and pruritus.

The most common AEs (≥20% of patients) were alopecia (56.2%), palmar plantar erythrodysaesthesia (PPE) syndrome (51.6%), arthralgia (42.9%), hyperkeratosis (41%), nausea (37.8%), dry skin (31.3%), myalgia (29.5%), headache (28.1%), fatigue (27.6%), vomiting (26.7%), palmoplantar keratoderma (23%), decreased appetite (22.6%), insomnia (22.1%), rash (21.7%), pruritus (21.7%) and pain in extremity (20.7%).

Grade 3/4 AEs (≥5% of patients) were PPE (12.4%), arthralgia (9.2%) and myalgia (9.2%).

AEs requiring dose adjustment or study-drug interruption (≥5% of patients) were PPE (22.6%), arthralgia (12%), myalgia (11.5%), nausea (7.8%), hyperkeratosis (7.4%) and headache (5.5%).

AEs requiring additional therapy (≥10% of patients) were nausea (20.8%), diarrhoea (13.5%) and constipation (12.4%).

Of the 122 patients who received Enco 300 for ≥6 months, 81 (66.4%) reported Grade 3/4 AEs.

AEs reported at a higher incidence (≥10% difference) in patients exposed more than 6 months (n=122) compared with patients exposed less than 6 months (n=95) included arthralgia (54.1% vs 28.4%), musculoskeletal pain (21.3 vs 10.5%), alopecia (69.7% vs 38.9%), dry skin (38.5% vs 22.1%) hyperkeratosis (50.8% vs 28.4%), pruritus (26.2% vs 15.8%), palmoplantar keratoderma (30.3% vs 13.7%) and PPE (55.7% vs 46.3%).

Of patients exposed for ≥6 months (n=122), 108 had a first or worst occurrence of an AE, with 37 patients (30.3%) having Grade 3/4 events. Most frequently reported AEs were arthralgia (14.8%), hyperkeratosis (9.8%), and dry skin (7.4%). The only Grade 3/4 AE (≥2 % of patients) was anaemia (2.5%).

In the Combo 450 RP compared to the Enco 300 P population, the incidence of AEs in patients who received ≥6 months of treatment showed a:

· lower incidence of skin disorders including alopecia (16.3% vs 69.7%), hyperkeratosis (15.3% vs 50.8%), PPE (6.6% vs 55.7%), palmoplantar keratoderma (9.7% vs 33.3%) and melanocytic naevus (2% vs 13.9%)

· a higher incidence of blurred vision (16.8% vs 4.1%), abdominal pain (21.4% vs 5.7%), dizziness (15.1% vs 5.3%) and retinopathy (9.2% vs. 0.8%). The incidence of any grade retinopathy with a first or worst occurrence ≥ 6 months after treatment start in the Combo 450 arm was 2.7%.

## Vemurafenib

The most common AEs (≥20% of patients) were arthralgia (44.6%), alopecia (36.6%), diarrhoea (33.9%), nausea (33.9%), fatigue (30.6%), rash (29%), hyperkeratosis (29%), pyrexia (28%), photosensitivity reaction (24.2%), keratosis pilaris (23.1%) and dry skin (22.6%).

Other AEs reported in≥10% of patients in the vemurafenib arm and at a higher incidence as compared to the Combo 450 arm included decreased appetite (19.4% vs 8.3%), PPE (16.7% vs 6.8%), skin hyperpigmentation (14.5% vs 1.6%) and sunburn (10.2% vs 0%).

The only Grade 3/4 AE (≥5% of patients) was arthralgia (5.9%).

AEs requiring dose adjustment or study-drug interruption (≥5% of patients) were arthralgia (8.6%), pyrexia (7.5%), nausea (7.5%), rash (7.5%), generalised rash (5.4%) and maculo-papular rash (5.4%).

<div style=\"page-break-after: always\"></div>

AEs requiring additional therapy (≥10% patients) were nausea (20.3%), diarrhoea (12.5%), constipation (11.5%) and anaemia (10.4%).

Of the 95 patients who received treatment for ≥6 months, 62 (65.3%) reported Grade 3/4 AEs.

The incidence of AEs with a first or worst occurrence ≥ 6 months was 86.3%; only diarrhoea was reported in ≥ 10% patients (11.8%). Grade 3/4 AEs (≥2% of patients) included general physical health deterioration (3.2%) and keratoacanthoma, central nervous system metastasis and anaemia (all 2.1%).

Based on the updated review, Gamma glutamyl transferase (GGT) increased was identified as meeting the criteria for inclusion as an ADR for both Enco 300 and Combo 450. In addition, Blood creatinine increased and Renal failure, which were already identified as ADRs for Enco 300, were identified as meeting the criteria for inclusion as ADRs for Combo 450.

Table 61: ADRs Reported with a ≥ 5% Difference in Incidence Between the Combo 450 RP Population and the Enco 300 P Population or Between the Combo 450 (or Enco 300) and Vemurafenib Arms of Study CMEK162B2301 (Broad Safety Set) (4-month update)

| PT                                    | Enco 300 P% Overall (Grade 3-4 %)     | Combo 450 RP% overall (Grade 3-4)   | Combo 450 arm% overall (Grade 3-4)   | Vemurafenib   |
|---------------------------------------|---------------------------------------|-------------------------------------|--------------------------------------|---------------|
| Skin                                  |                                       |                                     |                                      |               |
| Hyperkeratosis                        | 58. 5(6.0)                            | 20.8 (0.4)                          | 24.0 (0.5)                           | 50.0 (1.1)    |
| Alopecia                              | 57.1 (-)                              | 14.6 (-)                            | 14.6 (-)                             | 37.6 (-)-     |
| PPES                                  | 51.6 (12.4)                           | 6.2(0.0)                            | 7.3 (0.0)                            | 14.0 (1.1)    |
| Rash                                  | 43.3 (4.6)                            | 19.7 (0.7)                          | 22.9 (1.0)                           | 53.2 (13.4)   |
| Dry skin                              | 37.8 (-)                              | 14.6 (-)                            | 16.7 (-)                             | 26.3 (-)      |
| Pruritus                              | 29.5 (0.5)                            | 12.7 (0.4)                          | 13.5 (0.5)                           | 21.0 (1.1)    |
| Erythema                              | 16.6 (1.4)                            | 8.0 (0.0)                           | 7.8 (0.0)                            | 17.2 (0.5)    |
| Dermatitis acneiform                  | 7.8 (0.0)                             | 4.4 (0.0)                           | 3.1 (0.0)                            | 6.5 (0.0)     |
| Skin exfoliation                      | 6.5 (0.5)                             | 1.1(0.0)                            | 1.6 (0.0)                            | 3.2 (0.0)     |
| Skin hyperpigmentation                | 10.1 (-)                              | 1.8(-.)                             | 2.6 (-)                              | 2.7 (-)       |
| Panniculitis                          | 0.5 (0.0)                             | 1.5 (0.0)                           | 1.6 (0.0)                            | 3.2 (0.5)     |
| Gastrointestinal Disorders            | Gastrointestinal Disorders            |                                     |                                      |               |
| Nausea                                | 37.8 (3.7)                            | 41.6 (2.6)                          | 43.2 (1.6)                           | 34.9 (1.6)    |
| Vomiting                              | 27.6 (4.1)                            | 28.1 (2.2)                          | 30.2 (1.6)                           | 16.1 (1.1)    |
| Constipation                          | 16.1 (0.0)                            | 24.1 (0.0)                          | 22.4 (0.0)                           | 6.5 (0.5)     |
| Abdominal pain                        | 15.7 (2.8)                            | 27.4 (2.6)                          | 28.6 (3.6)                           | 16.1 (1.1)    |
| Diarrhoea                             | 12.4 (1.4)                            | 38.0 (3.3)                          | 37.0 (2.6)                           | 34.2 (2.2)    |
| Colitis                               | 0.0 (0.0)                             | 1.8 (0.7)                           | 2.6 (1.0)                            | 0.5 (0)       |
| Pancreatitis                          | 0.5 (0.5)                             | 0.7(0.7)                            | 1.0(1.0)                             | 1.1 (0.5)     |
| Musculoskeletal and Connective Tissue | Musculoskeletal and Connective Tissue | Disorders                           |                                      |               |
| Muscular disorder/ Myopathy-Myalgia   | 35.9 (9.2)                            | 25.9(0.4)                           | 26.6 (0.5)                           | 22.0 (0.5)    |
| Arthralgia                            | 43.3 (9.2)                            | 27 (0.7)                            | 25.5(0.5)                            | 45.7 (5.9)    |
| Pain in extremity                     | 21.2 (0.9)                            | 10.6 (1.5)                          | 11.5 (1.0)                           | 14.0 (1.1)    |
| Back pain                             | 15.3 (2.3)                            | 10.5 (0.7)                          | 9.9(0.5)                             | 6.5 (1.6)     |
| Arthritis                             | 5.1 (1.8)                             | 1.5 (1.1)                           | 2.1(1.6)                             | 2.2 (0.5)     |
| Rhabdomyolysis                        | 0                                     | 0.4 (0.0)                           | 0.5(0.0)                             | 0             |
| Nervous System Disorders              | Nervous System Disorders              |                                     |                                      |               |
| Headache                              | 29.0 (3.2)                            | 21.4 (1.5)                          | 22.9(1.6)                            | 19.9 (0.5)    |
| Dysgeusia                             | 13.8(0.0)                             | 6.6(0.0)                            | 5.7(0.0)                             | 10.8 (0.0)    |
| Neuropathy                            | 22.6 (1.8)                            | 13.1 (1.1)                          | 12.0(1.0)                            | 13.4 (1.6)    |

<div style=\"page-break-after: always\"></div>

| PT                                   | Enco 300 P% Overall (Grade 3-4 %)    | Combo 450 RP% overall (Grade 3-4)   | Combo 450 arm% overall (Grade 3-4)   | Vemurafenib   |
|--------------------------------------|--------------------------------------|-------------------------------------|--------------------------------------|---------------|
| Facial paresis                       | 7.4 (1.4)                            | 0.7 (0.4)                           | 1.0(0.5)                             | 0.5 (0.0)     |
| Dizziness                            | 6.0 (0.5)                            | 16.3 (2.6)                          | 15.1(2.6)                            | 4.3 (0.0)     |
| General Disorders                    |                                      |                                     |                                      |               |
| Fatigue                              | 43.8 (2.9)                           | 41.6 (2.9)                          | 43.2(3.1)                            | 46.2 (6.5)    |
| Pyrexia                              | 15.2 (0.9)                           | 17.2 (2.9)                          | 18.2(4.2)                            | 29.6 (0.0)    |
| Oedema peripheral                    | 10.1 (0.0)                           | 15.3 (1.1)                          | 13.5(1.1)                            | 14.5 (1.1)    |
| Investigations                       |                                      |                                     |                                      |               |
| Transaminases increased              | 6.5 (1.4)                            | 15.7 (5.5)                          | 13.5(6.3)                            | 10.2(1.6)     |
| GGT increased                        | 11.5 (5.1)                           | 14.6(8.4)                           | 15.1(9.4)                            | 11.3 (3.2)    |
| Blood ALP increased                  | 2.8 (0.0)                            | 7.3 (0.7)                           | 8.3(0.5)                             | 5.4 (1.1)     |
| Lipase increased                     | 2.3 (1.4%)                           | 5.1 (2.6)                           | 2.1 (1.6)                            | 1.6 (1.1)     |
| Blood CK increased                   | 0.9(0.0)                             | 27.0 (5.8)                          | 22.9 (6.8)                           | 2.2 (0.0)     |
| Amylase increased                    | 0.5 (0.0)                            | 3.3 (1.5)                           | 2.1(1.6)                             | 1.1 (1.1)     |
| Blood creatinine increased           | 2.3(0.0)                             | 6.2(0.7)                            | 6.8 (1.0)                            | 6.5 (1.1)     |
| Eye disorders                        |                                      |                                     |                                      |               |
| Visual impairment                    | 5.5 (0.0)                            | 21.5 (0.4)                          | 21.4(0.0)                            | 4.3(0.0)      |
| Retinal detachment                   | 1.8(0.0)                             | 29.6 (1.8)                          | 19.8(2.6)                            | 2.2(0.0)      |
| Uveitis                              | 0.5(0.0)                             | 4.4 (0.4)                           | 4.1(0.5)                             | 3.8 (0.0)     |
| Vascular Disorders                   |                                      |                                     |                                      |               |
| Haemorrhage                          | 11.5(1.8)                            | 17.9 (3.3)                          | 19.3(3.6)                            | 8.6(1.6)      |
| Hypertension                         | 5.1(2.8)                             | 11.7 (5.5)                          | 11.5(5.2)                            | 11.8(3.2)     |
| Venous Thromboembolism               | 2.8 (0.5)                            | 4.7 (0.7)                           | 5.7(1.6)                             | 2.2(1.1)      |
| Blood and Lymphatic System Disorders | Blood and Lymphatic System Disorders |                                     |                                      |               |
| Anaemia                              | 7.4 (2.3)                            | 19.7 (4.7)                          | 16.7(4.7)                            | 10.2(2.7)     |
| Immune system disorders              | Immune system disorders              |                                     |                                      |               |
| Drug hypersensitivity                | 4.1 (0.5)                            | 3.3 (0.0)                           | 3.6(0.0)                             | 4.8(1.6)      |
| Cardiac disorders                    |                                      |                                     |                                      |               |
| Left ventricular dysfunction         | 1.8 (0.9)                            | 8.4(1.1)                            | 7.8(1.6)                             | 0.5(0.0)      |
| Supraventricular tachycardia         | 4.1(0.9)                             | 1.8(0.0)                            | 2.1(0.0)                             | 4.3(0.5)      |
| Metabolic disorders                  |                                      |                                     |                                      |               |
| Decreased appetite                   | 22.1(0.5)                            | 7.7(0.0)                            | 8.3(0.0)                             | 19.4(0.0)     |
| Psychiatric disorders                | Psychiatric disorders                |                                     |                                      |               |
| Insomnia                             | 22.1(2.8)                            | 8.4(0.0)                            | 9.4(0)                               | 8.1(0.0)      |
| Skin neoplasm and malignancies       | Skin neoplasm and malignancies       |                                     |                                      |               |
| Melanocytic neavus                   | 10.6(-)                              | 1.5(0.0)                            | 1.6(0.0)                             | 3.8(0.0)      |
| Skin papilloma                       | 10.6(0.0)                            | 6.9(0.0)                            | 8.9(0.0)                             | 19.4(0.0)     |
| Squamous Cell Carcinoma              | 6.9(0.0)                             | 3.3(0.0)                            | 3.6(0.0)                             | 17.2(7.0)     |
| Basal cell carcinoma                 | 0.9(0.0)                             | 1.1(0.0)                            | 1.6(0.0)                             | 2.2(0.0)      |
| New primary melanoma                 | 4.1(1.0)                             | 0.4 (0.4)                           | 0.5(0.5)                             | 2.7(1.1)      |
| Renal and urinary disorders          | Renal and urinary disorders          |                                     |                                      |               |
| Renal failure                        | 2.8(1.4)                             | 3.3(2.2)                            | 4.2(3.1)                             | 4.8(1.6)      |

Source ISS-Part 1\\_u Tables: 2.6.1.a, 2.6.1.b, 2.6.2.1.a, 2.6.2.1.b

Very common ADRs with a ≥10% incidence difference and common ADR with a ≥5% incidence difference between Combo 450 RP and Enco 300 P are highlighted in green

Very common ADRs with a ≥10% incidence difference and common ADR with a ≥5% incidence difference between Combo 450arm and Vemurafenib are highlighted in blue

Encorafenib specific ADR not considered for the Combo 450

<div style=\"page-break-after: always\"></div>

## Table 62: Adverse reactions

|                                      |                              | Encorafenib single agent 300 mg (n=217)   | Encorafenib single agent 300 mg (n=217)   | Encorafenib 450 mg in combination with binimetinb (n=274)   | Encorafenib 450 mg in combination with binimetinb (n=274)   |
|--------------------------------------|------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| System Organ Class                   | Adverse reaction             | Frequency (All grades) n (%)              | Frequency (Grade 3-4) n (%)               | Frequency (All grades) n (%)                                | Frequency (Grade 3-4) n (%)                                 |
| Neoplasms benign, malignant and      | CuSCC                        | 16 (7.4)                                  | 0                                         | 9 (3.3)                                                     | 1 (0.4)                                                     |
| Neoplasms benign, malignant and      | Basal cell carcinoma         | 2 (0.9)                                   | 1 (0.5)                                   | 3 (1.1)                                                     | 0                                                           |
| Neoplasms benign, malignant and      | Skin papilloma               | 25 (11.5)                                 | 0                                         | 22 (8.0)                                                    | 0                                                           |
| unspecified                          | Melanocytic naevus           | 23 (10.6)                                 | 0                                         |                                                             |                                                             |
| Neoplasms benign, malignant and      | New Primary Melanoma         | 9 (4.1)                                   | 2 (0.9)                                   |                                                             |                                                             |
| Blood and lymphatic system disorders | Anaemia                      |                                           |                                           | 54 (19.7)                                                   | 13 (4.7)                                                    |
| Immune system disorders              | Hypersensitivity             | 8 (3.7)                                   | 1 (0.5)                                   | 9 (3.3)                                                     | 0                                                           |
| Metabolism and nutrition disorders   | Decreased appetite           | 48 (22.1)                                 | 1 (0.5)                                   |                                                             |                                                             |
| Psychiatric disorders                | Insomnia                     | 48 (22.1)                                 | 6 (2.8)                                   |                                                             |                                                             |
| Nervous system disorders             | Neuropathy peripheral        | 49 (22.6)                                 | 4 (1.8)                                   | 36 (13.1)                                                   | 3 (1.1)                                                     |
| Nervous system disorders             | Dizziness                    |                                           |                                           | 42 (15.3)                                                   | 7 (2.6)                                                     |
| Nervous system disorders             | Headache                     | 64 (29.5)                                 | 7 (3.2)                                   | 59 (21.5)                                                   | 4 (1.5)                                                     |
| Nervous system disorders             | Dysgeusia                    | 30 (13.8)                                 | 0                                         | 18 (6.6)                                                    | 0                                                           |
| Nervous system disorders             | Facial paresis               | 16 (7.4)                                  | 3 (1.4)                                   | 2 (0.7)                                                     | 1 (0.4)                                                     |
| Eye disorders                        | Visual impairment            |                                           |                                           | 59 (21.5)                                                   | 1 (0.4)                                                     |
| Eye disorders                        | RPED                         |                                           |                                           | 81 (29.6)                                                   | 5 (1.8)                                                     |
| Eye disorders                        | Uveitis                      | 1 (0.5)                                   | 0                                         | 12 (4.4)                                                    | 1 (0.4)                                                     |
| Cardiac disorders                    | Left ventricular dysfunction |                                           |                                           | 23 (8.4)                                                    | 3 (1.1)                                                     |
| Cardiac disorders                    | Supraventricular tachycardia | 9 (4.1)                                   | 2 (0.9)                                   |                                                             |                                                             |
| Vascular disorders                   | Haemorrhage                  |                                           |                                           | 49 (17.9)                                                   | 9 (3.3)                                                     |
| Vascular disorders                   | Hypertension                 |                                           |                                           | 32 (11.7)                                                   | 15 (5.5)                                                    |
| Vascular disorders                   | VTE                          |                                           |                                           | 13 (4.7)                                                    | 3 (1.1)                                                     |

<div style=\"page-break-after: always\"></div>

| Gastrointestinal disorders                           | Abdominal pain                         |            |           | 75 (27.4)   | 7 (2.6)   |
|------------------------------------------------------|----------------------------------------|------------|-----------|-------------|-----------|
| Gastrointestinal disorders                           | Diarrhoea                              |            |           | 104 (38.0)  | 9 (3.3)   |
| Gastrointestinal disorders                           | Vomiting                               | 60 (27.6)  | 9 (4.1)   | 77 (28.1)   | 6 (2.2)   |
| Gastrointestinal disorders                           | Nausea                                 | 82 (37.8)  | 8 (3.7)   | 114 (41.6)  | 7 (2.6)   |
| Gastrointestinal disorders                           | Constipation                           | 37 (17.1)  | 0         | 66 (24.1)   | 0         |
| Gastrointestinal disorders                           | Colitis                                |            |           | 6 (2.2)     | 2 (0.7)   |
| Gastrointestinal disorders                           | Pancreatitis                           | 1 (0.5)    | 1 (0.5)   | 2 (0.7)     | 2 (0.7)   |
|                                                      | Hyperkeratosis                         | 127 (58.5) | 13 (6.0)  | 57 (20.8)   | 1 (0.4)   |
|                                                      | Rash                                   | 94 (43.3)  | 10 (4.6)  | 54 (19.7)   | 2 (0.7)   |
|                                                      | Dry skin                               | 82 (37.8)  | 0         | 40 (14.6)   | 0         |
|                                                      | Pruritus                               | 64 (29.5)  | 1 (0.5)   | 32 (11.7)   | 1 (0.4)   |
|                                                      | Alopecia                               | 124 (57.1) | 0         | 40 (14.6)   | 0         |
| Skin and                                             | Photosensitivity                       | 9 (4.1)    | 0         | 11 (4.0)    | 1 (0.4)   |
| subcutaneous tissue disorders                        | Dermatitis acneiform                   | 17 (7.8)   | 0         | 12 (4.4)    | 0         |
|                                                      | PPES                                   | 112 (51.6) | 27 (12.4) | 17 (6.2)    | 0         |
|                                                      | Erythema                               | 37 (17.1)  | 3 (1.4)   | 22 (8.0)    | 0         |
|                                                      | Panniculitis                           |            |           | 4 (1.5)     | 0         |
|                                                      | Skin hyperpigmentation                 | 22 (10.1)  | 0         |             |           |
|                                                      | Skin exfoliation                       | 14 (6.5)   | 1 (0.5)   |             |           |
| Musculoskeletal and connective tissue disorders      | Arthralgia                             | 94 (43.3)  | 20 (9.2)  | 74 (27.0)   | 2 (0.7)   |
| Musculoskeletal and connective tissue disorders      | Muscular disorders/Myalgia             | 78 (35.9)  | 20 (9.2)  | 71 (25.9)   | 2 (0.7)   |
| Musculoskeletal and connective tissue disorders      | Back pain                              | 33 (15.2)  | 5 (2.3)   | 30 (10.9)   | 2 (0.7)   |
| Musculoskeletal and connective tissue disorders      | Pain in extremity                      | 46 (21.2)  | 2 (0.9)   | 29 (10.6)   | 4 (1.5)   |
| Musculoskeletal and connective tissue disorders      | Arthritis                              | 11 (5.1)   | 3 (1.4)   |             |           |
| Musculoskeletal and connective tissue disorders      | Rhabdomyolysis                         |            |           | 1 (0.4)     | 1 (0.4)   |
| Renal and urinary disorders                          | Renal failure                          | 6 (2.8)    | 3 (1.4)   | 9 (3.3)     | 6 (2.2)   |
| General disorders and administration site conditions | Pyrexia                                | 33 (15.2)  | 2 (0.9)   | 47 (17.2)   | 8 (2.9)   |
| General disorders and administration site conditions | Peripheral oedema                      |            |           | 42 (15.3)   | 3 (1.1)   |
|                                                      | Fatigue                                | 95 (43.8)  | 10 (4.6)  | 120 (43.8)  | 8 (2.9)   |
| Investigations                                       | Blood creatine phosphokinase increased |            |           | 74 (27.0)   | 16 (5.8)  |
|                                                      | Transaminase increased                 | 14 (6.5)   | 3 (1.4)   | 43 (15.7)   | 15 (5.5)  |
|                                                      | Gamma-glutamyl transferase increased   | 25 (11.5)  | 11 (5.1)  | 40 (14.6)   | 23 (8.4)  |
|                                                      | Blood creatinine increased             | 5 (2.3)    | 0         | 17 (6.2)    | 2 (0.7)   |
|                                                      | Blood alkaline phosphatase increased   |            |           | 20 (7.3)    | 2 (0.7)   |
|                                                      | Amylase increased                      | 1 (0.5)    | 0         | 9 (3.3)     | 4 (1.5)   |
|                                                      | Lipase increased                       | 5 (2.3)    | 3 (1.4)   | 14 (5.1)    | 7 (2.6)   |

Adverse events of special interest (AESI) were identified based on the known class effects of BRAF (encorafenib) and MEK (binimetinib) inhibitors.

<div style=\"page-break-after: always\"></div>

Class effects of BRAF inhibitors include cutaneous malignancies (mostly squamous cell carcinoma and new primary melanoma), cutaneous papilloma, arthralgia, skin toxicities including rash, hyperkeratosis, palmarplantar erythrodysaesthesia (PPE) syndrome and QTc prolongation.

Class effects of MEK inhibitors include ocular toxicities, elevations of CK, left ventricular dysfunction, skin toxicities including rash and acneiform dermatitis, hypertension, venous thromboembolic events (VTEs), diarrhoea, interstitial lung disease, oedema and haemorrhage.

The AESI groupings for each component of Combo 450 RP were reported and analysed as follows in the initial MAA:

| Common to Both                                                                                                                                                                                                                                         | Specific to encorafenib                                                                        | Specific to binimetinib                                                                                                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Ocular: retinopathy excluding RVO, RVO, uveitis-type events Hepatic: LFT abnormalities, hepatic failure Myopathy/rhabdomyolysis-related Dermatologic: rash, skin infections, photosensitivity, nail disorders, PPE, severe cutaneous adverse reactions | Tachycardia Acute renal failure Facial paresis Cutaneous malignancies: SCC, non-SCC, melanomas | Cardiac: bradycardia, left ventricular dysfunction Hypertension Peripheral oedema Haemorrhage Venous thromboembolism Pneumonitis |

## Cutaneous malignancies

## Cutaneous squamous cell carcinoma

In the pooled Combo 450 population, cuSCC including keratoacanthomas was observed in 3.3% (9/274) of patients. The median time to onset of the first event of cuSCC (all grades) was 6.5 months (range 1.0 to 22.8 months).

In the pooled encorafenib 300 population, cuSCC was reported in 7.4% (16/217) patients. For patients in the Phase III study (CMEK162B2301) who developed cuSCC, the median time to onset of the first event of cuSCC (all grades) was 2.3 months (range 0.3 to 12.0 months).

## New primary melanoma

In the pooled encorafenib 300 population, new primary melanoma events occurred in 4.1% of patients (9 /217) and was reported as Grade 1 in 1.4% (3/217) of patients, Grade 2 in 2.1% (4/217) of patients, Grade 3 in 0.5% (1/217) of patients and Grade 4 in 0.5% (1/217) of patients.

## Ocular events

In the pooled Combo 450 population, uveitis was reported in 4.4% (12/274) of patients, and was Grade 1 in 0.4% (1/274), Grade 2 in 3.6% (10/274) and Grade 3 in 0.4% (1/274). Visual impairment, including blurred vision and reduced visual acuity, occurred in 21.5% (59/274) of patients. Uveitis and visual impairment were generally reversible.

RPED occurred in 29.6% (81/274) of patients, most of them had Grade 1-2 and 1.8% (5/274) had Grade 3 events.

<div style=\"page-break-after: always\"></div>

In Study CMEK162B2301-Part 2, in the Combo 300 arm, RPED was observed in 12.5% (32/257) of patients with 0.4% (1/257) Grade 4 event.

## Left ventricular dysfunction

LVD was reported when encorafenib is used in combination with binimetinib (see section 4.8 of binimetinib SmPC).

## Haemorrhage

Haemorrhagic events were observed in 17.9% (49/274) of patients in the pooled Combo 450 population. Most events were Grade 1 or 2 (14.6%) and 3.3% were Grade 3-4 events. Few patients required dose interruptions or dose reductions (0.7% or 2/274). Haemorrhagic events led to discontinuation of treatment in 1.1% (3/274) of patients. The most frequent haemorrhagic events were haematuria in 3.3% (9/274) of patients, rectal haemorrhage in 2.9% (8/274) and haematochezia in 2.9% (8/274) of patients. Fatal gastric ulcer haemorrhage, with multiple organ failure as a concurrent cause of death, occurred in one patient. Cerebral haemorrhage was reported in 1.5% (4/274) of patients, with fatal outcome in 3 patients. All events occurred in the setting of new or progressive brain metastases.

In Study CMEK162B2301-Part 2, in the Combo 300 arm, haemorrhagic events were observed in 6.6% (17/257) of patients and were Grade 3-4 in 1.6% (4/257) of patients.

## Hypertension

Hypertension was reported when encorafenib was used in combination with binimetinib (see section 4.8 of binimetinib SmPC).

## Venous thromboembolism

VTE was reported when encorafenib is used in combination with binimetinib (see section 4.8 of binimetinib SmPC).

## Pancreatitis

Pancreatic enzyme elevation, mostly asymptomatic, was reported in the pooled Combo 450 population. Amylase and lipase elevations were reported in 3.3% (9/274) and 5.1% (14/274) of patients, respectively. Pancreatitis was reported in 0.7% (2/274) of patients. Both patients experienced Grade 3 events. Pancreatitis led to dose interruption or adjustment in (0.4 %) 1/274 of patients.

## Dermatologic reactions

## Rash

In the pooled Combo 450 population, rash occurred in 19.7% (54/274) of patients. Most events were mild, with Grade 3 or 4 events reported in 0.7% (2/274) of patients. Rash led to discontinuation in 0.4% (1/274) patients and to dose interruption or dose modification in 1.1% (3/274) of patients.

In the pooled encorafenib 300 population, rash was reported in 43.3% (94/217) of patients. Most events were mild, with Grade 3 or 4 events reported in 4.6% (10/217) of patients. Rash led to discontinuation in 0.5% (1/217) of patients and to dose interruption or dose modification in 7.4% (16/217) of patients.

<div style=\"page-break-after: always\"></div>

## Palmar-plantar erythrodysaesthesia syndrome (PPES)

PPES was reported in 6.2% (17/274) of patients in the pooled Combo 450 population. All the PPES adverse reactions were either Grade 1 (3.3%) or Grade 2 (2.9%). Dose interruption or dose modification occurred in 1.1% (3/274) of patients.

In the Combo 300 arm in Part 2 of the pivotal study, PPES was observed in 3.9% (10/257) of patients with Grade 3 reported in 0.4% (1/257) of patients.

In the pooled encorafenib 300 population, PPES was reported in 51.6% (112/217) of patients. Most events were mild-moderate: Grade 1 in 12.4% (27/217) of patients, Grade 2 in 26.7% (58/217) and Grade 3 in 12.4% (27/217) of patients. PPES led to discontinuation in 4.1% (9/217) of patients and to dose interruption or dose modification in 23.0% (50/217) of patients.

## Dermatitis acneiform

Dermatitis acneiform was reported when encorafenib is used in combination with binimetinib (see section 4.8 of binimetinib SmPC).

## Photosensitivity

In the pooled Combo 450 population, photosensitivity was observed in 4.0% (11/274) of patients. Most events were Grade 1-2, with Grade 3 reported in 0.4% (1/274) of patients and no event led to discontinuation. Dose interruption or dose modification was reported in 0.4% (1/274) of patients.

In the pooled encorafenib 300 population, photosensitivity was reported in 4.1% (9/217) of patients. All events were Grade 1-2. No event required discontinuation, dose modification or interruption.

## Facial paresis

In the pooled Combo 450 population, facial paresis occurred in 0.7% (2/274) of patients including Grade 3 in 0.4% (1/274) of patients. The events were reversible, and no event led to treatment discontinuation. Dose interruption or modification was reported in 0.4% (1/274) of patients.

In the pooled encorafenib 300 population, facial paresis was observed in 7.4% (16/217) of patients. Most events were mild-moderate: Grade 1 in 2.3% (5/217); Grade 2 in 3.7% (8/217) and Grade 3 in 1.4% (3/217) of patients. The median time to onset of the first event of facial paresis was 0.3 months (range 0.1 to 12.1 months). Facial paresis was generally reversible and led to treatment discontinuation in 0.9% (2/217). Dose interruption or modification was reported in 3.7% (8/217) and symptomatic treatment including corticosteroids was reported in 5.1% (11/217) of patients.

## CK elevation and rhabdomyolysis

CK elevation and rhabdomyolysis occurred when encorafenib is used in combination with binimetinib (see section 4.8 of binimetinib SmPC).

## Renal dysfunction

In the pooled Combo 450 population, mild, mostly Grade 1, asymptomatic blood creatinine elevation was noted in 6.2% (17/274) of patients treated with the Combo 450 mg. The incidence of Grade 3 or 4 elevation was 0.7% (2/274). Renal failure events, including acute kidney injury and renal impairment, were reported in 3.3% (9/274) patients treated with encorafenib and binimetinib with Grade 3 or 4 events in 2.2% (6/274) of

<div style=\"page-break-after: always\"></div>

patients. Renal failure was generally reversible with dose interruption, rehydration and other general supportive measures.

## Liver laboratory abnormality

The incidences of liver laboratory abnormalities reported in the pooled Combo 450 population are listed below:

- Increased transaminases: 15.7% (43/274) overall - Grade 3-4: 5.5% (15/274)
- Increased GGT: 14.6% (40/274) overall - Grade 3-4: 8.4% (23/274)

In Study CMEK162B2301-Part 2, in the Combo 300 arm, the incidence of liver laboratory abnormalities was:

- Increased transaminases: 13.2% (34/257) overall - Grade 3-4: 5.4% (14/257)
- Increased GGT: 14.0% (36/257) overall - Grade 3-4: 4.7% (12/257)

## Gastrointestinal disorders

In the pooled Combo 450 population, diarrhoea was observed in 38% (104/274) of patients and was Grade 3-4 in 3.3% (9/274) patients. Diarrhoea led to dose discontinuation in 0.4% of patients and to dose interruption or dose modification in 4.4% of patients.

Constipation occurred in 24.1% (66/274) of patients and was Grade 1 or 2. Abdominal pain was reported in 27.4% (75/274) of patients and was Grade 3 in 2.6% (7/274) patients. Nausea occurred in 41.6% (114/274) with Grade 3 or 4 observed in 2.6% (7/274) of patients. Vomiting occurred in 28.1% (77/274) of patients with Grade 3 or 4 reported in 2.2% (6/274) of patients.

In Study CMEK162B2301-Part 2, in the Combo 300 arm, nausea was observed in 27.2% (70/257) of patients and was Grade 3 in 1.6% (4/257) of patients. Vomiting occurred in 15.2% (39/257) of patients with Grade 3 reported in 0.4% (1/257) of patients. Diarrhoea occurred in 28.4% (73/257) of patients with Grade 3 reported in 1.6% (4/257) of patients.

Gastrointestinal disorders were typically managed with standard therapy.

## Anaemia

In the pooled Combo 450 population, anaemia was reported in 19.7% (54/274) of patients; 4.7% (13/274) patients had a Grade 3 or 4. No patients discontinued treatment due to anaemia, 1.5% (4/274) required dose interruption or dose modification.

In Study CMEK162B2301-Part 2, in the Combo 300 arm, anaemia was observed in 9.7% (25/257) of patients with Grade 3-4 reported in 2.7% (7/257) patients.

## Headache

In the pooled Combo 450 population, headache occurred in 21.5% (59/274) of patients, including Grade 3 in 1.5% (4/274) of patients.

In Study CMEK162B2301-Part 2, in the Combo 300 arm, headache was reported in 12.1% (31/257) of patients and was Grade 3 in 0.4% (1/257) of patients.

<div style=\"page-break-after: always\"></div>

## Fatigue

In the pooled Combo 450 population, fatigue occurred in 43.8% (120/274) of patients including Grade 3 in 2.9% (8/274) of patients.

In Study CMEK162B2301-Part 2, in the Combo 300 arm, fatigue was observed in 33.5% (86/257) of patients with 1.6% (4/257) Grade 3-4 events.

## Cardiac Electrophysiology

In the safety analysis of pooled studies, the incidence of new QTc prolongation &gt;500 ms was 0.7% (2/268) in the encorafenib 450 mg plus binimetinib group, and 2.5% (5/203) in the encorafenib single agent group. QTc prolongation of &gt;60 ms compared to pre-treatment values was observed in 4.9% (13/268) patients in the encorafenib plus binimetinib group, and in 3.4% (7/204) in the encorafenib single agent group (see Sections 4.2 and 4.4).

## Serious adverse event/deaths/other significant events

## Deaths

The  incidence  of  on-treatment  deaths  was  similar  in  the  Combo  450  RP  and  the  Enco  300  P  populations (8.4% vs 6.9%, with an EAIR of 0.74 deaths per 100 patient-months in both populations).

Most deaths were due to progression of malignant melanoma (5.8% Combo 450 vs 5.5% Enco 300 P).

In the Combo 450 RP population, on-treatment deaths due to events other than disease progression included AEs by PT of multiple organ dysfunction syndrome, cerebral haemorrhage (in the context of brain metastasis), completed suicide, euthanasia, myocardial infarction, reported in 1 patient each, and AEs of death, reported in 2 patients; 0.7% of deaths were attributed to related AEs.

Adverse events resulting in death for patients in the Enco 300 P population were reported under the PTs of myocardial infarction, unknown cause, general physical health deterioration and pneumonia (1 patient each); 0.5% of deaths were attributed to related AEs.

At the four month safety update, the overall incidence of on-treatment deaths (with or without adjustment for study drug exposure) was higher in the Combo 450 RP than in Enco 300 P populations (10.2% vs 7.4%), with similar EAIRs (as per the initial MAA) of 0.73 vs 0.71 deaths per 100 patient-months respectively. Most deaths remained due to progression of malignant melanoma (7.7% Combo 450 vs 6.0% Enco 300 P).

<div style=\"page-break-after: always\"></div>

Table 63: On-treatment Deaths by Preferred Term and Treatment (Broad Safety Set) - Updated MAA (9 November 2016)

|                                                     | Melanoma                  | Melanoma                  | Melanoma                       | Melanoma                   | Study CMEK162B2301         | Study CMEK162B2301        | Study CMEK162B2301      |
|-----------------------------------------------------|---------------------------|---------------------------|--------------------------------|----------------------------|----------------------------|---------------------------|-------------------------|
| Primary system organ class Principal cause of death | Bini 45mg BID N=427 n (%) | Enco 300mg QD N=217 n (%) | Combo pooled doses N=433 n (%) | Combo 450mg QD N=274 n (%) | Combo 450mg QD N=192 n (%) | Enco 300mg QD N=192 n (%) | Vemurafenib N=186 n (%) |
| Any primary system organ class                      | 46 (10.8)                 | 16 (7.4)                  | 50 (11.5)                      | 28 (10.2)                  | 19 (9.9)                   | 15 (7.8)                  | 19 (10.2)               |
| Acute myocardial infarction                         | 0                         | 1 (0.5)                   | 0                              | 0                          | 0                          | 1 (0.5)                   | 0                       |
| Myocardialinfarction                                | 0                         | 0                         | 1 (0.2)                        | 0                          | 0                          | 0                         | 0                       |
| Death                                               | 0                         | 1 (0.5)                   | 3 (0.7)                        | 2 (0.7)                    | 2 (1.0)                    | 1 (0.5)                   | 0                       |
| Euthanasia                                          | 1 (0.2)                   | 0                         | 1 (0.2)                        | 1 (0.4)                    | 1 (0.5)                    | 0                         | 0                       |
| Multiple organ dysfunction syndrome                 | 0                         | 0                         | 1 (0.2)                        | 1 (0.4)                    | 1 (0.5)                    | 0                         | 0                       |
| Disease progression                                 | 0                         | 0                         | 1 (0.2)                        | 0                          | 0                          | 0                         | 0                       |
| Multi-organ failure                                 | 1 (0.2)                   | 0                         | 0                              | 0                          | 0                          | 0                         | 0                       |
| Intestinal sepsis                                   | 0                         | 0                         | 0                              | 0                          | 0                          | 0                         | 1 (0.5)                 |
| Pneumonia                                           | 0                         | 1 (0.5)                   | 0                              | 0                          | 0                          | 0                         | 0                       |
| Sepsis                                              | 2 (0.5)                   | 0                         | 0                              | 0                          | 0                          | 0                         | 0                       |
| Malignant melanoma                                  | 40 (9.4)                  | 13 (6.0)                  | 34 (7.9)                       | 21 (7.7)                   | 12 (6.3)                   | 13 (6.8)                  | 18 (9.7)                |
| Metastases to central nervous system                | 0                         | 0                         | 1 (0.2)                        | 1 (0.4)                    | 1 (0.5)                    | 0                         | 0                       |
| Malignant melanoma stage iv                         | 0                         | 0                         | 1 (0.2)                        | 0                          | 0                          | 0                         | 0                       |
| Metastatic malignant melanoma                       | 0                         | 0                         | 4 (0.9)                        | 0                          | 0                          | 0                         | 0                       |
| Neoplasm progression                                | 0                         | 0                         | 1 (0.2)                        | 0                          | 0                          | 0                         | 0                       |
| Cerebralhaemorrhage                                 | 0                         | 0                         | 1 (0.2)                        | 1 (0.4)                    | 1 (0.5)                    | 0                         | 0                       |
| Completed suicide                                   | 0                         | 0                         | 1 (0.2)                        | 1 (0.4)                    | 1 (0.5)                    | 0                         | 0                       |
| Dyspnoea                                            | 1 (0.2)                   | 0                         | 0                              | 0                          | 0                          | 0                         | 0                       |
| Embolism                                            | 1 (0.2)                   | 0                         | 0                              | 0                          | 0                          | 0                         | 0                       |

## Serious Adverse Events

<div style=\"page-break-after: always\"></div>

Table 64: Serious Adverse Events, Regardless of Study Drug Relationship, by Preferred Term and Treatment - Overall and Maximum Grade 3 or 4 ( ≥ 2% in any population) -initial MAA

|                         | Melanoma                  | Melanoma                  | Melanoma                       | Melanoma                   | Study CMEK162B2301         | Study CMEK162B2301        | Study CMEK162B2301     |
|-------------------------|---------------------------|---------------------------|--------------------------------|----------------------------|----------------------------|---------------------------|------------------------|
| Prefered Term Grades    | Bimi 45mg BID N=427 n (%) | Enco 300mg QD N=217 n (%) | Combo pooled doses N=433 n (%) | Combo 450mg QD N=274 n (%) | Combo 450mg QD N=192 n (%) | Enco 300mg QD N=192 n (%) | Vemwafenib N=186 n (%) |
| Any preferred tenm      |                           |                           |                                |                            |                            |                           |                        |
| All grades              | 141 (33.0)                | 69 (31.8)                 | 158 (36.5)                     | 98 (35.8)                  | 66 (34.4)                  | 65 (33.9)                 | 69 (37.1)              |
| Grades 3/4              | 116 (27.2)                | 58 (26.7)                 | 142 (32.8)                     | 87 (31.8)                  | 57 (29.7)                  | 54 (28.1)                 | 60 (32.3)              |
| Nausea                  |                           |                           |                                |                            |                            |                           |                        |
| All grades              | 3 (0.7)                   | 6 (2.8)                   | 15 (3.5)                       | 6 (2.2)                    | 2 (1.0)                    | 6 (3.1)                   | 0                      |
| Grades 3/4              | 2 (0.5)                   | 4 (1.8)                   | 11 (2.5)                       | 5 (1.8)                    | 1 (0.5)                    | 4 (2.1)                   | 0                      |
| Pyrexia                 |                           |                           |                                |                            |                            |                           |                        |
| All grades              | 0                         | 3 (1.4)                   | 15 (3.5)                       | 6 (2.2)                    | 6 (3.1)                    | 3 (1.6)                   | 2 (1.1)                |
| Grades 3/4              | 0                         | 2 (0.9)                   | 9 (2.1)                        | 5 (1.8)                    | 5 (2.6)                    | 2 (1.0)                   | 0                      |
| Pneumonia               |                           |                           |                                |                            |                            |                           |                        |
| All grades              | 2 (0.5)                   | 1 (0.5)                   | 7 (1.6)                        | 6 (2.2)                    | 3 (1.6)                    | 0                         | 0                      |
| Grades 3/4              | 2 (0.5)                   | 1 (0.5)                   | 4 (0.9)                        | 4 (1.5)                    | 3 (1.6)                    | 0                         | 0                      |
| Vomiting                |                           |                           |                                |                            |                            |                           |                        |
| All grades              | 5 (1.2)                   | 6 (2.8)                   | 17 (3.9)                       | 5 (1.8)                    | 3 (1.6)                    | 6 (3.1)                   | 2 (1.1)                |
| Grades 3/4              | 4 (0.9)                   | 6 (2.8)                   | 11 (2.5)                       | 4 (1.5)                    | 2 (1.0)                    | 6 (3.1)                   | 1 (0.5)                |
| Anaemia                 |                           |                           |                                |                            |                            |                           |                        |
| All grades              | 3 (0.7)                   | 1 (0.5)                   | 8 (1.8)                        | 5 (1.8)                    | 4 (2.1)                    | 1 (0.5)                   | 2 (1.1)                |
| Grades 3/4              | 3 (0.7)                   | 1 (0.5)                   | 8 (1.8)                        | 5 (1.8)                    | 4 (2.1)                    | 1 (0.5)                   | 1 (0.5)                |
| Abdominal pain          |                           |                           |                                |                            |                            |                           |                        |
| All grades              | 2 (0.5)                   | 2 (0.9)                   | 8 (1.8)                        | 4 (1.5)                    | 4 (2.1)                    | 2 (1.0)                   | 1 (0.5)                |
| Grades 3/4              | 1 (0.2)                   | 2 (0.9)                   | 6 (1.4)                        | 3 (1.1)                    | 3 (1.6)                    | 2 (1.0)                   | 1 (0.5)                |
| General physical health |                           |                           |                                |                            |                            |                           |                        |
| deterioration           |                           |                           |                                |                            |                            |                           |                        |
| All grades              | 16 (3.7)                  | 2 (0.9)                   | 8 (1.8)                        | 4 (1.5)                    | 3 (1.6)                    | 2 (1.0)                   | 6 (3.2)                |
| Grades 3/4              | 15 (3.5)                  | 2 (0.9)                   | 7 (1.6)                        | 3 (1.1)                    | 2 (1.0)                    | 2 (1.0)                   | 6 (3.2)                |
| Pain                    |                           |                           |                                |                            |                            |                           |                        |
| All grades              | 0                         | 4 (1.8)                   | 2 (0.5)                        | 2 (0.7)                    | 1 (0.5)                    | 4 (2.1)                   | 0                      |
| Grades 3/4              | 0                         | 4 (1.8)                   | 2 (0.5)                        | 2 (0.7)                    | 1 (0.5)                    | 4 (2.1)                   | 0                      |
| Back pain               |                           |                           |                                |                            |                            |                           |                        |
| All grades              | 1 (0.2)                   | 4 (1.8)                   | 0                              | 0                          | 0                          | 4 (2.1)                   | 2 (1.1)                |
| Grades 3/4              | 1 (0.2)                   | 3 (1.4)                   | 0                              | 0                          | 0                          | 3 (1.6)                   | 2 (1.1)                |

Source: ISS Table 2.3.2

The incidence of SAEs was similar in the different treatment groups: 35.8%, 31.8% and 37.1% of patients in Combo 450 RP, Enco 300 P group and the vemurafenib arm of the Phase 3 study, respectively. The median time to first SAE for the Enco 300 P population was shorter than the Combo 450 RP population (1.8 months [95% CI: 0.4, 2.9] vs 3.8 months [95% CI: 3.2, 4.9]).

In the Combo 450 arm of Study CMEK162B2301 Part 1 SAEs were reported most frequently (&gt; 5.0% of patients) under the SOCs of gastrointestinal disorders (9.4%), infections and infestations (8.9%), general disorders and administration site conditions (8.3%) and nervous system disorders (7.3%).

For the Combo 450 RP population, SAEs reported more frequently by PT were pyrexia, pneumonia and nausea (2.2% each), for the Enco P population they were nausea and vomiting (2.8% each) and in the vemurafenib arm of Study B2301 SAEs were reported most frequently under the PT of general physical health deterioration (3.2%).

SAEs by duration of exposure reflected the unadjusted rate of SAEs, being marginally higher for Combo 450 RP than Enco 300 P (3.91 vs. 3.50 per 100 patient-months, respectively). The most common PTs were similar for EAIR adjusted and non-adjusted rates; for Combo 450 RP the most common exposure adjusted SAEs

<div style=\"page-break-after: always\"></div>

were nausea, pneumonia and pyrexia (0.16 per 100 patient-months each), anaemia and vomiting (0.13 per 100 patient-months each) and diarrhoea (0.11 per 100 patient-months). This was followed by abdominal pain, acute kidney injury, cerebral haemorrhage and general physical health deterioration (all 0.10 per 100 patient-months).

For the Enco 300 P population, the most common SAE PTs by EAIR were nausea and vomiting (0.27 per 100 patient-months each), back pain, CNS metastases and pain (0.18 per 100 patient-months each), facial paralysis, hyperglycaemia, myalgia and pyrexia (0.14 per 100 patient-months each) and dehydration and musculoskeletal pain (0.13 per 100 patient-months each).

In the 4-month safety update in the Combo 450 RP, the overall incidence of SAEs regardless of study drug relationship increased from 35.8% (grade 3-4, 31.8%) at the time of the initial MAA to 40.1% (grade 3-4, 34.3%). No SAEs were reported under new SOCs in ≥10% of patients or new PTs in ≥2% of patients in the impacted populations as compared to the initial MAA.

## Comparison of the Safety Profile of Combo 300 and Combo 450

The safety profile comparison is based on the 192 patients randomised to the Combo 450 arm as of the 19 May 2016 cut-off date (Part 1) and the 258 patients randomised to the Combo 300 arm (one of whom was not treated) as of the 09 November 2016 cut-off date (Part 2).

The median durations of potential follow-up for PFS of 16.7 months for Combo 450 part 1 and 13.9 months for Combo 300 part 2 were broadly comparable. The median duration of exposure in the Combo 450 arm and Combo 300 arms were similar with 52.6% and 54.9% of patients having received ≥ 48 weeks of study treatment, respectively.

In the Combo300, the median relative dose intensity (RDI) of encorafenib and binimetinib was 100% and 99.76% respectively, similar to the median RDI of encorafenib and binimetinib in the Combo450.

The overall safety profiles for the Combo 450 and Combo 300 arms are similar in terms of incidence (difference &lt;5%) of deaths, AEs, treatment discontinuation due to AEs and AEs leading to dose modifications/ interruptions or additional therapy. The overall incidence of Grade 3-4 AEs, as well as the overall incidences of SAEs, was lower in the Combo 300 as compared to Combo 450.

Table 65: Overall Safety summary [Restricted Safety Set]

| Category                       |            | Study - CMEK162B2301                                         | Study - CMEK162B2301                                         |
|--------------------------------|------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Median duration of exposure:   | Grade      | Combo 450mg QD Cutoff Date 19MAY2016 N=192 n (%) 51.21 weeks | Combo 300mg QD Cutoff Date 09NOV2016 N=257 n (%) 52.14 weeks |
| On-treatment deaths a          | All Grades | 17 (8.9)                                                     | 25 (9.7)                                                     |
|                                | Grade 3/4  | --                                                           | --                                                           |
| AEs                            | All Grades | 189 (98.4)                                                   | 252 (98.1)                                                   |
|                                | Grade 3/4  | 111 (57.8)                                                   | 120 (46.7)                                                   |
| Serious AEs                    | All Grades | 66 (34.4)                                                    | 75 (29.2)                                                    |
|                                | Grade 3/4  | 57 (29.7)                                                    | 65 (25.3)                                                    |
| AEs leading to discontinuation | All Grades | 24 (12.5)                                                    | 32 (12.5)                                                    |
|                                | Grade 3/4  | 22 (11.5)                                                    | 23 (8.9)                                                     |

<div style=\"page-break-after: always\"></div>

| Category                                          |            | Study - CMEK162B2301                                         | Study - CMEK162B2301                                         |
|---------------------------------------------------|------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Median duration of exposure:                      | Grade      | Combo 450mg QD Cutoff Date 19MAY2016 N=192 n (%) 51.21 weeks | Combo 300mg QD Cutoff Date 09NOV2016 N=257 n (%) 52.14 weeks |
| AEs requiring dose interruption and/or adjustment | All Grades | 92 (47.9)                                                    | 115 (44.7)                                                   |
|                                                   | Grade 3/4  | 63 (32.8)                                                    | 59 (23.0)                                                    |
| AEs requiring additional therapy b                | All Grades | 165 (85.9)                                                   | 211 (82.1)                                                   |
|                                                   | Grade 3/4  | 67 (34.9)                                                    | 77 (30.0)                                                    |

## Source Safety Appendix: Q96E T.1.1

Melanoma: Naive to BRAF inhibitors and MEK inhibitors. Combo = Binimetinib + Encorafenib (doses 300 mg QD or 450 mg QD).

Combo 450 mg under Melanoma column = Restricted safety pool. All Binimetinib doses were 45 mg BID.

Abbreviations: AE=adverse event; EOT=end of treatment; PT=preferred term.

Categories are not mutually exclusive. Patients with multiple events in the same category were counted only once in that category.

Patients with events in more than 1 category were counted once in each of those categories.

a Deaths occurring &gt;30 days after EOT were not included.

b Additional therapy includes all non-drug therapy and concomitant medications.

* A patient may have had both a dose interruption and a dose adjustment for a single AE PT.

# A patient with only a dose adjustment with no dose interruption for a single AE PT.

MedDRA Version 19.0 has been used for the reporting of adverse events.

The safety of encorafenib (300 mg orally once daily) in combination with binimetinib (45 mg orally twice daily) was evaluated in 257 patients with BRAF V600 mutant unresectable or metastatic melanoma (hereafter referred to as the Combo 300 population), based on the Phase III study (CMEK162B2301, Part 2). The most common adverse reactions (&gt;25%) occurring in patients treated with encorafenib 300 mg administered with binimetinib were fatigue, nausea and diarrhoea.

AEs more frequent in the Combo 450 arm are shown in Table 66 and those more frequent in the Combo 300 arm are shown in Table 67. The EAIR values were consistent with the imbalances in AE incidences between the Combo 450 vs the Combo 300 arm.

Table 66: Overall incidence of AEs (increased by ≥ 5%) or grade 3-4 (increased by ≥ 2%) in the Combo 450 arm as compared to Combo 300 arm [Restricted Safety Set]

|                       | Combo 450mg QD Cutoff Date 19MAY2016 N=192 N%(grade 3- 4%)   | EAIR*   | Combo 300mg QD Cutoff Date 09NOV2016 N=257 N%(grade 3- 4%)   | EAIR*   |
|-----------------------|--------------------------------------------------------------|---------|--------------------------------------------------------------|---------|
| Any preferred term AE | 98.4(57.8)                                                   |         | 98.1 (46.7)                                                  |         |
| Nausea                | 41.1(1.6)                                                    | 5.03    | 27.2(1.6)                                                    | 3.12    |
| Diarrhoea             | 36.5(2.6)                                                    | 4.43    | 28.4 (1.6)                                                   | 3.43    |
| Vomiting              | 29.7 (1.6)                                                   | 3.05    | 15.2(0.4)                                                    | 1.55    |
| Fatigue               | 28.6 (2.1)                                                   | 3.02    | 22.2 (0.8)                                                   | 2.47    |
| Constipation          | 21.9 (-)                                                     | 3.05    | 16.7 (-)                                                     | 1.75    |
| Headache              | 21.9 (1.6)                                                   | 2.04    | 11.7 (0.4)                                                   | 1.15    |
| Pyrexia               | 18.2(3.6)                                                    | 1.69    | 16.7(0)                                                      | 1.69    |

<div style=\"page-break-after: always\"></div>

| Abdominal pain   | 16.7(2.6)   |   1.57 | 10.5(1.2)   |   1.03 |
|------------------|-------------|--------|-------------|--------|
| Vision blurred   | 15.6(0)     |   1.5  | 10.1(0.4)   |   1.02 |
| Anaemia          | 15.1(4.2)   |   1.5  | 9.3 (2.7)   |   0.89 |
| GGT increased    | 15.1 (9.4)  |   1.35 | 14 (4.7)    |   1.4  |
| Dry skin         | 14.1 (-)    |   1.29 | 8.2 (-)     |   0.8  |
| Rash             | 14.1 (1.0)  |   1.19 | 7.0 (0.8)   |   0.68 |
| Hypertension     | 10.9 (5.7)  |   0.96 | 8.2 (3.5)   |   0.79 |

* EAIR (Exposure adjusted incidence rate per 100 patient-months) = (n*100)/ (total exposure time (in months) of Broad Safety Set).

Table 67: Overall incidence of AEs (increased ≥ 5%) or grade 3-4 (increased ≥ 2%) increased in the Combo 300 arm as compared to Combo 450 arm [Restricted Safety Set]

|               | Combo 450mg QD N=192 50.64 weeks %(%grade 3-4)   |   EAIR* | Combo 300mg QD N=257 52.14 weeks %(%grade 3-4)   |   EAIR* |
|---------------|--------------------------------------------------|---------|--------------------------------------------------|---------|
| Back pain     | 9.4 (0.5)                                        |    0.8  | 14 (0.8)                                         |    1.39 |
| AST increased | 8.3 (2.1)                                        |    0.71 | 8.2 (4.3)                                        |    0.78 |

* EAIR (Exposure adjusted incidence rate per 100 patient-months) = (n*100)/(total exposure time (in months) of Broad Safety Set).

The increase in GI events in the Combo 450 arm did not have a big impact on the renal function; PTs of renal failure, blood creatinine increased and clinically notable shifts from baseline of creatinine lab parameter were similar in both arms. Worsening creatinine from baseline by at least 2 grades or to ≥ Grade 3 occurred for 17.7 % of patients in the Combo 300 vs 17.1% in the Combo 450. Worst post-baseline Grade 3 increased creatinine values occurred in 1.6% in the Combo 300 arm vs 3.6% in the Combo 450.

The overall incidence of SAEs was lower (difference &lt;5%) in the Combo 300 arm as compared to Combo 450 arm (29.7% vs 34.4%). The most frequently reported SAEs that were ≥ 2.0% of patients in either treatment group occurred under the SOCs of gastrointestinal disorders (3.1% Combo 300 arm, 9.4% Combo 450), infections and infestations (6.2% Combo 300 arm, 8.9% Combo 450), general disorders and administration site conditions (3.5% Combo 300 arm, 8.3% Combo 450) and nervous system disorders (Combo 450 arm 8.2% Combo 300 arm, 7.3%).

The incidence of on-treatment deaths was similar between the treatment groups (9.7% Combo 300 arm, 9.9% Combo 450). Most on-treatment deaths were considered due to disease progression. In the Combo 300 arm and the Combo 450 group, 3 (1.2%) and 2 (1.0%) on-treatment deaths, respectively, were considered due to AEs other than disease progression (malignant melanoma/metastases).

The percentage of patients with AESIs (any grade) considered common to both drugs was higher in the Combo 450 arm compared with the Combo 300 arm (66.1% vs 51.4%). The mitigating effect of adding binimetinib to encorafenib remined evident for PTs of retinal or pigment epithelium detachment, RVO,

<div style=\"page-break-after: always\"></div>

myopathy, muscle enzyme elevations, rash, nail disorders, and facial paresis. However, retinopathy (excluding retinal vein occlusion), rash, LFT abnormalities, haemorrhage and hypertension were more common for Combo 450 vs Combo 300.

Table 68: AESIs, Regardless of Relationship to Study Drug, by Grouping and Contribution of Each Component of the Combination- Overall, Maximum Grades 3 and 4 [Restricted Safety Set]

|                                                              | Combo 450 arm QD N=192 n (%)   | Combo 300mg QD N=257 n (%)   |
|--------------------------------------------------------------|--------------------------------|------------------------------|
| AESIs common to both drugs                                   |                                |                              |
| Any AESI N%(%Grade3-4)                                       | 66.1 (22.9)                    | 51.4 (14.8)                  |
| Serious AESI N%(%Grade3-4)                                   | 10.4 (8.3)                     | 6.2(4.7)                     |
| AESI leading to discontinuation N%(%Grade3-4)                | 5.2(3.6)                       | 4.3(3.1)                     |
| AESI requiring dose interruption and/or change N%(%Grade3-4) | 15.6(10.9)                     | 12.5(7.8)                    |
| AESI requiring additional therapy N%(%Grade3-4)              | 33.3(8.3)                      | 27.6(6.6)                    |
| Liver function test abnormalities                            | 48 (25.0)                      | 51 (19.8)                    |
| Grade 3/4                                                    | 28 (14.6)                      | 24(9.3)                      |
| EAIR                                                         | 2.1                            | 2.06                         |
| Rash                                                         | 50(26.0)                       | 44 (17.1)                    |
| Grade 3/4                                                    | 2(1.0)                         | 7 (2.7)                      |
| EAIR                                                         | 2.61                           | 0.68                         |
| Myopathy                                                     | 32(16.7)                       | 39 (15.2)                    |
| Grade 3/4                                                    | 0                              | 2 (0.8)                      |
| Haemorrhage                                                  | 32(16.7)                       | 18 (7.0)                     |
| Grade 3/4                                                    | 0                              | 3 (1.2)                      |
| EAIR                                                         | 1.61                           | 0.67                         |
| Skin infections                                              | 22(11.5)                       | 30 (11.7)                    |
| Grade 3/4                                                    | 4(2.1)                         | 7 (2.7)                      |
| EAIR                                                         | 0.88                           | 1.15                         |
| Photosensitivity                                             | 9(4.7)                         | 6 (2.3)                      |
| Grade 3/4                                                    | 1(0.5)                         | 0                            |
| EAIR                                                         | 0.39                           | 0.22                         |
| Acute renal failure                                          | 7 (3.6)                        | 6 (2.3)                      |
| Grade 3/4                                                    | 5(2.6)                         | 1 (0.4)                      |
| Tachycardia                                                  | 3 (1.6)                        | 8 (3.1)                      |
| Grade 3/4                                                    | 1(0.5)                         | 1 (0.4)                      |
| Severe cutaneous adverse reactions                           | 1 (0.5)                        | 2 (0.8)                      |
| Grade 3/4                                                    | 0                              | 0                            |
| Nail disorders                                               | 3 (1.6)                        | 4 (1.6)                      |
| Grade 3/4                                                    | 0                              | 0                            |
| Hepatic failure                                              | 1(0.5)                         | 0                            |
| Grade 3/4                                                    | 1(0.5)                         | 0                            |
|                                                              | 450 arm                        | QD                           |
|                                                              | Combo                          | Combo 300mg                  |
|                                                              | QD                             | N=257                        |
|                                                              | N=192                          | n (%)                        |
|                                                              | n (%)                          |                              |
| AESIs Specific to Binimetinib                                |                                |                              |
| Any AESI N%(%Grade3-4)                                       | 69.3(18.2)                     | 56.8(12.8)                   |
| Serious AESI N%(%Grade3-4)                                   | 4.7(2.6)                       | 2.7 (1.6)                    |
| AESI leading to discontinuation N%(%Grade3-4)                | 1.0(0.5)                       | 2.3 (0.8)                    |
| AESI requiring dose interruption or change N%(%Grade3-4)     | 19.8(8.3)                      | 16.7(5.1)                    |
| AESI requiring additional therapy N%(%Grade3-4)              | 19.3(8.3)                      | 12.8(3.5)                    |
| Retinopathy excluding RVO                                    | 93 (48.4)                      | 79 (30.7)                    |

<div style=\"page-break-after: always\"></div>

| Grade 3/4                                                | 5(2.6)         | 4 (1.6)   |
|----------------------------------------------------------|----------------|-----------|
| EAIR Muscle enzyme/protein changes                       | 7.06 44 (22.9) | 51 (19.8) |
| Grade ¾                                                  | 13 (6.8)       | 14 (5.4)  |
| EAIR                                                     | 2.20           | 2.13      |
| Peripheral oedema                                        | 24(12.5)       | 30 (11.7) |
| Grade ¾                                                  | 2(1.0)         | 9 (3.5)   |
| EAIR                                                     | 1.01           | 1.13      |
| Hypertension                                             | 22(11.5)       | 23 (8.9)  |
| Grade 3/4                                                | 11(5.7)        | 9(3.5)    |
| EAIR                                                     | 0.89           | 0.87      |
| Left ventricular dysfunction                             | 15(7.8)        | 15 (5.8)  |
| Grade 3/4                                                | 3(1.6)         | 3 (1.2)   |
| Venous thromboembolism                                   | 10(5.2)        | 5 (1.9)   |
| Grade 3/4                                                | 2(1.0)         | 3 (1.2)   |
| EAIR                                                     | 0.42           | 0.18      |
| Bradycardia                                              | 2(1.0)         | 2(0.8)    |
| Grade 3/4                                                |                | 0         |
|                                                          | 0              |           |
| EAIR                                                     | 0.08           |           |
| Pneumonitis                                              | 1(0.5)         | 1(0.4)    |
| Grade 3/4                                                | 0              | 0         |
| EAIR                                                     | 0.04           | 0.04      |
| Rhabdomyolysis                                           | 1(0.5)         | 0         |
| Grade ¾                                                  | 1(0.5)         | 0         |
| Retinal vein occlusion                                   | 0              | 1 (0.4)   |
| Grade 3/4                                                | 0              | 0         |
| AESIs Specific to Encorafenib                            |                |           |
| Any AESI N%(%Grade3-4)                                   | 14.6 (1.0)     | 14.4(3.1) |
| Serious AESI N%(%Grade3-4)                               | 0              | 1.6 (1.2) |
| AESI leading to discontinuation N%(%Grade3-4)            | 0              | 1.6(1.2)  |
| AESI requiring dose interruption or change N%(%Grade3-4) | 4.2(1.0)       | 3.9(1.2)  |
| AESI requiring additional therapy N%(%Grade3-4)          | 9.4(1.0)       | 8.9(1.9)  |
| PPE syndrome                                             | 13 (6.8)       | 10 (3.9)  |
| Grade 3/4                                                | 0              | 4 (1.6)   |
| EAIR                                                     | 0.57           | 0.36      |
| Uveitis                                                  | 7(3.6)         | 10 (3.9)  |
| Grade 3/4                                                | 1(0.5)         |           |
| Cutaneous squamous cell carcinoma                        | 5(2.6)         | 8 (3.1)   |
| Grade 3/4                                                | 0              | 0         |
| EAIR                                                     | 0.23           | 0.31      |
| Cutaneous non-squamous cell carcinoma                    | 4 (2.1)        | 8 (3.1)   |
| Grade 3/4                                                | 0              | 2 (0.8)   |
| Melanomas                                                | 2 (1.0)        | 3 (1.2)   |
| Grade 3/4                                                | -              | 1 (0.4)   |
| Facial paresis                                           | 2(1.0)         | 1 (0.4)   |
| Grade 3/4                                                | 1(0.5)         | 0         |
| EAIR                                                     | 0.08           | 0.04      |

* EAIR (Exposure adjusted incidence rate per 100 patient-months) = (n*100)/(total exposure time (in months) of Broad Safety Set).

Source Safety appendix Table Q96E\\_T\\_6\\_1

## Laboratory findings

## Haematology

<div style=\"page-break-after: always\"></div>

Table 69: Newly occurring or worsening haematology abnormalities based on CTCAE Grade

|                          | Melanoma                             | Melanoma                             | Melanoma                       | Study CMIEK162B2301Part 1      | Study CMIEK162B2301Part 1            | Study CMIEK162B2301Part 1   |
|--------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|--------------------------------------|-----------------------------|
| Parameter Worsened grade | Binimetinib 45 mg BID N=427 n/m (90) | Encorafenib 300 mg QD N=217 n/m (96) | Combo 450 mg QD N=274 n/m (96) | Combo 450 mg QD N=192 n/m (96) | Encorafenib 300 mg QD N=192 n/m (90) | Temurafenib N=186 n/m (90)  |
| Hemoglobin low (g/L)     | Hemoglobin low (g/L)                 | Hemoglobin low (g/L)                 | Hemoglobin low (g/L)           | Hemoglobin low (g/L)           | Hemoglobin low (g/L)                 | Hemoglobin low (g/L)        |
| Grade 1                  | 128/272 (47.1)                       | 59/155 (38.1)                        |                                | 61/190 (32.1)43/140 (30.7)     | 54/138 (39.1)                        | 46/127 (36.2)               |
| Grade 2                  | 57/401 (14.2)                        | 19/208 (9.1)                         | 27/258 (10.5)                  | 20/184 (10.9)                  | 14/183 (7.7)                         | 13/177 (7.3)                |
| Gmade 3                  | 12/415 (2.9)                         | 3/210 (1.4)                          | 12/269 (4.5)                   | 7/187 (3.7)                    | 3/185 (1.6)                          | 4/181 (2.2)                 |
| Grade 4                  | 0/415                                | 0/210                                | 0/269                          | 0/187                          | 0/185                                | 0/182                       |
| Hemoglobin high (g/L)    | Hemoglobin high (g/L)                | Hemoglobin high (g/L)                | Hemoglobin high (g/L)          | Hemoglobin high (g/L)          | Hemoglobin high (g/L)                | Hemoglobin high (g/L)       |
| Grade 1                  | 2/415 (0.5)                          | 6/210 (2.9)                          | 4/269 (1.5)                    | 1/187 (0.5)                    | 5/185 (2.7)                          | 8/182 (4.4)                 |
| Grade 2                  | 0/415                                | 0/210                                | 0/269                          | 0/187                          | 0/185                                | 0/182                       |
| Grade 3                  | 0/415                                | 0/210                                | 0/269                          | 0/187                          | 0/185                                | 0/182                       |
| Grade 4                  | 0/415                                | 0/210                                | 0/269                          | 0/187                          | 0/185                                | 0/182                       |
| Leukocytes low (l0'/L)   | Leukocytes low (l0'/L)               | Leukocytes low (l0'/L)               | Leukocytes low (l0'/L)         | Leukocytes low (l0'/L)         | Leukocytes low (l0'/L)               | Leukocytes low (l0'/L)      |
| Grade 1                  | 46/392 (11.7)                        | 7/204 (3.4)                          | 28/255 (11.0)                  | 17/183 (9.3)                   | 5/181 (2.8)                          | 14/179 (7.8)                |
| Grade 2                  | 9/410 (2.2)                          | 2/209 (1.0)                          | 10/259 (3.9)                   | 8/186 (4.3)                    | 2/184 (1.1)                          | 3/182 (1.6)                 |
| Grade 3                  | 0/415                                | 0/210                                | 0/260                          | 0/187                          | 0/185                                | 1/182 (0.5)                 |
| Grade 4                  | 0/415                                | 0/210                                | 0/260                          | 0/187                          | 0/185                                | 0/182                       |
| Lymphocytes low (10/L)   | Lymphocytes low (10/L)               | Lymphocytes low (10/L)               | Lymphocytes low (10/L)         | Lymphocytes low (10/L)         | Lymphocytes low (10/L)               | Lymphocytes low (10/L)      |
| Grade 1                  | 43/256 (16.8)                        | 18/191 (9.4)                         | 17/221 (7.7)                   | 5/177 (2.8)                    | 15/179 (8.4)                         | 14/171 (8.2)                |
| Gmade 2                  | 33/308 (10.7)                        | 16/198 (8.1)                         | 26/244 (10.7)                  | 16/179 (8.9)                   | 12/179 (6.7)                         | 30/174 (17.2)               |
| Grade 3                  | 21/339 (6.2)                         | 3/207 (1.4)                          | 6/255 (2.4)                    | 4/187 (2.1)                    | 2/185 (1.1)                          | 11/180 (6.1)                |
| Grade 4                  | 2/344 (0.6)                          | 0/207                                | 0/256                          | 0/187                          | 0/185                                | 1/182 (0.5)                 |
| Lymphocytes high (10²/L) | Lymphocytes high (10²/L)             | Lymphocytes high (10²/L)             | Lymphocytes high (10²/L)       | Lymphocytes high (10²/L)       | Lymphocytes high (10²/L)             | Lymphocytes high (10²/L)    |
| Grade 1                  | 0/343                                | 0/206                                | 0/254                          | 0/185                          | 0/184                                | 0/181                       |
| Grade 2                  | 28/343 (8.2)                         | 11/206 (5.3)                         | 15/254 (5.9)                   | 14/185 (7.6)                   | 9/184 (4.9)                          | 5/181 (2.8)                 |
| Grade 3                  | 1/345 (0.3)                          | 0/207                                | 0/256                          | 0/187                          | 0/185                                | 0/182                       |
| Grade 4                  | 0/345                                | 0/207                                | 0/256                          | 0/187                          | 0/185                                | 0/182                       |
| Neutrophils low (10'/L)  | Neutrophils low (10'/L)              | Neutrophils low (10'/L)              | Neutrophils low (10'/L)        | Neutrophils low (10'/L)        | Neutrophils low (10'/L)              | Neutrophils low (10'/L)     |
| Grade 1                  | 30/357 (8.4)                         | 7/204 (3.4)                          | 13/253 (5.1)                   | 11/186 (5.9)                   | 5/182 (2.7)                          | 6/181 (3.3)                 |
| Grade 2                  | 9/362 (2.5)                          | 2/205 (1.0)                          | 13/256 (5.1)                   | 8/187 (4.3)                    | 2/183 (1.1)                          | 2/182 (1.1)                 |
| Grade 3                  | 3/362 (0.8)                          | 1/206 (0.5)                          | 6/256 (2.3)                    | 4/187 (2.1)                    | 1/184 (0.5)                          | 0/182                       |
| Grade 4                  | 0/362                                | 1/207 (0.5)                          | 2/256 (0.8)                    | 2/187 (1.1)                    | 1/185 (0.5)                          | 1/182 (0.5)                 |
| Platelets low (10'/L)    | Platelets low (10'/L)                | Platelets low (10'/L)                | Platelets low (10'/L)          | Platelets low (10'/L)          | Platelets low (10'/L)                | Platelets low (10'/L)       |
| Grade 1                  | 53/403 (13.2)                        | 9/204 (4.4)                          | 23/267 (8.6)                   | 16/186 (8.6)                   | 6/181 (3.3)                          | 5/179 (2.8)                 |
| Grade 2                  | 3/413 (0.7)                          | 0/209                                | 3/269 (1.1)                    | 1/187 (0.5)                    | 0/184                                | 1/182 (0.5)                 |
| Grade 3                  | 1/413 (0.2)                          | 1/209 (0.5)                          | 0/269                          | 0/187                          | 1/184 (0.5)                          | 0/182                       |
| Grade 4                  | 1/413 (0.2)                          | 0/209                                | 2/269 (0.7)                    | 1/187 (0.5)                    | 0/184                                | 0/182                       |

No new or worsened haematology abnormality was reported at a higher or lower incidence (≥5% difference for any CTCAE Grade) in the Combo 450 RP population than the Enco 300 P population. Most common in all populations was decreased haemoglobin, mainly Grade 1 (Grade 1: 38.1% vs 32.1% of patients, respectively; Grade 2: 9.1% vs 10.5%; Grade 3: 1.4% vs 4.5%; Grade 4: none). No patients discontinued Combo 450 mg due to anaemia, 1.5% required dose adjustment or study drug interruption and 9.5% patients required additional therapy.

<div style=\"page-break-after: always\"></div>

Decreased neutrophil count was reported in a higher proportion of patients in the Combo 450 arm of Study CMEK162B2301 vs the Enco 300 and vemurafenib arms: 13% vs 4.7% vs 4.8%, respectively with Grade 3/4 abnormalities reported in 3.1% vs 1% vs 0.5%, respectively.

## Biochemistry

In the Enco 300 P and Combo 450 RP populations, increased creatinine was the most common new or worsened biochemistry abnormality, mainly Grade 1 (Grade 1: 71.3% vs 79.2% of patients, respectively; Grade 2: 9% vs 15.2%; Grade 3: 0.5% vs 3%; Grade 4: none). More patients in the Combo 450 RP population had a worsening of post-baseline creatinine by ≥2 grades (17.3% vs 9.5%).

In the Combo 450 RP population, hepatic laboratory values of &gt;3 x ULN increases in ALT occurred in 9.7% of patients and &gt;3 x ULN increases in ALT or AST occurred in 4.3% of patients. The median time to first onset was 29.0 days [range 1-534 days]. In the Enco 300 P population, no common newly occurring notable hepatic laboratory values were reported in ≥5% of patients for any class.

<div style=\"page-break-after: always\"></div>

Table 70: Newly Occurring or Worsening Biochemistry Abnormalities Based on CTCAE Grade in ≥ 10.0% of Patients in the Combo 450 Arm of Study CMEK162B2301 Part 1 (Restricted Safety Set, Part 1)

|                                 | Melanoma                            | Melanoma                            | Melanoma                      | StudyCMEK162B2301Part1        | StudyCMEK162B2301Part1                       | StudyCMEK162B2301Part1    |
|---------------------------------|-------------------------------------|-------------------------------------|-------------------------------|-------------------------------|----------------------------------------------|---------------------------|
| Parameter Worsened grade        | Binimetinib 45 mg BID N=427 n/m (%) | Encorafenib 300 mg QD N=217 n/m (%) | Combo 450 mg QD N=274 n/m (%) | Combo 450 mg QD N=192 n/m (%) | Encorafenib 300 mg QD N=192 n/m (%)          | Vemurafenib N=186 n/m (%) |
| Sodium low (mmol/L)             |                                     |                                     |                               |                               |                                              |                           |
| Grade 1                         | 41/397 (10.3)                       | 26/206 (12.6)                       | 39/258 (15.1)                 | 27/179 (15.1)                 | 18/184 (9.8)                                 | 26/172 (15.1)             |
| Grade 2                         | 0/413                               | 0/211                               | 0/268                         | 0/186                         | 0/186                                        | 0/181                     |
| Grade 3                         | 11/413 (2.7)                        | 3/211 (1.4)                         | 7/268 (2.6)                   | 7/186 (3.8)                   | 1/186 (0.5)                                  | 1/181 (0.6)               |
| Grade 4                         | 0/415                               | 0/211                               | 0/268                         | 0/186                         | 0/186                                        | 0/183                     |
| ALT high (U/L)                  |                                     |                                     |                               |                               |                                              |                           |
| Grade 1                         | 156/382 (40.8)                      | 25/206 (12.1)                       | 57/242 (23.6)                 | 40/173 (23.1)                 | 21/183 (11.5)                                | 42/176 (23.9)             |
| Grade 2                         | 16/414 (3.9)                        | 6/210 (2.9)                         | 12/268 (4.5)                  | 5/187 (2.7)                   | 5/185 (2.7)                                  | 4/182 (2.2)               |
| Grade 3                         | 12/416 (2.9)                        | 3/210 (1.4)                         | 14/269 (5.2)                  | 11/187 (5.9)                  | 3/185 (1.6)                                  | 4/183 (2.2)               |
| Grade 4                         | 1/416 (0.2)                         | 0/210                               | 0/269                         | 0/187                         | 0/185                                        | 0/183                     |
| Alkaline phosphatase high (U/L) |                                     |                                     |                               |                               |                                              |                           |
| Grade 1                         | 72/299 (24.1)                       | 26/194 (13.4)                       | 51/230 (22.2)                 | 33/161 (20.5)                 | 22/171 (12.9)                                | 58/157 (36.9)             |
| Grade 2                         | 14/336 (4.2)                        | 6/210 (2.9)                         | 9/264 (3.4)                   | 6/185 (3.2)                   | 5/185 (2.7)                                  | 4/180 (2.2)               |
| Grade 3                         | 8/343 (2.3)                         | 0/210                               | 4/267 (1.5)                   | 1/186 (0.5)                   | 0/185                                        | 4/183 (2.2)               |
| Grade 4                         | 0/345                               | 0/210                               | 0/269                         | 0/187                         | 0/185                                        | 0/183                     |
| AST high (U/L)                  |                                     |                                     |                               |                               |                                              |                           |
| Grade 1                         | 263/379 (69.4)                      | 22/205 (10.7)                       | 63/251 (25.1)                 | 39/181 (21.5)                 | 18/182 (9.9)                                 | 40/177 (22.6)             |
| Grade 2                         | 23/412 (5.6)                        | 3/210 (1.4)                         | 8/267 (3.0)                   | 7/186 (3.8)                   | 3/185 (1.6)                                  | 2/183 (1.1)               |
| Grade 3                         | 11/414 (2.7)                        | 1/210 (0.5)                         | 8/269 (3.0)                   | 5/187 (2.7)                   | 1/185 (0.5)                                  | 3/183 (1.6)               |
| Grade 4                         | 1/415 (0.2)                         | 0/210                               | 0/269                         | 0/187                         | 0/185                                        | 0/183                     |
| CK high (U/L)                   |                                     |                                     |                               |                               |                                              |                           |
| Grade 1                         | 140/397 (35.3)                      | 5/191 (2.6)                         | 111/257 (43.2)77/177 (43.5)   |                               | 5/171 (2.9)                                  | 6/168 (3.6)               |
| Grade 2                         | 93/410 (22.7)                       | 1/199 (0.5)                         | 39/264 (14.8)                 | 24/182 (13.2)                 | 1/178 (0.6)                                  | 1/173 (0.6)               |
| Grade 3                         | 60/413 (14.5)                       | 0/199                               | 9/264 (3.4)                   | 8/182 (4.4)                   | 0/178                                        | 0/174                     |
| Grade 4                         | 36/413 (8.7)                        | 0/199                               | 2/264 (0.8)                   | 2/182 (1.1)                   | 0/178                                        | 0/174                     |
| Creatinine high (jumol/L)       |                                     |                                     |                               |                               |                                              |                           |
| Grade 1                         | 291/366 (79.5)                      | 149/209 (71.3)                      |                               |                               | 206/260 (79.2) 142/183 (77.6) 132/185 (71.4) | 122/181 (67.4)            |
| Grade 2                         | 22/415 (5.3)                        | 19/211 (9.0)                        | 41/269 (15.2)                 | 29/187 (15.5)                 | 14/186 (7.5)                                 | 47/183 (25.7)             |
| Grade 3                         | 2/416 (0.5)                         | 1/211 (0.5)                         | 8/269 (3.0)                   | 7/187 (3.7)                   | 1/186 (0.5)                                  | 2/183 (1.1)               |
| Grade 4                         | 3/416 (0.7)                         | 0/211                               | 0/269                         | 0/187                         | 0/186                                        | 0/183                     |
| Fasting glucose high (mmol/L)   | Fasting glucose high (mmol/L)       |                                     |                               |                               |                                              |                           |
| Grade 1                         | 10/25 (40.0)                        | 43/168 (25.6)                       | 35/183 (19.1)                 | 27/153 (17.6)                 | 38/149 (25.5)                                | 23/128 (18.0)             |
| Grade 2                         | 2/25 (8.0)                          | 8/181 (4.4)                         | 21/197 (10.7)                 | 16/164 (9.8)                  | 6/159 (3.8)                                  | 9/135 (6.7)               |
| Grade 3                         | 0/25                                | 7/187 (3.7)                         | 10/202 (5.0)                  | 9/169 (5.3)                   | 6/164 (3.7)                                  | 4/138 (2.9)               |
| Grade 4                         | 0/26                                | 2/187 (1.1)                         | 1/204 (0.5)                   | 1/171 (0.6)                   | 2/164 (1.2)                                  | 1/140 (0.7)               |

<div style=\"page-break-after: always\"></div>

| GGT high (U/L)          | GGT high (U/L)          | GGT high (U/L)          | GGT high (U/L)          | GGT high (U/L)          | GGT high (U/L)          | GGT high (U/L)          |
|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Grade 1                 | 32/207 (15.5)           | 39/156 (25.0)           | 43/197 (21.8)           | 36/145 (24.8)           | 35/145 (24.1)           | 44/144 (30.6)           |
| Grade 2                 | 11/239 (4.6)            | 20/192 (10.4)           | 41/238 (17.2)           | 29/172 (16.9)           | 17/179 (9.5)            | 10/170 (5.9)            |
| Grade 3                 | 8/249 (3.2)             | 16/196 (8.2)            | 35/254 (13.8)           | 22/184 (12.0)           | 15/182 (8.2)            | 7/174 (4.0)             |
| Grade 4                 | 0/258                   | 3/200 (1.5)             | 2/261 (0.8)             | 0/186                   | 3/185 (1.6)             | 2/183 (1.1)             |
| Magnesium high (mmol/L) | Magnesium high (mmol/L) | Magnesium high (mmol/L) | Magnesium high (mmol/L) | Magnesium high (mmol/L) | Magnesium high (mmol/L) | Magnesium high (mmol/L) |
| Grade 1                 | 2/411 (0.5)             | 31/206 (15.0)           | 19/266 (7.1)            | 18/184 (9.8)            | 29/181 (16.0)           | 48/179 (26.8)           |
| Grade 2                 | 0/412                   | 0/211                   | 0/269                   | 0/187                   | 0/186                   | 0/183                   |
| Grade 3                 | 1/412 (0.2)             | 2/211 (0.9)             | 2/269 (0.7)             | 2/187 (1.1)             | 0/186                   | 1/183 (0.5)             |
| Grade 4                 | 0/413                   | 0/211                   | 0/269                   | 0/187                   | 0/186                   | 0/183                   |

There were too few patients in the Enco 300 P population with notable hepatic laboratory values and even fewer patients with baseline liver metastases to detect a difference in notable hepatic laboratory values. An assessment of the larger number of patients in the Combo 450 RP population revealed no increase in notable hepatic laboratory values in the patients with liver metastases as compared with patients without liver metastases.

Table 71: Summary of Patients with Newly Occurring Notable Hepatic Laboratory Values

|                                       | Melanoma                            | Melanoma                            | Melanoma                   | Study CMEK162B2301         | Study CMEK162B2301         | Study CMEK162B2301                               |
|---------------------------------------|-------------------------------------|-------------------------------------|----------------------------|----------------------------|----------------------------|--------------------------------------------------|
| Variable                              | Binimetinib 45 mg BID N=427 n/m (%) | Encorafenib 300 mg QD N=217 n/m (%) | Combo N=274 n/m (%)        | Combo N=192 n/m (%)        | Encorafenib N=192 n/m (%)  | 450mgQD450 mg QD300mgQDVemurafenib N=186 n/m (%) |
| ALT >5xULN                            | 13/416 (3.1)                        | 3/210 (1.4)                         | 14/269 (5.2)               | 11/187 (5.9)               | 3/185 (1.6)                | 4/183 (2.2)                                      |
| AST >5 xULN                           | 12/413 (2.9)                        | 1/210 (0.5)                         | 8/269 (3.0)                | 5/187 (2.7)                | 1/185 (0.5)                | 3/183 (1.6)                                      |
| ALT or AST (AT) >5 x ULN              | 17/413 (4.1)                        | 3/210 (1.4)                         | 16/269 (5.9)               | 12/187 (6.4)               | 3/185 (1.6)                | 4/183 (2.2)                                      |
| Total bilirubin (TBL) >2 x ULN        | 5/412 (1.2)                         | 0                                   | 1/267 (0.4)                | 1/185 (0.5)                | 0                          | 6/183 (3.3)                                      |
| ALP >3 xULN                           | 14/337 (4.2)                        | 5/210 (2.4)                         | 7/265 (2.6)                | 3/185 (1.6)                | 4/185 (2.2)                | 6/182 (3.3)                                      |
| ALT or AST (AT) and TBL               | ALT or AST (AT) and TBL             | ALT or AST (AT) and TBL             | ALT or AST (AT) and TBL    | ALT or AST (AT) and TBL    | ALT or AST (AT) and TBL    | ALT or AST (AT) and TBL                          |
| AT>3xULN&TBL>2xULN                    | 2/413 (0.5)                         | 0                                   | 1/268 (0.4)                | 1/186 (0.5)                | 0/185                      | 2/183 (1.1)                                      |
| ALP and TBL                           | ALP and TBL                         | ALP and TBL                         | ALP and TBL                | ALP and TBL                | ALP and TBL                | ALP and TBL                                      |
| ALP >3 x ULN & TBL >2 x ULN           | 1/342 (0.3)                         | 0                                   | 0                          | 0                          | 0                          | 1/183 (0.5)                                      |
| ALT or AST and TBL and ALP            | ALT or AST and TBL and ALP          | ALT or AST and TBL and ALP          | ALT or AST and TBL and ALP | ALT or AST and TBL and ALP | ALT or AST and TBL and ALP | ALT or AST and TBL and ALP                       |
| AT>3xULN& TBL >2 x ULN & ALP<2 x ULNa | 1/340 (0.3) b                       | 0                                   | 0                          | 0                          | 0                          | 1/183 (0.5) c                                    |

No cases meeting the case-finding criteria of Hy's law were identified in the Combo 450 RP or Enco 300 P populations. As per the 4-month safety update, no new cases of hepatic events fulfilling the Hy's Law criteria was identified in any patient within the same investigated population.

In the Combo 450 RP population 2 patients had Grade 4 CK elevation, which resolved in 0.3 and 1.0 months respectively. A total of 47/259 (18.1%) patients with baseline Grade 0/1 CK level had a ≥2-grade increase. In the subgroup of patients using statins this proportion was 3/24 (12.5%) with no increases to Grade 3/4 levels. In the Enco 300 P population and the vemurafenib arm of the trial no patients were reported with Grade 4 CK elevation. None of the 15 patients who experienced left ventricular dysfunction AESI events had concomitant CK elevations, thus no blood samplings for CK isoenzymes and troponin I were undertaken as per study protocol. However, the presented results regarding elevations / shifts of CK values (including

<div style=\"page-break-after: always\"></div>

isoenzymes) argue in favour of skeletal muscle cell damage-induced elevations of CK with no evidence of cardiac damage in the Combo 450 arm.

Increased blood glucose was recorded across the treatment arms with an incidence of Grade 3/4 of 5.5%, 4.8% and 3.6% for Combo 450 RP, Enco 300 P and vemurafenib respectively.

The incidence of newly occurring or worsening proteinuria was similar in the Enco 300 P and Combo 450 RP populations for both Grade 1 and 2 values (Grade 1: 5.4% vs 8%, Grade 2: 3.7% vs 2.9%).

## Blood pressure (BP)

Newly abnormal BP values were reported with a higher incidence (≥5% difference) in Combo 450 RP than the Enco 300 P population for both systolic (15.5% vs 8.6%) and diastolic BP (11% vs 2.9%). This corresponds with a higher incidence of hypertension AESIs in the Combo 450 RP vs Enco 300 P population (12% vs. 5.5%).

## Electrocardiogram (QTc Effects)

In Study CMEK162B2301, QTcF increases by &gt;60 ms were observed in 5.4%, 3.9% and 5.6% of patients in the Combo 450, Enco 300 and vemurafenib arms, respectively, QTcF increases by &gt;30ms were observed in 26.9%, 29.1% and 42.5% of patients, respectively and new QTcF values &gt;500 ms were observed in 0.5%, 2.8% and 1.7% of patients, respectively.

## Left Ventricular Ejection Fraction (LVEF)

Mean worst absolute change in LVEF from baseline was similar in the Enco 300 P and Combo 450 RP populations (4.6% vs 5.9%), as was mean worst LVEF value (61.1% [SD 5.9%] vs. 58.1% [5.6%], respectively). However, more patients in the Combo 450 RP than in the Enco 300 P population experienced a CTCAE Grade 0 to Grade 2 LVEF shift (24.7% vs. 8.5%). Similar magnitude of change was seen in patients with or without baseline cardiac, LVD and hypertension risk factors.

Mean worst absolute change in LVEF from baseline was similar in the Combo 450 and vemurafenib arms (6.2% vs 4.3%). A higher percentage of patients in the Combo 450 arm than in the vemurafenib arm experienced a CTCAE Grade 0 to Grade 2 LVEF shift (28.4% vs 8.2%).

## Ophthalmologic Evaluation

Changes in visual acuity (assessed by Snellen logMAR score) and intraocular pressure from baseline to end of treatment were similar between the Enco 300 P and Combo 450 RP populations. However, there was less of a shift towards reduced visual acuity in the Enco 300 P compared with the Combo 450 RP population (patients with a logMAR ≤0 with a shift to ≥0.3, 4.4% vs 10.1%, respectively).

There was less of a shift towards reduced visual acuity in the Enco 300 arm compared with the vemurafenib arm (patients with a logMAR ≤0 with a shift to ≥0.3, 4.6% vs 8.1%, respectively).

## Safety in special populations

## Elderly

In the Combo 450 RP population, 194 patients were &lt;65 years and 80 patients were ≥65 years; 259 patients were &lt;75 years and 15 patients were ≥75 years.

<div style=\"page-break-after: always\"></div>

AEs (all grades) reported in more patients ≥65 years than patients &lt;65 years included diarrhoea (43.8% vs 33%), increased GGT (21.3% vs 10.8%), pruritus (16.3% vs 6.2%) and increased blood ALP (15% vs 4.1%).

AEs (all grades) that were reported in at least 3 patients and in &gt;25% more patients ≥ 75 years than patients &lt; 75 years included nausea (66.7% vs. 37.8%), diarrhoea (60% vs. 34.7%) and asthenia (53.3% vs. 11.6%).

In the Enco 300 P population, 172 patients were &lt;65 years and 45 patients were ≥ 65 years, 205 patients were &lt; 75 years and 12 patients were ≥ 75 years.

AEs (all grades) reported in more patients ≥65 years than patients &lt;65 years included asthenia (28.9% vs 16.9%), constipation (24.4% vs 14%) and increased GGT (22.2% vs 7.6%).

AEs (all grades) reported in at least 3 patients and in ≥ 25% more patients ≥ 75 years than patients &lt; 75 years in the Enco 300 P population included, respectively: GGT increased (41.7% vs. 8.8%) and anaemia (33.3% vs. 5.4%).

A higher proportion of patients ≥65 years had Grade 3/4 AEs compared with those patients aged &lt;65 years across all the study populations and all treatment arms in Study CMEK162B2301.

<div style=\"page-break-after: always\"></div>

Table 72: Overview of Safety according to age in Combo 450 RP

|                                  |            | <65 years N=194 N (%)   | 65-74 years N=65 N (%)   | 75-84 year's N=14 N (%)   | ≥85 year's N=1 N (%)   |
|----------------------------------|------------|-------------------------|--------------------------|---------------------------|------------------------|
| Atleast one TEAEs                | All grades | 192 (99.0)              | 64 (98.5)                | 14 (100.0)                | 1 (100.0)              |
|                                  | Grade 3-4  | 116 (59.8)              | 41 (63.1)                | 10 (71.4)                 | 1 (100.0)              |
| At least one SAEs                | All grades | 76 (39.2)               | 27 (41.5)                | 7 (50.0)                  | 0 (0.0)                |
|                                  | Grade 3-4  | 64 (33.0)               | 23 (35.4)                | 7 (50.0)                  | 0 (0.0)                |
| Fatal                            | All grades | 13(6.7)                 | 2(3.1)                   | 2(14.3)                   | 0 (0.0)                |
| Hospitalization/prolong existing | All grades | 58(29.9)                | 24(36.9)                 | 7(50.0)                   | 0 (0.0)                |
| hospitalization                  |            |                         |                          |                           |                        |
| Life-threatening                 | All grades | 4(2.1)                  | 2(3.1)                   | 2(14.3)                   | 0 (0.0)                |
| Disability/incapacity            | All grades | 1(0.5)                  | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                |
| Other (medically significant)    | All grades | 5(2.6)                  | 2(3.1)                   | 0 (0.0)                   | 0 (0.0)                |
| AEs leading to discontinuation   | All grades | 20 (10.3)               | 6 (9.2)                  | 5 (35.7)                  | 1 (100.0)              |
|                                  | Grade 3-4  | 16 (8.2)                | 4 (6.2)                  | 5 (35.7)                  | 1 (100.0)              |
| SOC Psychiatric disorders        | All grades | 39 (20.1)               | 14 (21.5)                | 3 (21.4)                  | 0 (0.0)                |
|                                  | Grade 3-4  | 2 (1.0)                 | 2 (3.1)                  | 1 (7.1)                   | 0 (0.0)                |
| SOC Nervous system               | All grades | 92 (47.4)               | 33 (50.8)                | 9 (64.3)                  | 1 (100.0)              |
|                                  | Grade 3-4  | 22 (11.3)               | 7 (10.8)                 | 2 (14.3)                  | 0 (0.0)                |
| Accidents and injuries SMQ       | All grades | 48 (24.7)               | 19 (29.2)                | 2 (14.3)                  | 0 (0.0)                |
|                                  | Grade 3-4  | 0 (0.0)                 | 3 (4.6)                  | 0 (0.0)                   | 0 (0.0)                |
| SOC Cardiac disorders            | All grades | 27 (13.9)               | 12 (18.5)                | 3 (21.4)                  | 0 (0.0)                |
|                                  | Grade 3-4  | 1 (0.5)                 | 1 (1.5)                  | 2 (14.3)                  | 0 (0.0)                |
| SOC Vascular disorders           | All grades | 38 (19.6)               | 13 (20.0)                | 1 (7.1)                   | 1 (100.0)              |
|                                  | Grade 3-4  | 10 (5.2)                | 6 (9.2)                  | 0 (0.0)                   | 0 (0.0)                |
| SMQ Cerebrovascular disordersa   | All grades | 13 (6.7)                | 3 (4.6)                  | 2 (14.3)                  | 0 (0.0)                |
|                                  | Grade 3-4  | 8 (4.1)                 | 2 (3.1)                  | 1 (7.1)                   | 0 (0.0)                |
| SOCInfections andinfestations    | All grades | 97 (50.0)               | 36 (55.4)                | 9 (64.3)                  | 0 (0.0)                |
|                                  | Grade 3-4  | 18 (9.3)                | 8 (12.3)                 | 0 (0.0)                   | 0 (0.0)                |
| Sum of following PT              | All grades | 32 (16.5)               | 15 (23.1)                | 4 (28.6)                  | 0 (0.0)                |
|                                  | Grade 3-4  | 3 (1.5)                 | 6 (9.2)                  | 1 (7.1)                   | 0 (0.0)                |

<div style=\"page-break-after: always\"></div>

| Postural Hypotensionb                                  | All grades   | 1 (0.5)   | 0 (0.0)   | 0 (0.0)   | 0 (0.0)   |
|--------------------------------------------------------|--------------|-----------|-----------|-----------|-----------|
| Fall                                                   | All grades   | 4 (2.1)   | 5 (7.7)   | 2 (14.3)  | 0 (0.0)   |
| Loss of consciousness                                  | All grades   | 0 (0.0)   | 0 (0.0)   | 0 (0.0)   | 0 (0.0)   |
| Syncope                                                | All grades   | 1 (0.5)   | 1 (1.5)   | 0 (0.0)   | 0 (0.0)   |
| Dizziness                                              | All grades   | 23 (11.9) | 8 (12.3)  | 3 (21.4)  | 0 (0.0)   |
| Ataxia                                                 | All grades   | 1 (0.5)   | 1 (1.5)   | 0 (0.0)   | 0 (0.0)   |
| Fracturec                                              | All grades   | 5 (2.6)   | 4 (6.2)   | 0 (0.0)   | 0 (0.0)   |
| PT Anticholinergic syndrome                            | All grades   | 0 (0.0)   | 0 (0.0)   | 0 (0.0)   | 0 (0.0)   |
|                                                        | Grade 3-4    | 0 (0.0)   | 0 (0.0)   | 0 (0.0)   | 0 (0.0)   |
| PT Quality of life decreased                           | All grades   | 0 (0.0)   | 0 (0.0)   | 0 (0.0)   | 0 (0.0)   |
|                                                        | Grade 3-4    | 0 (0.0)   | 0 (0.0)   | 0 (0.0)   | 0 (0.0)   |
| Other AEs appearing more frequently in older patientsd |              |           |           |           |           |
| Blood alkaline phosphatase increased                   | All grades   | 8 (4.1)   | 8 (12.3)  | 3 (21.4)  | 1 (100.0) |
|                                                        | Grade 3-4    | 1 (0.5)   | 1 (1.5)   | 0 (0.0)   | 0 (0.0)   |
| Diarrhoea                                              | All grades   | 66 (34.0) | 28 (43.1) | 9 (64.3)  | 1 (100.0) |
|                                                        | Grade 3-4    | 5 (2.6)   | 2 (3.1)   | 2 (14.3)  | 0 (0.0)   |
| Gamma-glutamyltransferase increased                    | All grades   | 22 (11.3) | 13 (20.0) | 4 (28.6)  | 1 (100.0) |
|                                                        | Grade 3-4    | 11 (5.7)  | 8 (12.3)  | 3 (21.4)  | 1 (100.0) |
| Pruritus                                               | All grades   | 12 (6.2)  | 13 (20.0) | 1 (7.1)   | 1 (100.0) |
|                                                        | Grade 3-4    | 1 (0.5)   | 0 (0.0)   | 0 (0.0)   | 0 (0.0)   |

<div style=\"page-break-after: always\"></div>

Table 73: Overview of Safety according to age Enco 300P

|                                                                   |                       | <65 years N=172 N (%)   | 65-74 years N=33 N (%)   | 75-84 years N=1l N (%)   | ≥85 year's N=1 N (%)   |
|-------------------------------------------------------------------|-----------------------|-------------------------|--------------------------|--------------------------|------------------------|
| At least one TEAEs                                                | All grades            | 172 (100.0) 114 (66.3)  | 32 (97.0) 23 (69.7)      | 11 (100.0) 9 (81.8)      | 1 (100.0) 1 (100.0)    |
| At least one SAEs                                                 | All grades            | 55 (32.0) 47 (27.3)     | 11 (33.3) 8 (24.2)       | 5 (45.5) 5 (45.5)        | 0 (0.0) 0 (0.0)        |
| Fatal                                                             | All grades            | 10(5.8)                 | 1(3.0) 10(30.3)          | 1(9.1) 5(45.5)           | 0 (0.0)                |
| Hospitalization/prolong existing hospitalization Life-threatening | All grades All grades | 39(22.7) 1(0.6)         | 1(3.0) 0 (0.0)           | 1(9.1) 0 (0.0)           | 0 (0.0) 0 (0.0)        |
| Disability/incapacity                                             | All grades All grades | 1(0.6) 9(5.2)           | 1(3.0)                   | 1(9.1)                   | 0 (0.0) 0 (0.0)        |
| Other (medically significant) AEsleading to discontinuation       | All grades Grade 3-4  | 30 (17.4) 21 (12.2)     | 5 (15.2) 4 (12.1)        | 4 (36.4) 3 (27.3)        | 1 (100.0)              |
|                                                                   | All grades            | 63 (36.6) 7 (4.1)       | 1 (3.0)                  | 4 (36.4)                 | 1 (100.0) 0 (0.0)      |
|                                                                   | Grade 3-4             |                         | 12 (36.4)                | 0 (0.0)                  |                        |
| SOC Psychiatric disorders                                         |                       |                         |                          |                          | 1 (100.0)              |
| SOC Nervous system                                                | All grades Grade 3-4  | 108 (62.8)              | 18 (54.5)                |                          | 0 (0.0)                |
|                                                                   | All grades            | 14 (8.1)                | 4 (12.1)                 | 3 (27.3) 0 (0.0)         |                        |
| Accidents and injuries SMQ                                        | Grade 3-4             | 18 (10.5)               | 4 (12.1)                 | 1 (9.1)                  | 0 (0.0)                |
| SOC Cardiac disorders                                             | All grades            | 24 (14.0)               | 4 (12.1) 1 (3.0)         | 0 (0.0) 3 (27.3)         | 1 (100.0) 0 (0.0)      |
|                                                                   | Grade 3-4             | 2 (1.2) 2 (1.2)         | 1 (3.0)                  | 2 (18.2)                 | 0 (0.0) 0 (0.0)        |
| SOC Vascular disorders                                            | All grades Grade 3-4  | 30 (17.4) 4 (2.3)       | 10 (30.3)                | 3 (27.3)                 | 1 (100.0)              |
| SMQ Cerebrovascular disordersa                                    |                       | 5 (2.9)                 | 2 (6.1)                  | 0 (0.0)                  | 0 (0.0)                |
|                                                                   | All grades            |                         |                          | 1 (9.1)                  |                        |
|                                                                   |                       |                         | 3 (9.1)                  | 0 (0.0)                  | 0 (0.0)                |
|                                                                   | Grade 3-4             | 3 (1.7)                 | 1 (3.0)                  |                          | 0 (0.0)                |
| SOC Infections and infestations                                   | Grade 3-4             |                         | 12 (36.4)                | 2 (18.2)                 |                        |
|                                                                   | All grades            | 79 (45.9)               |                          | 3 (27.3)                 | 1 (100.0)              |
|                                                                   |                       | 6 (3.5)                 | 0 (0.0)                  |                          | 0 (0.0)                |
| Sum of following PT                                               | All grades            | 17 (9.9)                | 3 (9.1)                  | 0 (0.0)                  |                        |
|                                                                   |                       |                         |                          |                          | 1 (100.0)              |
|                                                                   | Grade 3-4             | 3 (1.7)                 | 2 (6.1)                  | 0 (0.0)                  | 0 (0.0)                |

## Other subgroups

Regarding race, results should be interpreted with caution due to the relatively small number of patients in the Asian and Other (often &lt;10) compared with the Caucasian subgroup.

No clinically relevant differences in the proportion of AEs were noted by gender or presence/ absence of baseline brain metastases, although the numbers with baseline brain metastases were low (8 in the Enco 300 P and 15 in the Combo 450 RP populations).

## Hepatic Impairment

<div style=\"page-break-after: always\"></div>

Study ARRAY-818-101 investigated the PK of encorafenib in subjects with mild hepatic impairment, as defined by Child-Pugh Score. Preliminary results indicate an approximate 25% increase in overall encorafenib exposure (AUCinf) compared to matching healthy subjects. Most AEs were mild or moderate, except for 1 Grade 3 AE of increased pancreatic enzymes deemed related and 1 Grade 3 AE of food allergy deemed not related.

## Immunological events

Drug hypersensitivity is a known BRAFi class effect. Drug hypersensitivity (PTs of drug hypersensitivity, hypersensitivity, urticaria and angioedema) occurred in 2.9% of patients with no discontinuations, dose adjustments or study drug interruptions.

Drug hypersensitivity was recorded in 4.1% of the Enco 300 P population, with 0.5% Grade 3 events; 0.9% of patients discontinued and 1.8% patients required dose adjustment or study drug interruption.

In CMEK162B2301, the incidence of drug hypersensitivity was similar in the Combo 450 and vemurafenib arm (3.6% vs 4.8%) but the median time to first was longer in the Combo 450 arm (88.0 vs.  21.0 days).

## Safety related to drug-drug interactions and other interactions

Study ARRAY-818-105 investigated the effects of posaconazole and diltiazem (strong and moderate CYP3A4 inhibitors, respectively) on the single-dose PK of encorafenib in healthy subjects. The higher encorafenib exposure resulted in more treatment emergent AEs. Concomitant administration of encorafenib with strong CYP3A4 inhibitors should be avoided due to increased encorafenib exposure and potential increase in toxicity.

For additional information, please refer to the Clinical Pharmacology section.

## Discontinuation due to adverse events

About 10% of patients discontinued due to an AE in the Combo 450 RP population and 17.5% in the Enco 300 P population (Grade 3/4 AEs: 8.8% vs 13.4%).  No AEs leading to study drug discontinuation were reported in ≥ 2% of patients in the Combo 450 RP population whilst PPE (3.7%) was the only AE in the Enco 300 P population.

In the Phase 3 study, AEs leading to study drug discontinuation in the Combo 450 arm included increased ALT and AST (2.6% each) whilst no specific AEs led to discontinuation in ≥ 2% of patients in either the Enco 300 or vemurafenib arms.

<div style=\"page-break-after: always\"></div>

Table 74: Adverse Events Leading to Study Drug Discontinuation, Regardless of Study Drug Relationship, by Preferred Term and Treatment -Overall and Maximum Grade 3 or 4 (any grade and Grade 3/4 AE ≥ 1% in any population)

|                                       | Melanoma    | Melanoma                                               | Melanoma                       | Melanoma                    | StudyCMEK162B2301           | StudyCMEK162B2301                         | StudyCMEK162B2301   |
|---------------------------------------|-------------|--------------------------------------------------------|--------------------------------|-----------------------------|-----------------------------|-------------------------------------------|---------------------|
| Preferred Term                        | N=427 n (%) | BinimetinibEncorafenib 45 mg BID 300 mg QD N=217 n (%) | Combo pooled doses N=433 n (%) | Combo 450 mg QD N=274 n (%) | Combo 450 mg QD N=192 n (%) | Encorafenib 300mgQDVemurafeni N=192 n (%) | N=186 n (%)         |
| Any preferred term                    |             |                                                        |                                |                             |                             |                                           |                     |
| All grades                            | 103 (24.1)  | 38 (17.5)                                              | 45 (10.4)                      | 28 (10.2)                   | 24 (12.5)                   | 27 (14.1)                                 | 31 (16.7)           |
| Grades 3/4                            | 70 (16.4)   | 29 (13.4)                                              | 33 (7.6)                       | 24 (8.8)                    | 22 (11.5)                   | 21 (10.9)                                 | 18 (9.7)            |
| ALT increased                         | 4 (0.9)     | 0                                                      | 8 (1.8)                        | 5 (1.8)                     | 5 (2.6)                     | 0                                         | 2 (1.1)             |
| Grades 3/4                            | 3 (0.7)     | 0                                                      | 5 (1.2)                        | 4 (1.5)                     | 4 (2.1)                     | 0                                         | 2 (1.1)             |
| ASTincreased                          | 4 (0.9)     | 0                                                      | 8 (1.8)                        | 5 (1.8)                     | 5 (2.6)                     | 0                                         | 2 (1.1)             |
| Grades 3/4                            | 4 (0.9)     | 0                                                      | 3 (0.7)                        | 2 (0.7)                     | 2 (1.0)                     | 0                                         | 2 (1.1)             |
| Blood creatinine increased            | 0           | 0                                                      | 5 (1.2)                        | 3 (1.1)                     | 2 (1.0)                     | 0                                         | 0                   |
| GGT increased                         | 0           | 1 (0.5)                                                | 2 (0.5)                        | 2 (0.7)                     | 2 (1.0)                     | 1 (0.5)                                   | 3 (1.6)             |
| Grades 3/4                            | 0           | 1 (0.5)                                                | 1 (0.2)                        | 1 (0.4)                     | (0.5)                       | 1 (0.5)                                   | 3 (1.6)             |
| Headache                              | 0           | 2 (0.9)                                                | 2 (0.5)                        | 2  (0.7)                    | 2 (1.0)                     | 2 (1.0)                                   | 1 (0.5)             |
| Grades 3/4                            | 0           | 2 (0.9)                                                | 1 (0.2)                        | (0.4)                       | (0.5)                       | 2 (1.0)                                   | 0                   |
| Blood CK increased                    | 8 (1.9)     | 0                                                      | 2 (0.5)                        | (0.4)                       | (0.5)                       | 0                                         | 0                   |
| Grades 3/4                            | 8 (1.9)     | 0                                                      | 0                              | 0                           | 0                           | 0                                         | 0                   |
| Diamhoea                              | 2 (0.5)     | 2 (0.9)                                                | 2 (0.5)                        | (0.4)                       | (0.5)                       | 2 (1.0)                                   | 0                   |
| Grades 3/4                            | 1 (0.2)     | 2 (0.9)                                                | 2 (0.5)                        | 1 (0.4)                     | (0.5)                       | 2 (1.0)                                   | 0                   |
| Metastases to CNS                     | 0           | 2 (0.9)                                                | 1 (0.2)                        | 1 (0.4)                     | (0.5)                       | 2 (1.0)                                   | 0                   |
| Rash                                  | 4 (0.9)     | 1 (0.5)                                                | (0.2)                          | (0.4)                       | (0.5)                       | 1 (0.5)                                   | 2 (1.1)             |
| Arthralgia                            | 0           | 1 (0.5)                                                | 0                              | 0                           | 0                           | 1 (0.5)                                   | 3 (1.6)             |
| Dermatitis acneifom                   | 5 (1.2)     | 0                                                      | 0                              | 0                           | 0                           | 0                                         | 0                   |
| Ejection fraction decreased           | 16 (3.7)    | 2 (0.9)                                                | 1 (0.2)                        | 0                           | 0                           | 2 (1.0)                                   | 0                   |
| Grades 3/4                            | 8 (1.9)     | 2 (0.9)                                                | 0                              | 0                           | 0                           | 2 (1.0)                                   | 0                   |
| Facial paralysis                      | 0           | 2 (0.9)                                                | 0                              | 0                           | 0                           | 2 (1.0)                                   | 0                   |
| General physical health deterioration | 5 (1.2)     | 0                                                      | 1 (0.2)                        | 0                           | 0                           | 0                                         | 1 (0.5)             |
| Grades 3/4                            | 5 (1.2)     | 0                                                      | 1 (0.2)                        | 0                           | 0                           | 0                                         | 1 (0.5)             |
| Hepatotoxicity                        | 0           | 0                                                      | 0                              | 0                           | 0                           | 0                                         | 2 (1.1)             |
| Grades 3/4                            | 0           | 0                                                      | 0                              | 0                           | 0                           | 0                                         | 2 (1.1)             |
| Hypersensitivity                      | 0           | 2 (0.9)                                                | 0                              | 0                           | 0                           | 2 (1.0)                                   | 1 (0.5)             |
| Nausea                                | 2 (0.5)     | 0                                                      | 0                              | 0                           | 0                           | 0                                         | 2 (1.1)             |
| Oedema peripheral                     | 5 (1.2)     | 0                                                      | 0                              | 0                           | 0                           | 0                                         | 0                   |
| PPE syndrome                          | 1 (0.2)     | 8 (3.7)                                                | 0                              | 0                           | 0                           | 5 (2.0)                                   | 0                   |
| Grades 3/4                            | 0           | 4 (1.8)                                                | 0                              | 0                           | 0                           | 3 (1.6)                                   | 0                   |
| Photosensitivity reaction             | 0           | 0                                                      | 0                              | 0                           | 0                           | 0                                         | 3 (1.6)             |
| Retinal vein occlusion                | 7 (1.6)     | 0                                                      | 0                              | 0                           | 0                           | 0                                         | 0                   |
| Grades 3/4                            | 5 (1.2)     | 0                                                      | 0                              | 0                           | 0                           | 0                                         | 0                   |
| Vomiting                              | 2 (0.5)     | 3 (1.4)                                                | 2 (0.5)                        |                             |                             |                                           | 1 (0.5)             |
| Grades 3/4                            | 1 (0.2)     | 2 (0.9)                                                | 2 (0.5)                        | 0 0                         | 0 0                         | 3 (1.6) 2 (1.0)                           | 0                   |

At the 4-month safety update, no AEs leading to study drug discontinuation were reported under new PTs in ≥2% of patients in any populations as compared to the initial MAA (except few switches to ~2% due to a single additional case in the population concerned).

## Post marketing experience

The applicant did not submit post-marketing experience as the product has not yet been marketed.

<div style=\"page-break-after: always\"></div>

## 2.6.1. Discussion on clinical safety

Safety information on encorafenib in combination with binimetinib in the proposed indication is based primarily on data from 274 patients in 3 clinical trials treated at the recommended dose of encorafenib 450 mg QD and binimetinib 45 mg BID [Combo 450 RP] in BRAF/ MEK inhibitor naïve patients. This is a small data set but considered sufficient to characterise the safety of the combination given that other BRAF/ MEK inhibitor combinations are already authorised. This data is supplemented by information from an additional 216 patients (total number 433 = Combo BP) treated with a combination of binimetinib 45 mg BID and encorafenib at doses from 300 mg to 600mg QD (Combo 400, n=4; Combo 600, n=62; Combo 450, n=367). In the Combo 450 subgroup, 274 patients were BRAF/MEK-treatment naïve (corresponding to the Combo 450 RP population) and 97 were non-naïve.

Safety data from 217 BRAF inhibitor naïve patients who received single agent encorafenib (Enco 300 P) population were provided for comparison. Data from the pivotal Study CMEK162B2301 were presented separately, for comparison of Combo 450, encorafenib and vemurafenib monotherapy (N=186).

The 4-month safety update provides an additional 750 patient-months of exposure in the Combo 450 RP population and 219 patient-months in the Enco 300 P population.

Safety data were also provided from the 258 patients randomised to the Combo 300 arm (one of whom was not treated) as of the 09 November 2016 cut-off date (Part 2). This was compared to the Combo 450 trial population.

The safety population is consistent with the target patient population with respect to gender and race, although the mean age of the trial patients was slightly lower than might be anticipated clinically; the results can be extrapolated to the intended population.

The median duration of exposure to study treatment was longer in the Combo 450 RP population than in the Enco 300 P population (50.6 weeks vs 29.7 weeks). The median relative dose intensity (RDI) was also higher for the combination (encorafenib 99.66%; binimetinib 99.5%) than single agent encorafenib (84.98%).

Despite the higher median relative dose intensity and longer median duration of exposure to study treatment in Combo 450 RP vs Enco 300 P, better general tolerability of Combo 450 (with encorafenib 450 mg QD) was observed compared to encorafenib single agent 300 mg QD or vemurafenib. A slightly lower percentage of patients in the Combo 450 RP, compared with the Enco 300 P population, experienced at least one Grade 3/4 AE (61.3% vs. 67.7%) or an AE leading to treatment discontinuation (11.7% vs. 18.0%). A bigger reduction was evident in AEs requiring dose interruption/change (52.2% vs. 71%). Similar percentages of patients experienced AEs requiring additional therapy (89.8% Combo 450 RP, 94.9% Enco 300 P).

The median time to onset of first Grade 3/4 AEs was longer in the Combo 450 RP population than in the Enco 300 P population: 2.6 months (95% CI: 1.8, 3.2) vs 0.4 months (95%CI: 0.3,0.9) [initial MAA].

Similarly, the proportion of patients experiencing these events was lower in the Combo 450 RP population than in the vemurafenib arm of Study CMEK162B2301.

However, the overall incidence of on-treatment deaths was higher in the Combo 450 RP than in Enco 300 P populations (10.2% vs 7.4%), with similar EAIRs of 0.73 vs 0.71 deaths per 100 patient-months respectively. Most on treatment deaths were due to malignant melanoma. Other causes of death in the Combo 450 RP population included multiple organ dysfunction, suicide, cerebral haemorrhage, euthanasia and myocardial infarction. In the Enco 300 P population, causes of death included pneumonia and acute MI. Mostly there was a single event involving a PT and no pattern was evident.

<div style=\"page-break-after: always\"></div>

The proportion of patients with SAEs was higher in the Combo 450 RP population than in Enco 300 P (40.1% vs 32.7%) but similar after adjustment for treatment exposure (EAIRs of 3.9 and 3.5 per 100 patientmonths); the EAIR was higher in the vemurafenib arm (4.96 per 100 patient-months). The only SAE which was increased by ≥2% in the Combo 450 RP vs Enco 300 P population was pyrexia (3.5% vs. 1.4%).

The overall safety profile of single agent encorafenib (Enco 300 P) was consistent with the mechanism of action and the known toxicities of BRAF inhibitors. The AE profile of the two BRAF inhibitors was similar but differences were evident. The overall EAIR was notably higher in the Enco 300 P population than in the vemurafenib arm (604.83 vs 226.32 per 100 patient-months). Vemurafenib caused relatively more photosensitivity, diarrhoea, pyrexia and squamous cell carcinoma whilst encorafenib (Enco 300 P) caused more constipation, neuropathy, facial paresis, myalgia and melanocytic naevus.

The most common ADRs ( ≥ 25 %) for Enco 300 P were hyperkeratosis (58.5%), alopecia (57.1%), palmar plantar erythrodysaesthesia syndrome (51.6%), rash (43.3%), arthralgia (43.3%), nausea (37.8%), dry skin (37.8%), myalgia (35.9%), headache (29%), fatigue (43.8%), vomiting (27.6%), pruritus (29.5%). The most common Grade 3/4 ADRs ( ≥ 5%) were PPE syndrome (12.4%), arthralgia (9.2%), myalgia (9.2%) and hyperkeratosis (6%). When adjusted for exposure, AEs with an EAIR of ≥ 5 per 100 patient-months in the Enco 300 P population included alopecia (13.14), PPE syndrome (10.45), arthralgia (8.4), hyperkeratosis (7.13) and nausea (5.87).

In the Combo 450 RP population, most of the observed toxicities were BRAF or MEK inhibitor driven and involved gastrointestinal, ocular, liver, muscular and cutaneous events. The most commonly reported adverse events ( ≥ 20%) in the Combo 450 RP population included fatigue (41.6%) and gastrointestinal disorders: nausea (41.6%), diarrhoea (38%), vomiting (28.1%), constipation (24.1%), arthralgia and increased blood CK (both 27.0%). Most of the events were Grade 1 or 2 in severity. The most common Grade 3/4 AEs were increased transaminases (5.5%), increased gamma GT (8.4%), hypertension (5.5%) and CK elevation (5.8%).

With combination treatment, the incidence of non-malignant skin AEs, arthralgia, myalgia, decreased appetite and insomnia was decreased compared to single agent encorafenib. The decreases in overall incidences of these AESIs with Combo 450 were generally associated with relevant decreases in Grade 3/4 events, dose adjustments/study drug interruptions and use of additional therapies. Conversely, the incidence of diarrhoea, abdominal pain, retinopathy, hypertension, increased blood CK and increased transaminases was greater with Combo 450 vs. Enco 300.

Adjusted for exposure, the only AE in the Combo 450 RP arm with an EAIR of ≥ 5 per 100 patient-months was nausea (5.21). Adjusted for exposure, the rates of alopecia, PPE, arthralgia, hyperkeratosis and rash were higher with single agent encorafenib than combination treatment. Although no AEs with an EAIR of ≥ 5 per 100 patient-months were reported at a higher incidence in the Combo 450 RP population than in the Enco 300 P population (difference of ≥ 5) the rate of diarrhoea (4.87 vs. 1.46) and increased CK (2.66 vs. 0.1) was higher with combination treatment (Combo 450 RP vs Enco 300 P respectively). The increase in blood CK observed with Combo 450 was rarely associated with clinical symptoms.

The proportion of patients with haemorrhagic events was higher in the combination but the incidence was similar  when  adjusted  for  treatment  duration  (1.55  vs  1.52  cases  per  100  patient  months).  No  serious haemorrhage with established causal relationship to the combination was reported, although there were 3 cases  of  intracranial  haemorrhage  (1  fatal)  in  the  setting  of  brain  metastases.  On  review  none  of  the hemorrhagic events correlated with changes in coagulation parameters (i.e. increased INR) or thrombocytopenia.

<div style=\"page-break-after: always\"></div>

Haemorrhages, including major haemorrhagic events, can occur with encorafenib (see section 4.8). The risk of haemorrhage may be increased with concomitant use of anticoagulant and antiplatelet therapy. The occurrence of Grade ≥ 3 haemorrhagic events should be managed with dose interruption or treatment discontinuation (see Table 3 in section 4.2) and as clinically indicated.

New primary malignancies, cutaneous and non-cutaneous, have been observed in patients treated with BRAF inhibitors and can occur when encorafenib is administered (see section 4.8). No case of new primary melanoma was reported in the Combo 450 RP population compared to 4.1% in the Enco 300 P population, and fewer patients experienced cutaneous squamous cell carcinoma in the Combo 450 RP compared to Enco 300 P single agent group (2.6% vs. 6.9%). Cutaneous malignancies such as cutaneous squamous cell carcinoma (cuSCC) including kerathoacanthoma has been observed in patients treated with BRAF-inhibitors including encorafenib.

New primary melanoma has been observed in patients treated with BRAF inhibitors including encorafenib (see section 4.8). For new primary cutaneous malignancies: No dose modifications are required for encorafenib. For new primary non-cutaneous RAS mutation-positive malignancies: it should be considered to discontinue encorafenib and binimetinib permanently.

Dermatologic evaluations should be performed prior to initiation of therapy with encorafenib in combination with binimetinib, every 2 months while on therapy and for up to 6 months following discontinuation of the combination. Suspicious skin lesions should be managed with dermatological excision and dermatopathologic evaluation. Patients should be instructed to immediately inform their physicians if new skin lesions develop. Encorafenib and binimetinib should be continued without any dose modification.

Based on its mechanism of action, encorafenib may promote malignancies associated with activation of RAS through mutation or other mechanisms. Patients receiving encorafenib should undergo a head and neck examination, chest/abdomen computerised tomography (CT) scan, anal and pelvic examinations (for women) and complete blood cell counts prior to initiation, during and at the end of treatment as clinically appropriate. It should be considered to permanently discontinue encorafenib in patients who develop RAS mutationpositive non-cutaneous malignancies. Benefits and risks should be carefully considered before administering encorafenib to patients with a prior or concurrent cancer associated with RAS mutation.

The most common binimetinib-driven ADRs included skin reactions, ocular reactions (retinal detachment, visual impairment), left ventricular dysfunction, hypertension and CK elevation. These can be managed via monitoring of left ventricular function, blood pressure and ophthalmological assessments with dose modifications as needed.

LVD defined as symptomatic or asymptomatic decreases in ejection fraction has been reported when encorafenib is used in combination with binimetinib.

It is recommended that left ventricular ejection fraction (LVEF) is assessed by echocardiogram or multi-gated acquisition (MUGA) scan before initiation of encorafenib and binimetinib, one month after initiation, and then at approximately 3-month intervals or more frequently as clinically indicated, while on treatment. If during treatment LVD occurs, see section 4.2 of binimetinib SmPC.

The safety of encorafenib in combination with binimetinib has not been established in patients with a baseline LVEF that is either below 50% or below the institutional lower limits of normal. Therefore, in these patients, binimetinib should be used with caution and for any symptomatic left ventricular dysfunction, Grade 3-4 LVEF or for absolute decrease of LVEF from baseline of ≥ 10%, binimetinib and encorafenib should be discontinued and LVEF should be evaluated every 2 weeks until recovery.

<div style=\"page-break-after: always\"></div>

Ocular toxicities including uveitis, iritis and iridocyclitis can occur when encorafenib is administered. RPED has also been reported in patients treated with encorafenib in combination with binimetinib (see section 4.8).

Patients should be assessed at each visit for symptoms of new or worsening visual disturbance. If symptoms of new or worsening visual disturbances including diminished central vision, blurred vision or loss of vision are identified, a prompt ophthalmologic examination is recommended.

If, uveitis including iridocyclitis and iritis occurs during treatment, see section 4.2.

If during treatment patient develops RPED or RVO, see section 4.2 of binimetinib SmPC for guidance.

The incidence of liver function test abnormalities, including Grade 3/4 events, was higher with combination treatment compared to single agent encorafenib. However, none met the criteria for Hy's Law. There was one case of hepatic failure associated with disease progression that was not considered related to the combination treatment but attributed to new hepatic metastases. The incidence of GGT abnormalities was higher with combination treatment (14.6% overall; Grade 3/4 8.4%). This parameter is less specific for hepatic toxicity than ALT, ALP, bilirubin and other hepatic parameters and may not reflect hepatic toxicity. It may be due to the inducer effect of encorafenib on liver metabolism via CYP3A4.

Liver laboratory abnormalities including AST and ALT elevations have been observed with encorafenib (see section 4.8). Liver laboratory values should be monitored before initiation of encorafenib and binimetinib and monitored at least monthly during the 6 first months of treatment, then as clinically indicated. Liver laboratory abnormalities should be managed with dose interruption, reduction or treatment discontinuation (see section 4.2).

Renal dysfunction including creatinine elevation and renal failure (renal failure, acute kidney injury and renal impairment) was a common adverse effect for encorafenib as single agent and in combination with binimetinib in Combo 450. Renal dysfunction was frequently associated with gastrointestinal events/dehydration. Clinical data shows reversibility when it is managed through dose modification, standard care and corrective therapy.

Relatively few patients discontinued treatment due to an AE (11.7% vs. 18.0% - Combo 450 vs Enco 300).

In patients treated with Combo 450 (n = 274), 194 patients (70.8%) were &lt;65 years old, 65 patients (23.7%) were 65 -74 years old and 15 patients (5.5%) were aged &gt; 75. No overall differences in safety or efficacy were observed between elderly patients (≥ 65) and younger patients. The proportions of patients experiencing adverse events (AE) and serious adverse events (SAE) were similar in patients aged &lt;65 years and those aged ≥65 years. The most common AEs reported with a higher incidence in patients aged ≥ 65 years compared to patients aged &lt; 65 years included diarrhoea, pruritus, GGT and blood phosphatase alkaline elevation. In the small group of patients aged ≥75 years (n=15), patients were more likely to experience serious adverse events and adverse events leading to discontinuation of treatment.

The incidence of pyrexia was distinctly lower in the Combo 450 RP population and secondary causes were generally evident. Pyrexia was the most commonly reported SAE by PT in the Combo 450 arm of Study CMEK162B2301 in 6 (3.1%) patients. None of the 6 patients had concurrent events of hypotension, chills/rigors, dehydration, renal failure or syncope and most had concurrent factors including disease progression or underlying infection which may have contributed to the pyrexia. Compared to other MEK/BRAF inhibitors, Grade 3/4 anaemia was reported more often with binimetinib/encorafenib. The incidence of abdominal pain was higher compared to other MEK/BRAF inhibitor combinations.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

<div style=\"page-break-after: always\"></div>

Encorafenib has minor influence on the ability to drive or use machines. Visual disturbances have been reported in some patients treated with encorafenib during clinical studies. Patients should be advised not to drive or use machines if they experience visual disturbances or any other adverse reactions that may affect their ability to drive and use machines (see sections 4.4 and 4.8).

## Overdose Symptoms

At doses of encorafenib between 600 to 800 mg once daily, renal dysfunction (Grade 3 hypercreatinaemia) was observed in 3 out of 14 patients. The highest administered dose occurred as a dosing error in one patient who took encorafenib at a dose of 600 mg twice daily for 1 day (total dose 1200 mg). Adverse reactions reported by this patient were Grade 1 events of nausea, vomiting and blurred vision; all subsequently resolved.

## Management

There is no specific treatment for overdose.

Since encorafenib is moderately bound to plasma proteins, haemodialysis is likely to be ineffective in the treatment of overdose with encorafenib. There is no known antidote for encorafenib. In the event of an overdose, encorafenib treatment should be interrupted and renal function must be monitored as well as adverse reactions. Symptomatic treatment and supportive care should be provided as needed.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

Dose modifications in case of adverse reactions are provided below and in Table 2 and 3 of the SmPC.

If treatment-related toxicities occur, then encorafenib and binimetinib should be simultaneously dose reduced, interrupted or discontinued. Exceptions where dose modifications are necessary for binimetinib only (adverse reactions primarily related to binimetinib) are: retinal pigment epithelial detachment (RPED), retinal vein occlusion (RVO), interstitial lung disease/pneumonitis, cardiac dysfunction, creatine phosphokinase (CK) elevation and rhabdomyolysis, and venous thromboembolism (VTE).

If one of these toxicities occurs, see section 4.2 of binimetinib SmPC for dose modification instructions for binimetinib.

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics.

## Combo 450 vs Combo 300

The median duration of exposure in the Combo 450 and Combo 300 arms were similar with, respectively, 52.6% and 54.9% of patients having received ≥ 48 weeks of study treatment.

The overall tolerability profiles of these two combinations were broadly similar (for AEs requiring discontinuation, dose modifications or additional therapy) but Combo 450 led to an increased incidence of SAEs and Grade 3-4 AEs. Combo 450 generated an increased incidence of the most common side effects compared to Combo 300, particularly nausea (41.1 vs. 27.2%), vomiting (29.7 vs. 15.2) and headache (21.9 vs. 11.7%).

The median time to onset of key tolerability parameters was longer in the Combo 300 arm compared with the Combo 450 arm for:

<div style=\"page-break-after: always\"></div>

- First SAE (3.5 vs 4.7 months respectively)
- First AE resulting in study drug discontinuation (3.8 vs 4.7 months respectively)

The percentage of patients with one or more encorafenib AESI (any grade) was similar in the two populations (14.6% vs 14.4%). Surprisingly, the percentage of patients with one or more binimetinib specific AESIs (any grade) was higher too in the Combo 450 arm compared with the Combo 300 arm (69.3% vs 56.8% respectively). However, the incidence of binimetinib specific AESIS leading to drug discontinuation or drug modification were similar between Combo 450 and Combo 300. This may be due to a rather arbitrary allocation of AESI between encorafenib and binimetinib in the original assessment, which has since been changed/ rectified. Retinopathy (excluding retinal vein occlusion), rash, liver function tests (LFT) abnormalities, haemorrhage and hypertension were more common for Combo 450 vs Combo 300.

This is comparison of Combo 450 vs. Combo 300 is a post-hoc analysis and patients were recruited at different times (30 Dec 2013 to 10 Apr 2015 for Combo 450 and 19 March 2015 to 12 Nov 2015 for Combo 300). It is possible that investigators had more experience in treating/ preventing AEs by the time of recruitment to Combo 300; given that different centres participated in Part 1 and Part 2 of the study it is more likely that the difference is simply due to the encorafenib dose.

## 2.6.2. Conclusions on the clinical safety

Encorafenib  was  associated  with  more  AEs  than  vemurafenib.  The  overall  incidence  was  reduced  by  the combination with binimetinib, mainly due to the reduction in skin-related AEs. Diarrhoea, increased blood CK and liver function test abnormalities were more prevalent with the Combo 450 than single agent encorafenib 300mg.  There  was  no  difference  in  the  exposure-adjusted  incidence  of  SAEs  between  Combo  450  and encorafenib  monotherapy.  Most  AEs  appeared  to  be  manageable  with  dose  reduction/  interruption  and additional therapy. Combo 450 led to an increased incidence of SAEs and Grade 3/4 AEs compared to Combo 300. The AE profile for Combo 300 should be conveyed in the SmPC, section 4.8 ( OC ).

## 2.7. Risk Management Plan

## Safety concerns

| Safety concerns for encorafenib                                                                                                                                                                                                     | Additional safety concerns for encorafenib in combination with binimetinib   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Important identified risks                                                                                                                                                                                                          |                                                                              |
| - Secondary skin neoplasms: cuSCC and new primary melanoma - Palmar-plantar erythrodysaesthesia syndrome                                                                                                                            | - Haemorrhage                                                                |
| Important potential risks                                                                                                                                                                                                           |                                                                              |
| - QT prolongation - Non-cutaneous malignancies with RAS mutation - Over-exposure due to concomitant use with strong and moderate CYP450 3A4 inhibitors - Embryo-foetal toxicity - Over-exposure in patients with moderate to severe | - Hepatotoxicity                                                             |

<div style=\"page-break-after: always\"></div>

| -                   | hepatic impairment Potential for renal dysfunction due to overdose   |                     |
|---------------------|----------------------------------------------------------------------|---------------------|
| Missing information | Missing information                                                  | Missing information |
| -                   | Use in patients with severe renal impairment                         | None                |

## Pharmacovigilance plan

There is no planned or ongoing additional study in the pharmacovigilance plan.

Routine pharmacovigilance activities are sufficient to address the safety concerns of this medicinal product.

## Risk minimisation measures

| Safety concern                                                                        | Risk minimisation measures                                                                                                                                                                                                                                                                     | Pharmacovigilance activities                                                          |
|---------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| Important identified risks for encorafenib                                            | Important identified risks for encorafenib                                                                                                                                                                                                                                                     | Important identified risks for encorafenib                                            |
| Secondary skin neoplasms: cutaneous squamous cell carcinoma and new primary melanoma  | Routine: Warning in Section 4.4 of the SmPC and relevant PIL section Listed in Section 4.8 of the SmPC and relevant PIL section Prescription only medicine. Use restricted to physicians experienced in the treatment of cancer Additional: none                                               | Routine Additional: none                                                              |
| Palmar-plantar erythrodysaesthesia syndrome                                           | Routine: Dose modification recommendations in Section 4.2 of the SmPC Listed in Section 4.8 of the SmPC and relevant PIL section Prescription only medicine. Use restricted to physicians experienced in the treatment of cancer Additional: none                                              | Routine Additional: none                                                              |
| Additional important identified risks for encorafenib in combination with binimetinib | Additional important identified risks for encorafenib in combination with binimetinib                                                                                                                                                                                                          | Additional important identified risks for encorafenib in combination with binimetinib |
| Haemorrhage                                                                           | Routine: Dose modification recommendations in section 4.2 of the SmPC Warning in section 4.4 of the SmPC and relevant PIL section Listed in Section 4.8 of the SmPC and relevant PIL section. Prescription only medicine. Use restricted to physicians experienced in the treatment of cancer. | Routine Additional: none                                                              |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                      | Risk minimisation measures                                                                                                                                                                                                                                      | Pharmacovigilance activities              |
|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
|                                                                                     | Additional: none                                                                                                                                                                                                                                                |                                           |
| Important potential risks for encorafenib                                           | Important potential risks for encorafenib                                                                                                                                                                                                                       | Important potential risks for encorafenib |
| QT prolongation                                                                     | Routine: Dose modification recommendations in section 4.2 of the SmPC Warning in Section 4.4 of the SmPC and relevant PIL section Prescription only medicine. Use restricted to physicians experienced in the treatment of cancer Additional: none              | Routine Additional: none                  |
| Non-cutaneous malignancies with RAS mutation                                        | Routine: Dose modification recommendations in section 4.2 of the SmPC Warning in Section 4.4 of the SmPC and relevant PIL section Prescription only medicine. Use restricted to physicians experienced in the treatment of cancer Additional: none              | Routine Additional: none                  |
| Over-exposure due to concomitant use with strong and moderate CYP450 3A4 inhibitors | Routine: Warning in section 4.4 of the SmPC and relevant PIL sections Discussion in section 4.5 Prescription only medicine. Use restricted to physicians experienced in the treatment of cancer Additional: none                                                | Routine Additional: none                  |
| Embryo-foetal toxicity                                                              | Routine: Warning in Section 4.6 and information in Section 5.3 of the SmPC and relevant PIL section. Prescription only medicine. Use restricted to physicians experienced in the treatment of cancer. Additional: none                                          | Routine Additional: none                  |
| Over-exposure in patients with moderate to severe hepatic impairment                | Routine: Dose modification recommendations in section 4.2 of the SmPC and PIL relevant section Warning in section 4.4 and relevant PIL section Prescription only medicine. Use restricted to physicians experienced in the treatment of cancer Additional: none | Routine Additional: none                  |
| Potential for renal dysfunction due to overdose                                     | Routine:                                                                                                                                                                                                                                                        | Routine                                   |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                           | Risk minimisation measures                                                                                                                                                                                                                                                                                       | Pharmacovigilance activities                                                             |
|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
|                                                                                          | Listed in section 4.9 of SmPC Prescription only medicine. Use restricted to physicians experienced in the treatment of cancer Additional: none                                                                                                                                                                   | Additional: none                                                                         |
| Additional important potential risks for encorafenib in combination with binimetinib     | Additional important potential risks for encorafenib in combination with binimetinib                                                                                                                                                                                                                             | Additional important potential risks for encorafenib in combination with binimetinib     |
| Hepatotoxicity                                                                           | Routine: Dose modification recommendations in Section 4.2 of the SmPC Warning in Section 4.4 of the SmPC and relevant PIL section. Listed in Section 4.8 of the SmPC and relevant PIL section. Prescription only medicine. Use restricted to physicians experienced in the treatment of cancer. Additional: none | Routine Additional: none                                                                 |
| Missing information for encorafenib                                                      | Missing information for encorafenib                                                                                                                                                                                                                                                                              | Missing information for encorafenib                                                      |
| Use in patients with severe renal impairment                                             | Routine: Dosing recommendations in section 4.2 of the SmPC Warning in section 4.4 of the SmPC and relevant PIL section Prescription only medicine. Use restricted to physicians experienced in the treatment of cancer Additional: none                                                                          | Routine Additional: none                                                                 |
| Additional missing information for risks for encorafenib in combination with binimetinib | Additional missing information for risks for encorafenib in combination with binimetinib                                                                                                                                                                                                                         | Additional missing information for risks for encorafenib in combination with binimetinib |
| None                                                                                     |                                                                                                                                                                                                                                                                                                                  |                                                                                          |

Routine risk minimisation measures are considered sufficient to minimise the safety concerns of this medicinal product.

## Conclusion

The CHMP and PRAC considered that the risk management plan version 0.5 is acceptable.

## 2.8. Pharmacovigilance

## Pharmacovigilance system

The  CHMP  considered  that  the  pharmacovigilance  system  summary  submitted  by  the  applicant  fulfils  the requirements of Article 8(3) of Directive 2001/83/EC.

<div style=\"page-break-after: always\"></div>

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 27 June 2018. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points.

## 2.9. New Active Substance

The applicant compared the structure of encorafenib with active substances contained in authorised medicinal products in the European Union and declared that it is not a salt, ester, ether, isomer, mixture of isomers, complex or derivative of any of them.

The CHMP, based on the available data, considers encorafenib to be a new active substance as it is not a constituent of a medicinal product previously authorised within the European Union.

## 2.10. Product information

## 2.10.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.10.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Braftovi (encorafenib) is included in the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU.

Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The MAH applied for an indication of encorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

## 3.1.2. Available therapies and unmet medical need

BRAF- MEK inhibitor combination regimens are currently the main standard of care for treatment of advanced unresectable or metastatic melanoma that have tumours harbouring the BRAF V600 mutation.  Tumour

<div style=\"page-break-after: always\"></div>

responses have reported as high as up to 70% and rapid response induction has been associated with symptom control. Median PFS has been shown to be increased to approximately 12 months and this has translated into an improvement in median OS to 22-25 months.

Other treatment options include anti PD-1 antibodies, nivolumab and pembrolizumab, which showed a clinically and statistically significant PFS benefit over the anti-CTLA4 antibody ipilimumab. Emerging data suggest that BRAF inhibition is effective following immunotherapy, and checkpoint inhibitors are still effective in patients who have progressed on kinase-inhibitor therapy.

Although there are treatments for metastatic melanoma with BRAFV600 mutation that have shown clinical benefit, patients usually relapse or discontinue due to AE or tolerability issues. Therefore, there is still a need for treatment choices with improved efficacy or different safety profiles over existing medicinal products.

## 3.1.3. Main clinical studies

The Phase 3 clinical study (COLUMBUS) was a randomised, open label trial in patients with advanced unresectable or metastatic BRAF (either V600 E or K) mutation-positive melanoma comprised of 2 parts:

- -Part 1 randomised 577 patients in a 1:1:1 ratio to encorafenib 450mg QD and binimetinib 45mg BID (Combo 450, N=192), encorafenib 300mg QD (N=194) or vemurafenib 960mg BID (N=191). Randomisation was stratified by AJCC stage, ECOG performance status and prior first line immunotherapy.
- -Part 2 was planned to randomise 320 patients in a 3: 1 ratio to Combo 300 (encorafenib 300mg QD and binimetinib 45mg BID) or encorafenib 300mg QD. This part of the trial was to estimate the treatment effect of Combo 300 vs. LGX818 in terms of overall survival (OS), estimate the treatment effect of Combo 300 vs. vemurafenib in terms of PFS and OS and estimate the treatment effect of Combo 300 vs. Combo 450 in terms of PFS and OS.

The DMC advised study termination on 14 October 2016 based on unblinded efficacy data, including OS results to which the Sponsor remained blinded. The Part 1 efficacy data were presented in the initial dossier and the Part 2 results were provided during the procedure.

## 3.2. Favourable effects

The trial met its primary endpoint, with an improved median PFS by 7.6 months in the Combo 450 arm compared to single agent vemurafenib with a median PFS of 14.9 months vs. 7.3 months, respectively, HR = 0.54 (95% CI 0.41, 0.71, 1 -sided stratified log-rank p&lt;0.001) is the FAS.

The results in the per protocol set (PPS) by BIRC were supportive of the primary analysis. Median PFS was 15.5 months (95% CI, 11.0, 18.7) in the Combo 450 arm and 7.3 months (95% CI, 5.6, 8.3) in the vemurafenib arm, HR=0.53 (95% CI, 0.40, 0.70; nominal p &lt; 0.001).

The HR was consistent by investigator review and in the sensitivity analyses, including an analysis counting new therapy as an event (HR=0.53).

The median PFS of single agent vemurafenib (7.3 months) was consistent with what has been seen in previous studies and, it was noted that the median PFS of the Combo 450 (14.9 months) was longer than that reported for  other BRAF- MEK inhibitor combination treatments (median PFS for trametinib and dabrafenib = 11.4 months; cobimetinib and vemurafenib = 12.3 months).

<div style=\"page-break-after: always\"></div>

Encorafenib monotherapy increased median PFS by 2.3 months compared to vemurafenib (9.6 months vs. 7.3 months; nominal one-sided log-rank p = 0.004; HR = 0.68, 95% CI 0.52, 0.90) by BIRC. This was a secondary efficacy endpoint, downgraded from a co-primary endpoint with Protocol Amendment 3 (post randomisation of 364 patients). Investigator assessment of response gave similar median PFS durations. Median PFS values by BIRC were the same in the PPS as in the FAS.

The confirmed overall response rate (ORR) per BIRC was higher with combination treatment: 63.0% (95% CI 55.8, 69.9) in the Combo 450 arm compared with 50.5% (95% CI 43.3, 57.8) in the encorafenib arm and 40.3% (95% CI 33.3, 47.6) in the vemurafenib arm.

The disease control rate (DCR) per BIRC was 92.2% (95% CI 87.4, 95.6) in the Combo 450 arm compared with 84.0% (95% CI 78.1, 88.9) in the encorafenib arm and 81.7% (95% CI 75.4, 86.9) in the vemurafenib arm.

Median time to objective response (TTR) per BIRC, calculated for responding patients only (confirmation not required), was 1.9 months in the Combo 450 arm (95% CI 1.9, 1.9), 2.0 months in the encorafenib arm (95% CI 1.9, 3.6) and 2.1 months in the vemurafenib arm (95% CI 1.9, 3.7).

The median time to definitive 10% deterioration in the FACT-M global health status score was not reached in the Combo 450 arm (95% CI 22.1, NE) and was 22.1 months (95% CI 15.2, NE) in the vemurafenib arm with a HR for the difference of 0.46 (95% CI 0.29, 0.72) using a stratified Cox regression model. The median time to definitive 10% deterioration in the FACT-M was 20.3 months (95% CI 15.0, NE) in the encorafenib arm with a HR for the difference between Combo 450 and encorafenib of 0.48 (95% CI 0.31, 0.75) using a stratified Cox regression model.

The median time to definitive 10% deterioration in the EORTC QLQ-C30 global health status score was delayed by 7.3 months in the Combo 450 arm compared to the vemurafenib arm: 23.9 months (95% CI 20.4, NE) vs. 16.6 months (95% CI 11.9, NE) with a HR for the difference of 0.55 (95% CI 0.37, 0.80) using a stratified Cox regression model. The median time to definitive 10% deterioration in the QLQ-C30 global health status scores was 9.2 months longer in the Combo 450 arm compared with the Enco 300 arm (14.7 months [95% CI 9.2, 18.4]), with a HR for the difference of 0.45 (95% CI 0.31, 0.65) using a stratified Cox regression model.

The median OS was 33.6 months (95% CI [24.4, 39.2]) and 16.9 months ((95% CI [14.0, 24.5]) for Combo 450 compared to vemurafenib (HR 0.61, 95% CI 0.47, 0.79, nominal p value &lt;0.0001). Estimates of OS at 12 months and 24 months were 75.5% (95% CI [68.8, 81.0]) and 57.6% ((95% CI [50.3, 64.3]) for Combo 450 compared to 63.1% ((95% CI [55.7, 69.6]) and 43.2% ((95% CI [35.9, 50.2]) for vemurafenib.

The  median  (95%  CI)  OS  was  33.6  months  (24.4,  39.2)  and  23.5  months  (19.6,  33.6)  with  Combo  450 compared to  encorafenib,  respectively,  with  a  HR  0.81  (95%  CI  0.61,  1.0;  nominal  p  value  =0.0613,  2sided). Estimates of OS at 12 months and 24 months were 75.5% (68.8, 81.0) and 57.6% (50.3, 64.3) for Combo 450 compared to 74.6% (67.6, 80.3) and 49.1% (41.5, 56.2) for encorafenib.

## 3.3. Uncertainties and limitations about favourable effects

There were some uncertainties concerning the best dose for encorafenib (450mg vs 300 mg) that should be used in combination with binimetinib. Single agent binimetinib has limited activity in BRAF-mutated melanoma patients. In the phase II study CMEK162X2201, the 4.9% response rate in 41 patients, based on locally assessed unconfirmed responses, is low for a monotherapy MEK inhibitor compared to results of

<div style=\"page-break-after: always\"></div>

trametinib reported in a pivotal phase III study. Binimetinib 45mg BID contributed to the efficacy of Combo 300 and allowed a higher dose of encorafenib to be administered in Combo 450.

It was unclear whether Combo 450 offered an additional PFS benefit over Combo 300. In the analysis with comparable median duration of potential follow-up for PFS (16.7 months and 13.9 months), Combo 450 showed a median 2-month improvement in PFS compared with Combo 300 (14.9 vs 12.9 months). This difference was not statistically significant (HR of 0.79 [95% CI 0.60, 1.03]) one-sided log-rank p=0.0845). The second analysis performed using the 09 November 2016 cut-off date for the two arms was statistically significant (HR 0.73 95%CI [0.55 0.97]; 2-sided p=0.0278). However, this result is due to a very uneven duration of follow-up for PFS per BIRC (Kaplan Meier) with 22.5 months for Part 1 Combo 450 arm compared with 13.9 months for Part 2 Combo 300 arm. Combo 450 did not improve the response rate compared with Combo 300 (63.0% vs 65.9%) but did lead to a numerically longer duration of confirmed responses (16.6 months vs 12.7 months).

Normally statistical significance would not be demanded between the two parts of the study and the 2.8month improvement in median PFS with Combo 450 compared with Combo 300 could be considered clinically relevant. However, in this instance, the fact that encorafenib 300mg performed significantly better in Part 1 than in Part 2 with a 2.2-month difference in median PFS hinders the PFS comparison of the combination treatment (Combo 450 vs Combo 300) between the two parts of the study. Therefore, the OS results for Combo 300 and updated Combo 300 PFS analysis, including more mature data for the Enco300 Part 2 arm will be provide as a post-authorisation measure.

The Exposure-Response analyses suggest that increasing encorafenib AUCss in Combo 450 has a negative influence on ORR and PFS. Baseline LDH &gt;ULN was more common in patients with a higher AUCss; high LDH is known to be a negative prognostic marker predicting a shorter PFS. In Part 1, in the high LDH group only patients with high encorafenib exposure in Combo 450 did worse. There was no such finding with Combo 300 in Part 2. There remains the possibility that this association in the Combo 450 arm is a chance finding or artefact. It remains possible that the B/R ratio could be improved in patients with high baseline LDH by identification of other factors that potentially influence encorafenib exposure. Therefore, the applicant is requested to submit the overall survival results stratified by LDH level for Combo 300 and Enco 300 (Part 2) as a post-authorisation measure.

In order to characterise the patient population that responds to treatment, the applicant is requested to submit the results of the planned biomarker analyses for Study B2301 (from all 3 treatment arms) for evaluation as soon as available, to support the synergistic pharmacodynamic activity of encorafenib in combination with binimetinib. The results will be provided as a recommendation.

In addition, genomic analysis of baseline samples remaining after centralized BRAF testing would be informative to assess whether there is a relationship between baseline mutations and efficacy outcomes. As indicated in the protocol, genomic alterations in BRAF, HRAS, KRAS, NRAS, PTEN, cKIT, PIK3CA, MAP2K1, MAP2K2, ARAF, c-MET, CRAF, EGFR and CCND1 may be explored to find a potential association between baseline mutations and efficacy outcomes. The results will be provided as a recommendation.

## 3.4. Unfavourable effects

For Combo 450 P, the incidence of AEs was 98.9% with Grade 3/4 AEs reported in 58.0% patients (Grade 4, 9.9%); the median time to onset of the first Grade 3/4 AE was 2.5 months. AEs led to dose interruption/ change in 47.1% patients, additional therapy in 86.1% and treatment discontinuation in 10.4%.

<div style=\"page-break-after: always\"></div>

The safety of encorafenib (450 mg orally once daily) in combination with binimetinib (45 mg orally twice daily) was evaluated in 274 patients with BRAF V600 mutant unresectable or metastatic melanoma (hereafter referred to as the pooled Combo 450 population), based on two Phase II studies (CMEK162X2110 and CLGX818X2109) and one Phase III study (CMEK162B2301, Part 1). At the recommended dose (n = 274) in patients with unresectable or metastatic melanoma, the most common adverse reactions (&gt;25%) occurring in patients treated with encorafenib administered with binimetinib were fatigue, nausea, diarrhoea, vomiting, retinal detachment, abdominal pain, arthralgia, blood CK increased and myalgia.

When encorafenib was used at a dose of 300 mg once daily in combination with binimetinib 45 mg twice daily (Combo 300) in study CMEK162B2301-Part 2, the frequency category was lower compared to the pooled Combo 450 population for the following adverse reactions: anemia, peripheral neuropathy, haemorrhage, hypertension, pruritus (common); and colitis, increased amylase and increased lipase (uncommon).

Encorafenib exposure and risk of toxicity is increased in patients with mild hepatic impairment and use of concomitant CYP3A4 inhibitors.

The addition of binimetinib (Combo 450 RP) attenuated some of the adverse events of special interest (AESIs) compared to single agent encorafenib (Enco 300 P). These were mainly non-malignant skin AESIs, myopathy -related AESIs (myalgia), cutaneous squamous cell carcinoma and new melanoma. Facial paresis (facial paralysis) was an AE associated with encorafenib monotherapy that was also reduced with combination treatment (7.4% vs. 0.7%), as was tachycardia (6% vs. 1.8%).

Other AESI were worsened or enhanced by the addition of binimetinib (Combo 450 RP compared to Enco 300 P). These included retinopathies (52.6% vs 12.4%); increased blood CK (24.8% vs 1.4%) with 5.5% Grade 3/4 events; left ventricular dysfunction (8.4% vs 1.8%); hypertension (12% vs 5.5%) with Grade 3/4 (6.2% vs 2.8%) and abnormal liver function tests (25.2% vs 13.8%). No cases consistent with Hy's Law were reported. There was one event of liver failure in the context of liver metastases, deemed unrelated to treatment.

The incidence of haemorrhage-related events was similar in the Combo 450 RP and Enco 300 P populations (15.7%-1.55 cases per 100 patient-months vs 12.9%-1.52 cases per 100 patient-months) Haemorrhage is a class effect for MEK inhibitors and is an important identified risk for binimetinib. Haemorrhagic events in the Combo 450 RP population (16.8%, 46/274) were mainly Grade 1/2 (14.2%) with few dose reductions or interruptions and treatment discontinuations in 3 (1.1%). The most frequent haemorrhagic events were GI. Intracranial haemorrhage was reported in 1.6% (3/192) of patients in the setting of new or progressive brain metastases including one fatal event.

The incidence of on-treatment deaths (within 30 days of the last dose) was similar for Combo 450 RP (8.4%), Enco300 P (6.9%) and vemurafenib (10.2%) and most of the deaths were due to malignant melanoma.

The overall tolerability profiles of Combo 450 and Combo 300 were broadly similar in terms of AEs requiring discontinuation, dose modifications or additional therapy but Combo 450 led to increased incidence of SAEs and Grade 3-4 AEs. Combo 450 generated an increased incidence of the most common side effects compared to Combo 300, particularly nausea (41.1 vs. 27.2%), vomiting (29.7 vs. 15.2) and headache (21.9 vs. 11.7%). The time to first SAE and AE resulting in study drug discontinuation was shorter for Combo 450.

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

There were no studies or data in patients with moderate or severe hepatic impairment and studies have shown that there is a risk for over-exposure in patients with moderate to severe hepatic impairment. Therefore, a warning in section 4.4 has been included that in the absence of clinical data, encorafenib is not recommended in patients with moderate or severe hepatic impairment.

Although a QT study has not been conducted, encorafenib was shown to have the potential to cause QT prolongation at clinically relevant doses. In Study CMEK162B2301, QTcF increases by &gt;60 ms were observed in 5.4%, 3.9% and 5.6% of patients in the Combo 450, Enco 300 and vemurafenib arms, respectively and new QTcF values &gt;500 ms were observed in 0.5%, 2.8% and 1.7% of patients, respectively. QTc prolongation is a class-effect of BRAF inhibitors. Therefore, a warning in the SmPC section 4.4 has been included.

Based on the mechanism of action, non-cutaneous malignancies could potentially arise as a result of treatment with encorafenib and binimetinib and therefore, a warning has been included in the SmPC section 4.4.

Encorafenib is mainly metabolised via CYP3A4 and there is a possibility of over-exposure due to concomitant use with strong and moderate CYP450 3A4 inhibitors. A warning has been included in 4.4, with a description of concomitant administration of CYP3A4 inducers and inhibitors to avoid in section 4.5. Furthermore, a drugdrug cocktail interaction study will be submitted as a post-authorisation measure in order to better characterise the metabolic pathways and transporters involved in encorafenib elimination.

In non-clinical models, there is some evidence that there may be embryo-foetal toxicity associated with encorafenib administration. Therefore a warning has been included in section 4.6.

There are no data available in patients with severe renal impairment and PK population analysis has provided an indication that there is the potential for renal dysfunction due to overdose. Therefore, a warning has been included in section 4.4 that encorafenib should be used with caution in patients with severe renal impairment and that blood creatinine should be monitored as clinically indicated and managed with dose modification or discontinuation.  In addition, there is a potential of over-exposure in patients with moderate to severe hepatic impairment. The CHMP considers that the applicant should collect PK samples from BRAF melanoma patients with moderate and severe hepatic impairment after repeated dosing of encorafenib in combination with binimetinib to determine the plasma concentrations in relation to administered dose and AEs observed to guide dosing recommendations in these patient populations.

## 3.6. Effects Table

Table 75: Effects Table for Encorafenib in Combination with Binimetinib for the Treatment of Adult Patients with Unresectable or Metastatic Melanoma with BRAF V600 mutation (data cut-off: 19 May 2016 - PFS Part 1; 9 Nov 2016PFS Part 2; 7 Nov 2017 - OS

| Effect             | Short Description   | Unit   | Treatment   | Control   | Uncertainties/ Strength of evidence                            | Refere nces   |
|--------------------|---------------------|--------|-------------|-----------|----------------------------------------------------------------|---------------|
| Favourable Effects | Favourable Effects  |        |             |           |                                                                |               |
| Median PFS         | Combo 450 vs Vem    | mon    | 14.9        | 7.3       | Strong; consistent across analyses + previous BRAF-MEKi combos |               |

<div style=\"page-break-after: always\"></div>

| Effect     | Short Description              | Unit   |   Treatment |   Control | Uncertainties/ Strength of evidence   | Refere nces   |
|------------|--------------------------------|--------|-------------|-----------|---------------------------------------|---------------|
| Median PFS | Enco 300 vs. Vem               | mon    |         9.6 |       7.3 | Strong; little uncertainty            |               |
| Median PFS | Combo 450 vs Enco 300          | mon    |        14.9 |       9.6 | Lacks statistical significance        |               |
| Median OS  | Combo 450 vs Vem               | mon    |        33.6 |      16.9 | strong                                |               |
| Median OS  | Combo 450 vs Enco 300          | mon    |        33.6 |      23.5 |                                       |               |
| Median PFS | Combo 300 vs Enco 300 (Part 2) | mon    |        12.9 |       7.4 | Enco 300 PFS shorter than in Part 1   |               |

## Unfavourable Effects - initial MAA (except deaths updated 9 November 2016)

|                    |                         |   Combo 450 RP |   Enco 300 P |    Vem |           |
|--------------------|-------------------------|----------------|--------------|--------|-----------|
| EAIR All grade AEs | Per 100 patient- months |         142.83 |       604.83 | 226.32 |           |
| G3/4 AEs           | Treatment emergent%     |          58    |        67.3  |  63.4  |           |
| SAEs               | Treatment emergent%     |          35.8  |        31.8  |  37.1  |           |
| Dis-contin         | Treatment emergent%     |          10.2  |        17.5  |  16.7  |           |
| G3/4 PPE           | Treatment emergent%     |           0    |        12.4  |   1.1  |           |
| G3/4 vomiting      | Treatment emergent%     |           2.2  |         4.1  |   1.6  |           |
| G3/4 diarrhoea     | Treatment emergent%     |           3.3  |         1.4  |   2.2  |           |
| G3/4 inc. CK       | Treatment emergent%     |           5.5  |         0    |   0    |           |
| G3/4 inc GGT       | Treatment emergent%     |           8    |         4.6  |   3.2  |           |
| G3/4 inc           | Treatment emergent%     |           5.8  |         1.4  |   1.6  | transamin |
| G3/4 haemorrh      | Treatment emergent%     |           2.6  |         1.8  |   1    | age       |
| SCC                | Treatment emergent%     |           2.6  |         6.9  |  17.2  |           |

<div style=\"page-break-after: always\"></div>

| Effect              | Short Description       |   Unit |   Treatment | Control   | Uncertainties/ Strength of evidence   | Refere nces   |
|---------------------|-------------------------|--------|-------------|-----------|---------------------------------------|---------------|
| On treatment deaths | %                       |  10.2  |        7.4  | 10.2      |                                       |               |
| EAIR deaths         | Per 100 patient- months |   0.73 |        0.71 |           |                                       |               |

Abbreviations: Combo 450: encorafenib 450mg QD + binimetinib 45mg BID; Enco: encorafenib 300mg QD; Vem: vemurafenib 960mg BID; mon: months; EAIR: exposure adjusted incidence rate; G: Grade; AE: adverse event; Dis-contin: discontinuation due to AE; transamin: transaminases; inc: increased; HTN: hypertension; SCC: squamous cell carcinoma; aPPE: -Palmar-plantar erythrodysaesthesia syndrome

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The PFS improvement for Combo 450 compared to vemurafenib is considered clinically meaningful. In addition, the significant prolongation in OS with a difference in median survival of 16.7 months in favour of Combo 450 is clinically important.

The median PFS result for Combo 450 (14.9 months) compares very favourably with other BRAF-MEK inhibitor combinations already authorised (trametinib and dabrafenib, median PFS is 11.4 months or cobimetinib and vemurafenib with a median PFS of 12.3 months).  The median potential durations of followup for OS were 37.2 months (Combo 450) and 35.9 months (vemurafenib) in Study CMEK162B2301 (using Kaplan Meier Approach), 22.3 months (vemurafenib/cobimetinib) and 17.4 months (vemurafenib) in coBRIM, and 26.1 months (dabrafenib/trametinib) and 17.8 months (vemurafenib) in COMBI-v. The median OS of 33.6 months with Combo 450 is impressive in comparison with the other regimens (median OS 22.3 to 26.1 months).

The ORR and the disease control rate were high for Combo 450 and the onset of response was rapid, within around 2 months, in responders. This corresponds to the first clinical visit and it is possible that responses occurred earlier, allowing relief of symptoms, particularly for patients with bulky disease.

Combo 450 had better general tolerability than encorafenib monotherapy, as evidenced by the QoL analysis and the lower overall rate of AEs. Treatment continued at high relative dose intensity in the combination arm. Still, the proportion of SAEs was not reduced compared to encorafenib monotherapy, and the combination did introduce additional toxicities, specifically increased CK, hypertension, abnormal LFTs, LV dysfunction and eye disorders. These events may not have influenced tolerability, but decreased ejection fraction and increased ALT did result in dose adjustment or study drug interruption. These AEs have the potential to be serious but are manageable if the routine regular screening of patients whilst on treatment is adhered to and recommendations from the SmPC are followed.

## 3.7.2. Balance of benefits and risks

BRAF-MEK inhibitor combinations are known to be effective in BRAF V600 mutant malignant melanoma. Combo 450 led to an improved PFS compared to monotherapy vemurafenib and a median OS at the upper end of the range of survivals currently reported for metastatic malignant melanoma. While vemurafenib monotherapy is no longer the main standard of care for metastatic melanoma with BRAF V600 mutations and

<div style=\"page-break-after: always\"></div>

as a result, the comparison with a treatment arm which is currently regarded as suboptimal is not encouraged, it nevertheless remains evident that there is a clinically relevant benefit that has been demonstrated with the combination treatment of encorafenib with binimetinb in patients with metastatic melanoma harbouring BRAF V600 mutation.  The safety of the combination is considered acceptable and ADRs can be managed through routine risk minimisation activities with no further additional risk minimisation activities required.

## 3.7.3. Additional considerations on the benefit-risk balance

Approximately  37-50%  of  patients  with  metastatic  melanoma  have  mutations  in BRAF ,  and  over  95%  of these are in BRAF exon 15 at the V600 position. The most common V600 mutations are V600E and V600K accounting  for  80-90%  and  7-30%  of  all BRAF V600  mutations,  respectively.  Other  more  rare  activating mutations  include  V600R  and  V600D.  These  mutations  constitutively  activate  BRAF  protein  and  signal downstream to activate the RAF/MEK/ERK pathway, which signals for cancer cell proliferation and survival. The patient population recruited in the pivotal clinical trial were tested for the presence of BRAF V600 E or K mutation, which was an inclusion criteria that a patient's tumour had to be confirmed by a validated test prior to treatment initiation. Based on the mechanism of action and the non-clinical data showing the inhibitory activity of encorafenib against BRAF V600E/K/R, the indication has been expanded to include all BRAF V600 mutations  as  it  is  expected  that  encorafenib  may  target  and  inhibit  BRAF  regardless  of  the  type  of  V600 substitution.

The patient population included in the pivotal study were patients with histologically confirmed diagnosis of locally advanced, unresectable or metastatic cutaneous melanoma or unknown primary melanoma (AJCC Stage IIIB, IIIC or IV) and excluded patients with uveal and mucosal melanoma. The indication includes all types of melanoma as the prevalence of uveal melanoma and mucosal melanoma is low and few patients would have been recruited in the trial. In addition, there is no standard of care for these types of melanoma and it is expected that all melanoma patients with a BRAF V600 mutation would benefit from having treatment options that are targeted and have demonstrated efficacy. Patients also had not received prior treatment with a BRAF or MEK inhibitor. A warning has been included in section 4.4 of the SmPC to inform treating physicians that it appears that patients who have received prior BRAF treatment seem to have lower efficacy when treated with the combination. It is also noteworthy that the trial population included naive untreated patients or patients who have progressed on or after prior first-line immunotherapy for unresectable locally advanced or metastatic melanoma. Nevertheless, the indication does not specify the line of treatment as it is left to the treating physician and clinical practice to determine the best treatment algorithm for an individual patient. Section 5.1 of the SmPC describes the patient population that was included in trial.

## 3.8. Conclusions

The overall B/R of Braftovi is positive.

The CHMP requests the following measures to address the issues related to pharmacology:

- -OS results for Combo 300 and updated Combo 300 PFS analysis, including more mature data for the Enco300 Part 2 arm.
- -DDI cocktail study: OATP and BCRP will be explored in the ongoing DDI study with rosuvastatin (study ARRAY-818-103)

<div style=\"page-break-after: always\"></div>

- -Overall survival results stratified by LDH level for Combo 300 and Enco 300 (Part 2).
- -To collect PK samples from BRAF melanoma patients with moderate and severe hepatic impairment after repeated dosing of encorafenib in combination with binimetinib to determine the plasma concentrations in relation to administered dose and AEs observed to guide dosing recommendations in these patient populations.

The CHMP recommends the applicant to submit the following measures to address the issues related to pharmacology:

- -The applicant should commit to submit the results of the planned biomarker analyses for Study B2301 (from all 3 treatment arms) for evaluation as soon as available, to support the synergistic pharmacodynamic activity of encorafenib in combination with binimetinib. Genomic analysis of baseline samples remaining after centralized BRAF testing. As indicated in the protocol, genomic alterations in BRAF, HRAS, KRAS, NRAS, PTEN, cKIT, PIK3CA, MAP2K1, MAP2K2, ARAF, c-MET, CRAF, EGFR and CCND1 may be explored to find a potential association between baseline mutations and efficacy outcomes.
- -The relationship between baseline mutations and efficacy outcomes should be performed, and a date provided to submit the results.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus decision that the benefit-risk balance of Braftovi is favourable in the following indication:

Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that encorafenib is a new active substance as it is not a constituent of a medicinal product previously authorised within the European Union.